

ATTORNEY DOCKET NO.: 5568/1048

ONCOLOGY TISSUE MICROARRAYS

Field of the Invention

The invention relates to microarrays comprising a plurality of tissue samples for comparison to test tissue samples. The microarrays enable a user to evaluate disease progression and the likelihood of disease reoccurrence in a patient. In particular, the invention relates to microarrays comprising tissues representing a plurality of different stages of cancer.

Background Of The Invention

The ability to monitor disease progression is an important tool in cancer therapy because it allows an attending physician to select the most appropriate course of treatment. For example, patients who are likely to relapse should be treated aggressively with powerful systemic chemotherapy and/or radiation therapy, while patients who are less likely to relapse can be treated less aggressively. Because using more aggressive therapeutic regimens can cause severe patient distress, it is desirable to determine whether a patient actually requires such aggressive treatment.

The characteristic morphology of normal cells and tissues is ordinarily not preserved when they are transformed. Therefore, most, if not all, tumors can be identified and distinguished from normal tissues on the basis of histology. A cancerous tissue cell will typically lose morphological features in a process of dedifferentiation and will not maintain appropriate tissue boundaries (e.g., proliferating and invading regions where it would not normally be found). However, it is generally not possible on the basis of morphology alone to predict the likelihood that a given tumor cell will respond to a given therapeutic regimen or to determine whether the disease is likely to recur after treatment.

Molecular medicine aims to address the shortcomings of basic histology by providing information on the expression of specific gene products or variant gene products within a tissue sample. The expression or form of a gene product can be used as a marker if it appears characteristically when a phenotype such as disease (e.g., cancer) is observed. Numerous gene products have been shown to participate in or to be associated with human disease, and their measurement can provide diagnostic and prognostic tools to the clinician. However, the knowledge that a particular gene product is overexpressed in a tumor relative to a normal tissue still does not

necessarily provide a predictive advantage if there is a continuum of harmful effects relating to varying levels of the gene product. For example, a range of levels of expression 1-5 of a gene product might be associated with phenotype A in which a cancer cell is relatively differentiated and respects its normal tissue boundaries, while an overlapping range of levels of expression, 4-8 would be associated with a phenotype B, in which a cancer cell is relatively undifferentiated but has not yet metastasized. At the boundaries between phenotypes (e.g., where the gene is expressed at levels 5-6), it is particularly difficult to make an accurate prognosis. The situation is complicated by the fact that a disease, such as cancer, represents the interactions of multiple genes, each of which may be expressed at varying levels.

By increasing the numbers of markers measured simultaneously, the accuracy of a prognosis can be improved. For example, Levine et al. (U.S. Patent No. 5,843,684) describes a method of diagnosing or predicting the prognosis of cancer based on the co-expression of elevated levels of p53 and dm2. Patient samples are categorized into one of three groups depending upon whether either gene or both is expressed at an elevated level relative to normal tissue. Kamb et al. (U.S. Patent No. 5,998,136) describes methods of identifying cell proliferation genes and methods of diagnosing or prognosing of diseases affecting cell proliferation based on altered expression of cell proliferation genes relative to normal tissues. Kallioniemi et al. (WO 00/24940) describes the use of tissue arrays to determine the correlation of genetic marker expression with various stages of disease.

In addition to the use of prognostic markers to inform the decision making of a physician, such markers serve as targets for drug development where a causal relationship exists between the marker and the disease. Due to the masses of genomic data being acquired in the human genome project, genomics-based drug development is now dependent upon the ability to rapidly prioritize and effectively exploit the new research leads identified. While hundreds of thousands of potential markers have been identified, information relating to the biological role of these markers is limited. The ability of pharmaceutical companies to develop new drugs and clinical products is becoming dependent upon their ability to choose the right targets out of these hundreds of thousands of targets and then to validate the chosen targets *in vivo*. This is where the current bottleneck lies. The drug developer must find a way to prioritize and select the most promising targets for further studies, be able to abandon the less promising targets as early as possible, and finally, to develop clinical and phenotypic information based on the characteristics of a target gene product at a population scale.

Summary Of The Invention

There is a need in the art for new diagnostic and prognostic markers for disease. In addition, there is a need in the art for ways to correlate the expression characteristics of prognostic markers, new and old, with the severity of disease and the anticipated success of a range of treatment approaches. The microarrays and methods according to the present invention can be used to inform the decision making of clinicians with regard to the treatment of diseases, particularly cell proliferative diseases, such as cancer. The microarrays and methods according to the present invention further can be used to prioritize and validate drug targets identified in high throughput genomic screening techniques.

In one aspect of the invention, a microarray is provided comprising a plurality of tissue and/or cell samples, each sample stably associated with a different sublocation on the array, and comprising at least one known biological characteristic. The microarray can comprise from about 2 to greater than about 2000 sublocations. Preferably, at least 50% of the sublocations comprise different tissue types. In one aspect of the invention, at least one sublocation comprises human cells. In another aspect of the invention, at least one sublocation of the microarray comprises a cancer cell. Preferably, the microarray comprises a plurality of different types of cancer (e.g., from different tissues), while in another aspect of the invention, different grades of the same cancer are provided on the same microarray. More preferably, at least one sublocation comprises a healthy or normal tissue or cell sample.

The microarrays according to the present invention provide, on a single substrate, DNA, RNA, protein, and other biomolecule arrays as contained with cells and/or tissues. Detection of each of these different types of molecules may be performed optimally under different conditions. For example, while paraffin embedded sections may provide good morphology, such sections may not be optimal for detection of nucleic acids. Therefore, in one aspect of the invention, invention provides microarrays comprising heterogeneous sample types, such as paraffin-embedded or plastic-embedded tissue, frozen tissue, and a serum sample specimen, all on the same substrate and all from the same patient. In another aspect of the invention, sets of microarrays are provided comprising paraffin-embedded or plastic-embedded sections, frozen sections, and serum sample specimens all from the same patient. In a further aspect, a plurality of sets are provided representing a population of patients. Alternatively a single substrate can represent a "population microarray" comprising cells and/or tissues from a plurality of individuals.

The invention further provides a method for comparing the biological characteristics of a test tissue or cell(s) ("a test sample"), comprising providing a test sample, contacting the test sample with a molecular probe, and identifying the reactivity of the molecular probe with the test sample and cell and/or tissue samples within a microarray. In one aspect of the invention, reactivity is any of: specific labeling, binding, enzymatic catalysis, and/or hybridization. In another aspect of the invention, the reactivity of the test sample and cells and/or tissues on the microarray is correlated with information relating to the source of the cells and/or tissues on the microarray. Preferably, the information includes patient information. The reactivity of the sample also can be correlated with molecular profiling data which has been obtained for cells and/or tissues on the microarray.

In one aspect of the invention, a profile array substrate is provided comprising a first location for placement of a test tissue and a second location comprising a microarray. In this aspect, the biological characteristics of a test tissue can be evaluated at the same time and under the same conditions as the biological characteristics of the cells/tissues within the microarray.

In a preferred aspect of the invention, information relating to samples on the microarrays is stored in a specimen-linked database. Such information can include one or more of: gene expression (e.g., such as RNA expression, RNA processing; and protein expression, protein modifications, cleavage, and processing); expression of other cellular biomolecules, tissue type, disease status, and patient information (e.g., patient medical history, including drug exposure, age, sex, age and cause of death if appropriate, family medical history, and the like). In one aspect of the invention, the information is displayed on the display of a user computer or a wireless device connectable to a network. Preferably, as information relating to test samples is obtained, this information is also stored in the database. The specimen-linked database is also used to store information relating to correlations between biological characteristics of test samples and the biological characteristics of specimens for which data exists in the database (e.g., such as data obtained from one or more microarrays).

The microarrays according to the invention are used in methods of selecting promising gene targets, sorting/prioritizing cDNA array data, surveying entire populations, validating gene discoveries in 100's of human tissue specimens, investigating disease pathogenesis and progression, and searching for diagnostic, prognostic and clinical correlations, such as the likelihood of disease reoccurrence.

In one aspect of the invention, an oncology array is provided comprising different cell and/or tissue types from a patient with cancer, including cancerous cells (both primary and secondary sites of cancer), and normal cells. The patient may have additional characteristics affecting disease progression (e.g., age, exposure to an environmental condition, treatment with a drug, or radiation, one or more underlying or concurrent illnesses, and the like). The oncology microarray can be reacted with molecular probes to generate a diagnostic matrix which correlates information relating to the reactivity of the probes with other biological characteristics which identify that patient, such that reactivity of the molecular probes can then be used to predict the presence of these other biological characteristics in that patient.

In one aspect of the invention, the diagnostic matrix provides a correlation between the expression of cancer-specific gene and a particular stage of cancer, e.g., enabling a user to diagnose the progression of a cancer in a patient. Information relating to the expression of the cancer-specific gene in a test sample from a patient is then compared to information within the diagnostic matrix to identify the particular stage of cancer associated with that level of expression. This information can be used to provide a prognosis and to guide a physician as to what course of therapy to use in treating the patient.

In another aspect of the invention, a set of arrays is provided, each array representing a different patient. By increasing the number of biological characteristics and patients looked at, a highly informative database is generated which a user can access to evaluate disease progression, the efficacy of a particular treatment, and the effects of underlying conditions (e.g., such as age, other types of disease, etc). In one aspect, the database is used to prioritize drug targets. A plurality of disease microarrays, each representing different cells/tissues from different patients with diseases can be used to profile a known or unknown biological molecule, using the power of parallel analysis to determine the biological relevance of these molecules.

In a further aspect of the invention, samples within a microarray are ordered into groups which represent the patients from which these tissues are derived. In one aspect, the groupings are based on multiple patient parameters that can be reproducibly defined from the development of molecular disease profiles. A clinical diagnosis/prognosis can be made using any or all of the parameters identified.

Brief Description of the Drawings

The objects and features of the invention can be better understood with reference to the following detailed description and accompanying drawings.

Figure 1A shows a flow chart according to one aspect of the invention in which microarrays according to the invention are used in conjunction with gene chips to identify, prioritize, and validate drug targets. Figure 1B shows a schematic diagram of how data from a microarray is used in this process.

Figure 2A is an illustration of a profile array substrate according to one aspect of the invention, comprising a first location for placing a test tissue sample and a second location comprising a microarray. The microarray comprises a plurality of sublocations, each sublocation comprising a sample stably associated therewith representing a different stage of breast cancer. Figure 2B shows an array locator according to one aspect of the invention next to a profile array substrate for identifying samples which have reacted with molecular probes. Figure 2C shows six different tissue samples representing different stages of breast cancer stained with a CK7 antibody. Figure 2D shows information provided in a kit which comprises the profile array substrate shown in Figure 2A and the array locator shown in Figure 2B. Figure 2E shows a profile array substrate comprising a test tissue at a first location and a microarray at a second location. The test tissue is stained with a breast cancer specific antibody.

Figure 3 shows a tissue microarray according to the present invention comprising a plurality of sublocations, each sublocation comprising a tissue sample whose morphological features can be distinguished under a microscope.

Figures 4A-4C show an interface on a display of a user device connectable to a network which displays information relating to the biological characteristics of tissues at different sublocations on the microarray. Figure 4A shows an interface for addressing a breast cancer microarray and for inputting information into a specimen-linked database comprising information relating to the biological characteristics of breast cancer tissues at different sublocations on the microarray. Figure 4B shows a display of a portion of a specimen-linked database. Figure 4C shows a display enabling a user to access a relational database for identifying relationships between biological characteristics of tissues at different sublocations on the array.

Description

The invention provides oncology microarrays which comprise a substrate on which a plurality of tissue and/or cell samples are provided, each sample being stably associated with the substrate at a different, known, position on the substrate. Preferably, samples represent different types or stages of cancer. Samples can be ordered on the substrate of a microarray into groups according to common characteristics of the patients from whom the samples are obtained (e.g., a group of samples from patients treated with chemotherapy, a group of samples from patients not treated with chemotherapy, a group from patients treated with hormones, a group from patients not treated with hormones, etc.). By dividing samples on the substrate into different groupings representing different cell/tissue types, subtypes, histological lesions, and clinical subgroups, the microarrays according to the invention enable ultra-high-throughput molecular profiling

Definitions

The following definitions are provided for specific terms which are used in the following written description.

As used herein, the term "biological characteristics" refers to the phenotype and/or genotype of one or more cells or tissues being arrayed and can include one or more of cell type tissue type, morphological features of the cells and/or tissues, and the expression of biological molecules with the cells/tissues. The "expression of biological molecules" can include the expression and accumulation of RNA sequences, the expression and accumulation of proteins (including the expression of their modified, cleaved, and/or processed forms, and further including the expression and accumulation of enzymes, their substrates, products and intermediates) as well as the presence or absence or copy number of particular chromosomes or chromosome regions within the cell. "Biological characteristics of a cell source" or "biological characteristics of tissue source" refers to the characteristic of the patient who is the source of the cells (e.g., such as the age, sex and physiological state of the organism) and encompasses patient information.

As used herein, "a diagnostic trait" is an identifying characteristic which includes both biological characteristics and experiences (e.g., exposure to a drug). A trait can be a marker for a transformed, immortalized, pre-cancerous, or cancerous state, or a marker for a particular cell type, or the ability of a tissue to bind, incorporate, or respond to a drug or agent. A trait also refers to the response of a tissue or cell to a protein, drug, or other agent. In one aspect, a trait is a marker for a

particular cell type such as a transformed, immortalized, pre-cancerous, or cancerous cell or a state, such as a disease, and detection of the trait provides a reliable indicia that the sample comprises the cell(s). Screening or evaluating for a diagnostic trait thus refers identifying an agent which can cause a detectable change in a trait which is statistically significant when compared to cells not so treated using routine statistical tests. As used herein, a "trait" can be the expression of one or more biological characteristics.

As defined herein, a "molecular probe" is any detectable molecule or molecule which produces a detectable molecule upon reacting with a biological molecule. "Reacting" encompasses binding, labeling, or catalyzing an enzymatic reaction. A "biological molecule" is any molecule which is found in a cell or within the body of an organism.

As used herein, the term "substantially matches", when referring to an expression characteristic, means that the score assigned to a patient's tissue sample for a given polypeptide using a scoring method as described herein is the same (which is defined as not being significantly different using routine statistical tests to within 95% confidence levels) as the score for a tissue sample to which it is being compared for at least that polypeptide. The scoring methods useful in the invention assign a value to every expression characteristic, with each such value actually representing a range of values. Since both the patient sample and the standard samples are scored using the same method and the same ranges of values for each class, there will always be a substantial match between a patient sample and one or more tumor or normal samples on the panel, even though the level of expression does not exactly match between the respective samples.

As used herein, the term "expression" refers to the level, form or localization of a product. For example, the "expression of a protein" refers to one or more of the level, form (e.g., presence, absence, or amount of modifications, and/or presence, absence or amount of cleaved or otherwise processed products of a protein), or localization of the protein.

As used herein, the term "difference in biological characteristics" refers to an increase or decrease in a measurable expression of given biological characteristic. A difference may be an increase or decrease in a quantitative measure (e.g., an amount of protein or amount of RNA encoding the protein) or a change in a qualitative measure (e.g., the localization of an RNA or protein). Where a difference is observed in a quantitative measure, the difference according to the invention will be at least about 10% greater or less than the level in a normal standard sample (e.g., a

control). Where a difference is an increase, the increase may be as much as about 20%, about 30%, about 50%, about 70%, about 90% to about 100% (about two-fold) or more, up to and including about 5-fold, 10-fold, 20-fold, 50-fold or more. Where a difference is a decrease, the decrease may be as much as about 20%, 30%, 50%, 70%, 90%, 95%, 100% (e.g., where there is no specific protein or RNA present). It should be noted that even a qualitative difference could be represented in quantitative terms if desired. For example, a change in the intracellular localization of a polypeptide may be represented as a change in the percentage of cells showing the original localization.

A “disease or pathology” is a change in one or more biological characteristics that impairs normal functioning of a cell, tissue, and/or organism. A “pathological condition” encompasses disease but also encompasses abnormal responses which are not associated with any particular infectious organism or single genetic alteration in an individual. For example, as defined herein, a stroke or immune response occurring after the transplantation of an organism would be encompassed by the term “pathological condition”.

As defined herein, “a cell proliferative disorder” is a condition marked by any abnormal or aberrant increase in the number of cells of a given type or in a given tissue. Cancer is often thought of as the prototypical cell proliferative disorder, yet disorders such as atherosclerosis, restenosis, psoriasis, inflammatory disorders, some autoimmune disorders (e.g., rheumatoid arthritis) are also caused by abnormal proliferation of cells, and are thus examples of cell proliferative disorders.

As used herein, “a tumor” is a neoplasm that may either be malignant or non-malignant. Tumors of the same tissue type originate in the same tissue, and may be divided into different subtypes based on their biological characteristics.

As used herein, the term “disease recurrence” refers to the development or emergence of cells of a proliferative disease, such as a tumor, after a treatment that has substantially removed such cells. A disease recurrence may be at the same site as the original disease or elsewhere, but will involve accumulation of cells of the same tissue of origin as in the original disease.

As used herein, the term “guiding treatment” refers to the process of informing the decision making for the treatment of a disease. As used herein, treatment guidance is based on the comparative levels of one or more cell growth-related polypeptides in a patient’s tissue sample relative to the levels of the same polypeptide(s) in a plurality of normal and diseased tissue samples

from individuals for whom patient information, including treatment approaches and outcomes is available.

The term “donor block” as used herein, refers to tissue that may be embedded in an embedding matrix, from which a tissue sample is obtained and placed directly onto a slide or placed
5 into a receptacle of a recipient block.

The term “donor sample” as used herein, refers to a tissue sample obtained from the donor block.

The term “recipient block” as used herein, refers to a block formed from an embedding matrix, having receptacles to hold donor samples in a regular pattern so that the location of the donor samples will be maintained when the recipient block is sectioned to produce an array of tissue
10 samples.

As used herein, the term “course of disease” refers to the sequence of events in which a disease develops, causes symptoms and is either recovered from or continues and/or increases in severity.

As used herein, the term “cancer” refers to a malignant disease caused or characterized by the proliferation of cells which have lost susceptibility to normal growth control. “Malignant disease” refers to a disease caused by cells that have gained the ability to invade either the tissue of
15 origin or to travel to sites removed from the tissue of origin.

As used herein, the term “tumor suppressor gene” refers to a gene, the normal expression of
20 which tends to prevent the establishment or growth of oncogenically transformed cells. A tumor suppressor gene may act, for example, to halt or slow the proliferation of cells or, for example, to cause the cells to undergo apoptosis in response to a particular stimulus or condition.

As used herein, the term “tumor stage” refers to a measure of the degree of advancement or progression of a tumor. A tumor’s stage is determined according to criteria including, for example,
25 the morphology of the cells, morphology of the tissue, whether tumor cells have infiltrated the tissue of origin, whether tumor cells have invaded lymph nodes, and whether distant metastasis has occurred. Clinical staging for many tumors follows the TNM system, described herein below, but other clinical staging scales adapted to specific diseases are known in the art.

As used herein, the term "non-tumor samples" refers to tissue samples obtained from normal tissue. A sample may be judged a non-tumor sample by one of skill in the art on the basis of morphology.

As used herein, the term "computer-accessible file" refers to a collection of information regarding a tissue sample, which collection is stored in a computer's memory and is retrievable or can be accessed through that computer or one linked to it.

As used herein, the term "information about the patient" refers to any information known about the individual from whom a tissue sample was obtained. Examples of information that would be useful in a given file of information about the patient include age, sex, weight, height, ethnic background, family medical background, the patient's medical history (e.g., information pertaining to prior cell proliferative disorders, infectious diseases and metabolic disorders, diagnostic and prognostic test results, drug exposure, responses to drug exposure, other treatment approaches and their success or failure, cause of death, etc.).

As used herein, the term "degree of disease severity" refers to measure of how advanced a disease is, on a scale from no disease to the worst possible disease. One of skill in the art can place a set of tissue samples representing a disease in order of ascending or descending severity of disease. In order to do so, samples may be compared not only to known standards, but also to each other.

As used herein, the term "detectable binding reagent" refers to an agent that specifically recognizes and interacts or binds with an entity one wishes to measure, wherein the agent has a property permitting detection when bound. "Specifically interact" means that a binding agent physically interacts with the entity one wishes to measure, to the exclusion of other entities also present in the sample. The binding of a detectable binding reagent useful according to the invention has stability permitting the measurement of the binding. A detectable binding reagent may possess an intrinsic property that permits direct detection, or it may be labeled with a detectable moiety.

As used herein, the term "detectable moiety" refers to a moiety that can be attached to a binding reagent that confers detection of the binding reagent by a particular method or methods. Detectable moieties include, but are not limited to radiolabels (e.g., ^{32}P , ^{35}S , ^{125}I , etc.), enzymes (e.g., alkaline phosphatase, peroxidase, etc.), fluorophores (e.g., fluorescein, amino coumarin acetic acid, tetramethylrhodamine isothiocyanate (TRITC), Texas Red, Cy3.0, Cy5.0, green fluorescent protein, etc.) and colloidal metal particles.

As used herein, the term "labeled" means that a detectable moiety has been physically attached to a binding reagent.

As used herein, the term "antibody or antigen binding fragment thereof" refers to an immunoglobulin having the capacity to specifically bind a given antigen. The term "antibody" as used herein is intended to include whole antibodies of any isotype (IgG, IgA, IgM, IgE, etc), and fragments thereof which are also specifically reactive with a vertebrate, e.g., mammalian, protein. Antibodies can be fragmented using conventional techniques and the fragments screened for utility in the same manner as whole antibodies. Thus, the term includes segments of proteolytically-cleaved or recombinantly-prepared portions of an antibody molecule that are capable of selectively reacting with a certain protein. Non-limiting examples of such proteolytic and/or recombinant fragments include Fab, F(ab')₂, Fab', Fv, and single chain antibodies (scFv) containing a V[L] and/or V[H] domain joined by a peptide linker. The scFv's may be covalently or non-covalently linked to form antibodies having two or more binding sites. Antibodies may be labeled with detectable moieties by one of skill in the art. In some aspects, the antibody that binds to an entity one wishes to measure (the primary antibody) is not labeled, but is instead detected by binding of a labeled secondary antibody that specifically binds to the primary antibody.

As defined herein, a "nucleic acid array," "peptide array", "a polypeptide array", "protein array" or "small molecule" array refers to a plurality of nucleic acids, peptides, polypeptides, proteins, or small molecules, respectively that are immobilized on a substrate in different, known locations on the substrate.

As defined herein, a "tissue" is an aggregate of cells that perform a particular function in an organism. The term "tissue" as used herein refers to cellular material from a particular physiological region. The cells in a particular tissue may comprise several different cell types. A non-limiting example of this would be brain tissue that further comprises neurons and glial cells, as well as capillary endothelial cells and blood cells, all contained in the tissue section.

As defined herein a "cell and/or tissue microarray" is a microarray which comprises a plurality of sublocations, each sublocation comprising one or more cell(s) or a portion of a tissue stably associated with a substrate at that sublocation. The term "microarray" implies no upper limit on size on samples in the array but merely encompasses a plurality of samples stably associated with distinct, known sublocations on a substrate, which, in one aspect, can be viewed using a microscope.

As used herein, a sample or portion of a sample which is "stably associated with a substrate" refers to a sample or portion thereof which does not substantially move from its position on the substrate during one or more molecular procedures.

As used herein "molecular procedure" refers to contact with a test reagent or molecular probe such as an antibody, nucleic acid probe, enzyme, chromagen, label, and the like. In one aspect, a molecular procedure comprises a plurality of hybridizations, incubations, fixation steps, changes of temperature (from -4°C to 100°C), exposures to solvents, and/or wash steps

As used herein, "a whole body microarray" is a microarray comprising cell and/or tissue samples representing the whole body of an organism. In one aspect, the microarray comprises at least about five different types of cells/tissues from a single organism, at least about ten different types of cells/tissues or at least about 20 different types of cells/tissues from the organism, each different type of cell/tissue stably associated with a different, distinct, known sublocation of the microarray. As used herein, "different types of cells" refer to cells which differ in the expression of a least one peptide, polypeptide, or protein. Preferably, different types of cells and/or tissues are from different organs or are from anatomically and/or histologically distinct sites in the same organ. For example, in one aspect, a whole body microarray comprises at least five different types of tissues selected from the group consisting of brain, cardiac tissue, liver, pancreas, spleen, stomach, lung, skin, eye, colon, reproductive organ (male or female) and kidney cells. In preferred aspects, a sample of cells from a bodily fluid is also included such as a blood sample, lymph sample, CSF sample, urine sample, amniotic fluid sample, leukapheris sample, and the like. Cells can also be selected from the group consisting of hematopoietic cells, stem cells and progenitor cells, T cells, B cells, monocytes, granulocytes, dendritic cells, macrophages, erythroid cells, mekaryocytes, platelets, endothelial cells, epithelial cells, tumor cells, fibroblasts and the like.

As used herein "substantially identical mircroarrays" refer to microarrays obtained by sectioning a single microarray block. Preferably, substantially identical microarrays comprise sections which are within about 0-500µm of each other in a microarray block. Substantially identical microarrays comprise a one-to-one correspondence of samples, such that samples at identical coordinates in a plurality of substantially identical microarrays will be substantially identical (e.g., express substantially the same biomolecules and have substantially the same morphological features).

As defined herein, a “database” or a “specimen-linked database” refers to a collection of information or facts organized according to a data model which determines whether the data is ordered using linked files, hierarchically, according to relational tables, or according to some other model determined by the system operator. The organization scheme the database uses is not critical to performing the invention, so long as information within the database is accessible to the user through an information management system. Data in the database are stored in a format consistent with an interpretation based on definitions established by the system operator (i.e., the system operator determines the fields which are used to define patient information, molecular profiling information, or another type of information category. Preferably, a “specimen-linked database” is one which cross-references information in the database to specimens provided on one or more microarrays, and preferably using codes such as SNOMED codes, ICD-9 codes, and/or DSM-IV TR codes.

As used herein, “a system operator” is one who controls access to the database.

As used herein, the term “information management system” refers to a system which comprises a plurality of functions for accessing and managing information within the database. Minimally, an information management system according to the invention comprises a search function for locating information within the database and for displaying at least a portion of the information to a user, and a relationship-determining function, for identifying relationships between information or facts stored in the database.

As used herein, “an interface” or “user interface” or “graphical user interface” is a display comprising text and/or graphical information displayed by the screen or monitor of a user device connectable to the network (e.g., such as the world wide web) which enables a user to interact with the specimen-linked database and information management system.

As used herein, the term “link” refers to a point-and-click mechanism implemented on a user device connectable to the network which enables a user/viewer to link (or jump) from one display or interface where information is referred to (“a link source”) to other screen displays where information exists (“a link destination”). The term “link” encompasses both the display element that indicates the information is available and the program which finds the information (e.g., within the database) and displays it on the destination screen). In one aspect, a link is associated with text; however, in other aspects, links are associated with images or icons. In some aspects, selecting a

link (e.g., by right clicking on a mouse) will cause a drop-down menu to be displayed which provides the user with the option of viewing one of several interfaces. Links also can be provided in the form of action buttons, radio buttons, check buttons, and the like.

As defined herein, a “browser” is a program which supports the displaying of documents across a network. Browsers enable accessing linked information over the Internet and other networks as well as from magnetic disks, CD-ROMs, or other memory sources”

The term “providing access to a database” or “providing access to a portion of a database” as defined herein refers to making information in the database available to end users in a usable format. A usable format depends on the capabilities and needs of the user, and the complexity and volume of the information, and may be for example, written text, an image, a combination of written and visual information, verbal, by electronic means, including a computer readable format (e.g., software, optical discs, and the light), or any other format for conveying information such as text or visual data. The term “providing access” should not be necessarily construed as providing full access to all records in a database, or that all tissues/cells on a microarray have records in the database.

The term “research report” as used herein refers to report or analytical summary of the information obtained during the process of providing a microarray according to the invention, and providing access to a specimen-linked database. The report or analysis is intended to reflect the needs of the clients. The report may be provided in written format, electronic format such as, for example, electronic mail, or contained on a magnetic storage device such as a computer disk or tape, by facsimile, verbally, or by telephone, or by written or visual or any other means.

The term “analysis” as used herein refers to any scientific, medical, or general use of the tissue microarray and/or the database for the purpose of obtaining information or data, including tissue identification data. This term is intended to cover any of the techniques disclosed in this application. Likewise, as scientific techniques are under constant refinement, it also comprehends the use of other manipulations or experimentation that involve the investigation of nucleic acids or proteins of the tissues on the tissue microarray.

As defined herein, “an individual” is a single organism and includes humans, animals, plants, multicellular and unicellular organisms.

“High throughput techniques” are techniques that evaluate large numbers (at least 10) of samples at a single time.

As used herein, a “correlation” refers to a statistically significant relationship using routine statistical methods known in the art. For example, in one aspect, statistical significance of a correlation is determined using a Student’s unpaired t-test, considering differences as statistically significant at $p < 0.05$.

As used herein, a “diagnostic probe” is probe whose reactivity with a sample provides an indication of the presence or absence of a diagnostic trait. In one aspect, a probe is considered to be diagnostic if it binds to a diseased cell and/or cells in at least about 80% of a plurality of samples comprising diseased cells (“disease samples”) and binds to less than 10% of non-disease cell(s). Preferably, the probe binds to at least about 90% or at least about 80% of disease samples and binds to less than about 5% or less than about 1% of non-disease samples.

Microarrays

The microarrays according to the invention comprise a plurality of sublocations, each sublocation comprising a cell or tissue sample having at least one known biological characteristic (e.g., such as cell or tissue type) which is stably associated with a substrate at the sublocation. In a preferred aspect of the invention, the plurality of sublocations comprise cancerous tissue at different neoplastic stages. The sublocations are distinct from each other in that they are separated by regions of substrate with no sample stably associated therewith.

Substrates

The substrate facilitates handling of the microarray through a variety of molecular procedures. In one aspect of the invention, the microarray substrate is solvent resistant. In another aspect of the invention, the substrate is transparent. In still another aspect of the invention, the microarray substrate comprises any of: glass; quartz; fused silica; or other nonporous substrate; plastic, such as polyolefin, polyamide, polyacrylamide, polyester, polyacrylic ester, polycarbonate, polytetrafluoroethylene, polyvinyl acetate, and/or can comprise a plastic composition containing fillers (such as glass fillers), extenders, stabilizers, and/or antioxidants; celluloid, cellophane or urea formaldehyde resins, or other synthetic resins such as cellulose acetate ethylcellulose, or other transparent polymer.

In one aspect, the microarray substrate is rigid; however, in another aspect, the substrate is semi-rigid or flexible (e.g., a flexible plastic comprising polycarbonate, cellular acetate, polyvinyl chloride, and the like). In a further aspect, the substrate is optically opaque and substantially non-fluorescent. Nylon or nitrocellulose membranes also can be used as substrates and can include materials such as polycarbonate, polyvinylidene fluoride (PVDF), polysulfone, mixed esters of cellulose and nitrocellulose, and the like.

The size and shape of the substrate may generally be varied. However, preferably, the substrate fits entirely on the stage of a microscope. In one aspect, the substrate is planar. In another aspect, the substrate is about 1 inch by 3 inches, 77 x 50 mm, or 22 x 50 mm. In a further aspect of the invention, the microarray substrate is at least about 10-200 mm x 10-200 mm.

As shown in Figure 2B, the substrate also can be configured as a profile array substrate designed to accommodate a control microarray (a microarray comprising cell and/or tissue samples for which at least one biological characteristic being assayed for is known) and a test sample for comparison with the control microarray. Profile array substrates generally comprise a first location for placing a test sample and a second location comprising the microarray. In this aspect, the first location is for placing a test tissue sample while the second sublocation comprises the microarray. The profile array substrate allows testing of a test tissue sample to be done simultaneously with the testing of samples on the control microarray allowing for a side-by-side comparison of biological characteristics of the test sample with the characteristics of the cells/tissues in the microarray.

Additional Features of the Substrate

In one aspect of the invention, the substrate comprises a location for placing an identifier (e.g., a wax pencil or crayon mark, an etched mark, a label, a bar code, a microchip for transmitting radio or electronic signals, and the like) which provides a user of the microarray with access to a specimen-linked database comprising information relating to one or more samples (and preferably, all) of the microarray. Where the identifier is microchip, the microchip communicates with a processor which comprises or can access the specimen-linked database.

Sublocations

Each sublocation of the microarray comprises cell(s) or a tissue sample stably associated therewith. In one aspect, the cells/tissue have morphological features substantially intact which can

be at least viewed under a microscope to distinguish subcellular features (e.g., such as a nucleus, an intact cell membrane, organelles, and/or other cytological features), i.e., the sample is not lysed (see, as shown in Figure 3).

In one aspect of the invention, the microarray comprises from about 2-1000 sublocations. In another aspect, the microarray comprises about 2 sublocations, about 5 sublocations, about 10 sublocations, about 20 sublocations, about 25 sublocations, about 30 sublocations, about 45 sublocations, about 50 sublocations, about 55 sublocations, about 60 sublocations, about 65 sublocations, about 75 sublocations, about 100 sublocations, about 150 sublocations, about 200 sublocations, about 250 sublocations, or about 500 sublocations, about 550 sublocations, about 600 sublocations, about 650 sublocations, about 700 sublocations, about 750 sublocations, about 800 sublocations, about 850 sublocations, about 900 sublocations, about 950 sublocations, or about 1000 sublocations. In one aspect of the invention, each sublocation is from about 2-10 mm apart. In another aspect of the invention, each sublocation comprises at least one dimension which is about 0.3 μ m-20 mm. The sublocations can be organized in any pattern, and each sublocation can be generally any shape (square, circular, oval, elliptical, disc-shaped, rectangular, triangular, and the like).

In a preferred aspect, the sublocations are positioned in a regular repeating pattern (e.g., rows and columns) such that the identification of each sublocation as to cell/tissue type can be ascertained by the use of an array locator (as shown in Figure 2D). In one aspect, the array locator is a template having a plurality of shapes, each shape corresponding to the shape of each sublocation in the array and maintaining the same relationships as each sublocation on the array. The array locator is marked by coordinate, allowing the user to readily identify a sublocation on the array by virtue of unique coordinates. In one aspect of the invention, the array locator is a transparent sheet (e.g., plastic, acetate, and the like). In another aspect of the invention, the array locator is a sheet comprising a plurality of holes, each hole corresponding in shape and location to each sublocation on the array.

Oncology Microarrays

In a preferred aspect of the invention, a plurality of sublocations on the microarray comprise abnormally proliferating cells. In one aspect, the sublocations comprise one or more of: cells from a brain tumor, pituitary tumor, cancerous eye tissue (e.g., a retinoblastoma), cancerous tongue tissue,

cancerous tracheal tissue, cancerous esophageal tissue, liver tumor, spleen tumor, a lymphoma, cancerous testicular or prostate tissue, cancerous cervical tissue, cancerous uterine tissue, cancerous bladder tissue, cancerous kidney tissue, cancerous thyroid, cancerous colon tissue, cancerous pancreatic tissue, cancerous skin tissue, cancerous breast tissue, cancerous stomach tissue. The microarray also can include cells from adenomas and sarcomas from various tissues.

In one aspect of the invention, each sublocation comprises the same cell or tissue type, to form a brain tumor array, a pituitary tumor array, a retinoblastoma array, cancerous tongue array, cancerous tracheal tissue array, cancerous esophageal tissue array, liver tumor array, cancerous spleen tissue array, lymphoma array, cancerous testicular tissue array, cancerous cervical tissue array, cancerous uterine tissue array, cancerous kidney tissue array, cancerous bladder tissue array, cancerous thyroid tissue array, cancerous prostate tissue array, cancerous colon tissue array, cancerous pancreas tissue array, cancerous breast tissue array, and cancerous stomach tissue array. Preferably, for each type of cancerous tissue in the microarray there is at least one noncancerous cell or tissue of the same type.

In one aspect of the invention, the microarray comprises at least one sublocation comprising cancerous cells including, but not limited to, breast ductal carcinoma, bladder carcinoma, leiomyoma, meningioma, melanoma, melanoma with a Clark score of 1-5 with nevus, seminoma, lymphoma, and colon adenocarcinoma, and any of the cancer types listed above.

In another aspect of the invention, the microarray comprises at least two sublocations comprising cells from different tissues. In one aspect of the invention, at least 50% of the sublocations in the microarray comprise cells from different tissues. In still a further aspect of the invention, at least 60%, 70%, 80%, 90%, or 100% of the array comprises cells from different tissues. Preferably, these different tissues are from the same patient.

In another aspect of the invention, the microarray comprises a plurality of sublocations, and at least one sublocation comprises at least about one, at least about five, at least about ten, substantially duplicate sublocations (e.g., comprising cells from the same tissue, and/or from the same representative area of a donor sample, as described further below).

In still another aspect, an oncology microarray is provided comprising at least about 10, at least 20, at least 30, at least 40, at least 50, at least 100, at least 150, or at least 200 different tumor types.

In another aspect of the invention, at least one sublocation comprises cells from an individual with an enhanced cancer susceptibility (e.g., there is a family history of cancer or the patient has had cancer previously or has been or is being exposed to carcinogen(s)).

In a further aspect of the invention, the microarray comprises at least one sublocation comprising cells or tissue from an individual with a disease other than cancer or in addition to cancer (e.g., including, but not limited to: a blood disorder, blood lipid disease, autoimmune disease, bone or joint disorder, a cardiovascular disorder, respiratory disease, endocrine disorder, immune disorder, infectious disease, muscle wasting and whole body wasting disorder, neurological disorder, skin disorder, kidney disease caused by excessive fibrosis, scleroderma, stroke, hereditary hemorrhage telangiectasia, disorders associated with diabetes, hypertension, diabetes, manic depression, depression, borderline personality disorder, anxiety, schizophrenia, Gaucher disease, cystic fibrosis and sickle cell anemia, and the like). For further discussion of human genetic diseases, see *Mendelian Inheritance in Man: A Catalog of Human Genes and Genetic Disorders* by Victor A. McKusick (12th Edition (3 volume set) June 1998, Johns Hopkins University Press, ISBN: 0801857422), the entirety of which is incorporated herein.

Samples at individual sublocations of the microarrays also can be obtained from individuals exposed to the same environmental conditions (past or ongoing). For example, samples from patients exposed to carcinogens (known or suspected), pollutants, asbestos, and other agents also can be arrayed.

In a different aspect, a microarray is provided comprising cells from a plurality of individuals who have all died from the same pathology or from individuals being treated with the same drug (including those who recovered from the disease and/or those who did not).

In still a further aspect, samples can be obtained from patients comprising substantially the same molecular profile (e.g., expression of RNA and/or protein) with respect to one or more genes or sets of genes.

In a further aspect of the invention, each sublocation of the microarray comprises cells from different members of a pedigree sharing a family history of cancer (e.g., selected from the group consisting of sibs, twins, cousins, mothers, fathers, grandmothers, grandfathers, uncles, aunts, and the like). In another aspect of the invention, the "pedigree microarray" comprises environment-matched controls (e.g., husbands, wives, adopted children, stepparents, and the like). In still a

further aspect of the invention, the microarray is a reflection of a plurality of traits representing a particular patient demographic group of interest, e.g., overweight smokers, diabetics with peripheral vascular disease, individuals having a particular predisposition to disease (e.g., sickle cell anemia, Tay Sachs, severe combined immunodeficiency), where individuals in each group have cancer.

5 In another aspect, an oncology microarray is provided comprising at least one sublocation comprising cells from a cell line of cancerous cells. In one aspect of the invention, the cell line is a continuous cell line, while in another aspect, the cells are from primary cell cultures.

10 In a further aspect, the oncology microarray comprises substantially homogeneous cells expressing a cancer-specific marker. As used herein, "substantially homogeneous" refers to cells which comprise at least about 80% of cells of a given cell type, preferably at least about 90%, at least about 95%, or at least about 100% of cells of a given cell type. Substantially homogeneous cells can be obtained using methods known in the art, such as by flow sorting, panning, magnetic sorting or by using some other affinity-based technique (i.e., relying on antibodies which recognize specific cell types), density gradient centrifugation, cloning (e.g., by limiting dilution), by synchronization, by induction (e.g., by using an agent such as Fas, Apol-2L, by exposing cells expressing a GPCR to its cognate ligand, by exposing cells to chemokines, cytokines, neurotransmitters, adhesion molecules, or by exposing the cells to chemical agents such as forbol esters), and the like. It should be obvious to those of skill in the art that combinations of these methods and other additional methods of sorting cells can be used.

20 In another aspect, an oncology microarray is provided comprising cells genetically engineered to proliferate abnormally. For example, cells can be genetically engineered to express cell proliferation genes, or to lack tumor suppressor genes, or to express modified forms of such genes. In this aspect, cells may stably or transiently transfected cell lines, or genetically engineered tumors (e.g., such as tumors infected with a recombinant retroviral vector).

25 Although in one aspect, at least some of the sublocations on the microarrays comprise substantially homogeneous cells, in other aspects, sublocations comprise cells from cancerous tissue which are selected from at least about two of the group consisting of neoplastic cells, fibrous tissue, inflammatory tissue, necrotic cells, apoptotic cells, normal cells, and combinations thereof. In one aspect, each sublocation on the microarray comprising neoplastic cells comprises at least one of:
30 fibrous tissue, inflammatory tissue, necrotic cells and apoptotic cells.

Although in a preferred aspect of the invention, the microarrays comprise human tissues, in one aspect of the invention, abnormally proliferating tissues from other organisms are arrayed. For example, the microarrays can comprise tissues from mice which have either spontaneously developed cancer or which have received transplants of tumor cells. Preferably, the microarray comprises multiple tissues from such mice (e.g., at least about five).

In another aspect of the invention, the microarray comprises tissues from mice which have spontaneously developed cancer or which have received transplants of tumor cells, and which have been treated with a cancer therapy (e.g., drugs, antibodies, protein therapies, gene therapies, antisense therapies, and the like).

In still a further aspect of the invention, tissues from a mouse genetically engineered to over express or under express cell proliferation genes or tumor suppressor genes are provided. In one aspect, a microarray is provided comprising tissues from mice expressing different doses of the same cell proliferation gene or tumor suppressor gene.

Staged Oncology Microarrays

In one aspect of the invention, an oncology microarray is provided comprising a plurality of sublocations which represent different stages of cell proliferation disorder. The microarray can include metastases to tissues other than the primary cancer site. Preferably, the microarray comprises normal tissues from the same patient from whom abnormally proliferating cell and/or tissue samples were derived.

Staging of a Tissue Sample

The inappropriate new growth of cells is neoplasia, and the masses resulting from such inappropriate new growth are termed "neoplasms". A neoplasm may be either benign or malignant, and the term "cancer" is applied generally to any malignant neoplasm. The term "tumor" originally applied to any neoplasm, benign or malignant. However, in common usage and herein, "tumor" refers to a malignant neoplasm, as does the term "cancer".

The discrimination between malignant and benign neoplasms is made on the basis of the differentiation status of the neoplastic cells, their rate of growth, local invasion of tissues and metastasis. Benign neoplasms are generally well differentiated, closely resembling the corresponding normal tissue both morphologically and functionally, while malignant tumors may be

either well differentiated or poorly differentiated. The lack of differentiation, or anaplasia, that is characteristic of many, but not all, malignant cells is evidenced by changes in the size and shape of the cells themselves, and often by changes in the appearance of the cell nuclei. Anaplastic cells are often larger or smaller than normal cells of the same tissue, and tend to be irregularly shaped. The nuclei of anaplastic cells may also be larger than in normal cells, irregularly shaped, and hyperchromatic.

Benign neoplasms generally have a lower rate of growth than malignant tumors, growing steadily over a period of years or even decades, while malignant tumors tend to grow rapidly and erratically. This generalization is not absolute, however. Some benign tumors can grow more rapidly than some malignant tumors, and benign tumor growth can also be erratic. Generally, growth rate correlates well with differentiation status; poorly differentiated neoplasms tend to have higher growth rates.

Benign neoplasms almost always grow as defined cohesive masses confined to the tissue of origin. A benign neoplasm most often has a layer of connective tissue or capsule largely separating it from surrounding tissues, while malignant tumors tend to lack such defining boundaries.

The most clearly defining difference between benign neoplasms and malignant tumors is the ability of malignant tumors to metastasize or invade tissues other than the tissue of origin. Benign tumors do not have the capacity to metastasize. Invasive tumors have gained the ability to penetrate blood vessels, lymphatic ducts and barriers such as the peritoneum. Tumor cells that have penetrated such a barrier are capable of seeding new tumors at sites distant from the tissue of origin.

One of skill in the art (e.g., a pathologist) can generally determine whether a given neoplasm is benign or malignant by examining the morphology of cells in a tissue sample. It is not possible, however, on the basis of morphology alone, to reliably predict the likelihood that a given tumor will metastasize. Tumors are classified in the art according to grade and stage of the disease, factors that are more useful in predicting disease progression.

Tumor grade is a classification of the degree of differentiation of cells in a tumor. Following diagnosis of cancer on the basis of cell morphology in a biopsy, a tumor is graded with regard to the degree of differentiation in order to begin the process of deciding which treatment options to implement and predicting the outcome of such treatment. The American Joint Commission on Cancer recommends a four tiered tumor grading system, with Grades 1-4. Grade 1 (G1) refers to a

well-differentiated tumor, and is often referred to as “low grade”. Grade 2 (G2) refers to a moderately well-differentiated tumor, and is often referred to as “intermediate grade”. Grade 3 (G3) refers to a poorly differentiated tumor which is often referred to as “high grade”, and Grade 4 (G4) refers to an undifferentiated tumor, also referred to as “high grade”. Grades 1 and 2 are generally considered the least aggressive (less likely to invade or metastasize), while grades 3 and 4 are considered the most aggressive.

The classification system recommended by the American Joint Commission on Cancer is widely used by pathologists, but particularly for certain types of cancers, such as soft tissue sarcomas, primary brain tumors, lymphomas, and breast cancer. Other types of cancers are graded using different scales specific to those types of cancer.

The stage of a tumor is determined by considering all available information regarding a patient’s tumor relative to what is known about the impact of each particular variable on the patient’s prognosis. One accepted staging system is the TNM system (Tumor, Nodes, Metastasis), recommended by the American Joint Commission on Cancer and the International Union Against Cancer. In this system, also referred to as the International Classification System, a number from 0 to 4, describing the tumor’s size and spread to adjacent tissues, is assigned for T. A number for N from 0 to 3 is assigned to indicate whether and to what extent the cancer has spread to adjacent lymph nodes, and a number for M (0 or 1) is assigned to indicate the presence of distant metastases. The total TNM score is used to place the tumor into a stage group with a corresponding likely prognosis. For each type of tumor, the higher the stage number, the worse the prognosis. The TNM stage for a given tumor can signify the presence of different groups of indicators, depending on the tissue involved. Examples are given below.

In the TNM system applied to renal cell cancer, for example, stages 1-4 mean the following:

Stage 1: Tumors are less than 2.5 cm, show no evidence of local invasion, no lymph node involvement and no distant metastases.

Stage 2: Tumors are larger than 2.5 cm, show no evidence of local invasion, no lymph node involvement and no distant metastases.

Stage 3: Tumors of any size showing involvement of at least one lymph node, tumors that invade the adrenal gland or surrounding renal tissues, or tumors that invade the renal vein or the inferior vena cava.

Stage 4: Tumors of any size that invade adjacent structures or have evidence of distant metastasis, or any tumor where more than one lymph node is involved.

The standards for determining various TNM stages of cervical carcinoma and endometrial cancer are defined by the Federation Internationale de Gynecologie et d'Obstetrique (FIGO); (Shepherd, 1996, *Brit. J. Obst. Gyn.* 103: 405-406; Creasman, 1995, *Gynecol. Oncol.* 58: 157-158). Guidelines for cancer staging for other tumor types are provided by the American Joint Committee on Cancer (*AJCC Cancer Staging Manual*, 1997, Lippincott-Raven Publishers, 5th Ed., Philadelphia, PA, pp. 189-194).

Generally, the American Joint Commission on Cancer grading system is useful in the absence of a more specialized grading system for a given type of tumor. Other more specialized grading systems are known to those skilled in the art. The grade of a tumor is but one indicator of prognosis. The process of tumor staging factors the tumor grade for a given tumor along with other prognostic indicia in order to more accurately provide prognostic information. In the methods of the invention, the tumor grade and tumor stage may be used to arrange the samples of a tissue array in order of increasing or decreasing prognosis.

It should be obvious to those of skill in the art that grading systems evolve and that the examples discussed above are non-limiting.

In addition to formal grading schemes, cytogenetic, immunohistochemical and enzymatic function tests may be performed to identify other risk factors or to obtain a molecular profile that is diagnostic and/or prognostic of cancer and/or cancer progression. Taking breast cancer as an example, the expression or altered expression of estrogen receptors, HER2/neu, mutant or wild-type p53, and EGF receptor may be considered in the analysis of tumor prognosis.

Breast Cancer Progression Microarrays

For *in situ* breast cancers (e.g., ductal carcinoma *in situ*), grades are assigned on the appearance of their cell nuclei (nuclear grade) and the presence or absence of necrosis. The Van Nuys Prognostic Index considers these two factors along with information regarding the distance of the tumor from the edge of the lumpectomy specimen and the size of the tumor to estimate prognosis (Silverstein & Lagios, 1997, *Oncology* 11: 393-410).

Breast cancer is graded on the Bloom-Richardson scale, sometimes referred to as the Scharrf-Bloom-Richardson scale or Elston-Ellis scale (see Elston & Ellis, 1991, *Histopathology* 19: 403-410; Frierson et al., 1994, *Am. J. Clin. Pathol.* 102 (Suppl 1): S3-S8; and Dalton et al., 1994, *Cancer* 73: 2765-2770). This scheme and those related to it also categorize tumors according to their similarity to the normal tissue architecture. Tubule formation, nuclear pleomorphism and mitotic activity are factored into the scores under this scheme. For invasive cancers, Grade 1 tumors have relatively normal looking cells that are arranged in small tubules. Grade 3 tumors do not have recognizable tubule structures, and Grade 2 tumors are in between (i.e., some tubule structure evident, but poorly organized).

In one aspect, the microarray comprises a plurality of tissues representative of disease progression in breast cancer. Tissues can be selected from the group consisting of normal breast tissue, ductal carcinoma *in situ*, invasive ductal breast cancer (grade 1), invasive ductal breast cancer (grade 2), invasive ductal breast cancer (grade 3), lymph node metastases from the same any of: ductal carcinoma in situ, invasive ductal breast cancer (grade 1), invasive ductal breast cancer (grade 2), invasive ductal breast cancer (grade 3). In a further aspect of the invention, the at least one control tissue selected from the group comprising of brain, heart, liver, spleen, muscle, lymph node, testis, kidney, thyroid, adrenal gland and prostate, but at least normal breast tissue, is provided on the same or a different microarray. In another aspect of the invention, the sublocations represent Grade I T1N0M0, Grade II T2N1M0, Grade III T3N2M1, Grade IV T3N2M2 tissue samples, Grade HER-2/neu+, ER/PR+, and Breast ER/PR- (grading according to the World Health Organization).

Figure 2A shows an example of a breast cancer progression micorarray which is part of a profile array substrate. Figure 2C shows six different tissue specimens representing different stages of breast cancer stained with a CK7 antibody. As shown in Figure 2D, cancer progression microarrays are preferably provided with along with access to information relating to patients from whom tissue samples on the array were obtained. The information may be written, as shown in Figure 2D; however, preferably, the microarrays are provided in kits comprising microarray identifiers which can be used to access a specimen-linked database comprising patient information indexed according to the position of a specimen on a particular microarray. A sample of data obtained from a plurality of breast cancer progression arrays is provided in the attached Appendix.

Prostate Cancer Progression Microarray

Prostate cancer typically is classified according to the “Gleason grading system” (see D.F. Gleason, “The Veteran’s Administration Cooperative Urologic Research Group: Histologic grading and clinical staging of prostatic carcinoma.” in M. Tannenbaum (ed.) *Urologic Pathology: The Prostate*. Lea & Febiger, Philadelphia, 1977, pp. 171-198). In the Gleason grading system, there are 5 grades, with grade 5 being the worst with regard to prognosis:

Grade 1 is well-differentiated, closely resembling the normal prostate. Grade 1 prostate cancer are characterized by pale-staining (hematoxylin/eosin stain) glands that grow closely together in a compact mass.

Grade 2 is also well differentiated and has pale-staining glands, but they are more loosely aggregated than Grade 1 cells and tend to invade the surrounding muscle.

Grade 3 is also considered well-differentiated, since it retains a “gland unit” as seen in the normal prostate. The gland unit has a well defined lumen, and each gland unit in Grade 3 tumors is surrounded by prostate muscle, which keeps the gland units separated. However, Grade 3 has extensive invasion of glands into the surrounding muscle. Cells of Grade 3 tumors also stain more darkly and are of variable shapes. Grade 3 is the most common grade seen.

Grade 4 is considered poorly differentiated, and is characterized by the disruption of the normal gland unit. Grade 4 tumors will still have evidence of lumen formation, but the gland units are not clearly distinct, such that the lumens are not separate.

Grade 5 is considered undifferentiated. Grade 5 prostate tumors show no evidence of an attempt to form gland units.

The most important aspect of the Gleason grading system is that it does not stop after the assignment of one grade. In the Gleason system, a pathologist always tries to identify two characteristic patterns and assign a Gleason grade reflecting each one. That is, in a given biopsy, there may be a primary pattern that fits one grade, and a secondary pattern that fits another grade. Rather than setting the grade at the pattern that is most prevalent in a tissue sample, the pathologist assigns grades fitting the two most prevalent patterns. The combination of two grades, known as the “Gleason sum”, was found in Dr. Gleason’s original study of 2,900 men to provide a more accurate

prognosis estimate than a grade based on a single architectural pattern. In the Gleason system then, the lowest possible score is 2 (only a pattern fitting grade 1 is evident, $1+1=2$), and the highest is 10 (only a pattern fitting grade 5 is evident, $5+5=10$). Intermediate scores of 7 may result, for example from a sample in which the prevalent pattern fits grade 4 and the minor pattern fits grade 3.

- 5 Generally, the lower the Gleason score, the better the prognosis for the patient. In addition to the Gleason score, a physician will want to consider other elements in their analysis of prognosis, including, for example, PSA (prostate serum antigen) level and the clinical stage of disease (see below).

10 Therefore, in one aspect, a microarray is provided which comprises a plurality of cells representative of disease progression in prostate cancer, including sublocations which represent Gleason Grades 1-10, or 1-6, 4-10, and/or 6-10, and including a standard control section, comprising one or more of brain, heart, liver, spleen, muscle, lymph node, testis, kidney, thyroid, adrenal gland and prostate cells/tissue, but at least prostate cells/tissue.

Colon Cancer Progression Microarray

15 In another aspect, a microarray is provided comprising a plurality of cells representative of disease progression in colorectal cancer. In one aspect, the microarray comprises normal colon mucosa from patients having no history of colorectal cancer and cancerous colon mucosa, preferably from the same patients. Additional samples can include: adenoma with mild dysplasia, adenoma with severe dysplasia, nodal negative colorectal cancer, nodal positive colorectal cancer, paired
20 metastases (e.g., such as lymph node metastases from tumors). Preferably, a standard control section, comprising one or more of brain, heart, liver, spleen, muscle, lymph node, testis, kidney, thyroid, adrenal gland and prostate is provided on the same or a different microarray. In another aspect of the invention, the colon cancer progression microarray comprises at least cells from tumors representing the Colonic 4 Dukes' stages: A, tumor within the intestinal mucosa; B, tumor into
25 muscularis mucosa; C, metastasis to lymph nodes and D, metastasis to other tissues.

Lung Cancer Progression Microarray

In a further aspect, a microarray is provided comprising a plurality of cells representative of disease progression in lung cancer. In one aspect, the microarray comprises normal lung
30 parenchyma, normal bronchi, adenocarcinoma (different subtypes), squamous cell carcinoma, undifferentiated large cell carcinoma, small cell carcinoma, lymph node metastases from tumors

included in this microarray (paired metastases). As above, standard control sections, comprising at least one of brain, heart, liver, spleen, muscle, lymph node, testis, kidney, thyroid, adrenal gland and prostate, can be provided on the same or a different microarray.

Sources of Tissue

5 In one aspect, the cells/tissues at individual sublocations are from cadavers, from autopsies, from surgical specimens, pathology specimens, or represent "clinical waste" that would normally be discarded from other procedures. In addition to tissue sections, microarrays can also include cells from body fluids such as serum, leukapheresis products, pleural effusions, urine (e.g., where the patient has bladder cancer) and the like.

10 In one aspect of the invention, cell culture lines are used as sources of cancer cells for at least one location. Cell lines can be developed from isolated cancer cells and immortalized with oncogenic viruses (e.g., Epstein Barr Virus).

Exemplary cell lines which can be used in this aspect, include, but are not limited to those listed below:

Tumor Cell Line	Source	ATCC No.	Normal Cells from the Same Patient	ATCC No.
carcinoma; non-small cell lung cancer	lung	CCL-256	peripheral blood	CCL-256.1
adenocarcinoma	lung	CRL-5868	peripheral blood	CRL-5957
adenocarcinoma	lung	CRL-5872	peripheral blood	CRL-5958
adenocarcinoma	lung	CRL-5882	peripheral blood	CRL-5954
adenocarcinoma	lung	CRL-5911	peripheral blood	CRL-5961
adenocarcinoma	pleural effusion	CRL-5985	peripheral blood	CRL-5967
adenocarcinoma	lymph node (metastasis)	CRL-5922	peripheral blood	CRL-5965
carcinoma; classic small cell lung cancer	lung	CRL-5886	peripheral blood	CRL-5959
carcinoma; small cell lung cancer	lung	CRL-5929	peripheral blood	CRL-5969
carcinoma; small cell lung cancer	lung	CRL-5931	peripheral blood	CRL-5956
carcinoma; small cell lung cancer	lymph node (metastasis)	CRL-5858	peripheral blood	CRL-5949
carcinoma; small cell lung cancer	bone marrow (metastasis)	HTB-172	peripheral blood	CRL-5948

carcinoma; small cell lung cancer	bone marrow (metastasis)	<u>CRL-5983</u>	peripheral blood	<u>CRL-5966</u>
carcinoma; small cell lung cancer	pleural effusion	<u>HTB-120</u>	peripheral blood	<u>CRL-5947</u>
mesothelioma	pleural effusion	<u>CRL-5915</u>	peripheral blood	<u>CRL-5963</u>
neuroendocrine carcinoma	lymph node (metastasis)	<u>CRL-5893</u>	peripheral blood	<u>CRL-5960</u>
ductal carcinoma	mammary gland; breast	<u>HTB-126</u>	mammary gland; breast	<u>HTB-125</u>
ductal carcinoma	mammary gland; breast	<u>CRL-2320</u>	peripheral blood	<u>CRL-2319</u>
ductal carcinoma	mammary gland; breast	<u>CRL-2338</u>	peripheral blood	<u>CRL-2339</u>
primary ductal carcinoma	mammary gland; breast	<u>CRL-2314</u>	peripheral blood	<u>CRL-2346</u>
primary ductal carcinoma	mammary gland; breast	<u>CRL-2321</u>	peripheral blood	<u>CRL-2362</u>
primary ductal carcinoma	mammary gland; breast	<u>CRL-2322</u>	peripheral blood	<u>CRL-2323</u>
primary ductal carcinoma	mammary gland; breast	<u>CRL-2324</u>	peripheral blood	<u>CRL-2325</u>
primary ductal carcinoma	mammary gland; breast	<u>CRL-2331</u>	peripheral blood	<u>CRL-2332</u>
Tumor Cell Line	Source	ATCC No.	Normal Cells from the Same Patient	ATCC No.
primary ductal carcinoma	mammary gland; breast	<u>CRL-2336</u>	peripheral blood	<u>CRL-2337</u>
primary ductal carcinoma	mammary gland; breast	<u>CRL-2340</u>	peripheral blood	<u>CRL-2341</u>
primary ductal carcinoma	mammary gland; breast	<u>CRL-2343</u>	peripheral blood	<u>CRL-2363</u>
ductal carcinoma	mammary gland; breast	<u>CRL-7345</u>	skin	<u>CRL-7346</u>
scirrhous adenocarcinoma	mammary gland; breast	<u>CRL-7482</u>	skin	<u>CRL-7481</u>
adenocarcinoma	mammary gland; breast	<u>CRL-7484</u>	skin	<u>CRL-7483</u>
cancer	mammary gland; breast	<u>CRL-7303</u>	skin	<u>CRL-7302</u>
cancer	mammary gland; breast	<u>CRL-7486</u>	skin	<u>CRL-7485</u>
carcinoma	mammary gland; breast	<u>CRL-7365</u>	skin	<u>CRL-7364</u>
carcinoma	mammary gland; breast	<u>CRL-7368</u>	skin	<u>CRL-7367</u>
carcinoma	mammary gland; breast	<u>CRL-7590</u>	skin	<u>CRL-7589</u>
malignant melanoma	skin	<u>CRL-1974</u>	peripheral blood	<u>CRL-1980</u>
basal cell carcinoma	skin	<u>CRL-7762</u>	skin	<u>CRL-7761</u>
malignant melanoma	skin	<u>CRL-7690</u>	skin	<u>CRL-7689</u>
melanoma	skin	<u>CRL-7357</u>	skin	<u>CRL-7356</u>

melanoma	skin	<u>CRL-7360</u>	skin	<u>CRL-7359</u>
pagetoid sarcoma	skin	<u>CRL-7677</u>	skin	<u>CRL-7676</u>
benign osteoid osteoma	bone	<u>CRL-7672</u>	skin	<u>CRL-7671</u>
giant cell sarcoma	bone	<u>CRL-7554</u>	skin	<u>CRL-7553</u>
heterophilic osteofication	bone	<u>CRL-7552</u>	skin	<u>CRL-7551</u>
osteosarcoma	bone	<u>CRL-7444</u>	skin	<u>CRL-7443</u>
osteosarcoma	bone	<u>CRL-7448</u>	skin	<u>CRL-7449</u>
osteosarcoma	bone	<u>CRL-7471</u>	skin	<u>CRL-7865</u>
osteosarcoma	bone	<u>CRL-7496</u>	skin	<u>CRL-7603</u>
osteosarcoma	bone	<u>CRL-7571</u>	skin	<u>CRL-7570</u>
osteosarcoma	bone	<u>CRL-7595</u>	skin	<u>CRL-7519</u>
osteosarcoma	bone	<u>CRL-7622</u>	lung	<u>CCL-211</u>
osteosarcoma	bone	<u>CRL-7626</u>	skin	<u>CRL-7625</u>
osteosarcoma	bone	<u>CRL-7628</u>	skin	<u>CRL-7627</u>
periostitis; granuloma	bone	<u>CRL-7453</u>	skin	<u>CRL-7452</u>
fibrosarcoma	connective tissue	<u>CRL-7663</u>	skin	<u>CRL-7662</u>
Tumor Cell Line	Source	ATCC No.	Normal Cells from the Same Patient	ATCC No.
fibrosarcoma	connective tissue	<u>CRL-7664</u>	skin	<u>CRL-7662</u>
fibrosarcoma	connective tissue	<u>CRL-7665</u>	skin	<u>CRL-7662</u>
fibrosarcoma	connective tissue	<u>CRL-7666</u>	skin	<u>CRL-7662</u>
fibrosarcoma	connective tissue	<u>CRL-7668</u>	skin	<u>CRL-7662</u>
adenocarcinoma	unknown	<u>CRL-7432</u>	skin	<u>CRL-7431</u>
transitional cell carcinoma	ureter	<u>CRL-7886</u>	skin	<u>CRL-7518</u>
giant cell sarcoma	vertebral column	<u>CRL-7547</u>	skin	<u>CRL-7546</u>

In a further aspect, the cell lines used are primary cell lines, including, but not limited to: colorectal adenocarcinoma (ATCC No. CCL-228); and gastric adenocarcinoma from the stomach (ATCC No. CRL-1864); and melanoma (ATCC No. CRL-1675, CRL-7425). In still a further aspect of the invention, the cell lines are obtained from a metastatic cancer, including but not limited to: lymph node (ATCC No. CCL-227, CRL-7426). Additional cell lines can be obtained through the American Tissue Type Culture collection (www.atcc.org), which have been developed or characterized at the NCI-Navy Medical Oncology Branch. Cell lines within this collection are catalogued in a database (NCI-Navy Cell Line database) which provides information regarding the

patient from whom the cell line is derived (see, e.g. *Journal of Cellular Biochemistry Supplement* 24: 32-91, 1996, the entirety of which is incorporated by reference herein).

In one aspect, sample tissues are selected from an oncology repository or a collection of tissue specimens that represent the most common neoplastic diseases. These include, but are not

5 limited to:

Specimen	Disease Type
prostate	BPH: adenocarcinoma
breast	benign and metastatic, DCIS, stage I-IV
colon	adenoma, adenocarcinoma
brain	cerebellar hemangiomas, gliomas
ovary	ovarian cancer
cervix	cervical cancer, dysplastic, CIN
lung	adenocarcinoma, small cell carcinoma
hepatic	hepatocellular carcinoma
bladder	transitional carcinoma
thyroid	medullary carcinoma
adrenal	adrenal carcinoma
parathyroid	parathyroid tumors
pancreas	pancreatic cancer, islet cell tumors
soft tissue	Ewing sarcoma
integumentary	malignant melanoma, benign nevi

In one aspect, the microarray comprises at least one sublocation comprising a disease tissue selected from the repository listed above and at least one sublocation comprising a normal tissue, either from the same specimen from which the disease tissue was obtained, or from a normal specimen of the same tissue type (e.g., if the disease tissue is lung, normal lung tissue is selected).

10 In a preferred aspect of the invention, sets of sublocations (e.g., two or more) comprise tissues of the same type but different disease stages.

Tissues are also obtainable from the National Cancer Institute Cooperative Human Tissue Network (<http://www.chtn.ims.nci.nih.gov/>).

In another aspect, the sublocations are selected from a repository representing cell proliferative disorders affecting women.

Specimen	Disease Types
breast	pagets, cancer, benign disease
uterus	endometriosis
cervix	dysplasia, HPV, cancer
ovaries	diseased, including cancer
fallopian tubes	diseased, including cancer

In one aspect, the microarray comprises at least one sublocation comprising a disease tissue selected from the repository listed above and at least one sublocation comprising a normal tissue, either from the same specimen from which the disease tissue obtained, or from a normal specimen of the same tissue type from which the disease tissue is obtained. In another aspect of the invention, sets of sublocations (e.g., two or more) comprise tissues of the same type but representing different disease stages.

In another aspect of the invention, sublocations are selected from a repository of endocrine tissue specimens from patients having cell proliferative disorders:

Specimen	Disease Types
thyroid	hyper and hypo thyroidism
parathyroid	cancer, adenoma
adrenals	adenoma, cancer
pancreas	diabetes, islet cell tumors
breast	hyperplasia, tumor
ovary	benign cancer
bone	estrogen replacement, osteoporosis
prostate	bph, cancer

In one aspect, the microarray comprises at least one sublocation comprising a disease tissue selected from the endocrine tissue repository listed above and at least one sublocation comprising a normal tissue, either from the same specimen from which the disease tissue was obtained, or from a normal specimen of the same tissue type. In another aspect of the invention, sets of sublocations (e.g., two or more) comprise tissues of the same type but representing different disease stages.

As discussed above, normal cell/tissue samples can be provided on the same or different microarrays as those comprising abnormally proliferating cells. In one aspect of the invention, normal cells/tissues are selected from the group consisting of cerebrum, cerebellum, heart, lung, thyroid gland, adrenal gland, skin, parotis, pancreas, stomach (corpus), stomach (antrum), small intestine, colon, liver, gall bladder, tonsil, spleen, lymph node, endometrium, (proliferation), endometrium(secretion), placenta (last trimenon), placenta (first trimenon), kidney, prostate, testis, epididymis, skeletal muscle, smooth muscle. Preferably, such an array comprises duplicate samples of a given cell/tissue type.

Construction of Microarrays

Preparing Donor Cell/Tissue Blocks

In one aspect of the invention, cells and/or tissues are obtained and either paraffin-embedded, plastic-embedded or frozen into blocks from which portions (donor samples) can be obtained. Frozen tissues preferably are obtained where non-fixed samples are desired (e.g., when detecting nucleic acids). When paraffin- or plastic-embedded, a variety of tissue fixation techniques may be used to preserve the morphology of cellular structures within the samples. Examples of fixatives, include, but are not limited to, aldehyde fixatives such as formaldehyde; formalin or formol; glyoxal; glutaraldehyde; hydroxyadipaldehyde; crotonaldehyde; methacrolein; acetaldehyde; malonaldehyde; malialdehyde; and succinaldehyde; chloral hydrate; diethylpyrocarbonate; alcohols such as methanol and ethanol; acetone; lead fixatives such as basic lead acetates and lead citrate; mercuric salts such as mercuric chloride; formaldehyde; dichromate fluids; chromates; picric acid, and heat. Tissues are fixed until they are sufficiently hard to embed. The type of fixative employed will be determined by the type of molecular procedure being used, e.g., where the molecular characteristic(s) being examined include the expression of nucleic acids, isopentane, or PVA, or another alcohol-based fixative is preferred.

Embedding medium encompassed within the scope of the invention, includes, but is not limited to, paraffin or other waxes, plastic, gelatin, agar, polyethylene glycols, polyvinyl alcohol, celloidin, nitrocelluloses, methyl and butyl methacrylate resins or epoxy resins. Water-insoluble embedding media such as paraffin and nitrocellulose require that specimens be dehydrated in several changes of solvent such as ethyl alcohol, acetone, xylene, toluene, benzene, petroleum, ether, chloroform, carbon tetrachloride, carbon bisulfide, and cedar oil. or isopropyl alcohol prior to

immersion in a solvent in which the embedding medium is soluble. Water soluble embedding media such as polyvinyl alcohol, carbowax (polyethylene glycols), gelatin, and agar, can also be used.

In one aspect, specimens are freeze-dried by deep freezing in plastic cassettes and storing them at -80- 70° C, such as in liquid nitrogen, forming frozen donor blocks. Preferably, the samples are then covered with a cryogenic media, such as OCT®, and kept at -80- 70° C, until sectioned. Examples of embedding media for frozen samples include, but are not limited to, OCT, Histoprep®, TBS, CRYO-Gel®, and gelatin, to name a few. In another aspect, a freezing aerosol may be used to facilitate embedding of the donor sample block. An example of a freezing aerosol is tetrafluoroethane 2.2.

Cell donor blocks (comprising one or more cells typically found non-adherent in an organism and/or comprising cells which have been purified to be substantially homogeneous) are generated by washing cells one or more times in a suitable buffer which does not lyse the cells. The cells are collected by centrifugation and resuspended in a fixative and after fixation are centrifuged again and resuspended in an embedding material, such as plastic or paraffin. Alternatively, where cells are resuspended in a fast-freezing embedding material such as OCT, no prior fixation step is needed. Preferably, cells in embedding material are transferred to a mold which as a support web or plastic block. The cells and embedding material also can be co-centrifuged prior to being enclosed. The generation of cell blocks is described in EP 408,225; U.S. Patent No. 4,822,495; U.S. Patent No. 5,137,710; U.S. Patent No. 5,817,032; and U.S. Patent No. 4,656,047, the entireties of which are incorporated by reference herein.

Other methods known in the art may also be used to facilitate embedding of a cell or tissue sample to form a donor block.

Preparing Microarray Blocks

Blocks for receiving donor cell/tissue samples or "recipient blocks" generally are formed by providing a suitable embedding material and coring one or more holes into the material after it has hardened. The holes are sized to receive a desired cell or tissue donor sample from the donor block and when holes in the recipient block are filled with a desired number of donor samples, a microarray block is formed.

Information regarding the coordinates of the hole and the identity of the tissue sample at that hole is recorded, effectively addressing each sublocation on microarrays generated by sectioning the microarray block and placing each section on a substrate (e.g., such as a glass slide).

In a preferred aspect of the present invention, the donor sample is obtained by boring an elongated sample core from the donor block and placing the core in a hole cored in a recipient block at substantially the same time.

In another aspect, the recipient block is prepared prior to obtaining specimens from donor block(s). For example, the recipient block can be prepared by placing a fast-freezing, cryo-embedding matrix in a container and freezing the matrix so as to create a solid, frozen block.

Freezing can be facilitated using tetrafluorethane 2.2, or by any other methods known in the art. The block can be cored as described above, in preparation for receiving samples, and stored until needed to generate a microarray block.

Holes in the recipient block can be of any shape and size, but preferably are made in a regular pattern. In one aspect of the invention, the holes are elongated in shape. In another aspect, the holes are cylindrical in shape. Preferably, holes are sized to receive a cylindrical donor sample of about 1-4 mm long with a diameter of about 0.1-4 mm, and preferably, from about 0.3-2.0 mm. More preferably, the cylinder diameter is less than about 1.0 mm, for example, about 0.6 mm.

The coring process may be automated using core needles coupled to a motor or some other source of electrical or mechanical power. In one aspect of the invention, a microarray block is generated using a Beecher Instruments Tissue Arrayer (Beecher Instruments, Silver Springs, MD). This device basically consists of a turret containing two hollow core borer needles mounted on a platform with a spring mechanism. A smaller needle removes a core from the recipient block while a larger needle removes a core of tissue from the donor tissue block and by means of a stylet. The stylet is inserted into the smaller needle thereby injecting the donor tissue core into the hole made in the recipient block.

In one aspect of the invention, the recipient block is a paraffin block and the donor block(s) are individual archival tissue blocks that have been assembled for a particular type of microarray. In this aspect, an empty recipient block is placed in a holder and is held in position by restraining element, for example, magnets built into the arrayer. In one aspect, the arraying process is started by setting a spacing mechanism for controlling the spacing between cores/sublocations and X-Y

coordinates, to zero. In one aspect, the arrayer comprises a first hollow needle and a second hollow needle, the first needle smaller being smaller than the second needle. A depth stop which controls the depth of the hole created by the first needle is set to a selected depth (e.g., 0.5-1.0 mm) and the smaller needle is pushed downward (e.g., by hand). When the depth stop blocks the downward
5 motion of the needle, the needle is rotated (e.g., 45 degrees), facilitating the retrieval of a paraffin core whose diameter is defined by the bore of the first needle from the block. Downward pressure is now released and the needle, by spring action, or through some other mechanical or electrical force, moves upward. A stylet is used to empty the first needle and the paraffin core is discarded, leaving a recipient block comprising at least one hollow core for receiving a tissue or cell sample.

10 In one aspect, after a hole is made by the needle, a holder for a block of embedded donor tissue (e.g., frozen tissue or paraffin-embedded tissue) is placed over the recipient block with the core, and the donor block is placed on top or the holder. In one aspect, the holder is in the form of a block bridge or table. The needle turret is rotated and a second needle, which is larger than the first needle in diameter, is placed in position. In one aspect, the second needle has an inside diameter of approximately 600µm.

In other aspects of the invention, particularly where it is desired to obtain frozen microarray blocks, a microarrayer such as the one described in U.S. Patent Application Serial No. 09/779,753 filed February 8, 2001, is used. The entirety of this application is incorporated herein by reference.

15
20 Preferably, desired coordinates of the donor block to obtain a sample from are identified prior to coring a donor sample. For example, a section of the donor block can be treated to make tissue/cell morphology visible under a microscope (e.g., by hematoxylin and eosin staining) and a control sampling area can be identified and marked on the donor block. A donor core sample is then obtained from the sampling area.

25 In still other aspects, desired coordinates can be identified by reacting sections with one or more molecular probes and identifying coordinates in the donor block comprising cell(s) which do or do not express a particular biological characteristic of interest identified by the reaction or lack of reaction of an area of the section with the probe.

30 Generally, the order of donor samples within a recipient block can be varied to suit a user's needs. In a preferred aspect, microarrays comprise a plurality of tumor samples and different grades or stages of each tumor are represented on the array. Preferably, normal cell and/or tissue samples

are provided in the recipient block as well. Still more preferably, samples represent the progression of cancer from its earliest stage to its most advanced. Samples can also be arranged according to treatment approach, treatment outcome or prognosis, or according to any other scheme that facilitates the subsequent analysis of the samples and the data associated with them.

5 The finished recipient block, now a microarray block, comprising at least two cores of cell samples and/or tissue samples from the same or different donor blocks is then sectioned to about $2\mu\text{m}$ - $20\mu\text{m}$ with a microtome or other cutting implement. Sections preferably are mounted on a substrate to facilitate handling and/or storage. In one aspect, the microarray block is sectioned at about $4\text{--}10\mu\text{m}$ and the substrate is an about 1 inch x 3 inch positively charged microscope slide.

10 Other methods of generating microarrays are described in U. S. Provisional Application Number 60/213,321, the entirety of which is incorporated by reference herein, and in WO 99/44062 and WO 99/44062, incorporated entirely by reference herein, and are encompassed within the scope of the instant invention.

Preparation of Large Format Frozen Tissue Arrays

15 In one aspect of the invention, frozen microarrays are provided in which at least one sublocation comprises at least about two different types of cells. Preferably, the at least one sublocation comprises a section through a donor core sample having a diameter of larger than about 0.6 mm. Samples for such "large format" microarrays can include samples from repositories comprising frozen cells and/or tissue stored at about -80°C — -20°C .

20 In one aspect, about 20 samples of tumor specimens are obtained for one array and 20 samples of normal tissues are obtained for a second array. A portion measuring approximately $2\text{ x }2\text{ mm}$ is taken from each of the collected tissue specimens and smaller portions of tissue are arranged on a 2 mm thick layer of frozen cryogenic embedding compound (e.g., OCT) that has been previously set into a plastic embedding mold that measures $37\text{ x }24\text{ x }5\text{ mm}$ and frozen in a cryostat, thereby forming an "array block". The location of each specimen as it is placed in the array block is noted so that the identity of each specimen is maintained with 100% accuracy. After each specimen is set into the array block and its location is noted, the embedding mold containing the array block is then filled with additional OCT compound and allowed to completely freeze.

Once frozen, the block of OCT compound containing the tissue array is removed from the mold and mounted on a cryostat chuck using additional OCT compound as an adhesive. The chuck is allowed to freeze onto the array block to ensure a firm bond. When frozen, the chuck is placed on a microtome within a cryostat and sectioned in the same manner as a routine frozen section at about 4-6µm. Sections are then mounted on a positively-charged substrate, such as a glass microscope slide. The substrate can then be stained using any method that can be performed on frozen sections, such as methods which employ routine and special stains, as well as immunohistochemistry and *in situ* hybridization. The block can be stored for a period of time in a -80° C freezer for future use.

As above, data relating to the expression of one or more biological characteristics of samples of the large format array are preferably recorded, indexed according to the location of the samples of the array. Preferably, this information includes patient information.

It should be obvious to those of ordinary skill in the art that although dimensions of elements used in the above procedure can vary and that such variations are encompassed within the scope of the invention. The large format arrays according to the present invention are particularly useful for arraying samples of cancerous tissue which include a plurality of different cell types, such as one or more of: stromal cells, extracellular matrix, necrotic cells, and apoptotic cells, in addition to abnormally proliferating cells. Large format arrays can be used alone or in conjunction with small format arrays (e.g., comprising samples of one cell type or of about 0.6 mm or less in diameter). In one aspect of the invention, a large format array is used in conjunction with a small format array derived from the same patient's tissue sample. In this aspect, the large format array can be used to demonstrate that the biological characteristics of the smaller sublocations of a small format array are representative of the biological characteristics within a larger sample of tissue.

Mixed Format Microarrays

In another aspect of the invention, microarrays are generated using heterogeneous samples, e.g., such as paraffin-embedded and/or plastic-embedded, and frozen samples, all provided in the same microarray block. In still another aspect, at least one sublocation of the microarray comprises cells from a serum sample or other sample of body fluid (e.g., blood, urine, CSF, a perfusion sample, and the like). Preferably, both cells and tissue samples from the same patient are provided in a single microarray block. Still more preferably, a microarray block is provided comprising samples representing at least about five different tissue types from the same patient. This optimizes

the simultaneous use of the microarrays to examine cell and/or tissue morphology alongside with nucleic acid and protein expression by providing tissues in formats which are especially suited for particular assays. For example, while morphology will be maximized in paraffin-embedded or plastic-embedded sections, nucleic acid detection will be maximized using frozen sections or frozen samples from a bodily fluid.

In a preferred aspect, a microarray is used to screen for cancer-specific markers which are both diagnostic of disease progression and which can be assayed for in a bodily fluid. Such markers are particularly amenable for diagnostic/prognostic tests in clinical settings since they can be obtained readily from patients with minimally invasive measures.

Multiple donor blocks can be used to provide cores of samples which are either paraffin-embedded, or plastic-embedded, or frozen. Preferably, the recipient block/microarray block comprises a fast-freezing embedding material. More preferably, microarrays such as those described in U.S. Patent Application Serial Number 09/779,753 are used to create mixed format microarray blocks according to the invention.

Methods of Using Oncology Microarrays

The oncology microarrays according to the invention allow a user to access large data sets, to establish molecular profiles relating biological characteristics to the progression, recurrence, and response to treatment of neoplastic tissues, and to discover diagnostic/prognostic correlations relating biological characteristics with phenotypes. Each microarray arrays a plurality of different types of biomolecules on a single substrate. One to thousands of genes or proteins can be analyzed from the same set of clinical samples and a database can be constructed relating alterations in the expression and/or form of one or more biomolecules to the occurrence, progression and/or recurrence of cancer.

Applications for the oncology tissue microarrays according to the invention include, but are not limited to:

- selecting promising gene targets
- sorting/prioritizing cDNA array data
- surveying entire populations
- validating gene discoveries in 100's of human tissue specimens

- investigating pathogenesis and progression in cell proliferative disorders
- searching for diagnostic, prognostic and clinical correlations
- performing comprehensive molecular profiling of large numbers of specimens

For Prognostic/Predictive Indication-Immunohistochemistry (IHC): Automated and Manual

Methods

Most treatments for breast cancer are based on prognostic and predictive factors of which the traditional staging variables (tumor size, node status, metastasis) being the most important. Estrogen (ER) and Progesterone receptors (PgR) status, as determined by IHC, are the only two predictive factors recommended for clinical use. However, many other antibodies such as Ki67, c-erbB-2 and p53 are also being studied by IHC for their prognostic value but appear to be more valuable in the predictive sense.

In one aspect, substrates comprising breast cancer progression microarrays as described above provide sublocations which have already been identified as being positive or negative for a particular biomarker (such as a marker specifically recognized by an antibody or nucleic acid probe). Up to at least about 20 different types of breast cancers (from 20 individuals) and normal breast samples can be tested simultaneously with a test tissue to compare staining variability and antibody sensitivity on a single substrate at a single time. This provides a more accurate interpretation of results along with the quality assurance of laboratory competence.

In one aspect, the test sample is obtained from an individual suspected of having a disease (e.g., cancer), and is placed on a profile array substrate at a first location, the profile array substrate comprising at a second location, a microarray comprising a plurality of sublocations which each represent different stages in the progression of a disease. The test sample and the microarray are contacted with a molecular probe reactive with a biomolecule (e.g., an antibody specific for a tumor specific antigen, a nucleic acid probe which specifically hybridizes to another nucleic acid, an enzyme capable of recognizing a substrate bound to an antibody, polypeptide, nucleic acid), and the reactivity of the molecular probe is measured to provide an indicia of the presence or absence of the biomolecule. Reactivity can be any of binding, cleavage, processing, and/or labeling, and the like. Reactivity of the molecular probe with the test sample is compared with reactivity of the molecular probe with the different sublocations on the microarray. In one aspect of the invention, reactivity of the sublocations on the microarray in at least one test sample is known and is characteristic of a

biological trait, such that reactivity of the test sample is indicative that the test sample shares that biological trait.

Preferably, data relating to the reactivity of the test sample and the sublocations of the microarray is entered into a specimen-linked database, and information relating to the expression of the biological trait in different samples of the microarray is made accessible, along with other data relating to the samples (e.g., such as patient information) to the user. Preferably, the database represents information from a population of individuals. In one aspect of the invention, the individual from whom a test sample is obtained has at least one trait in common with the population.

In a particularly preferred aspect of the invention, data relating to an image of the test sample is stored within the database, and the image can be displayed by the user upon accessing the database.

In one aspect of the invention, reactivity of the molecular probe with different cell and/or tissue samples on the microarray is not known, and information relating to reactivity with the test sample and the cells in different sublocations in the array is determined and entered into a database. In another aspect of the invention, the test sample is contacted with different distinguishable molecular probes (e.g., a fluorescent antibody specific for Her-2/neu and a rhodamine labeled antibody specific for PSA), and a plurality of different reactivities is determined, and entered into the database. In still another aspect of the invention, sets of substantially identical microarrays (e.g., from the same recipient block) are assayed in parallel using multiple samples of the same test tissue (e.g., from neighboring sections of a test block of embedded test tissue), expanding the number of different molecular probes being tested against the test sample. In this way, a molecular profile of the test sample can be determined and compared with the molecular profile of the set of microarray samples. Most preferably, both RNA transcript molecular profiles and protein molecular profiles are obtained from identical or substantially identical sets of microarrays.

In one aspect of the invention, relationships are identified between the biological characteristics of a test sample and cells/tissues on the microarray, or from other previously characterized cells/tissues, by using a processor which accesses a database of information relating to the previously characterized tissues or cells and/or the patients from whom these cells and/or tissues were obtained. Programs for identifying relationships between data sets are known in the art and

include the Spotfire™ program as described in U.S. Patent Number 6,014,661, the entirety of which is incorporated by reference herein.

In a preferred aspect, a user of a microarray is provided with access to information regarding the microarray. In one aspect, as shown in Figure 2D, this information is in the form of printed information regarding the cells/tissues on the microarray. In another aspect of the invention, the user is provided with access to a processor (e.g., a device connectable to a network). The processor communicates with a database (either stored within the memory of the processor or in a server which the processor accesses through a client). In one aspect, the processor downloads records relating to the particular tissues on the microarray and classifies them by type or attribute (e.g., patient sex, age, disease, exposure to drug, tissue type, cancer grade, and the like) (see, e.g., Figures 4A-4C). Access to the database can be provided by providing a user with an identifier of the microarray which the user can input into the display of a user device connectable to the network. Upon receiving the input, the user device displays an interface which comprises information relating to the microarray and/or links to portions of the database comprising information relating to different samples on the microarray.

The processor analyzes the relationships between the stored data and the data relating to the test tissue using any method standardly used in the art, including, but not limited to, regression, decision trees, neural networks, and fuzzy logic, and combinations thereof. The processor displays at least one relationship or identifies that no discernable relationship can be found. In one aspect, the processor displays a plurality of relationships on the interface of a display (e.g., on a computer or a wireless device connectable to a network) and displays information relating to the statistical probability that the relationship exists (e.g., whether or not a correlation can be found). The user selects among a plurality of relationships identified by the processor by interfacing with the interface to determine those of interest (e.g., a relationship which is a disease might be of interest while a relationship regarding hair color might not be). In one aspect of the invention, rather than scanning an entire database, the system samples the database randomly until at least one statistically satisfactory relationship is identified, with the user setting parameters for what is "statistically satisfactory."

In one aspect of the invention, the relationship of interest is used to provide a diagnosis of a disease. In another aspect of the invention, the relationship of interest is used to identify the biological role of an uncharacterized gene. In another aspect of the invention, the processor

accesses other databases which comprise information relating to medical treatment of a particular disease, for example, demographic information, or actuarial data, relating to individuals who are the source of the tissue, and other information to further define relationships between the biological characteristics of the test tissue and the tissues for which information exists in the database.

Use of Cancer-Specific Markers To Evaluate Cancer Progression in Oncology Microarrays

In one aspect of the invention, the biological characteristic being assayed is the expression or form of a cancer-specific marker. As used herein, “a cancer-specific marker” or a “tumor specific antigen” is a biomolecule which is expressed preferentially on cancer cells and is not expressed or is expressed to small degree in noncancer cells of an adult individual. As used herein, “a small degree” means that the difference in expression of the marker in cancer cells and noncancer cells is large enough to be detected as a statistically significant difference when using routine statistical methods to within 95% confidence levels. A cancer-specific marker is any biomolecule that is involved in or correlates with the pathogenesis of a cell proliferative disease, and can act in a positive or negative manner, as long some aspect of its expression or form influences or correlates with the presence or progression of a cell proliferative disease. While in one aspect, expressed levels of a biomolecule provide an indicia of cancer progression or reoccurrence, in another aspect of the invention, the expressed form of a biomolecule provides the indicia (e.g., a cleaved or uncleaved state, a phosphorylated or unphosphorylated state).

In one aspect of the invention, the expression characteristics of cancer-specific markers are determined in test samples and compared to the expression characteristics of the marker in any of the oncology arrays described above. In one aspect, the cancer-specific marker is the product of a characterized gene. In another aspect, a cancer-specific marker is a cell growth related polypeptide which promotes cell proliferation. In a preferred aspect, the expression of the cancer specific marker is used to prognose and/or predict reoccurrence of abnormal cell proliferation.

Non-limiting examples of cancer-specific markers include growth factors, growth factor receptors, signal transduction pathway participants, and transcription factors involved in activating genes necessary for cell proliferation. Alternatively, or in addition, cell proliferative genes may function to suppress cell proliferation. Non-limiting examples include tumor suppressor genes (e.g., p57kip2, p53, Rb) and growth factors that act in a negative manner (e.g., TGF- β). A loss or

alteration in the function of a negatively acting growth regulator often has a positive effect on cell proliferation.

Among the cell growth related polypeptides, the cyclin-dependent kinase inhibitor p57Kip2 is of interest for its apparent tumor suppressor activity. The gene encoding the human p57Kip2 was located at 11p15.5 (Matsuoka et al., 1995, *Genes Dev.* 9: 650-662). This chromosomal region is known to develop frequent loss of heterozygosity implicated in a number of human cancers, including Wilms' Tumor, and Beckwith-Wiedemann syndrome (BWS), a cancer syndrome. BWS is characterized by numerous growth abnormalities and an increased risk of childhood tumors.

Several types of childhood tumors, including Wilms' tumor, adrenocortical carcinoma and rhabdomyosarcoma display a specific loss of maternal 11p15 alleles, suggesting that genomic imprinting at that locus plays an important role in the function of genes at that locus. This region also contains imprinted genes encoding Insulin-like Growth Factor II (IGF-II) and H19, both of which are implicated in adrenal neoplasms. The p57Kip2 polypeptide, also known as CDKN1C, is a potent tight-binding inhibitor of several kinases instrumental in the regulation of the G1 phase of the cell cycle. p57Kip2 negatively regulates cell proliferation. The growth inhibitory action of p57Kip2 and its association with a genomic locus showing frequent loss of heterozygosity highlight p57Kip2 as a candidate tumor suppressor.

Transcription of the p57kip2 gene results in the generation of a major transcript of 1.5 kb and a minor transcript of 7 kb. Compared with the related CDK inhibitors p21Waf1 and p27Kip1, the tissue distribution of p57Kip2 expression is limited (Lee et al., 1995, *Genes Dev.* 9: 639-49). The major 1.5 kb transcript is expressed at high levels in placenta, and at relatively lower levels in muscle, kidney, pancreas and heart. The 7 kb mRNA is also expressed in skeletal muscle and the heart (Lee et al., *supra*). The p57kip2 gene is also strongly expressed in the prostate.

The p57Kip2 polypeptide is a 348 amino acid protein with a calculated molecular mass of 37.3 kD. The polypeptide migrates anomalously on SDS PAGE, with an apparent relative molecular weight of 57 kD. The polypeptide comprises four primary domains. N-terminal amino acids 30 to 86 comprise a p21/27-related CDK inhibitory domain. After the inhibitory domain is a proline-rich domain comprising a MAP kinase consensus phosphorylation site. This is followed by an acidic domain from residues 178 to 284. Finally, the C-terminus of the polypeptide has sequence

conservation with the C-terminus of p27Kip1 and includes a nuclear localization signal and a CDK consensus phosphorylation site (Matsuoka et al., 1995, *supra*).

Overexpression of p57Kip2 arrests cells in G1. p57Kip2 can bind CDK2, CDK3, CDK4 and cyclins E, A and D1 and is able to inhibit the H1 kinase activity of cyclin E-CDK2 and cyclin A-CDK2. Inhibition is more potent against G1 CDK than against the mitotic CDK cyclin B1-CDK1. p57Kip2 can bind to cyclin/CDK complexes in a cyclin dependent manner (Matsuoka et al. 1995, *supra*).

Immunohistochemical studies have shown that p57Kip2 is localized to the nucleus in normal tissues. p57Kip2 is expressed in terminally differentiated cells, suggesting an involvement of this CKI in cell cycle exit during differentiation (Matsuoka et al., 1995, *supra*).

The so-called tumor antigens are also included among the growth-related polypeptides. Tumor antigens are a class of protein markers that tend to be expressed to a greater extent by transformed tumor cells than by non-transformed cells. As such, tumor antigens may be expressed by non-tumor cells, although usually at lower concentrations or during an earlier developmental stage of a tissue or organism. Tumor antigens include, but are not limited to, prostate specific antigen (PSA; Osterling, 1991, *J. Urol.*, 145: 907-923), epithelial membrane antigen (multiple epithelial carcinomas; Pinkus et al., 1986, *Am. J. Clin. Pathol.* 85: 269-277), CYFRA 21-1 (lung cancer; Lai et al., 1999, *Jpn. J. Clin. Oncol.* 29: 421-421) and Ep-CAM (pan-carcinoma; Chaubal et al., 1999, *Anticancer Res.* 19: 2237-2242). Additional examples of tumor antigens include CA125 (ovarian cancer), intact monoclonal immunoglobulin or light chain fragments (myeloma), and the beta subunit of human chorionic gonadotropin (HCG, germ cell tumors).

A sub-category of tumor antigens includes the oncofetal tumor antigens. The oncofetal tumor antigens alphafetoprotein and carcinoembryonic antigen (CEA) are usually only highly expressed in developing embryos, but are frequently highly expressed by tumors of the liver and colon, respectively, in adults. Other oncofetal tumor antigens include, but are not limited to, placental alkaline phosphatase (Deonarain et al., 1997, *Protein Eng.* 10: 89-98; Travers & Bodmer, 1984, *Int. J. Cancer* 33: 633-641), sialyl-Lewis X (adenocarcinoma, Wittig et al., 1996, *Int. J. Cancer* 67: 80-85), CA-125 and CA-19 (gastrointestinal, hepatic, and gynecological tumors; Pitkanen et al., 1994, *Pediatr. Res.* 35: 205-208), TAG-72 (colorectal tumors; Gaudagni et al., 1996, *Anticancer Res.* 16: 2141-2148), epithelial glycoprotein 2 (pan-carcinoma expression; Roovers et

al., 1998, *Br. J. Cancer*. 78: 1407-1416), pancreatic oncofetal antigen (Kithier et al., 1992, *Tumor Biol.* 13: 343-351), 5T4 (gastric carcinoma; Starzynska et al., 1998, *Eur. J. Gastroenterol. Hepatol.* 10: 479-484; alphafetoprotein receptor (multiple tumor types, particularly mammary tumors; Moro et al., 1993, *Tumour Biol.* 14: 11-130), and M2A (germ cell neoplasia; Marks et al., 1999, *Brit. J. Cancer* 80: 569-578).

The expression characteristics of cell growth related polypeptides are critical not only to their function, but also to their usefulness as prognostic or diagnostic indicators of disease. For example, when a given polypeptide (e.g., a tumor-suppressor gene product) or the RNA encoding it is used as a diagnostic or prognostic indicator, there are several characteristics of its expression that may be relevant. First, the total level of expression in the tumor, relative to the expression in normal cells of the corresponding cell type is important. In one aspect of the invention, the total level of expression is determined by, for example, immunoblot analysis or Northern Blot analysis. For a tumor suppressor gene, for example, a lower level of the tumor suppressor gene product in tumor samples suggests that the lack of the tumor suppressor protein may be involved in the progression of the tumor.

Even when no definitive mechanism of action in tumor etiology is known, the correlation of any expression characteristic (e.g., higher or lower expression) of a given polypeptide or its RNA with a particular clinical diagnosis or outcome in other patients makes the expression characteristics of that polypeptide or its RNA useful in the diagnosis or prognosis of disease. The level of expression of the given polypeptide or its RNA in a particular patient is used, along with the known correlation with its expression in that disease, to diagnose or predict a clinical outcome for that patient.

Another expression characteristic is the percentage of cells expressing the polypeptide in a given tissue sample. It is often found that not all cells of a given tumor express the same markers. Further, within the population of cells that do express a polypeptide, the extent of that expression can vary from cell to cell. In one aspect, the percentage of cells expressing the polypeptide is the criterion used in diagnosis and prognosis. In this aspect, the extent to which positive cells express the polypeptide is a diagnostic characteristic. For immunohistochemical detection, for example, the percentage of positive-staining cells can be further divided into those cells that express the polypeptide to a high, medium, or relatively low level (obviously, any other subdivision scheme may be used). It is possible, for example, that high expression by relatively few cells correlates with

a different prognosis than low expression by a larger number of cells, even though the total expression level between two such samples is approximately the same.

Another expression characteristic that can be useful is the localization of expression of the polypeptide. If, for example, the growth-related polypeptide is only expressed in certain cells of a functional structure within a tissue, a change of the expression within those cells that is found to correlate with a disease or the prognosis of that disease can be a useful characteristic. For instance, a marker that is normally expressed only in cells lining the lumen of a glandular structure may become more widely expressed throughout a tissue as the tissue becomes transformed.

In addition to localization within a tissue, the cellular localization of a polypeptide can be an important expression characteristic in disease prognosis or diagnosis. If, for example, a polypeptide that is normally predominantly cytoplasmic becomes predominantly nuclear in a disease, that change can be useful as a diagnostic or prognostic indicator.

Another expression characteristic that can be useful is a change in the conformation of a polypeptide. Conformational changes generally result from mutations to the gene encoding the polypeptide, but can also occur due to changes in the expression of a co-factor that influences the conformation of the polypeptide. Antibodies that distinguish between two conformations of a polypeptide are known in the art (e.g., there are antibodies known in the art that distinguish the conformation of mutant from wild-type p53).

Changes in post-translational modifications (e.g., phosphorylation, glycosylation, myristoylation, etc.) of a polypeptide can also be useful expression characteristics in diagnosis and/or prognosis of disease.

In some aspects of the invention, sets of cancer-specific markers are used to determine the progression of cancer in a test tissue sample. Perhaps one of the better examples of this application is the diagnosis of small round blue cell tumors in childhood. These tumors show no distinguishing morphological features but require positive identification because of their requirements for specific therapies and clinical outcomes. Immunohistochemistry (IHC) has proven to be one of the most powerful diagnostic tools to help categorize these tumors. In the majority of cases, a carefully selected panel of antibodies can assist in identifying most of the small blue round tumors such as leukemia/lymphoma, Ewing's Sarcoma, rhabdomyosarcoma, and mesenchymal chondrosarcoma.

Although no one specific antibody is diagnostic, each tumor will have a specific pattern of negative and positive antibodies.

Molecular Probes

Antibodies For Detection of Cancer-Specific Markers

Antibodies specific for a large number of known polypeptides are commercially available. Alternatively, or in the case where the expression characteristics of a new growth-related polypeptide is to be analyzed, one of skill in the art can raise their own antibodies. In order to produce antibodies, various host animals are immunized by injection with the growth-related polypeptide or an antigenic fragment thereof. Useful animals include, but are not limited to rabbits, mice, rats, goats, and sheep. Adjuvants may be used to increase the immunological response to the antigen. Examples include, but are not limited to, Freund's adjuvant (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, dinitrophenol, and adjuvants useful in humans, such as BCG (bacille Calmette-Guerin) and *Corynebacterium parvum*. These approaches will generate polyclonal antibodies.

Monoclonal antibodies specific for a growth-related polypeptide may be prepared using any technique that provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique originally described by Kohler and Milstein, 1975, *Nature* 256: 495-497, the human B-cell hybridoma technique (Kosbor et al., 1983, *Immunology Today* 4: 72; Cote et al., 1983, *Proc. Natl. Acad. Sci. U.S.A.* 80: 2026-2030) and the EBV-hybridoma technique (Cole et al., 1985, *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, Inc., pp. 77-96). In addition, techniques developed for the production of "chimeric antibodies" (Morrison et al., 1984, *Proc. Natl. Acad. Sci. U.S.A.* 81: 6851-6855; Neuberger et al., 1984, *Nature* 312: 604-608; Takeda et al., 1985, *Nature* 314: 452-454) by splicing the genes from a mouse antibody molecule of appropriate antigen specificity together with genes from a human antibody molecule of appropriate biological activity can be used. Alternatively, techniques described for the production of single chain antibodies (U.S. Patent No. 4,946,778) can be adapted to produce growth-related polypeptide-specific single chain antibodies.

Antibody fragments which contain specific binding sites of a growth-related polypeptide may be generated by known techniques. For example, such fragments include, but are not limited

to, F(ab')₂ fragments which can be produced by pepsin digestion of the antibody molecule and the Fab fragments which can be generated by reducing the disulfide bridges of the F(ab')₂ fragments. Alternatively, Fab expression libraries may be constructed (Huse et al., 1989, *Science* 246: 1275-1281) to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity to a growth-related polypeptide. An advantage of cloned Fab fragment genes is that it is a straightforward process to generate fusion proteins with, for example, green fluorescent protein for labeling.

Antibodies, or fragments of antibodies may be used to quantitatively or qualitatively detect the presence of growth-related polypeptides or conserved variants or peptide fragments thereof. For example, immunofluorescence techniques employing a fluorescently labeled antibody coupled with light microscopic, or fluorimetric detection can be used.

The antibodies or antigen binding fragments thereof may be employed histologically, as in immunofluorescence, immunoelectron microscopy or non-immunoassays, for in situ detection of growth-related polypeptides or conserved variants or peptide fragments thereof.

Detection of Cancer-Specific Markers in Oncology Tissue Microarrays Using Antibodies

In situ detection of a cancer-specific marker can be accomplished by contacting a test tissue and/or an oncology microarray with a labeled antibody that specifically binds the marker of interest. The antibody or antigen binding fragment thereof is preferably applied by overlaying the labeled antibody onto the microarray and/or test tissue. Through the use of such a procedure, it is possible to determine not only the presence of the cancer specific marker but also its amount and its localization in a test tissue and in the plurality of sublocations within the microarray.

In one aspect, antibodies are detectably labeled by linkage to an enzyme for use in an enzyme immunoassay (EIA) (Voller, 1978, *Diagnostic Horizons* 2: 1-7, Microbiological Associates Quarterly Publication, Walkersville, Md.); Voller et al., 1978, *J. Clin. Pathol.* 31: 507-520; Butler, 1981, *Meth. Enzymol.* 73: 482-523; Maggio, E. (ed.), 1980, *Enzyme Immunoassay*, CRC Press, Boca Raton, Fla.). The enzyme which is linked to the antibody will react with an appropriate substrate, preferably a chromogenic substrate, in such a manner as to produce a chemical moiety which is detectable, for example, by spectrophotometric, fluorimetric or visual means. Examples of enzymes useful in the methods of the invention include, but are not limited to peroxidase, alkaline phosphatase, and RTU AEC,

Detection of bound antibodies can alternatively be performed using radiolabeled antibodies. Following binding of the antibodies and washing, the samples may be processed for autoradiography to permit the detection of label on particular cells in the samples.

In a preferred aspect, antibodies are labeled with a fluorescent compound. When the fluorescently labeled antibody is exposed to light of the proper wavelength, its presence can be detected due to fluorescence. Many fluorescent labels are known in the art and may be used in the methods of the invention. Preferred fluorescent labels include fluorescein, amino coumarin acetic acid, tetramethylrhodamine isothiocyanate (TRITC), Texas Red, Cy3.0 and Cy5.0. Green fluorescent protein (GFP) is also useful for fluorescent labeling, and can be used to label non-antibody protein probes as well as antibodies or antigen binding fragments thereof by expression as fusion proteins. GFP-encoding vectors designed for the creation of fusion proteins are commercially available.

As mentioned previously, the primary antibody (the one specific for the polypeptide of interest) may alternatively be unlabeled, with detection based upon subsequent reaction of bound primary antibody with a detectably labeled secondary antibody specific for the primary antibody. Another alternative to labeling of the primary or secondary antibody is to label the antibody with one member of a specific binding pair. Following binding of the antibody-binding pair member complex to the sample, the other member of the specific binding pair, with a fluorescent or other label, is added. The interaction of the two partners of the specific binding pair results in binding the detectable label to the site of primary antibody binding, allowing detection. Specific binding pairs useful in the methods of the invention include, for example, biotin:avidin. A related labeling and detection scheme is to label the primary antibody with another antigen, such as digoxigenin. Following binding of the antigen-labeled antibody to the sample, detectably labeled secondary antibody specific for the labeling antigen, for example, anti-digoxigenin antibody, is added and binds to the antigen-labeled antibody, permitting detection.

The staining of tissues for antibody detection is well known in the art, and can be performed with molecular probes including, but not limited to AP-Labeled Affinity Purified Antibodies, FITC-Labeled Secondary Antibodies, Biotin-HRP Conjugate, Avidin-HRP Conjugate, Avidin-Colloidal Gold, Super-Low-Noise Avidin, Colloidal Gold, ABC Immu Detect, Lab Immunodetect, DAB Stain, ACE Stain, NI-DAB Stain, Polyclonal Secondary Antibodies, Biotinylated Affinity Purified Antibodies, HRP-Labeled Affinity Purified Antibodies, and/or Conjugated Antibodies.

Nucleic Acid Probes For Detection of Cancer-Specific Markers

Nucleic acid probes also are useful to correlate the differential expression of genes with abnormal cell proliferation. In one aspect of the invention, the sequences of any of the cancer-specific genes described above are used to generate probes or primers for use in the present invention. Means for detecting specific DNA sequences are well known to those of skill in the art. In one aspect, oligonucleotide probes chosen to be complementary to a selected subsequence within the gene can be used. Alternatively, sequences or subsequences of cells/ tissues within a microarray may be amplified by a variety of DNA amplification techniques (e.g., polymerase chain reaction, ligase chain reaction, transcription amplification, etc.) prior to detection using a probe. Amplification of nucleic acid sequences increases sensitivity providing more copies of possible target subsequences. In addition, by using labeled primers in the amplification process, the sequences are as they are amplified.

Methods of labeling nucleic acids are well known to those of skill in the art. Preferred labels are those that are suitable for use in *in situ* hybridization (e.g., FISH). In one aspect, nucleic acid probes are detectably labeled prior to hybridization with a sample. Alternatively, a detectable label which binds to the hybridization product can be used. Labels for nucleic acid probes include any composition detectable by spectroscopic, photochemical, biochemical, immunochemical, or chemical means and include, but are not limited to radioactive labels (e.g. ^{32}P , ^{125}I , ^{14}C , ^3H , and ^{35}S), fluorescent dyes (e.g. fluorescein, rhodamine, Texas Red, etc.), electron-dense reagents (e.g. gold), enzymes (as commonly used in an ELISA), colorimetric labels (e.g. colloidal gold), magnetic labels (e.g. DynabeadsTM), and the like. Examples of labels which are not directly detected include biotin and dioxigenin as well as haptens and proteins for which labeled antisera or monoclonal antibodies are available.

A direct-labeled probe, as used herein, is a probe to which a detectable label is attached. Because the direct label is already attached to the probe, no subsequent steps are required to associate the probe with the detectable label. In contrast, an indirect labeled probe is one which bears a moiety to which a detectable label is subsequently bound, typically after the probe is hybridized with the target nucleic acid.

Labels can be coupled to nucleic acid probes in a variety of means known to those of skill in the art. In some aspects the nucleic acid probes are labeled using nick translation or random primer

extension (Rigby et al., 1977, *J. Mol. Biol.* **113**: 237; or Sambrook et al., 1989, *Molecular Cloning-A Laboratory Manual*, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., the entireties of which are incorporated by reference herein).

Detection of Cancer-Specific Markers Using Nucleic Acid Probes

In situ hybridization (ISH) and Fluorescent *In Situ* Hybridization (FISH) are techniques that can avail themselves to paraffin-embedded sectioned tissue. Both techniques are genomic based rather than proteomic based as in IHC and involve RNA and DNA probes that will hybridize or specifically bind to their complement base sequence. Markers are attached to the genomic probes that allow the probes to be visualized under a microscope. ISH probes generally have a chromogenic marker and can be observed by traditional light microscopy. FISH probes generally have a fluorescent marker bonded and must be visualized with the use of a fluorescent microscope.

Although IHC markers are most useful in characterizing and identifying tumors, there are some lesions such as endocrine/neuroendocrine tumors in which ISH can add another level of specificity. This is because some tumors may take up proteins nonspecifically or may not be found in levels detectable by IHC. In these instances, genomic probes can be amplified and are more readily detectable. In breast cancer, FISH for the detection of *cerbB-2* is commonly used for its strong predictive power.

In one aspect, profile array substrates are used as control tools in ISH/FISH methodologies. Just as in IHC, the option of having 25 individual control specimens simultaneously processed with the test tissue is an extremely valuable tool in probe sensitivity and detection.

For *in situ* hybridization, sections of paraffin-embedded tissue immobilized on glass substrates are treated as follows, according to one aspect of the invention: Substrates are dewaxed in staining dishes by three changes in xylenes, for 2 minutes each (dewaxing is not necessary for non-embedded single cells). Dewaxed samples are then rehydrated using the following procedure: 100% ethanol, two times, for two minutes, then subsequent 2 minute incubations in 95%, 70%, and 50% ethanol. Samples are denatured by incubation for 20 minutes at room temperature in 0.2 N HCl, followed by heat denaturation for 15 minutes at 70°C in 2X SSC. Samples are then rinsed in 1X PBS for 2 minutes. In some situations, usually empirically determined, a pronase digestion step may be included here which later allows improved access of the probes to the nucleic acids contained within the tissue sections. In such cases, samples are digested for 15 minutes at 37°C with

predigested, lyophilized pronase at an empirically determined concentration which allows hybridization yet preserves the cellular morphology (0.1 to 10 µg/ml).

Digested samples are incubated for 30 seconds in 2 mg/ml glycine in 1X PBS to stop the digestion. Samples are then post-fixed using freshly prepared 4% paraformaldehyde in 1X PBS, for 5 minutes at room temperature. Fixation is then stopped by a 5 minute incubation in 3X PBS, followed by two 30 second rinses in 1X PBS. Samples are then soaked in 10 mM DTT, 1X PBS, for 10 minutes at 45°C. Samples are then soaked 2 minutes in freshly made 0.1 M triethanolamine, pH 8.0 (triethanolamine buffer). Next, samples are placed in fresh triethanolamine buffer to which acetic anhydride is added to 0.25% final concentration, followed by mixing and 5 minutes' incubation with gentle agitation. After the 5 minutes, more acetic anhydride is added to a final concentration of 0.5%, followed by 5 minutes' further incubation. Samples are blocked 5 minutes in 2X SSC, followed by dehydration through successive soaking in 50%, 70%, 95% (once each), and 100% ethanol (two times) for 2 minutes each at room temperature. Samples are air dried or dried with desiccant before proceeding to the hybridization step. The preceding series of steps may be automated in order to increase throughput.

Probes for *in situ* hybridization may be DNA or RNA oligonucleotides or, for example, RNA transcribed *in vitro*. In one aspect, RNA probes labeled with ³⁵S are dissolved in 5 µl of 50 mM dithiothreitol (DTT), and added to 2.5 µl (i.e., an amount approximately equal to one half the mass of labeled probe added) of a non-specific riboprobe competitor (RNA made in the same manner as the labeled specific probe, except from a transcription template with non-specific sequences (for example, vector with no insert) and no labeled ribonucleoside in the reaction). This probe/non-specific competitor mixture is heated at 100°C for 3 minutes, followed by addition of hybridization buffer (e.g., 50% (v/v) deionized formamide, 0.3 M NaCl, 10 mM Tris (pH 8.0), 1 mM EDTA, 1X Denhardt's solution, 500 mg/ml yeast tRNA, 500 mg/ml poly(A), 50 mM DTT, 10% polyethylene glycol 6000) to 0.3 µg/ml final probe concentration (estimate of amount of probe synthesized is based on calculation of the percent of the label incorporated and the proportion of the labeling base in the probe molecule as a whole).

The probe/hybridization mix is incubated at 45°C until applied to the microarrays as a thin layer of liquid. Hybridization reactions are then incubated in a moist chamber (closed container containing towels moistened with 50% deionized formamide, 0.3 M NaCl, 10 mM Tris (pH 8.0), 1 mM EDTA) at 45°C. If background proves to be a problem, a 1 to 2 hour pre-hybridization step

using only non-specific, unlabeled riboprobe competitor in hybridization buffer can be added prior to the step in which labeled probe is applied.

Hybridization is carried out for 30 minutes to 4 hours, followed by washing to remove the unbound probe. The microarrays are washed in an excess (100 ml each wash) of the following buffers: 50% formamide, 2X SSC, 20 mM β -mercaptoethanol, two times, for 15 minutes at 55°C; 50% formamide, 2X SSC, 20 mM β -mercaptoethanol, 0.5% Triton X-100, two times, for 15 minutes at 55°C; and 2X SSC, 20 mM β -mercaptoethanol, two times, for 2 minutes at 50°C.

The samples are then subjected to an RNase digestion for 15 minutes at room temperature using a solution containing 40 mg/ml RNase A, 2 mg/ml RNase T1, 10 mM Tris (pH 7.5), 5 mM EDTA and 0.3 M NaCl. After RNase digestion, slides are soaked two times for 30 minutes each in 2X SSC, 20 mM β -mercaptoethanol at 50°C, followed by two washes in 50% formamide, 2X SSC, 20 mM β -mercaptoethanol at 50°C and two washes of 5 minutes each in 2X SSC at room temperature. Hybridized, washed substrates comprising microarrays are dehydrated through successive two minute incubations in the following: 50% ethanol, 0.3 M ammonium acetate; 70% ethanol, 0.3 M ammonium acetate; 95% ethanol, 0.3 M ammonium acetate; 100% ethanol. Substrates are air dried overnight, followed by coating with emulsion for autoradiography according to standard methods.

Sections prepared, for example, from frozen tissues, may be hybridized by a similar method except that the dewaxing and paraformaldehyde fixation steps are omitted. For details, see Ausubel et al., 1992, *Short Protocols in Molecular Biology*, John Wiley and Sons, Inc., pp. 14-15 to 14-16.

As an alternative to the so-called "conventional" *in situ* hybridization methods described above and in the references therein, the method of *in situ* PCR can be used to examine the presence of nucleic acids encoding a growth-related polypeptide in cells, tissues, or other sample preparations in which the levels of such nucleic acids are low. A detailed description of the technique is presented in Ausubel, et al., 1992, *supra*, pp. 14-37 to 14-49, the contents of which are hereby incorporated by reference.

In a further aspect of the invention, ISH or FISH probes or other nucleic acid molecular probes (e.g., DAPI, acridine orange) are used to evaluate the absolute amounts of nucleic acids in

cells within a tissue (e.g., to determine the copy number of nucleic acids on the tissue); changes in copy number of nucleic acids are often associated with the development of pathology.

In still a further aspect of the invention, information obtained from a single sublocation can be combined by combining the detection of both proteins and nucleic acids. For example, in one aspect of the invention, after performing immunohistochemistry on cells/tissue at a sublocation, a portion of the sample is obtained to isolate nucleic acids which are further analyzed by amplification methods such as PCR. Detection of nucleic acids isolated from an embedded cell or tissue sample is known in the art and is described in, for example, U.S. Patent Number 6,013,461, U.S. Patent Number 6,110,902, and U.S. Patent Number 6,114, 110, the entireties of which are incorporated by reference herein.

Adaptation of these procedures to the specific needs of varying sample types is within the ability of those with ordinary skill in the art and those of skill in the art may select and employ appropriate and routine methods of detection (Ausubel et al., 1992, *supra*, pp. 14-18 to 14-19, describes autoradiographic detection) and counterstaining of the tissue sections (e.g., with hematoxylin/eosin, among others, described in Ausubel et al., 1992, *supra*, pp. 14-19 to 14-22) to make hybridization signal and cell and tissue morphology readily apparent using visual inspection, microscopy, or either visual inspection or microscopy enhanced through the used of optical systems placed in communication with the microarrays according to the invention.

Scoring Method for Classifying Biological Characteristics

In one aspect, a panel or collection of cell and/or tissues samples is obtained representing a plurality of different stages of cancer which is used to generate the sublocations of an oncology microarray. In order to establish a panel which is useful for predicting the prognosis of a given cell or tissue sample, a scoring method is established which relates the expression of a first biological characteristic (e.g., level of expression cancer-specific marker, as reflected by antibody staining) to a second biological characteristic (e.g., localization of the cancer-specific marker). Thus, in one aspect, the biological marker is nuclear staining for the polypeptide, and the tissue collection is classified according to the percentage of cells expressing the polypeptide and how intensely those cells express the polypeptide. Cancer cells are placed into groups based on 1) a range of percentages of cells expressing the marker polypeptide, for example, 5 groups of <20%, 20% to <40%, 40% to <60%, 60% to <80%, and 80% to 100%, and 2) a range of degrees of staining

intensity, for example, 4 groups ranging from light staining, light to medium staining, medium to dark staining and dark staining.

These quantities are used to place the expression characteristic for a given test sample into one of a number of categories that considers both elements of the characteristic being classified.

5 The number of categories in this case is determined as the product of the number ranges of percentages and the number of ranges of staining intensity (in the present example, there would be 20 categories; a single further category can be added that includes cancer cells with no nuclear staining for the polypeptide). The categories are illustrated below in Table 1. In reference to the table, for example, a sample with 35% of cells staining light to medium would be scored 2/2. One should also note that within a given tissue sample there are most frequently more than one cell type. The scoring of cells in the tissue samples can be done individually in those cases in which the tumor retains morphologically distinct cell types. Thus, for a given tissue sample, one may have separate expression characteristic scores for, e.g., epithelial cells, glandular cells and inflammatory cells; or other indicia of morphology that reflect any of the grading systems for abnormal cell growth described above (e.g., TNM, Duke's stage, Gleason stage, BRE stage, and the like). By correlating the matrix data (e.g., as in the Table below) with the grade of cancer, a user of the microarray can stage a test tissue by identifying the two biological characteristics expressed in the tissue.

Table 1. Percent (%) of Cells Staining

Degree of Staining	< 20%	20%- <40%	40%-60%	60%-<80%	80%-100%
Light	1/1	1/2	1/3	1/4	1/5
Light/Medium	2/1	2/2	2/3	2/4	2/5
Medium/Dark	3/1	3/2	3/3	3/4	3/5
Dark	4/1	4/2	4/3	4/4	4/5

Thus, when the score assigned to a patient's tissue sample for a given biological characteristic (e.g., a cancer-specific marker) substantially matches the score of a test sample for the same biological characteristic (i.e., is not statistically different based on routine statistical tests to within 95% confidence levels), the prognosis of the patient's disease is correlated to that of the patient from whom the standard sample was obtained. The accuracy of prognosis value increases as more markers are considered. Thus, the ability to screen serial sections of the cell/tissue microarray with multiple probes, and to correlate the expression characteristics of biomolecules reactive with

those probes on a single microarray with the same probes on another microarray, facilitates the generation of an expression profile representing multiple biological characteristics. These profiles are useful in diagnosis, prognosis, guidance of treatment and prediction of a patient's relapse.

Information relating to a diagnostic matrix established for a given type of cancer and a given microarray is stored in a database, along with all other information available relating to the patient from which a particular tissue sample came. However, in addition to the information regarding each tissue sample on the panel, the database can contain information on other tissue samples not included on the particular array (or arrays) examined by a given clinician. These data provide depth to the database beyond the samples on a given array, and enhances the statistical reliability of decisions based upon a given array. For example, a collection of 250,000 or more samples of breast cancer tissue may be available. A given tissue array will not necessarily have samples of all of them, but will more likely have a subset of those tissue samples. Therefore, there can be multiple arrays, each comprising a different subset of the total collection of samples. As each subset array is analyzed for different markers, the data are reported back to the database. When a clinician reports data back to the database for a given marker, they can be informed of whether other clinicians have examined the same marker in other samples on other subset arrays.

The information for those subset arrays examined for the same marker can then be provided to the clinician for use in diagnosis or prognosis of their patient's condition. The result of this is that examination of an array of, for example, 500 tissue samples can effectively yield information on many more tissue samples in other subset arrays. The predictive value of a standard panel and the database associated with it increases as data is reported back to the database for individual markers.

Selecting Promising Gene Targets and Validating Diagnostic Molecules Using Oncology Tissue Microarrays

In one aspect, test probes specifically reacting with a gene or gene product are used to identify candidate drug targets (see Figures 1A-B). Test probes can include antibodies, nucleic acids, aptamers, enzymes, substrates, and the like, and are obtained by screening one or more of a nucleic acid array (e.g., oligonucleotide arrays, cDNA arrays, Expressed Sequence Tag Arrays), a peptide, polypeptide, protein array, or other small molecule array, with a patient sample to identify a biomolecule or set of biomolecules whose expression is diagnostic of a trait (e.g., by determining which molecules on the array are substantially always present in a disease sample and substantially always absent in a healthy sample, or substantially always absent in a disease sample and

substantially always present in a healthy sample, or substantially always present in a certain form/amount in a disease sample and substantially always present in a certain other form/amount in a healthy sample). As used herein "substantially always" refers to a statistically significant difference between samples from healthy patients and patients having a disease.

5 Test probes identifying diagnostic biomolecules are then contacted with an oncology microarray according to the invention, to identify the presence and/or form of diagnostic biomolecules in a microarray comprising different types of healthy or diseased tissues. In this way, the correlation between the expression of the diagnostic biomolecule(s) and the disease state is validated.

10 In another aspect of the invention, the role of the diagnostic molecule(s) are evaluated by comparing the expression of the molecule(s) in different sublocations on the microarray(s) with information in a database relating to the type of tissue, its developmental stage, or to other traits of the individual(s) from which the tissue is obtained (e.g., patient information).

15 In a further aspect of the invention, the expression of diagnostic molecules is examined in a microarray comprising samples from a drug-treated patient and samples from an untreated diseased patient and/or from a healthy patient, and the efficacy of the drug is monitored by determining whether the expression profile of the diagnostic(s) molecule returns to that of a healthy patient. In one aspect of the invention, a test tissue which is the target of a disease is obtained from a patient treated with a drug and a microarray is provided which comprises tissue which is the target of
20 disease from a healthy patient and from a patient with the disease. The expression of diagnostic molecule(s) in the test tissue is compared with the expression pattern of these molecules in the target tissues in the microarray. A drug is identified as useful for further testing when the expression pattern in the test tissue is substantially the same as the expression pattern within the healthy tissue (to within 95% confidence levels). Preferably, one or more tissues which are not the target of the
25 disease also are arrayed and the expression of biomolecules in corresponding test tissues from drug-treated patients, non-drug treated diseased patients, and non-drug treated healthy patients, to evaluate whether the drug has non-specific effects on biomolecules in tissues other than the target of disease.

Kits

Kits are contemplated for use in the methods according to the invention including any of the oncology tissue microarrays described above, profile array substrates comprising the microarrays, and a means for providing access to information on each cell/tissue sample at each sublocation, the information including, but not limited to, full pathology and clinical data, including medications and treatment history of the individual from whom the tissue was obtained. In one aspect of the invention, a kit includes any or all of breast cancer tissue progression microarray comprising at least about 20 sublocations comprising different breast tumor types, and including about 5 normal sublocations; a colon cancer progression microarray comprising at least about 20 sublocations comprising different colon tumor types, and including about 5 normal sublocations; a prostate cancer progression microarray comprising at least 20 sublocations comprising different prostate tumor types, and including about 5 normal sublocation; a normal tissue microarray comprising different types of tissue; a tumor microarray comprising different tumors obtained from different tissue types, including at least one normal sublocation; and a non-human animal (e.g., rat or mouse) microarray comprising sublocations representing different tissue types, at least one tissue type comprising abnormally proliferating cells. In one aspect, cells/tissues from non-human animals genetically engineered to comprise one or more cells having less than two or more than two copies of a gene involved in cell proliferation or cell death, or to express modified forms of such genes.

In one aspect, low density microarrays are provided which comprise over about 45-60 sublocations per slide.

In a further aspect, a kit is provided comprising high density tissue microarrays which represent population surveys of normal and clinical conditions for the evaluation of gene expression patterns. In one aspect, the microarrays comprise over 200 tissue samples. In one aspect, a kit is provided comprising a cancer screening array comprising over 200 samples of normal and cancer tissue, and a standard control microarray comprising samples from the following organs: liver, lymph node, kidney, hyroid and prostate. In a further aspect, a kit is provided comprising a plurality of microarrays including one or more of a normal tissue microarray, a breast cancer progression microarray, prostate cancer progression microarray, a colorectal cancer progression microarray, a lung cancer progression microarray, and/or a cancer screening microarray described.

In still a further aspect of the invention, a kit is provided comprising microarrays comprising one or more samples pre-reacted with a labeled molecular probe or stain. For example, samples pre-reacted with labeled molecular probes which specifically react with a molecule selected from the group consisting of actin, CEA, chromogranin, desmin, EMA, GFAP, HMB, MSE, PLAP, PSA, PSAP and vimentin can be provided.

In other aspects, the following antigen-specific probe/tissue combinations are provided: Actin, normal colon; Actin, uterine smooth muscle; Carcinoembryonic antigen (CEA), colon adenocarcinoma; CD3, T-cell, tonsil; CD15/LeuM1, lymphoma; CD20/L26, B-cell, tonsil; CD30/BerH2, lymphoma; CD34, hematopoietic progenitor cells, tonsil; CD34, hematopoietic progenitor cells, normal skin; CD45/LCA, T-cell, tonsil; CD68/KPI, macrophage, tonsil; Chromogranin A, pancreas; Chromogranin A, pancreas slides; Cytokeratin, pan-keratin, normal prostate; Cytokeratin, pan-keratin, normal skin; Cytokeratin 7, breast ductal carcinoma; Cytokeratin 20, colon adenocarcinoma; Cytokeratin 20, bladder carcinoma; and Cytokeratin, high molecular weight, skin; Cytokeratin, high molecular weight, prostate; Desmin, leiomyoma; Desmin, normal colon; Epithelial membrane antigen (EMA), meningioma; Epithelial membrane antigen (EMA), breast; Glial fibrillary acidic protein (GFAP), brain; HMB45, melanosome, melanoma; HMB45, melanosome, melanoma, Clark score 1-5 w/nevus; Kappa light chains, tonsil; Lambda light chains, tonsil; Neuron specific enolase (NSE), pancreas; Placental alkaline phosphatase (PLAP), seminoma; Prostate specific antigen (PSA), prostate; 1132-5 Prostatic acid phosphatase (PSAP), prostate; S100, skin; S100, melanoma; Vimentin, tonsil; Vimentin, normal colon; Von Willebrand factor (Factor VIII), tonsil; Estrogen receptor, breast carcinoma; Progesterone receptor, breast carcinoma.

In a further aspect of the invention, the kit can comprise genomic DNA from one or more of bladder, brain, breast, cervix, colon, esophagus, heart, small intestine kidney, liver, lung, skeletal muscle, pancreas, prostate, rectum, skin, spleen, stomach, testis, and the like.

Additional reagents and kit components include, but are not limited to, antibodies, labels, DNA or RNA probes, and the like.

Examples

The invention will now be further illustrated with reference to the following examples. It will be appreciated that what follows is by way of example only and that modifications may be made while still falling within the scope of the invention.

Example 1. Normal Tissue Microarray (NO50 and NO200)

This tissue microarray is designed for identification of normal tissue types where expression of a particular gene/gene product, or other genetic alteration or biomarkers occurs.

Composition:

5 The NO50 Normal tissue microarray contains 4 samples each of 20 different tissue types all on a single microarray. For each tissue type, the samples are derived from multiple different individuals (2-4 individuals) and include: cerebrum, grey substance, cerebellum, heart, lung, thyroid gland, adrenal gland, pancreas, liver, tonsil, spleen, lymph node, endometrium, secretion, ovary-stroma, myometrium, placenta- third trimenon, kidney- cortex, prostate, seminal vesicle, and
10 skeletal muscle. Patient information and information relating to other biological characteristics of each tissue in the microarray are stored in a specimen-linked database. Information includes site of biopsy, tissue represented, histological diagnosis, underlying disease, age at time of diagnosis, source of tissue (e.g., from biopsy or from autopsy), in case of autopsies, the time span between death and autopsy is also provided (see Table 10, for example). The microarray is also provided
15 with an array locator to address the sublocations on the array.

Normal Tissue Microarray (NO200)

The NO200 set comprises a plurality of microarrays including: 2 NO200 Normal tissue array sections, 3 TE30 Test slides (described in Example 2), 1 NO200 data report, 1 TE30 data report and the NO200 database, of the associated pathology and clinical data (see Table 11).

Composition:

20 The NO200 Normal tissue microarray contains 10 samples each of 40 different tissue types. For each tissue type the samples are derived from multiple different individuals (2-6 individuals) and include: cerebrum- grey substance,- cerebrum, white substance, cerebellum, heart, bronchus, lung, thyroid gland, adrenal gland, skin, pancreas, submandibular gland,, stomach-corpus, stomach-
25 antrum, duodenum, ileum, appendix, colon, liver, gall bladder, tonsil, spleen, lymph node, ovary-stroma, ovary-corpus luteum, fallopian tube, endometrium-proliferation, endometrium secretion, endocervix, ectocervix, myometrium, placenta (last trimenom), kidney cortex, kidney -papilla, kidney-pelvis, prostate, seminal vesicle, testis, epidydimis, skeletal muscle, and smooth muscle.

Exemplary data relating to the biological characteristics of tissue samples in the microarray which are stored in the database is provided in Tables 2-22, in accompanying, Appendix A, the entirety of which is incorporated by reference herein. The coordinates of the sublocations on the microarray are defined using an array locator.

5 Example 2. Oncology Test Array (TE30)

This microarray been designed to find optimal conditions for molecular analysis to be performed on larger micorarrays.

Composition:

10 The TE30 test array contains a total of 30 tissue samples of the following types:
colon cancer (n=5);-breast cancer (n=5); lung cancer (n=5); prostate cancer (n=5); normal tissues
from the following organs: liver, skeletal muscle, lymph node, kidney cortex, thyroid, prostate,
spleen.

Exemplary data relating to the biological characteristics of tissue samples in the microarray
which are stored in the database is provided in Table 3, in accompanying Appendix A.. The
coordinates of the sublocations on the microarray are defined using an array locator.

Example 3. Head and Neck Cancer Progression Array

HN200

20 This oncology tissue microarray is designed do find associations between expression of a
particular gene/gene product, other genetic alterations or biomarkers and different stages of head and
neck cancer progression.

Composition:

25 The HN200 head and neck cancer array contains a total of 200 tissue samples (each at two
different sublocations on the array): normal oral mucosa from patients with no history of head and
neck cancer (10 sublocation), paired tissues: normal and cancerous oral mucosa from same patients
(20 sublocations), oral mucosa with mild to moderate dysplasia (20 sublocations) oral mucosa with
severe dysplasia/carcinoma in situ (10, sublocations), nodal negative head and neck cancer (80
sublocations), nodal positive head and neck cancer (80 sublocations), paired metastases: lymph node
30 metastases from tumors included in this microarray (40 sublocations), standard control section of the

array contains normal tissues from brain, heart, liver, spleen, muscle, lymph node, testis, kidney, thyroid, adrenal gland, lung and prostate (24 sublocations).

Head and Neck Cancer Screening Array (NH50)

This oncology tissue microarray has been designed to identify whether expression of a particular gene/gene product, other genetic alterations occur in head and neck cancer.

Composition:

The HN50 head and neck cancer array contains a total of 50-80 tissue samples (with duplicate sublocations): head and neck cancers of different locations / stages (30-60 sublocations), standard control section of the array contains normal tissues from oral mucosa, liver, spleen, lymph node, kidney, thyroid, and prostate (20 sublocations), and can also include, normal oral mucosa: tonsils, and cancers of: lip, tongue, tonsil, oral, pharynx.

Example 3. Prostate Cancer Progression Array Set - PR200

This Prostate Cancer Progression Array Set has been designed to find associations between molecular events and different stages of prostate cancer progression and comprises a set of microarrays.

Composition

The PR200 set contains: 2 PR200 Prostate cancer progression array sections, 3 TE30 Test slides, 1 PR200 data report, 1 TE30 data report, the PR200 database, of the associated pathology and clinical data.

The PR200 Prostate Cancer Progression Array contains a total of 200 tissue samples of the following types (double spotted): benign prostatic hyperplasia, prostatic intraepithelial neoplasia (PIN; high grade), prostate cancer (Gleason score 1-2), prostate cancer (Gleason score 3), prostate cancer (Gleason score 4), prostate cancer (Gleason score 5), prostate cancer metastases, standard control section of the array contains normal tissues from the following organs: brain, heart, liver, spleen, muscle, lymph node, testis, kidney, thyroid, adrenal gland, lung and prostate.

Example 4. Prostate Cancer Survey Array - PR50

The Prostate Cancer Survey Array has been designed as a first line screening tool to see whether expression of a particular gene, gene product, or other genetic alteration or biomarker occurs in prostate cancer.

5 Composition:

The PR50 microarray set contains: 4 PR50 Prostate cancer survey array sections, 1 H&E Stained prostate cancer survey array section, 1 PR50 data report, PR50 database including associated pathology and clinical data.

10 The PR50 Prostate Cancer Survey Array contains a total of 60-80 tissue samples of the following types: prostate cancer (45-60 sublocations); standard control section contains samples from the following organs: prostate, liver, lymph node, kidney, thyroid and seminal vesicles. Data relating to sublocations on the array is included in Table 4 in Appendix A.

15 Table 18 in Appendix A shows results of screening Prostate and Normal Tissue arrays using a molecular probe (e.g., an antibody) reactive with α -testosterone. Staining in the epithelium and/or stroma is correlated with coordinates on the microarray as well as patient sex, age, organ, tumor type, stage of cancer, and source (e.g., surgery). Tables 20 -22 provide data relating to the reactivity of the probe in cancerous but non-prostate tissues as well as prostate and normal tissues using frozen tissue microarrays. The information from these Tables is stored in the specimen-linked database.

Example 5. Colorectal Cancer Progression Array (CR200)

20 The Colorectal Cancer Progression Array set has been specifically designed to find associations between expression of a particular gene, gene product, other genetic alterations or biomarkers and the different stages of colorectal cancer progression.

Composition:

25 The CR200 set contains: 2 CR200 Colorectal cancer progression array sections, 3 TE30 Test slides, 1 CR200 data report, 1 TE30 data report, the CR200 database, of the associated pathology and clinical data.

The CR200 Colorectal Cancer Progression Array contains a total of 200 tissue samples (double spotted) of the following types: normal colon mucosa from patients having no history of colorectal cancer, paired tissues: normal and cancerous colon mucosa from same patients, adenoma with mild dysplasia, adenoma with moderate dysplasia, adenoma with severe dysplasia, nodal negative colorectal cancer, nodal positive colorectal cancer, paired metastases: lymph node metastases from tumors included in this TMA and a standard control section of the array contains normal tissues from the following organs: brain, heart, liver, spleen, muscle, lymph node, testis, kidney, thyroid, adrenal gland, lung, and prostate.

A smaller microarray (CR50) providing a total of 50 tissue samples is described in Tables 5 and 6 and can be used in screening or validation of target biomolecules.

Example 6. Cancer Screening Array - CS200

The Cancer Screening Array according to one aspect of the invention has been specifically designed to survey multiple cancer types for the identification of tumor types that express a particular gene, gene product, genetic alteration or other biomarker.

Composition:

The CS200 set contains: 2 CS200 Cancer screening array sections, 3 TE30 Test slides, 1 CS200 data report, 1 TE30 data report, and access to the CS200 database, of the associated pathology and clinical data (see Table 7).

The CS200 Cancer Screening Array contains a total of 200 tissue samples from a number of different tumor types: colorectal cancer, prostate cancer, lung cancer, breast cancer, kidney cancer, urinary bladder cancer, ovarian cancer, brain tumors, malignant melanoma, head and neck cancer and a standard control section of the array which contains normal tissues from the following organs: brain, heart, liver, spleen, muscle, lymph node, testis, kidney, thyroid, adrenal gland, and lung.

Results from screening such an array with a molecular probe reactive with immunophilin (α -FKBP51) which is suspected of modulating steroid receptor responses are shown in Table 15 of Appendix A. Reactivity of the microarray with the probe is correlated with age, sex, tumor type, grade, lymph node status, DM status, source (e.g., surgery or biopsy) and resection margins and this information is stored in the specimen-linked database.

Example 7. Lung Cancer Progression Array - LU200

The Lung Cancer Progression Array has been designed to find associations between molecular events and different histologic subtypes and stages of lung cancer.

5 Composition:

The LU200 set contains: 2 LU200 Lung cancer progression array sections, 3 TE30 Test slides, 1 LU200 data report, 1 TE30 data report, the LU200 database, of the associated pathology and clinical data.

10 The LU200 Lung Cancer Progression Array contains a total of 200 tissue samples of the following types (double spotted): normal lung parenchyma, normal bronchi (epithelium), adenocarcinoma (different subtypes), squamous cell carcinoma, adenocarcinoma, undifferentiated large cell carcinoma, small cell carcinoma, lymph node metastases from tumors included in this microarray (paired metastases), standard control section of the array contains normal tissues from the following organs: brain, heart, liver, spleen, muscle, lymph node, testis, kidney, thyroid, adrenal gland, and prostate.

Example 8. Cervical Cancer Progression Microarray

The Cervical Cancer Array has been designed to find associations between molecular events and different histologic subtypes and stages of cervical cancer. The tissues represented in this array, their locations, and associated patient information is provided in Table 8, in Appendix A.

20 Example 9. Breast Cancer Progression Microarray

The Breast Cancer Array has been designed to find associations between molecular events and different histologic subtypes and stages of breast cancer. The tissues represented in this array, their locations, and associated patient information is provided in Table 9, in Appendix A.

Example 10. Uterine and Ovarian Carcinoma Test

25 CA125 (receptor-binding cancer antigen expressed in SiSo cells) is a novel tumor associated antigen expressed in human uterine and ovarian carcinomas. The predicted amino acid sequence of CA125 (213a.a.) possesses an N-terminal transmembrane region and a coiled-coil structure in the C-terminal portion, indicating that CA125 is a type II membrane protein able to form oligomers

through the coiled-coil structure. CA125 revealed different expression pattern from the known tumor associated antigens such as YH206, GA733, CA125, CEA and sialyl Le molecules in human tumor cell lines. Recent studies indicate that CA125 acts as a ligand for a putative receptor present on various human cells including T, B, and NK cells. CA125 inhibits the *in vitro* growth of receptor-expressing cells and induced apoptosis. It has been suggested that tumor cells might evade immune surveillance by expression of CA125.

Anti-CA125 antibody can be obtained purified from mouse ascites fluid using protein-L Sepharose. Monoclonal antibodies can be obtained from hybridomas established by fusion of mouse myeloma cell x63. Ag8.653 with Balb/c splenocyte immunized with human uterine cervical adenocarcinoma cells. The antibody is preferably tested by flow cytometry and/or immunohistochemical staining. The antibody may be used for immunohistochemical analysis of ovarian, cervical, or endometrial adenocarcinoma.

Immunohistochemical staining of paraffin sections can be done as follows:

1. Deparaffinize section, hydrate to water (Xylene -3 times, Ethanol- 3 times, PBS-3 times)
2. Wash in PBS for 5 minutes before starting the stain.
3. Remove slides from PBS and cover each with 100 to 200 microliters of 3% H2O2 for 10 minutes to block endogenous Peroxidase activity. Wash in PBS twice for 5 minutes each.
4. Remove slides from PBS, wipe gently around each section and cover tissue with 100 to 200 microliters of protein blocking reagent for 5 minutes.
5. Tip off the blocking reagent, wipe gently around each section and cover tissue with 100 to 200 microliters of primary antibody CA125 at an about 1:500 dilution
6. Incubate for 1 hour at room temperature.
7. Wash slide with a stream of PBS from a wash bottle. Wash in PBS 3 times for 5 minutes each.
8. Wipe gently around each section and cover tissue with 100 to 200 microliters of polyvalent biotinylated antibody
9. Incubate for 30 min at room temperature.
10. Wash as in step 7.
11. Wipe gently around each section and cover tissue with 100 to 200 microliters of strepavidin conjugated HRP.

12. Incubate for 30 minutes at room temperature.
13. Wash as in step 7.
14. Visualize with DAB substrate/chromogen (20 mg of DAB in 400 ml of PBS containing 40 microliters 3% H₂O₂) for 15 min. Wash in distilled H₂O
15. Counterstain in Hematoxylin for 1 min
16. Wash in PBS.
17. Dehydrate and clear using ethanol and xylene.
18. Mount coverglass.

Results of such an evaluation are shown in Table 16 which correlates reactivity of an anti-CA125 molecular probe with information such as patient sex, age, organ, tumor type, grade, lymph node status, DM status, source (e.g., surgery or biopsy), and resection margins, and coordinates on a tissue microarray. Table 17 additionally correlates reactivity with diagnosis. Table 19 provides data from ovarian, endometrial and cervical carcinomas. The information in the Tables is obtained from the specimen-linked database.

Example 11. Diagnosing Lymph Node Positive Biopsies

Lymph node biopsies with known follow-up outcomes as non-metastatic (NM) or metastatic (M) are diagnosed using both morphological methods and IHC using an anti-bcl-2 antibody as a molecular probe after arraying the same on tissue microarrays. In one aspect, negative lymph node biopsies (determined to be negative based on morphological criteria) are examined to determine false negative rates using both reactivity to a bcl-2 specific molecular probe and morphological criteria. Data relating to reactivity is stored in a specimen-linked database in which the identity/location of biopsy tissue on the array is correlated to clinical data regarding cancer outcome and/or progression. The suitability of bcl-2 as a diagnostic probe is determined using the tissue information system according to the invention.

Example 12. Molecular Profiling of Breast Cancer Tissue

Table 12 and 13 of Appendix A show results of molecular profiling assays of breast tissue from 356 different patients. Table 12 provides a summary of pertinent clinical information stored in the specimen-linked database. Table 13 shows the results of reacting tissue microarrays comprising breast tissue with anti-Her-2/Neu probes and anti-Estrogen Receptor (ER probes). Samples 1-180

Table 2

Tissue MicroArray Normal 2000 (NO200)

Coordinates	Identical Biopsy	Age	Sex	Organ	Underlying Disease	Histologic DX	Tissue Represented, Lot ¹	Material
A1a	1	47	F	Thyroid	Adenoma	Normal	Ok	biopsy
A1b	1	47	F	Thyroid	Thyroid cancer	Normal	Ok	Biopsy
A1c	1	47	F	Thyroid	Adenoma	Normal	Ok	Biopsy
A1d	1	47	F	Thyroid	Adenoma	Normal	Ok	Biopsy
A1e	2	26	M	Thyroid	Adenoma	Normal	Ok	Biopsy
A1f	2	26	M	Thyroid	Adenoma	Normal	Ok	Biopsy
A1g	2	26	M	Thyroid	Adenoma	Normal	Ok	Biopsy
A1h	3	65	M	Thyroid	Adenoma	Normal	Ok	Biopsy
A1i	3	65	M	Thyroid	Adenoma	Normal	Ok	Biopsy
A1j	3	65	M	Thyroid	Adenoma	Normal	Ok	Biopsy
A1k	4	32	F	Adrenal gland	Depression, trauma	Normal	Ok	Autopsy, 3h
A1l	4	32	F	Adrenal gland	Depression, trauma	Normal	Ok	Autopsy, 3h
A1m	4	32	F	Adrenal gland	Depression, trauma	Normal	Ok	Autopsy, 3h
A1n	5	41	M	Adrenal gland	Trauma	Normal	Ok	Autopsy, 5h
A1o	5	41	M	Adrenal gland	Trauma	Normal	Ok	Autopsy, 5h
A1p	5	41	M	Adrenal gland	Trauma	Normal	Few epithelial cells	Autopsy, 5h
A2a	6	37	M	Adrenal gland	Trauma	Normal	Ok	Autopsy, 4h
A2b	6	37	M	Adrenal gland	Trauma	Normal	Ok	Autopsy, 4h
A2c	7	74	M	Adrenal gland	Clear cell RCC	Normal	Few epithelial cells	Biopsy
A2d	7	74	M	Adrenal gland	Clear cell RCC	Normal	Ok	Biopsy
A2e	12	28	F	Placenta, third trimester	Rapid labor	Normal	Ok	Biopsy
A2f	12	28	F	Placenta, third trimester	Rapid labor	Normal	Ok	Biopsy

Coordinates	Identical Biopsy	Age	Sex	Organ	Underlying Disease	Histologic DX	Tissue Represented, Lot1	Material
A2g	12	28	F	third trimester Placenta, third	Rapid labor	Normal	Ok	Biopsy
A2h	13	29	F	trimester Placenta, third	Prolonged labor	Normal	Ok	Biopsy
A2i	13	29	F	trimester Placenta, third	Prolonged labor	Normal	Ok	Biopsy
A2j	13	29	F	trimester Placenta, third	Prolonged labor	Normal	Ok	Biopsy
A2k	14	32	F	trimester Placenta, third		Normal	Ok	Biopsy
A2l	14	32	F	trimester Placenta, third		Normal	Ok	Biopsy
A2m	15	29	F	trimester Placenta, third	Full term pregnancy	Normal	Ok	Biopsy
A2n	15	29	F	trimester Placenta, third	Full term pregnancy	Normal	Ok	Biopsy
A2o	16	25	M	trimester Tonsil	Chronic tonsillitis	Normal	Ok	Biopsy
A2p	17	18	F	Tonsil	Chronic tonsillitis	Normal	Ok	Biopsy
A3a	18	17	F	Tonsil	Chronic tonsillitis	Normal	Ok	Biopsy
A3b	18	17	F	Tonsil	Chronic tonsillitis	Normal	Ok	Biopsy
A3c	19	22	M	Tonsil	Chronic tonsillitis	Normal	Ok	Biopsy
A3d	19	22	M	Tonsil	Chronic tonsillitis	Normal	Ok	Biopsy
A3e	20	42	F	Tonsil	Chronic tonsillitis	Normal	Ok	Biopsy
A3f	20	42	F	Tonsil	Chronic tonsillitis	Normal	Ok	Biopsy
A3g	21	34	M	Tonsil	Chronic tonsillitis	Normal	Ok	Biopsy
A3h	21	34	M	Tonsil	Chronic tonsillitis	Normal	Ok	Biopsy
A3i	22	16	M	Lymph node	Normal	Normal	Ok	Biopsy
A3j	22	16	M	Lymph node	Normal	Normal	Ok	Biopsy
A3k	23	76	M	Lymph node	Gastric cancer	Normal	Ok	Biopsy

Coordinates	Identical Biopsy	Age	Sex	Organ	Underlying Disease	Histologic DX	Tissue Represented, Lot1	Material
A31	23	76	M	Lymph node	Gastric cancer	Normal	Ok	Biopsy
A3m	24	62	F	Lymph node	Breast cancer	Normal	Ok	Biopsy
A3n	24	62	F	Lymph node	Breast cancer	Normal	Ok	Biopsy
A3o	24	62	F	Lymph node	Breast cancer	Normal	Ok	Biopsy
A3p	25	54	F	Lymph node	Breast cancer	Normal	Ok	Biopsy
A4a	25	54	F	Lymph node	Breast cancer	Normal	Ok	Biopsy
A4b	25	54	F	Lymph node	Breast cancer	Normal	Ok	Biopsy
A4c	26	32	F	Spleen	Depression, trauma	Normal	Ok	Autopsy, 3h
A4d	26	32	F	Spleen	Depression, trauma	Normal	Ok	Autopsy, 3h
A4e	27	21	F	Spleen	Trauma	Normal	Ok	Biopsy
A4f	27	21	F	Spleen	Trauma	Normal	Ok	Biopsy
A4g	28	43	M	Spleen	Old hematoma	Normal	Ok	Biopsy
A4h	28	43	M	Spleen	Old hematoma	Normal	Ok	Biopsy
A4i	29	74	F	Spleen	Right	Normal	Ok	Biopsy
A4j	29			Spleen		Normal	Ok	Biopsy
A4k	30	26	F	Spleen	Hodgkin disease	Normal	Ok	Biopsy
A4l	30	26	F	Spleen	Hodgkin disease	Normal	Ok	Biopsy
A4m	31	68	F	Skin	Breast Cancer	Normal	Ok	Biopsy
A4n	31	68	F	Skin	Breast Cancer	Normal	Ok	Biopsy
A4o	32	44	F	Skin	Breast Cancer	Normal	Ok	Biopsy
A4p	32	44	F	Skin	Breast Cancer	Normal	Ok	Biopsy
A5a	33	53	F	Skin	Breast Cancer	Normal	Ok	Biopsy
A5b	33	53	F	Skin	Breast Cancer	Normal	Ok	Biopsy
A5c	33	53	F	Skin	Breast Cancer	Normal	Ok	Biopsy
A5d	34	57	F	Skin	Breast Cancer	Normal	Ok	Biopsy
A5e	34	57	F	Skin	Breast Cancer	Normal	Ok	Biopsy
A5f	34	57	F	Skin	Breast Cancer	Normal	Ok	Biopsy
A5g	35	32	F	Heart	Depression, trauma	Normal	Ok	Autopsy, 3h
A5h	35	32	F	Heart	Depression, trauma	Normal	Ok	Autopsy, 3h
A5i	35	32	F	Heart	Depression, trauma	Normal	Ok	Autopsy, 3h
A5j	36	41	M	Heart	Trauma	Normal	Ok	Autopsy, 5h
A5k	36	41	M	Heart	Trauma	Normal	Ok	Autopsy, 5h
A5l	36	41	M	Heart	Trauma	Normal	Ok	Autopsy, 5h
A5m	37	37	M	Heart	Trauma	Normal	Ok	Autopsy, 4h
A5n	37	37	M	Heart	Trauma	Normal	Ok	Autopsy, 4h
A5o	37	37	M	Heart	Trauma	Normal	Ok	Autopsy, 4h
A5r	37	37	M	Heart	Trauma	Normal	Ok	Autopsy, 4h
A6a	38	25	M	Scapular muscle	Tonsillitis chronica	Normal	Ok	Biopsy

Coordinates	Identical Biopsy	Age	Sex	Organ	Underlying Disease	Histologic DX	Tissue Represented, Lot1	Material
A6b	39	27	M	Skeletal muscle	Seminoma	Normal	Ok	Biopsy
A6c	40	22	M	Skeletal muscle	Chronic tonsillitis	Normal	Ok	Biopsy
A6d	41	43	M	Skeletal muscle	Hernia	Normal	Ok	Biopsy
A6e	42	67	M	Skeletal muscle	Eyid resection	Normal	Ok	Biopsy
A6f	42	67	M	Skeletal muscle	Eyid resection	Normal	Ok	Biopsy
A6g	44	31	F	Skeletal muscle	Thyroid cancer	Normal	Bleeding, no muscle	Biopsy
A6h	45			Skeletal muscle	Breast cancer	Normal	Ok	Biopsy
A6i	46			Skeletal muscle	Breast cancer	Normal	Ok	Biopsy
A6j	46			Skeletal muscle	Breast cancer	Normal	Ok	Biopsy
A6k	47	75	F	Smooth muscle, intestine	Gastric ulcer	Normal	Ok	Biopsy
A6l	48	68	M	Smooth muscle, intestine	Gastric cancer	Normal	Ok	Biopsy
A6m	49	91	M	Smooth muscle, intestine	Gastric cancer	Normal	Ok	Biopsy
A6n	49	91	M	Smooth muscle, intestine	Gastric cancer	Normal	Ok	Biopsy
A6o	50	76	M	Smooth muscle, intestine	Gastric cancer	Normal	Ok	Biopsy
A6p	50	76	M	Smooth muscle, intestine	Gastric cancer	Normal	Ok	Biopsy
A7a	51	76	M	Smooth muscle, intestine	Gastric cancer	Normal	Ok	Biopsy

Coordinates	Identical Biopsy	Age	Sex	Organ	Underlying Disease	Histologic DX	Tissue Represented, Lot#	Material
A7b	51	47	F	Smooth muscle, intestine	Reflux esophagitis	Normal	Ok	Biopsy
A7c	52	47	F	Smooth muscle, intestine	Reflux esophagitis	Normal	Ok	Biopsy
A7d	52	47	F	Smooth muscle, intestine	Reflux esophagitis	Normal	Ok	Biopsy
A7e	53	75	F	Stomach, antrum	Gastric ulcer	Normal	Lipomatous tissue	Biopsy
A7f	53	75	F	Stomach, antrum	Gastric ulcer	Normal	Intestinal metaplasia	Biopsy
A7g	53	75	F	Stomach, antrum	Gastric ulcer	Normal	Ok	Biopsy
A7h	53	75	F	Stomach, antrum	Gastric ulcer	Normal	Chronic inflammation	Biopsy
A7i	53	75	F	Stomach, antrum	Gastric ulcer	Normal	Chronic inflammation	Biopsy
A7j	54	68	M	Stomach, antrum	Gastric cancer	Normal	Chronic inflammation	Biopsy
A7k	54	68	M	Stomach, antrum	Gastric cancer	Normal	Chronic inflammation	Biopsy
A7l	54	68	M	Stomach, antrum	Gastric cancer	Normal	Ok	Biopsy
A7m	54	68	M	Stomach, antrum	Gastric cancer	Normal	Ok	Biopsy
A7n	54	68	M	Stomach, antrum	Gastric cancer	Normal	Ok	Biopsy
A7o	56	68	M	Stomach, corpus	Gastric cancer	Normal	Ok	Biopsy
A7p	56	68	M	Stomach, corpus	Gastric cancer	Normal	Ok	Biopsy
A8a	57	76	M	Stomach, corpus	Gastric cancer	Normal	Ok	Biopsy
A8b	57	76	M	Stomach, corpus	Gastric cancer	Normal	Ok	Biopsy
A8c	58	47	F	Stomach, corpus	Reflux esophagitis	Normal	Ok	Biopsy

Coordinates	Identical Biopsy	Age	Sex	Organ	Underlying Disease	Histologic DX	Tissue Represented, Lot1	Material
A8d	58	47	F	Stomach, corpus	Reflux esophagitis	Normal	Ok	Biopsy
A8e	59	76	F	Stomach, corpus	Gastric cancer, chronic active gastritis	Normal	Ok	Biopsy
A8f	59	76	F	Stomach, corpus	Gastric cancer, chronic active gastritis	Normal	Ok	Biopsy
A8g	60	90	F	Stomach, corpus	Duodenal ulcer	Normal	No epithelial cells	Biopsy
A8h	60	90	F	Stomach, corpus	Duodenal ulcer	Normal	Ok	Biopsy
A8i	55	75	F	Duodenum	Gastric cancer	Normal	Ok	Biopsy
A8j	55	75	F	Duodenum	Gastric cancer	Normal	Ok	Biopsy
A8k	61	81	F	Duodenum	Colon cancer	Normal	Ok	Biopsy
A8l	61	81	F	Duodenum	Colon cancer	Normal	Ok	Biopsy
A8m	62	76	F	Duodenum	Gastric cancer, chronic active gastritis	Normal	Ok	Biopsy
A8n	62	76	F	Duodenum	Gastric cancer, chronic active gastritis	Normal	Ok	Biopsy
A8o	62	76	F	Duodenum	Gastric cancer, chronic active gastritis	Normal	Ok	Biopsy
A8p	63	90	F	Duodenum	Duodenal ulcer	Normal	Ok	Biopsy
A9a	63	90	F	Duodenum	Duodenal ulcer	Normal	Ok	Biopsy
A9b	63	90	F	Duodenum	Duodenal ulcer	Normal	Ok	Biopsy
A9c	64	66	F	Ileum	Colon cancer	Normal	Ok	Biopsy
A9d	65	79	M	Ileum	Colon cancer	Normal	Ok	Biopsy
A9e	66	72	M	Ileum	Colon cancer	Normal	Ok	Biopsy
A9f	67	57	M	Ileum	Colon cancer	Normal	Ok	Biopsy
A9g	68	72	M	Ileum	Colon cancer	Normal	Ok	Biopsy
A9h	68	72	M	Ileum	Colon cancer	Normal	Ok	Biopsy
A9i	69	85	M	Ileum	Colon cancer	Normal	Ok	Biopsy
A9j	69	85	M	Ileum	Colon cancer	Normal	Ok	Biopsy
A9k	70	82	F	Ileum	Colon cancer	Normal	Ok	Biopsy
A9l	70	82	F	Ileum	Colon cancer	Normal	Ok	Biopsy
A9m	71	79	M	Colon	Colon cancer	Normal	Ok	Biopsy
A9n	71	79	M	Colon	Colon cancer	Normal	Ok	Biopsy
A9o	72	85	F	Colon	Colon cancer	Normal	Ok	Biopsy
A9p	72	85	F	Colon	Colon cancer	Normal	No epithelial cells	Biopsy
B1a	73	72	M	Colon	Colon adenoma	Normal	Ok	Biopsy
B1b	73	72	M	Colon	Colon adenoma	Normal	Ok	Biopsy

Coordinates	Identical Biopsy	Age	Sex	Organ	Underlying Disease	Histologic DX	Tissue Represented, Lot#	Material
B1c	74	57	M	Colon	Colon cancer	Normal	Sample missing on first section	Biopsy
B1d	74	57	M	Colon	Colon cancer	Normal	Ok	Biopsy
B1e	75	85	M	Colon	Colon cancer	Normal	Ok	Biopsy
B1f	75	85	M	Colon	Colon cancer	Normal	Ok	Biopsy
B1g	76	72	M	Appendix	Colon adenoma	Normal	Ok	Biopsy
B1h	77	57	M	Appendix	Colon cancer	Normal	Ok	Biopsy
B1i	77	57	M	Appendix	Colon cancer	Normal	Only smooth muscle	Biopsy
B1j	78	25	F	Appendix	Idiopath megacolon	Normal	Connective tissue	Biopsy
B1k	79	85	M	Appendix	Colon cancer	Normal	Ok	Biopsy
B1l	79	85	M	Appendix	Colon cancer	Normal	Ok	Biopsy
B1m	80	32	F	Appendix	Uterus endometriosis	Normal	Ok	Biopsy
B1n	80	32	F	Appendix	Uterus endometriosis	Normal	Debris	Biopsy
B1o	81	88	M	Appendix	Colon cancer	Normal	Ok	Biopsy
B1p	81	88	M	Appendix	Colon cancer	Normal	Ok	Biopsy
B2a	82	78	M	Gall bladder	Normal	Normal	Ok	Biopsy
B2b	82	78	M	Gall bladder	Normal	Normal	Ok	Biopsy
B2c	83	16	M	Gall bladder	Normal	Normal	Ok	Biopsy
B2d	83	16	M	Gall bladder	Normal	Normal	Ok	Biopsy
B2e	84	56	F	Gall bladder	Normal	Normal	Ok	Biopsy
B2f	84	56	F	Gall bladder	Normal	Normal	Ok	Biopsy
B2g	85	54	F	Gall bladder	Normal	Normal	Ok	Biopsy
B2h	85	54	F	Gall bladder	Normal	Normal	Ok	Biopsy
B2i	86			Gall bladder	Normal	Normal	Ok	Biopsy
B2j	86			Gall bladder	Normal	Normal	Ok	Biopsy
B2k	87	74	F	Liver	Mild non-specific portal triaditis	Normal	Ok	Biopsy
B2l	87	74	F	Liver	Mild non-specific portal triaditis	Normal	Ok	Biopsy
B2m	88	85	M	Liver	Colon cancer, metastatic	Normal	Ok	Biopsy
B2n	88	85	M	Liver	Colon cancer, metastatic	Normal	Ok	Biopsy
B2o	89	71	M	Liver	Cholecystitis	Normal	Ok	Biopsy
B2p	89	71	M	Liver	Cholecystitis	Normal	Inflammation	Biopsy
B3a	89	71	M	Liver	Cholecystitis	Normal	Ok	Biopsy
B3b	90	26	F	Liver	Hodgkin disease	Normal	Ok	Biopsy
B3c	90	26	F	Liver	Hodgkin disease	Normal	Ok	Biopsy
B3d	90	26	F	Liver	Hodgkin disease	Normal	Ok	Biopsy
B3e	93			Pancreas		Normal	Ok	Autopsy, <12h
B3f	93			Pancreas		Normal	Ok	Autopsy, <12h

Coordinates	Identical Biopsy	Age	Sex	Organ	Underlying Disease	Histologic DX	Tissue Represented, Lot1	Material
B3g	93			Pancreas		Normal	Ok	Autopsy, <12h
B3h	93			Pancreas		Normal	Ok	Autopsy, <12h
B3i	91	32	F	Pancreas	Depression, trauma	Normal	Ok	Autopsy, 3h
B3j	91	32	F	Pancreas	Depression, trauma	Normal	Ok	Autopsy, 3h
B3k	91	32	F	Pancreas	Depression, trauma	Normal	Ok	Autopsy, 3h
B3l	92	41	M	Pancreas	Trauma	Normal	Ok	Autopsy, 5h
B3m	92	41	M	Pancreas	Trauma	Normal	Ok	Autopsy, 5h
B3n	92	41	M	Pancreas	Trauma	Normal	Ok	Autopsy, 5h
B3o	94	31	M	Submandibul ar gland	Sialadenitis other area (behind stone)	Normal	Ok	Autopsy, 5h Biopsy
B3p	94	31	M	Submandibul ar gland	Sialadenitis other area (behind stone)	Normal	Ok	Biopsy
B4a	94	31	M	Submandibul ar gland	Sialadenitis other area (behind stone)	Normal	Ok	Biopsy
B4b	95	62	F	Submandibul ar gland	Mucoepidermoid carcinoma	Normal	Ok	Biopsy
B4c	95	62	F	Submandibul ar gland	Mucoepidermoid carcinoma	Normal	Ok	Biopsy
B4d	95	62	F	Submandibul ar gland	Mucoepidermoid carcinoma	Normal	Ok	Biopsy
B4e	96	31	F	Submandibul ar gland	Thyroid cancer	Normal	Ok	Biopsy
B4f	96	31	F	Submandibul ar gland	Thyroid cancer	Normal	Ok	Biopsy
B4g	96	31	F	Submandibul ar gland	Thyroid cancer	Normal	Ok	Biopsy
B4h	96	31	F	Submandibul ar gland	Thyroid cancer	Normal	Ok	Biopsy
B4i	100	44	F	Ovary, stroma	Abnormal bleedings	Normal	Fallopian tube	Biopsy
B4j	98		F	Ovary, stroma	CIS cervix	Normal	Ok	Biopsy
B4k	99	45	F	Ovary, stroma	Menometrorrhagia	Normal	Ok	Biopsy
B4l	100	44	F	Ovary, stroma	Abnormal bleedings	Normal	Ok	Biopsy
B4m	101	45	F	Ovary, stroma	Myoma uterus	Normal	Ok	Biopsy
B4n	98		F	Ovary, stroma	CIS cervix	Normal	Ok	Biopsy

Coordinates	Identical Biopsy	Age	Sex	Organ	Underlying Disease	Histologic DX	Tissue Represented, Lot1	Material
B4o	102	47	F	stoma Ovary,	Hysterectomy	Normal	Sample missing on first section	Biopsy
B4p	102	47	F	stoma Ovary,	Hysterectomy	Normal	Ok	Biopsy
B5a	103	47	F	stoma Ovary,	Myoma uterus	Normal	Ok	Biopsy
B5b	103	47	F	stoma Ovary,	Myoma uterus	Normal	Ok	Biopsy
B5c	100	44	F	Ovary, corpus luteum	Abnormal bleedings	Normal	Ok	Biopsy
B5d	105	32	F	Ovary, corpus luteum	Endometriosis uterus	Normal	Ok	Biopsy
B5e	106	45	F	Ovary, corpus luteum	Menometrorrhagia	Normal	Ok	Biopsy
B5f	106	45	F	Ovary, corpus luteum	Menometrorrhagia	Normal	Ok	Biopsy
B5g	107	44	F	Ovary, corpus luteum	Abnormal bleedings	Normal	Ok	Biopsy
B5h	107	44	F	Ovary, corpus luteum	Abnormal bleedings	Normal	Ok	Biopsy
B5i	108	45	F	Ovary, corpus luteum	Myoma uterus	Normal	Ok	Biopsy
B5j	108	45	F	Ovary, corpus luteum	Myoma uterus	Normal	Ok	Biopsy
B5k	109	47	F	Ovary, corpus luteum	Hysterectomy	Normal	Ok	Biopsy
B5l	109	47	F	Ovary, corpus luteum	Hysterectomy	Normal	Ok	Biopsy
B5m	110	25	F	Fallopian tube		Normal	Ok	Biopsy
B5n	110	25	F	Fallopian tube		Normal	Ok	Biopsy
B5o	111	30	F	Fallopian tube		Normal	Ok	Biopsy
B5r	111	30	F	Fallopian tube		Normal	Ok	Biopsy
B6a	112		F	Fallopian tube	CIS cervix	Normal	Ok	Biopsy

Coordinates	Identical Biopsy	Age	Sex	Organ	Underlying Disease	Histologic DX	Tissue Represented, Lot1	Material
B6b	B11	30	F	Fallopian tube		Normal	Ok	Biopsy
B6c	B13	45	F	Fallopian tube	Myoma uterus	Normal	Ok	Biopsy
B6d	B13	45	F	Fallopian tube	Myoma uterus	Normal	Ok	Biopsy
B6e	B14	47	F	Fallopian tube	Myoma uterus	Normal	Ok	Biopsy
B6f	B14	47	F	Fallopian tube	Myoma uterus	Normal	Ok	Biopsy
B6g	B15	42	F	Myometrium	Dysfunctional bleeding, myoma, adenomyosis	Normal	Some endometrium included	Biopsy
B6h	B16	28	F	Myometrium	Ruptured ovarian cyst (endometriosis)	Normal	Ok	Biopsy
B6i	B19	30	F	Myometrium	Pelvic pain	Normal	Ok	Biopsy
B6j	B18	42	F	Myometrium	Ovarian cyst (endometriosis)	Normal	Endometrium	Biopsy
B6k	B19	30	F	Myometrium	Pelvic pain	Normal	Ok	Biopsy
B6l	B20	45	F	Myometrium	Menometrorrhagia	Normal	Ok	Biopsy
B6m	B21	49	F	Myometrium	Endometrium cancer	Normal	Ok	Biopsy
B6n	B21	49	F	Myometrium	Endometrium cancer	Normal	Ok	Biopsy
B6o	B22		F	Myometrium	CIS cervix	Normal	Ok	Biopsy
B6p	B22		F	Myometrium	CIS cervix	Normal	Ok	Biopsy
B7a	B7a	31	F	Endo sekr	Prolaps	Normal	Ok	Biopsy
B7b	B7b	31	F	Endo sekr	Prolaps	Normal	Ok	Biopsy
B7c	B7c	39	F	Endo sekr	Prolaps	Normal	Ok	Biopsy
B7d	B7d	31	F	Endo sekr	Prolaps	Normal	Ok	Biopsy
B7e	B7e	32	F	Endo sekr	CIS cervix	Normal	Ok	Biopsy
B7f	B7f	32	F	Endo sekr	CIS cervix	Normal	Ok	Biopsy
B7g	B7g	32	F	Endo sekr	CIS cervix	Normal	Ok	Biopsy
B7h	B7h	26	F	Endo sekr	CIS cervix	Normal	Ok	Biopsy
B7i	B7i	47	F	Endo sekr	Hysterectomy	Normal	Ok	Biopsy
B7j	B7j	47	F	Endo sekr	Hysterectomy	Normal	Ok	Biopsy
B7k	B7k	28	F	Endo prol	Ruptured ovarian cyst (endometriosis)	Normal	Ok	Biopsy
B7l	B7l	28	F	Endo prol	Ruptured ovarian cyst (endometriosis)	Normal	Ok	Biopsy
B7m	B7m	40	F	Endo prol	Menorrhagia	Normal	Ok	Biopsy
B7n	B7n	40	F	Endo prol	Menorrhagia	Normal	Few epithelial cells	Biopsy
B7o	B7o	41	F	Endo prol	Ovarian cyst (endometriosis)	Normal	Ok	Biopsy

Coordinates	Identical Biopsy	Age	Sex	Organ	Underlying Disease	Histologic DX	Tissue Represented, Lot	Material
B7p	130	41	F	Endo prol	Ovarian cyst (endometriosis)	Normal	Ok	Biopsy
B8a	130	41	F	Endo prol	Ovarian cyst (endometriosis)	Normal	Ok	Biopsy
B8b	131	42	F	Endo prol	Ovarian cyst (endometriosis)	Normal	Few epithelial cells	Biopsy
B8c	131	42	F	Endo prol	Ovarian cyst (endometriosis)	Normal	Few epithelial cells	Biopsy
B8d	131	42	F	Endo prol	Ovarian cyst (endometriosis)	Normal	Few epithelial cells	Biopsy
B8e	136	45	F	Endocervix	Menometrorrhagia	Normal	Ok	Biopsy
B8f	133		F	Endocervix	CIS cervix	Normal	Ok	Biopsy
B8g	134		F	Endocervix	CIS cervix	Normal	Ok	Biopsy
B8h	135		F	Endocervix	CIS cervix	Normal	Ok	Biopsy
B8i	136	45	F	Endocervix	Menometrorrhagia	Normal	Ok	Biopsy
B8j	136	45	F	Endocervix	Menometrorrhagia	Normal	Ok	Biopsy
B8k	137	49	F	Endocervix	Endometrium cancer	Normal	Ok	Biopsy
B8l	137	49	F	Endocervix	Endometrium cancer	Normal	Ok	Biopsy
B8m	138	47	F	Endocervix	Hysterectomy	Normal	Ok	Biopsy
B8n	138	47	F	Endocervix	Hysterectomy	Normal	Ok	Biopsy
B8o	139	41	F	Ektoecervix	Ovarian cyst (endometriosis)	Normal	Ok	Biopsy
B8p	140	32	F	Ektoecervix	Endometriosis	Normal	Ok	Biopsy
B9a	141		F	Ektoecervix	Endometriosis	Normal	Ok	Biopsy
B9b	142	39	F	Ektoecervix	CIS cervix	Normal	Ok	Biopsy
B9c	143	49	F	Ektoecervix	Endometrium cancer	Normal	Stroma only	Biopsy
B9d	143	49	F	Ektoecervix	Endometrium cancer	Normal	Ok	Biopsy
B9e	144	47	F	Ektoecervix	Hysterectomy	Normal	Ok	Biopsy
B9f	144	47	F	Ektoecervix	Hysterectomy	Normal	Ok	Biopsy
B9g	145	47	F	Ektoecervix	Myoma uterus	Normal	Ok	Biopsy
B9h	145	47	F	Ektoecervix	Myoma uterus	Normal	Ok	Biopsy
B9i	146	74	M	Kidney cortex	Clear cell RCC	Normal	Ok	Biopsy
B9j	146	74	M	Kidney cortex	Clear cell RCC	Normal	Ok	Biopsy
B9k	147	78	M	Kidney cortex	Cancer pyelon	Normal	Ok	Biopsy
B9l	147	78	M	Kidney cortex	Cancer pyelon	Normal	Ok	Biopsy
B9m	148	88	M	Kidney cortex	Clear cell RCC	Normal	Ok	Biopsy
B9n	148	88	m	Kidney cortex	Clear cell RCC	Normal	Ok	Biopsy
B9o	148	88	M	Kidney cortex	Clear cell RCC	Normal	Ok	Biopsy

Coordinates	Identical Biopsy	Age	Sex	Organ	Underlying Disease	Histologic DX	Tissue Represented, Lot1	Material
B9p	148	88	M	Kidney cortex	Clear cell RCC	Normal	Ok	Biopsy
C1a	149	87	M	Kidney cortex	Cancer pycelon	Normal	Ok	Biopsy
C1b	149	87	M	Kidney cortex	Cancer pycelon	Normal	Ok	Biopsy
C1c	150	74	M	Kidney papilla	Clear cell RCC	Normal	Ok	Biopsy
C1d	150	74	M	Kidney papilla	Clear cell RCC	Normal	Ok	Biopsy
C1e	151	78	M	Kidney papilla	Cancer pycelon	Normal	Ok	Biopsy
C1f	151	78	M	Kidney papilla	Cancer pycelon	Normal	Ok	Biopsy
C1g	152	88	M	Kidney papilla	Clear cell RCC	Normal	Ok	Biopsy
C1h	152	88	M	Kidney papilla	Clear cell RCC	Normal	Ok	Biopsy
C1i	152	88	m	Kidney papilla	Clear cell RCC	Normal	Ok	Biopsy
C1j	153	87	M	Kidney papilla	Cancer pycelon	Normal	Ok	Biopsy
C2a	153	87	M	Kidney papilla	Cancer pycelon	Normal	Ok	Biopsy
C2b	153	87	M	Kidney papilla	Cancer pycelon	Normal	Ok	Biopsy
C2c	154		M	Prostate	Benign prostatic hyperplasia	Normal	Ok	Biopsy
C2d	154		M	Prostate	Benign prostatic hyperplasia	Normal	Ok	Biopsy
C2e	155	66	M	Prostate	Benign prostatic hyperplasia	Normal	Ok	Biopsy
C2f	155	66	M	Prostate	Benign prostatic hyperplasia	Normal	Ok	Biopsy
C2g	156	70	M	Prostate	Benign prostatic hyperplasia	Normal	Ok	Biopsy
C2h	156	70	M	Prostate	Benign prostatic hyperplasia	Normal	Ok	Biopsy
C2i	156	70	M	Prostate	Benign prostatic hyperplasia	Normal	Ok	Biopsy
C2j	157	74	M	Prostate	Benign prostatic hyperplasia	Normal	Ok	Biopsy
C3a	157	74	M	Prostate	Benign prostatic hyperplasia	Normal	Ok	Biopsy
C3b	157	74	M	Prostate	Benign prostatic hyperplasia	Normal	Ok	Biopsy
C3c	158	60	M	Seminal vesicle	Prostate cancer	Normal	Ok	Biopsy
C3d	158	60	M	Seminal vesicle	Prostate cancer	Normal	Ok	Biopsy

Coordinates	Identical Biopsy	Age	Sex	Organ	Underlying Disease	Histologic DX	Tissue Represented, Lot1	Material
C3e	159	63	M	vesicle Seminal vesicle	Prostate cancer	Normal	Ok	Biopsy
C3f	159	63	M	Seminal vesicle	Prostate cancer	Normal	Ok	Biopsy
C3g	160			Seminal vesicle		Normal	Ok	Biopsy
C3h	160	66	M	Seminal vesicle	Prostate cancer	Normal	Ok	Biopsy
C3i	160	66	M	Seminal vesicle	Prostate cancer	Normal	Ok	Biopsy
C3j	161			Seminal vesicle		Normal	Ok	Biopsy
C4a	161			Seminal vesicle		Normal	Ok	Biopsy
C4b	161			Seminal vesicle		Normal	Ok	Biopsy
C4c	162	87	M	Epididymis	Prostate cancer	Normal	Ok	Biopsy
C4d	162	87	M	Epididymis	Prostate cancer	Normal	Few epithelial cells	Biopsy
C4e	162	87	M	Epididymis	Prostate cancer	Normal	Ok	Biopsy
C4f	163	86	M	Epididymis	Prostate cancer	Normal	Ok	Biopsy
C4g	163	86	M	Epididymis	Prostate cancer	Normal	Ok	Biopsy
C4h	163	86	M	Epididymis	Prostate cancer	Normal	Ok	Biopsy
C4i	163	86	M	Epididymis	Prostate cancer	Normal	Ok	Biopsy
C4j	163	86	M	Epididymis	Prostate cancer	Normal	Ok	Biopsy
C5a	163	86	M	Epididymis	Prostate cancer	Normal	Ok	Biopsy
C5b	163	86	M	Epididymis	Prostate cancer	Normal	Ok	Biopsy
C5c	164	77	M	Testis	Prostate cancer	Normal	Stroma only	Biopsy
C5d	164	77	M	Testis	Prostate cancer	Normal	Ok	Biopsy
C5e	164	77	M	Testis	Prostate cancer	Normal	Ok	Biopsy
C5f	165	87	M	Testis	Prostate cancer	Normal	Ok	Biopsy
C5g	165	87	M	Testis	Prostate cancer	Normal	Ok	Biopsy
C5h	165	87	M	Testis	Prostate cancer	Normal	Ok	Biopsy
C5i	166	86	M	Testis	Prostate cancer	Normal	Ok	Biopsy
C5j	167	73	M	Testis	Prostate cancer	Normal	Ok	Biopsy
C6a	167	73	M	Testis	Prostate cancer	Normal	Ok	Biopsy
C6b	167	73	M	Testis	Prostate cancer	Normal	Ok	Biopsy
C6c	168	87	M	Kidney pelvis	Prostate cancer	Normal	No epithelial cells	Biopsy
C6d	169	87	M	Kidney pelvis	Cancer pyelon	Normal	No epithelial cells	Biopsy

Coordinates	Identical Biopsy	Age	Sex	Organ	Underlying Disease	Histologic DX	Tissue Represented, Lot1	Material
C6e	168	87	M	Kidney pelvis	Cancer pylon	Normal	Ok	Biopsy
C6f	169	87	M	Kidney pelvis	Cancer pylon	Normal	No epithelial cells	Biopsy
C6g	168	87	M	Kidney pelvis	Cancer pylon	Normal	Ok	Biopsy
C6h	170	85	F	Kidney pelvis	Cancer pylon	Normal	No epithelial cells	Biopsy
C6i	170	85	F	Kidney pelvis	Cancer pylon	Normal	No epithelial cells	Biopsy
C6j	170	85	F	Kidney pelvis	Cancer pylon	Normal	No epithelial cells	Biopsy
C7a	170	85	F	Kidney pelvis	Cancer pylon	Normal	Ok	Biopsy
C7b	170	85	F	Kidney pelvis	Cancer pylon	Normal	Inflammation	Biopsy
C7c	171	63	F	Bronchus	Lung cancer	Normal	No epithelial cells	Biopsy
C7d	171	63	F	Bronchus	Lung cancer	Normal	Ok	Biopsy
C7e	172	74	M	Bronchus	Lung cancer	Normal	Ok	Biopsy
C7f	172	74	M	Bronchus	Lung cancer	Normal	Ok	Biopsy
C7g	172	74	M	Bronchus	Lung cancer	Normal	Ok	Biopsy
C7h	173	51	F	Bronchus	Lung cancer	Normal	Ok	Biopsy
C7i	173	51	F	Bronchus	Lung cancer	Normal	Ok	Biopsy
C7j	174			Bronchus	Lung cancer	Normal	Ok	Biopsy
C8a	174			Bronchus	Lung cancer	Normal	Ok	Biopsy
C8b	174			Bronchus	Lung cancer	Normal	No epithelial cells	Biopsy
C8c	175	74	F	Lung	Lung cancer	Normal	Ok	Biopsy
C8d	176	62	M	Lung	Lung cancer	Normal	Ok	Biopsy
C8e	177	68	F	Lung	Lung cancer	Normal	Ok	Biopsy
C8f	178	69	F	Lung	Lung cancer	Normal	Ok	Biopsy
C8g	179	51	F	Lung	Lung cancer	Normal	Ok	Biopsy
D2c	189	41	M	Cerebrum, white substance	Trauma	Normal	Ok	Autopsy, 5h
D2d	189	41	M	Cerebrum, white substance	Trauma	Normal	Ok	Autopsy, 5h
D2e	189	41	M	substance Cerebrum, white	Trauma	Normal	Ok	Autopsy, 5h
D2f	189	41	M	substance Cerebrum, white	Trauma	Normal	Ok	Autopsy, 5h
D2g	189	41	M	substance Cerebrum, white	Trauma	Normal	Ok	Autopsy, 5h
D2h	191	37	M	substance Cerebrum, white	Trauma	Normal	Ok	Autopsy, 4h

700260-220960

Coordinates	Identical Biopsy	Age	Sex	Organ	Underlying Disease	Histologic DX	Tissue Represented, Lot1	Material
D2i	191	37	M	white substance Cerebrum, white substance	Trauma	Normal	Ok	Autopsy, 4h
D2j	191	37	M	Cerebrum, white substance	Trauma	Normal	Ok	Autopsy, 4h
D3a	191	37	M	white substance Cerebrum, white substance	Trauma	Normal	Ok	Autopsy, 4h
D3b	191	37	m	white substance Cerebrum, white substance	Trauma	Normal	Ok	Autopsy, 4h

TABLE 3

Localisation	Organ	Histologic tumor type	Tissue represented Lot 1	Underlying disease	Sex	Age
1a	Breast	Breast cancer, ductal	Ok		F	83
1b	Breast	Breast cancer, ductal	Ok		F	59
1c	Breast	Breast cancer, ductal	Ok		F	74
1d	Breast	Breast cancer, ductal	Ok		F	61
1e	Breast	Breast cancer, ductal	Ok		F	68
1f	Lung	Lung cancer, squamous	Ok		M	78
1g	Lung	Lung cancer, adenocarcinoma	Ok		M	56
1h	Lung	Lung cancer, squamous	Ok		M	68
2a	Lung	Lung cancer, squamous	Ok		M	60
2b	Lung	Lung cancer, large cell	Ok		F	71
2c	Colon	Colon cancer, adenocarcinoma	Ok		F	71
2d	Colon	Colon cancer, adenocarcinoma	Ok		M	65
2e	Colon	Colon cancer, adenocarcinoma	Ok		M	79
2f	Colon	Colon cancer, adenocarcinoma	Ok		M	74
2g	Colon	Colon cancer, adenocarcinoma	Ok		M	85
2h	Prostate	Prostate cancer, adenocarcinoma	Ok		M	77
3a	Prostate	Prostate cancer, adenocarcinoma	Ok		M	70
3b	Prostate	Prostate cancer, adenocarcinoma	Ok		M	60
3c	Prostate	Prostate cancer, adenocarcinoma	Ok		M	68
3d	Prostate	Prostate cancer, adenocarcinoma	Ok		F	79
3e	Skel muscle	Normal	Ok	Breast cancer		
3f	Skel muscle	Normal	Ok	Breast cancer		
3g	Kidney, cortex	Normal	Ok	Renal pelvis cancer	M	78
3h	Kidney, cortex	Normal	Ok	Renal pelvis cancer	M	87
4a	Liver	Normal	Ok	Splenomegaly	F	71
4b	Liver	Normal	Ok	Hodgkin disease	F	26
4c	Lymph node	Normal	Ok	Cholecystitis	M	16
4d	Lymph node	Normal	Ok	Gastric cancer		
4e	Prostate	Normal	Ok	Prostate cancer	M	68
4f	Prostate	Normal	Ok	BPH	M	

Localisation	Organ	Histologic tumor type	Tissue represented Lot 1	Underlying disease	Sex	Age
4g	Thyroid	Normal	Ok	Thyroid adenoma	F	47
4h	Thyroid	Normal	Ok	Thyroid adenoma	M	26
5a	Spleen	Normal	Ok	Trauma	F	21
5b	Spleen	Normal	Ok	Old hemotoma	M	43

TABLE 4

BNR	Nr on block	localisation	coordinates	category	BI ca	BI gleason 1	BI gleason 2	BI gleason 3	BI gleason 4	BI gleason 5	gleason 1	gleason 2	gleason sum	Gleason array	disease
b89.2864	1	A 1a	0/0	cancer	0.9		1 to 11					2	4	2	
b89.2993	2	A 1b	800/0	cancer	2		1 to 9	1 to 9	1 to 9		3 to 4	3 to 4	7		
b89.6007	3	A 1c	1600/0	cancer	2				1 to 6	1 to 6	5	4	9		
b89.7460	4	A 1d	2400/0	cancer				1,2,3,4,5		dddd	3	5	8		
b89.8302	5	A 1e	3200/0	cancer	1.5					1,2	5	5	10	5	
b91.2234	6	A 1f	4000/0	cancer	1				1 to 5		4	4	8	4	
b91.7071	7	A 1g	4800/0	cancer	0		4,5,11,12	11,12			2	3	5		
b93.3679	8	A 1h	5600/0	cancer	1		1,2,3,4		1,2,3,4		4	2	6	4	
b93.4574	9	A 2a	0/800	cancer	0.6		1							3	
b93.8235	10	A 2b	800/800	cancer	1			1,2	1,2		4	3	7	4	
b97.1001	11	A 2c	1600/800	cancer	1.5		1 to 10	1 to 10			3	2	5		
b97.1588	12	A 2d	2400/800	cancer	1		1,4,5				2	2	4	2	
b97.1655	13	A 2e	3200/800	cancer	0.8			1,2			3				
b97.2635	14	A 2f	4000/800	cancer	0.6		1				2	2	4	2	
b97.3455	15	A 2g	4800/800	cancer	1		2	1			4	2	6	4	
b97.3465	16	A 2h	5600/800	cancer	1						3	2	5		
b97.4392	17	A 3a	0/1600	cancer	1.2			1						4	
b97.5666	18	A 3b	800/1600	cancer	1.2		1,2,3,4,5				2	2	4		
b97.6494	19	A 3c	1600/1600	cancer	1.3		1,2,3	1			3	2	5	3	
b97.730	20	A 3d	2400/1600	cancer	0.8		1,2				2	2	4	2	

BNr	Nr on block	localisation	coordinates	category	BI1 ca	BI1 gleason 1	BI1 gleason 2	BI1 gleason 3	BI1 gleason 4	BI1 gleason 5	gleason 1	gleason 2	gleason sum	Gleason army	disease
b97.9880	21	A 3e	3200/1600	cancer	0.6		1:2;3	1:2;3			2	3	5	2	
b86.1325	22	A 3f	4000/1600	cancer					1:2;3;4;5		5	4	8	5	
b86.1460	23	A 3g	4800/1600	cancer	1.5		1:2;3			1:2;3;4	2	2	4	2	
b87.10	24	A 3h	5600/1600	cancer	2						5	5	10	5	
b87.1104	25	A 4a	0/2400	cancer						1				5	
b87.1137	26	A 4b	800/2400	cancer	2				1:2;3;4		5	5	10	5	
b87.1545	27	A 4c	1600/2400	cancer	0.7		1:2;3				2	2	4	2	
b87.1748	28	A 4d	2400/2400	cancer	1;6		1:2;3;4;5; 6		1:2;3;4;5; 6		2	4	6	4	
b87.39	29	A 4e	3200/2400	cancer	1			1:2;3;4	2;3;4		3	4	7	3	
b87.410	30	A 4f	4000/2400	cancer	1.5		1:2;3;4;5	1:2;3;4;5			2	3	5	2	
b88.1898	31	A 4g	4800/2400	cancer	1.8			1:2;3;4;5; 6;7	1:2;3;4;5; 6;7		5	4	9	5	
b88.1936	32	A 4h	5600/2400	cancer	2.5; 0.3			1:2;3;4;5	1:2;3;4;5		3	4	7	3	
b88.470	33	A 5a	0/3200	cancer	0.8			1:2;3;4	1:2;3;4		4	5	9	4	
b89.1385	34	A 5b	800/3200	cancer	1;8			1;3		1:2;3;4;5	5	3		3	
b90.2002	35	A 5c	1600/3200	cancer			1:2;3				2	2	4	2	
b90.383	36	A 5d	2400/3200	cancer	2.5			1:2;3;4	3		3	4	7	3	
b91.566	37	A 5e	3200/3200	cancer	1;0; 8				1	1:2;3;4;5	4	5		5	
b91.73	38	A 5f	4000/3200	cancer	1.5				2;3;4;6		5	4	9	5	
b91.946	39	A 5g	4800/3200	cancer	2.5					1;0;7	5	5	10	5	

BNr	Nr on block	localisation	coordinates	category	BI1 ca	BI gleason 1	BI gleason 2	BI gleason 3	BI gleason 4	BI gleason 5	gleason 1	gleason 2	gleason sum	Gleason army ;	disease
b91.957	40	A 6a	0/4000	cancer	1.5			1;2;3;4;5	1;2;3;4;5		4	3	7	3 to 4	
b92.1219	41	A 6b	800/4000	cancer	3			1;2;3;4;5; 6	1;2;3;4;5; 6		4	3	7	4	
b92.1403	42	A 6c	1600/4000	cancer	0.6			1;2	1;2		3	4	7		
b92.238	43	A 6d	2400/4000	cancer	6.6			1;2;3;4	1;2;3		2	3	5	2	
b92.420	44	A 6e	3200/4000	cancer	1.5				1	1	5	5	9	5	
b92.550	45	A 6f	4000/4000	cancer	1;6; 5			some	5;some	1;2;3;4;5	5	3	8	3	
b93.1267	46	A 6g	4800/4000	cancer	2					1;2;3;4;5	5	5	10	5	
b93.1610	47	A 7a	0/4800	cancer	1.5		1;2;3;4	4, and some in others			2	3	5	3	
b93.804	48	A 7b	800/4800	cancer	7.6			1;2		1;2	5	3	8	3	
	49	A 7c	1600/4800	cancer											
	50	A 7d	2400/4800	cancer											
	51	A 7e	3200/4800	cancer											
	52	A 7f	4000/4800	cancer											
	53	A 7g	4800/4800	cancer											
	54	A 8a	0/5600	cancer											
	55	A 8b	800/5600	cancer											
	56	A 8c	1600/5600	cancer											
	57	A 8d	2400/5600	cancer											
	58	A 8e	3200/5600	cancer											

BNr	Nr on block	localisation	coordinates	category	BI1 ca	BI gleason 1	BI gleason 2	BI gleason 3	BI gleason 4	BI gleason 5	gleason sum	Cleason array	disease
	59	A 8f	4000/5600	cancer									
	60	A 8g	4800/5600	cancer									
h86.1441	61			normal									PBPH
h86.1810	62			normal									PBPH
b89.8510	63			normal									PBPH
h88.1377	64			normal									PBPH
h88.1744	65			normal									PBPH
h86.1565	66			normal									PBPH
h86.1605	67			normal									PBPH
h86.1601	68			normal									PBPH
h86.901	69			normal	0								PBPH
h91.1092	70			normal									PBPH
h91.1420	71	B 4b	800/2400	normal kidney									renal pelvis TCC
h93.1995	72	B 4c	1600/2400	normal kidney									renal pelvis TCC
h87.346	73	B 5a	0/3200	normal kidney									cholecystitis
h90.491	74	B 5b	800/3200	Normal kidney									Hodgkin disease
h89.590	75	B 6a	0/4000	normal lymph node									colon cancer
h91.463	76	B 6b	800/4000	normal lymph									colon cancer

TABLE 5

BNr	Coordinates	Identical biopsy	sex	age	Organ	Histologic diagnosis	Other tumor components	Tumor localization	Histologic grade	pT	pN	Dukes Stage	tumor diameter
b89.4539	A1a		f	84	colon	adenocarcinoma		cecum	G2	3	1	C	35
b89.4746	A1b		m	79	colon	mucinous carcinoma	glandular adenocarcinoma a, 35%	transverse colon	G2	3	0	B	70
b91.1771	A1c		m	70	colon	adenocarcinoma		ascending colon	G2	2	0	A	50
b91.1827	A1d		m	64	colon	adenocarcinoma		rectum	G2	2	0	A	25
b91.2771	A1e		m	79	colon	adenocarcinoma		cecum	G2	3	2	C	90
b91.2835	A1f		f	85	colon	adenocarcinoma		cecum	G2	3	0	B	35
b91.2844	A1g		m	72	colon	mucinous carcinoma		sigmoid	G3	3			
b91.318	A1h		m	70	colon	adenocarcinoma		sigmoid	G2	3			15
b91.5093	A2a		m	57	colon	adenocarcinoma		cecum	G2	3	0	B	30
b91.5906	A2b		f	68	colon	adenocarcinoma		sigmoid	G2	3			30
b91.6176	A2c		f	76	colon	adenocarcinoma		ascending colon	G1	3	0	B	25
b91.7315	A2d		f	71	colon	adenocarcinoma		left colon	G2	2	0	A	80
b89.2801	A2e		m	62	colon	adenocarcinoma		sigmoid	G2	1	0	A	20
b87.1943	A2f		f	81	colon	adenocarcinoma		cecum	G2	3			30
b91.747	A2g		m	74	colon	adenocarcinoma		sigmoid	G2	2	0	A	40

BNr	Coordinates	Identical biopsy	sex	age	Organ	Histologic diagnosis	Other tumor components	Tumor localization	Histologic grade	pT	pN	Dukes Stage	tumor diameter
b91.8316	A2h		m	65	colon	adenocarcinoma		ascending colon	G2	2	2	C	70
b91.8964	A3a		m	79	colon	adenocarcinoma		sigmoid	G3	3	2	C	40
b86.1400	A3b		m	82	colon	mucinous carcinoma		sigmoid	G2	3	1	C	28
b86.1710	A3c				colon	adenocarcinoma			G2				
b86.1788	A3d		m	80	colon	adenocarcinoma		cecum	G2	3	0	B	44
b86.1838	A3e		f	83	colon	adenocarcinoma	mucinous, 10%	sigmoid	G2	3	0	B	39
b86.1988	A3f		m	64	colon	adenocarcinoma		descending colon	G2	3	0	B	35
b86.2116	A3g		f	49	colon	adenocarcinoma		sigmoid	G2	3	1	C	32
b87.1203	A3h		f	67	colon	adenocarcinoma		sigmoid	G2	3	0	B	60
b87.1926	A4a		m	74	colon	adenocarcinoma		sigmoid	G3	3	0	B	50
b88.1998	A4b		m	58	colon	adenocarcinoma		rectum	G2				
b88.704	A4c		m	75	colon	adenocarcinoma		rectosigmoid	G2	3	0	B	50
b89.1392	A4d	1	m	72	colon	adenocarcinoma		rectum	G2	2	0	A	41
b89.143	A4e		m	88	colon	adenocarcinoma		sigmoid	G2	3	0	B	45
b89.1771	A4f		m	73	colon	adenocarcinoma		sigmoid	G2	3	0	B	52
b89.1801	A4g		f	72	colon	adenocarcinoma		sigmoid	G2	2	0	A	25
b89.511	A4h		f	81	colon	adenocarcinoma	mucinous, 30%	sigmoid	G2	3	0	B	50

BNr	Coordinates	Identical biopsy	sex	age	Organ	Histologic diagnosis	Other tumor components	Tumor localization	Histologic grade	pT	pN	Dukes Stage	tumor diameter
h89.555	A5a		m	77	colon	adenocarcinoma		ascending colon	G2	3	1	C	30
h89.564	A5b		f	87	colon	adenocarcinoma		sigmoid	G2	3	1	C	30
h89.590	A5c	2	m	60	colon	adenocarcinoma		sigmoid	G2	3	0	B	60
h90.1349	A5d		f	65	colon	adenocarcinoma		right colon	G2	3	0	B	43
h90.2023	A5e		m	75	colon	adenocarcinoma		rectosigmoid	G2	3	1	C	60
h90.322	A5f	3			colon	adenocarcinoma	mucinous, 5%	cecum	G2	2	0	A	37
h91.1028	A5g		m	43	colon	adenocarcinoma		sigmoid	G2	3	0	B	70
h91.1311	A6a		m	78	colon	adenocarcinoma		rectum	G2	3	0	B	40
h91.1911	A6b		f	56	colon	adenocarcinoma	mucinous, 40%	coecum	G2	3	0	B	164
h91.463	A6c	4	f	76	colon	medullary carcinoma		right colon	G3	3	0	B	70
h91.601	A6d		f	81	colon	adenocarcinoma	mucinous, 10%	right colon	G2	3	1	C	60
h91.643	A6e	5	f	82	colon	medullary carcinoma		right colon	G3	3	0	B	135
h92.1	A6f		m	61	colon	adenocarcinoma		rectosigmoid	G2	2	1	C	17
h92.1007	A6g		f	79	colon	adenocarcinoma		sigmoid	G2				22
h92.1102	A7a		f	77	colon	adenocarcinoma	mucinous, 10%	transverse colon	G3	3	1	C	30
h92.1606	A7b	6	f	74	colon	adenocarcinoma		cecum	G2				
h92.236	A7c	7	f	75	colon	adenocarcinoma		rectosigmoid	G2	2	0	A	

BNr	Coordinates	Identical biopsy	sex	age	Organ	Histologic diagnosis	Other tumor components	Tumor localization	Histologic grade	pT	pN	Dukes Stage	tumor diameter
h92.283	A7d		m	76	colon	adenocarcinoma		rectum	G2	3	1	C	25
h92.384	A7e		f	60	colon	adenocarcinoma		sigmoid	G2	1			14
h92.445	A7f		f	69	colon	adenocarcinoma	mucinous, 40%	colon	G2	3	2	C	75
h93.1039	A7g	8	m	34	colon	adenocarcinoma		colon	G2	1	0	A	40
h93.1402	A8a		f	49	colon	adenocarcinoma	mucinous, 10%	rectosigmoid	G2	4	0	B	38
h93.242	A8b		f	82	colon	adenocarcinoma		right colon	G2	3	0	B	40
h93.423	A8c	9	f	81	colon	adenocarcinoma		coecum	G2		0		
h93.501	A8d	10	m	85	colon	adenocarcinoma	mucinous, 20%	rectosigmoid	G2	3	0	B	95
h93.573	A8e	11	f	78	colon	medullary carcinoma		cecum	G3	4	1	C	110
h93.656	A8f		f	90	colon	adenocarcinoma		sigmoid	G2	2	0	A	15
h93.870	A8g		f	77	colon	adenocarcinoma	mucinous, 40%	rectum	G2	3	2	C	25
h89.1392	B1a	1	m	72	colon	normal							
h90.322	B1b	3			colon	normal							
h91.1023	B1c		m	63	colon	normal							
h91.643	B2a	5	f	82	colon	normal							
h92.1606	B2b	6	f	74	colon	normal							
h92.236	B2c	7	f	75	colon	normal							
h93.1039	B3a	8	m	34	colon	normal							

BNr	Coordinates	Identical biopsy	sex	age	Organ	Histologic diagnosis	Other tumor components	Tumor localization	Histologic grade	pT	pN	Dukes Stage	tumor diameter
h93.423	B3b	9	f	81	colon	normal							
h93.501	B3c	10	m	81	colon	normal							
h93.573	B4a	11	f	78	colon	normal							
h91.1460	B4b		m	78	kidney	normal							
h93.1995	B4c		m	87	kidney	normal							
h91.7359	B5a		f	71	liver	normal							
h90.491	B5b		f	26	liver	normal							
h89.590	B6a	2	m	60	lymph node	normal							
h91.463	B6b	4	f	76	lymph node	normal							
h90.1824	B7a		m		prostate	normal							
h91.1092	B7b		m	68	prostate	normal							
h87.315	B8a		f	57	thyroid	normal							
h87.449	B8b		m	26	thyroid	normal							

TABLE 6

Coordinates	identical biopsy	Sex	Age	Organ	Histologic diagnosis	Other tumor components	Tumor localization	Histologic grade	pT	Dukes stage	Tumor diameter	LN all	
A 1a	f	84	colon	adenocarcinoma	adenocarcinoma		cecum	G2	3	1	C	35	16
A 1b	m	79	colon	mucinous carcinoma	glandular adenocarcinoma, 35%		transverse colon	G2	3	0	B	70	10
A 1c	m	70	colon	adenocarcinoma	adenocarcinoma		ascending colon	G2	2	0	A	50	16
A 1d	m	64	colon	adenocarcinoma	adenocarcinoma		rectum	G2	2	0	A	25	5
A 1e	m	79	colon	adenocarcinoma	adenocarcinoma		cecum	G2	3	2	C	90	9
A 1f	f	85	colon	adenocarcinoma	adenocarcinoma		cecum	G2	3	0	B	35	8
A 1g	m	72	colon	mucinous carcinoma	mucinous carcinoma		sigmoid	G3	3				
A 1h	m	70	colon	adenocarcinoma	adenocarcinoma		sigmoid	G2	3		15		
A 2a	m	57	colon	adenocarcinoma	adenocarcinoma		cecum	G2	3	0	B	30	4
A 2b	f	68	colon	adenocarcinoma	adenocarcinoma		sigmoid	G2	3		30		
A 2c	f	76	colon	adenocarcinoma	adenocarcinoma		ascending colon	G1	3	0	B	25	7
A 2d	f	71	colon	adenocarcinoma	adenocarcinoma		left colon	G2	2	0	A	80	9
A 2e	m	62	colon	adenocarcinoma	adenocarcinoma		sigmoid	G2	1	0	A	20	7
A 2f	f	81	colon	adenocarcinoma	adenocarcinoma		cecum	G2	3		30		

TABLE 6

Coordinates	identical biopsy	Sex	Age	Organ	Histologic diagnosis	Other tumor components	Tumor localization	Histologic grade	pT	Dukes stage	Tumor diameter	LN all	
A 2g		m	74	colon	adenocarcinoma		sigmoid	G2	2	0	A	40	8
A 2h		m	65	colon	adenocarcinoma		ascending colon	G2	2	2	C	70	9
A 3a		m	79	colon	adenocarcinoma		sigmoid	G3	3	2	C	40	6
A 3b		m	82	colon	mucinous carcinoma		sigmoid	G2	3	1	C	28	5
A 3c				colon	adenocarcinoma			G2					
A 3d		m	80	colon	adenocarcinoma		cecum	G2	3	0	B	44	6
A 3e		f	83	colon	adenocarcinoma	mucinous, 10%	sigmoid	G2	3	0	B	39	8
A 3f		m	64	colon	adenocarcinoma		descending colon	G2	3	0	B	35	1
A 3g		f	49	colon	adenocarcinoma		sigmoid	G2	3	1	C	32	7
A 3h		f	67	colon	adenocarcinoma		sigmoid	G2	3	0	B	60	4
A 4a		m	74	colon	adenocarcinoma		sigmoid	G3	3	0	B	50	10
A 4b		m	58	colon	adenocarcinoma		rectum	G2					
A 4c		m	75	colon	adenocarcinoma		rectosigmoid	G2	3	0	B	50	2
A 4d 1		m	72	colon	adenocarcinoma		rectum	G2	2	0	A	41	5
A 4e		m	88	colon	adenocarcinoma		sigmoid	G2	3	0	B	45	3
A 4f		m	73	colon	adenocarcinoma		sigmoid	G2	3	0	B	52	3
A 4g		f	72	colon	adenocarcinoma		sigmoid	G2	2	0	A	25	5

TABLE 6

Coordinates	identical biopsy	Sex	Age	Organ	Histologic diagnosis	Other tumor components	Tumor localization	Histologic grade	pT	pN	Dukes stage	Tumor diameter	LN all
A 4h	f	81	colon	adenocarcinoma	mucinous, 30%	sigmoid	G2	3	0	B	50	5	
A 5a	m	77	colon	adenocarcinoma		ascending colon	G2	3	1	C	30	5	
A 5b	f	87	colon	adenocarcinoma		sigmoid	G2	3	1	C	30	6	
A 5c	2	60	colon	adenocarcinoma		sigmoid	G2	3	0	B	60	5	
A 5d	f	65	colon	adenocarcinoma		right colon	G2	3	0	B	43	14	
A 5e	m	75	colon	adenocarcinoma		rectosigmoid	G2	3	1	C	60	3	
A 5f	3		colon	adenocarcinoma	mucinous, 5%	cecum	G2	2	0	A	37	6	
A 5g	m	43	colon	adenocarcinoma		sigmoid	G2	3	0	B	70	9	
A 6a	m	78	colon	adenocarcinoma		rectum	G2	3	0	B	40	4	
A 6b	f	56	colon	adenocarcinoma	mucinous, 40%	coecum	G2	3	0	B	164	22	
A 6c	4	76	colon	medullary carcinoma		right colon	G3	3	0	B	70	10	
A 6d	f	81	colon	adenocarcinoma	mucinous, 10%	right colon	G2	3	1	C	60	5	
A 6e	5	82	colon	medullary carcinoma		right colon	G3	3	0	B	135	5	
A 6f	m	61	colon	adenocarcinoma		rectosigmoid	G2	2	1	C	17	5	
A 6g	f	79	colon	adenocarcinoma		sigmoid	G2				22		
A 7a	f	77	colon	adenocarcinoma	mucinous, 10%	transverse colon	G3	3	1	C	30	2	

TABLE 6

Coordinates	identical biopsy	Sex	Age	Organ	Histologic diagnosis	Other tumor components	Tumor localization	Histologic grade	pT	pN	Dukes stage	Tumor diameter	LN all
A 7b 6	f	f	74	colon	adenocarcinoma		cecum	G2					
A 7c 7	f	f	75	colon	adenocarcinoma		rectosigmoid	G2	2	0	A		9
A 7d	m	m	76	colon	adenocarcinoma		rectum	G2	3	1	C	25	3
A 7e	f	f	60	colon	adenocarcinoma		sigmoid	G2	1			14	
A 7f	f	f	69	colon	adenocarcinoma	mucinous, 40%	colon	G2	3	2	C	75	10
A 7g 8	m	m	34	colon	adenocarcinoma		colon	G2	1	0	A	40	8
A 8a	f	f	49	colon	adenocarcinoma	mucinous, 10%	rectosigmoid	G2	4	0	B	38	9
A 8b	f	f	82	colon	adenocarcinoma		right colon	G2	3	0	B	40	4
A 8c 9	f	f	81	colon	adenocarcinoma		cecum	G2		0			12
A 8d 10	m	m	85	colon	adenocarcinoma	mucinous, 20%	rectosigmoid	G2	3	0	B	95	7
A 8e 11	f	f	78	colon	medullary carcinoma		cecum	G3	4	1	C	110	5
A 8f	f	f	90	colon	adenocarcinoma		sigmoid	G2	2	0	A	15	1
A 8g	f	f	77	colon	adenocarcinoma	mucinous, 40%	rectum	G2	3	2	C	25	6
B 1a 1	m	m	72	colon	normal								
B 1b 3				colon	normal								
B 1c	m	m	63	colon	normal								
B 2a 5	f	f	82	colon	normal								

TABLE 6

Coordinates	identical biopsy	Sex	Age	Organ	Histologic diagnosis	Other tumor components	Tumor localization	Histologic grade	pT	Dukes stage	Tumor diameter	LN all
B 2b	6	f	74	colon	normal							
B 2c	7	f	75	colon	normal							
B 3a	8	m	34	colon	normal							
B 3b	9	f	81	colon	normal							
B 3c	10	m	81	colon	normal							
B 4a	11	f	78	colon	normal							
B 4b		m	78	kidney	normal							
B 4c		m	87	kidney	normal							
B 5a		f	71	liver	normal							
B 5b		f	26	liver	normal							
B 6a	2	m	60	lymph node	normal							
B 6b	4	f	76	lymph node	normal							
B 7a		m		prostate	normal							
B 7b		m	68	prostate	normal							
B 8a		f	47	thyroid	normal							
B 8b		m	26	thyroid	normal							

TABLE 7

CS 200 Microarray		
colon	done	20
prostate	done	4
lung	done	20
breast	done	20
bladder	easy	20
melanoma	easy	20
basalioma	easy	20
endometrium	easy	20
spinalioma	easy	20
kidney	possible	20
ovary	possible	20
brain	possible	20
		glioblastoma
		astrocytoma grade 3 rather than 2
gastric	possible	20
cervix	possible	20
		280
		56
		672
thyroid		
testis		
lymphoma		
head & neck		

TABLE 8

Localisation	Coordinates	BNr	status	Pat N°	max lesion	targeted lesion	CE1	CE2	CE3	CE4	CE5
A la	0/0	b91.4662	ok	1	NO	NO	NO	stroma	NO	NO	NO
A lb	800/0	b91.4662	ok	1	NO	NO	NO	stroma	NO	INFL	INFL
A lc	1600/0	b80.193	ok	3	CIN3	NO	NO	NO	NO	NO	NO
A ld	2400/0	b80.193	ok	3	CIN3	NO	NO	NO	NO	NO	NO
A le	3200/0	b86.1081	ok	9	NO	NO	NO	NO	NO	NO	NO
A lf	4000/0	b86.1081	ok	9	NO	NO	NO	NO	NO	NO	NO
A lg	4800/0	b86.1227	ok	10	NO	NO	NO	first empty	first empty	first empty	NO
A lh	5600/0	b86.1227	ok	10	NO	NO	first empty	first empty	NO	NO	NO
A li	6400/0	b86.1493	ok	12	CIN3	NO	NO	NO	NO	NO	NO
A lj	7200/0	b86.1493	ok	12	CIN3	NO	NO	NO	NO	NO	NO
A lk	8000/0	b86.1719	ok	13	NO	NO	first empty	first empty	NO	first empty	NO
A ll	8800/0	b86.1719	ok	13	NO	NO	NO	NO	NO	first empty	first empty
A lm	9600/0	b86.1772	ok	14	NO	NO	NO	NO	NO	NO	NO
A ln	10400/0	b86.1772	ok	14	NO	NO	NO	NO	first empty	NO	NO
A lo	11200/0	b87.1313	ok	15	CIN3	NO	first empty	first empty	first empty	first empty	first empty
A lp	12000/0	b87.1313	ok	15	CIN3	NO	NO	NO	first empty	NO	NO
A 2a	0/800	b88.1257	ok	22	CIN3	NO	NO	NO	NO	NO	NO
A 2b	800/800	b88.1257	ok	22	CIN3	NO	NO	NO	NO	NO	NO
A 2c	1600/800	b88.577	ok	27	CIN3	NO	NO	NO	NO	first empty	NO
A 2d	2400/800	b88.577	ok	27	CIN3	NO	NO	NO	NO	NO	NO
A 2e	3200/800	b89.114	ok	32	CIN3	NO	NO	NO	NO	NO	NO
A 2f	4000/800	b89.114	ok	32	CIN3	NO	NO	NO	NO	NO	NO
A 2g	4800/800	b89.1806	ok	37	CIN3	NO	NO	NO	NO	NO	NO
A 2h	5600/800	b89.1806	ok	37	CIN3	NO	first empty	stroma	empty	empty	empty
A 2i	6400/800	b90.1681	ok	44	NO	NO	NO	NO	NO	NO	NO
A 2j	7200/800	b90.1681	ok	44	NO	NO	first empty	NO	NO	NO	NO

Localisation	Coordinates	BNr	status	Pa Nr	max lesion	targeted lesion	CE1	CE2	CE3	CE4	CE5
A 2k	8000/800	h90.1709	ok	45	NO	NO	first empty	NO	NO	NO	NO
A 2l	8800/800	h90.1709	ok	45	NO	NO	NO	NO	NO	NO	NO
A 2m	9600/800	h90.1796	ok	46	NO	NO	NO	NO	NO	NO	INFL
A 2n	10400/800	h90.1796	ok	46	NO	NO	NO	NO	NO	NO	NO
A 2o	11200/800	h90.1850	ok	47	CIN3	NO	NO	NO	NO	NO	NO
A 2p	12000/800	h90.1850	ok	47	CIN3	NO	NO	NO	empty	empty	empty
A 3a	0/1600	h91.1044	ok	49	NO	NO	NO	NO	NO	NO	NO
A 3b	800/1600	h91.1044	ok	49	NO	NO	NO	NO	NO	NO	NO
A 3c	1600/1600	h91.1741	ok	54	CIN3	NO	NO	NO	NO	NO	NO
A 3d	2400/1600	h91.1741	ok	54	CIN3	NO	NO	NO	NO	first empty	empty
A 3e	3200/1600	h91.206	ok	57	NO	NO	stroma	NO	ENDO	NO	NO
A 3f	4000/1600	h91.206	ok	57	NO	NO	first empty	NO	stroma	NO	stroma
A 3g	4800/1600	h91.826	ok	62	CIN3	NO	stroma	CIN1	CIN1	NO	stroma
A 3h	5600/1600	h91.826	ok	62	CIN3	NO	stroma	first empty	empty	empty	empty
A 3i	6400/1600	h92.1411	ok	65	CIN3	NO	CIN1	CIN1	CIN1	CIN1	CIN1
A 3j	7200/1600	h92.1411	ok	65	CIN3	NO	CIN1	CIN1	empty	empty	empty
A 3k	8000/1600	h92.1424	ok	66	CIN2	NO	NO	NO	first empty	NO	NO
A 3l	8800/1600	h92.1424	ok	66	CIN2	NO	NO	NO	NO	NO	ENDO
A 3m	9600/1600	h92.1446	ok	67	CIN3	NO	NO	NO	NO	INFL	INFL
A 3n	10400/1600	h92.1446	ok	67	CIN3	NO	NO	NO	NO	NO	NO
A 3o	11200/1600	h92.1513	ok	68	CIN2	NO	CIN1	NO	NO	NO	empty
A 3p	12000/1600	h92.1513	ok	68	CIN2	NO	first empty	empty	empty	empty	empty
A 4a	0/2400	h92.1529	ok	69	CIN3	NO	CIN1-2 at one edge of sample	NO	NO	CIN1	NO
A 4b	800/2400	h92.1529	ok	69	CIN3	NO	NO	NO	empty	empty	empty
A 4c	1600/2400	h92.1676	ok	72	NO	NO	stroma	NO	NO	NO	ENDO
A 4d	2400/2400	h92.1676	ok	72	NO	NO	NO	NO	NO	NO	stroma

Localisation	Coordinates	BNr	status	Pat N°	max lesion	targeted lesion	CE1	CE2	CE3	CE4	CE5
A 4c	3200/2400	h92.1758	ok	73	CIN3	NO	first empty	NO	NO	NO	NO
A 4f	4000/2400	h92.1758	ok	73	CIN3	NO	stroma	stroma	stroma	first empty	NO
A 4g	4800/2400	h91.33	ok	59	NO	NO	INFL	ENDO	NO	NO	stroma
A 4h	5600/2400	h91.33	ok	59	NO	NO	NO	NO	stroma	NO	NO
A 4i	6400/2400	h92.554	ok	78	NO	NO	NO	NO	stroma	NO	NO
A 4j	7200/2400	h92.554	ok	78	NO	NO	NO	empty	empty	empty	empty
A 4k	8000/2400	h92.604	ok	79	CIN3	NO	NO	stroma	NO	NO	CIN1
A 4l	8800/2400	h92.604	ok	79	CIN3	NO	INFL	NO	NO	NO	NO
A 4m	9600/2400	h92.792	ok	81	NO	NO	NO	NO	INFL	NO	NO
A 4n	10400/2400	h92.792	ok	81	NO	NO	NO	stroma	NO	stroma	stroma
A 4o	11200/2400	h93.1016	ok	82	NO	NO	NO	NO	NO	stroma	NO
A 4p	12000/2400	h93.1016	ok	82	NO	NO	NO	NO	NO	NO	NO
A 5a	0/3200	h93.1762	ok	85	CIN2	NO	NO	empty	NO	NO	NO
A 5b	800/3200	h93.1762	ok	85	CIN2	NO	first empty	CIN1	NO	NO	CIN1
A 5c	1600/3200	h93.219	ok	91	CIN2	NO	CIN1	CIN1	NO	CIN1	CIN1
A 5d	2400/3200	h93.219	ok	91	CIN2	NO	CIN1	NO	empty	empty	empty
A 5e	3200/3200	h93.254	ok	93	NO	NO	NO	NO	NO	NO	stroma
A 5f	4000/3200	h93.254	ok	93	NO	NO	stroma	stroma	NO	empty	empty
A 5g	4800/3200	h93.317	ok	95	NO	NO	INFL	NO	stroma	stroma	stroma
A 5h	5600/3200	h93.317	ok	95	NO	NO	INFL	NO	NO	stroma	stroma
A 5i	6400/3200	h93.364	ok	97	NO	NO	NO	NO	NO	stroma	NO
A 5j	7200/3200	h93.364	ok	97	NO	NO	empty	empty	empty	empty	empty
A 5k	8000/3200	h80.193	ok	3	CIN3	ENDO	ENDO	stroma	stroma	stroma	str
A 5l	8800/3200	h89.11	ok	31	NO	ENDO	ENDO	ENDO	ENDO	ENDO	ENDO
A 5m	9600/3200	h89.114	ok	32	CIN3	ENDO	stroma	ENDO	ENDO	ENDO	ENDO
A 5n	10400/3200	h90.1681	ok	44	NO	ENDO	ENDO	ENDO	ENDO	ENDO	ENDO
A 5o	11200/3200	h90.1850	ok	47	CIN3	ENDO	ENDO	ENDO	stroma	ENDO	stroma

Localisation	Coordinates	BNr	status	Pat N°	max lesion	targeted lesion	CE1	CE2	CE3	CE4	CE5
A 5p	12000/3200	h92.1424	ok	66	CIN2	ENDO	ENDO	ENDO	ENDO	ENDO INFL	ENDO
A 6a	0/4000	h92.792	ok	81	NO	ENDO	ENDO	ENDO	ENDO	ENDO	ENDO
A 6b	800/4000	h93.2013	ok	89	CIN3	ENDO	stroma	ENDO	ENDO	ENDO	ENDO
A 6c	1600/4000	h93.219	ok	91	CIN2	ENDO	ENDO	stroma	stroma	ENDO	stroma
A 6d	2400/4000	h88.779	ok	29	CIN1	INFL ENDO	ENDO INFL	ENDO INFL	empty	empty	empty
A 6e	3200/4000	h86.1433	ok	12	squamous metaplasia	INFL	stroma	INFL	NO	INFL	stroma
A 6f	4000/4000	h91.206	ok	57	INFL	INFL	INFL	INFL	INFL	NO	INFL
A 6g	4800/4000	h81.910	ok	4	CIN3	CIN1	CIN1	CIN1	CIN1	CIN1	CIN1
A 6h	5600/4000	h82.352	ok	5	CIN1	CIN1	CIN1	CIN1	first empty	first empty	first empty
A 6i	6400/4000	h83.704	ok	8	CIN2	CIN1	CIN1	CIN1	CIN1	empty	empty
A 6j	7200/4000	h87.932	ok	21	CIN1	CIN1	ENDO INFL	INFL	CIN1	empty	empty
A 6k	8000/4000	h88.2032	ok	25	CIN3	CIN1	CINE3	CIN1	CIN1	CIN1	empty
A 6l	8800/4000	h88.647	ok	28	CIN3	CIN1	NO	NO	first empty	CIN1	empty
A 6m	9600/4000	h88.779	ok	29	CIN1	CIN1	unuseful	NO	CIN1	CIN1	empty
A 6n	10400/4000	h89.1529	ok	36	CIN1	CIN1	CIN1	ENDO	CIN1	CIN1	CIN1
A 6o	11200/4000	h89.1915	ok	39	CIN1	CIN1	CIN1	CIN1	CIN1	CIN1	CIN1
A 6p	12000/4000	h91.1572	ok	52	CIN1	CIN1	CIN1	CIN1	CIN1	CIN1	CIN1
A 7a	0/4800	h91.1615	ok	53	CIN1	CIN1	CIN1	NO	CIN1	CIN1	CIN1
A 7b	800/4800	h91.1788	ok	55	CIN1	CIN1	CIN1	CIN1	NO	CIN1	CIN1
A 7c	1600/4800	h91.237	ok	58	CIN1	CIN1	CIN1	CIN1	CIN1	CIN1	CIN1
A 7d	2400/4800	h92.441	ok	76	CIN3	CIN1	CIN1	CIN1	CIN1	CIN1	CIN1
A 7e	3200/4800	h92.731	ok	80	CIN1	CIN1	CIN1	CIN1	stroma	first empty	empty
A 7f	4000/4800	h93.1391	ok	83	CIN1	CIN1	CIN1	CIN1	CIN1	empty	empty
A 7g	4800/4800	h93.1600	ok	84	CIN1	CIN1	NO	CIN1	CIN1	CIN1	CIN1
A 7h	5600/4800	h93.2030	ok	90	CIN1	CIN1	CIN1	NO	CIN1	CIN1	CIN1
A 7i	6400/4800	h93.253	ok	92	CIN1	CIN1	CIN1	NO	CIN1	CIN1	NO
A 7j	7200/4800	h93.298	ok	94	CIN1	CIN1	NO	NO	empty	ENDO INFL	ENDO

Localisation	Coordinates	BNr	status	Pat N°	max lesion	targeted lesion	CE1	CE2	CE3	CE4	CE5
A 7k	8000/4800	h93.344	ok	96	CIN1	CIN1	CIN1	CIN1	CIN1	CIN1	CIN1
A 7l	8800/4800	h93.364	ok	97	CIN1	CIN1	ENDO	ENDO	empty	empty	empty
A 7m	9600/4800	h83.494	ok	7	CIN3	CIN2	CIN3	CIN3	empty	empty	empty
A 7n	10400/4800	h87.1932	ok	16	CIN2	CIN2	CIN2	CIN2	empty	empty	empty
A 7o	11200/4800	h89.1208	ok	34	CIN2	CIN2	CIN2	ENDO	CIN2	empty	empty
A 7p	12000/4800	h89.1527	ok	35	CIN2	CIN2	CIN1	CIN1	CIN2	empty	empty
A 8a	0/5600	h89.1837	ok	38	CIN2	CIN2	CIN2	CIN2	CIN2	empty	empty
A 8b	800/5600	H90.1323	ok	42	CIN2	CIN2	CIN2	CIN2	NO	CIN2	NO
A 8c	1600/5600	h91.1339	ok	60	CIN2	CIN2	CIN2	CIN2	CIN2	CIN2	CIN2
A 8d	2400/5600	h91.826	ok	62	CIN3	CIN2	CIN1	CIN2	ENDO	CIN2	empty
A 8e	3200/5600	h92.1357	ok	63	CIN2	CIN2	CIN1	ENDO INFL	CIN2	CIN2	empty
A 8f	4000/5600	h92.1371	ok	64	CIN2	CIN2	CIN1	CIN1	ENDO	INFL	CIN2
A 8g	4800/5600	h92.1578	ok	70	CIN3	CIN2	CIN2	CIN2	CIN2	CIN2	empty
A 8h	5600/5600	h92.458	ok	77	CIN3	CIN2	CIN2	CIN2	CIN2	CIN2	CIN2
A 8i	6400/5600	h93.1762	ok	85	CIN2	CIN2	CIN2	ENDO	CIN2	ENDO	first empty
A 8j	7200/5600	h93.219	ok	91	CIN2	CIN2	CIN2	CIN2	CIN2	stroma	INFL
A 8k	8000/5600	h87.2006	ok	17	CIN3	CIN2, INFL	stroma	stroma	ENDO	stroma	INFL
A 8l	8800/5600	H82.352	ok	5	CIN3	CIN3	CIN2	first empty	stroma	first empty	CIN3
A 8m	9600/5600	h83.2	ok	6	CIN3	CIN3	CIN3	CIN3	CIN3	CIN3	CIN3
A 8n	10400/5600	h86.1309	ok	11	CIN3	CIN3	CIN3	first empty	CIN3	CIN3	CIN3
A 8o	11200/5600	h86.1493	ok	12	CIN3	CIN3	CIN3	stroma	ENDO	CIN3	CIN3
A 8po	12000/5600	h87.1313	ok	15	CIN3	CIN3	CIN3	CIN3	CIN3	CIN3	CIN3
A 9a	0/6400	h87.465	ok	20	CIN3	CIN3	CIN3	CIN3	CIN3	CIN2	CIN2
A 9b	800/6400	h88.1257	ok	22	CIN3	CIN3	CIN3	CIN3	CIN3	CIN3	CIN3
A 9c	1600/6400	h88.1739	ok	24	CIN3	CIN3	CIN3	empty	empty	empty	empty
A 9d	2400/6400	h88.2032	ok	25	CIN3	CIN3	CIN3	CIN3	empty	empty	empty
A 9e	3200/6400	h88.451	ok	26	CIN3	CIN3	CIN3	CIN3	CIN3	empty	empty

Localisa- tion	Coordinates	BNr	status	Pat Nr	max lesion	targeted lesion	CE1	CE2	CE3	CE4	CE5
A 9f	4000/6400	h88.577	ok	27	CIN3	CIN3	CIN3	CIN3	small CIN3	CIN3	CIN3
A 9g	4800/6400	h89.114	ok	32	CIN3	CIN3	stroma	CIN3	CIN3	ENDO	empty
A 9h	5600/6400	h89.1172	ok	33	CIN3	CIN3	stroma	stroma	ENDO	CIN3	ENDO
A 9i	6400/6400	h89.608	ok	41	CIN3	CIN3	ENDO	INFL	INFL	stroma	ENDO
A 9j	7200/6400	h90.1471	ok	43	CIN3	CIN3	CIN3	CIN3	empty	empty	empty
A 9k	8000/6400	h90.1850	ok	47	CIN3	CIN3	CIN3	CIN3	CIN3	CIN3	empty
A 9l	8800/6400	h91.1741	ok	54	CIN3	CIN3	CIN3	CIN2	CIN1	empty	empty
A 9m	9600/6400	h91.1904	ok	56	CIN3	CIN3	NO	CIN1	CIN1	empty	empty
A 9n	10400/6400	h92.1411	ok	65	CIN3	CIN3	ENDO INFL	CIN1	CIN1	empty	empty
A 9o	11200/6400	h92.1446	ok	67	CIN3	CIN3	INFL	unclassifiable	CIN1	CIN3	CIN3
A 9p	12000/6400	h92.1513	ok	68	CIN2	CIN3	ENDO	ENDO	ENDO	CIN2	empty
B 1a	00	h92.1529	ok	69	CIN3	CIN3	CIN3	ENDO	CIN3	CIN3	CIN3
B 1b	8000/	h92.1639	ok	71	CIN2	CIN3	CIN3	CIN3	CIN3	unclassifiable	stroma
B 1c	16000	h92.1758	ok	73	CIN3	CIN3	ENDO	CIN3	CIN3	empty	empty
B 1d	24000	h92.1916	ok	74	CIN3	CIN3	first empty	CIN3	CIN3	empty	empty
B 1e	32000	h92.318	ok	75	CIN3	CIN3	CIN3	CIN3	CIN3	CIN1	first empty
B 1f	40000	h92.604	ok	79	CIN3	CIN3	unclassifiable	CIN3	CIN3	empty	empty
B 1g	48000	h93.1777	ok	86	CIN3	CIN3	CIN1	stroma	CIN1	empty	empty
B 1h	56000	h93.1810	ok	87	CIN3	CIN3	ENDO INFL	CIN3	CIN3	INFL	ENDO
B 1i	64000	h93.2013	ok	89	CIN3	CIN3	ENDO	ENDO	first empty	ENDO	empty
B 1j	72000	h93.2030	ok	90	CIN2	CIN3	CIN3	CIN3	CIN3	CIN3	unclassifiable
B 1k	80000	h81.910	ok	4	CA	CA	CIN1	CA	CIN3	empty	empty
B 1l	88000	h81.910	ok	4	CA	CA	empty	empty	empty	empty	empty
B 1m	96000	h88.934	ok	30	CA	CA	CA	CA	CA	CA	CA
B 1n	104000	h88.934	ok	30	CA	CA	CA	CA	CA	CA	CA
B 1o	112000	h91.1460	ok	51	normal control	kidney	kidney	kidney	kidney	kidney	kidney
B 1p	120000	h93.1995	ok	88	normal control	kidney	kidney	kidney	kidney	kidney	kidney

Localisation	Coordinates	BNr	status	Pst Nr	max lesion	targeted lesion	CE1	CE2	CE3	CE4	CE5
B 2a	0/800	h91.7359		2	normal control	liver	liver	liver	liver	liver	liver
B 2b	800/800	h90.491		48	normal control	liver	liver	liver	liver	liver	liver
B 2c	1600/800	h89.590		40	normal control	lymph node	lymph node	lymph node	lymph node	lymph node	lymph node
B 2d	2400/800	h91.463		61	normal control	lymph node	lymph node	lymph node	lymph node	lymph node	lymph node
B 2e	3200/800	h88.1377		23	normal control	prostate	prostate	prostate	prostate	prostate	prostate
B 2f	4000/800	h91.1092		50	normal control	prostate	prostate	prostate	prostate	prostate	prostate
B 2g	4800/800	h87.315		18	normal control	thyroid	thyroid	thyroid	thyroid	thyroid	thyroid
B 2h	5600/800	h87.449		19	normal control	thyroid	thyroid	thyroid	thyroid	thyroid	thyroid

Table 9

Coordinates	Organ	Histologic tumor type	sex	age	BRE grade	Tubuli	Polymorphy	Mitoses	pT	LN pos	LN all	Tumor diameter	surgery	
A 1a	breast	breast cancer, ductal	f	67	G2	3	2	1	1	0	0	23	mastectomy	
A 1b	breast	breast cancer, ductal	f	42	G3	3	3	2	1	1	10	17	lumpectomy	
A 1c	breast	breast cancer, ductal	f	71	G2	3	2	1	1	0	0	8	mastectomy	
A 1d	breast	breast cancer, ductal	f	65	G2	3	2	1	2	1	20	20	mastectomy	
A 1e	breast	breast cancer, lobular	f	54	G2	3	2	1	2	1	8	16	lumpectomy	
A 1f	breast	breast cancer, ductal	f	62	G2	3	2	1	2	0	0	14	mastectomy	
A 1g	breast	breast cancer, ductal	f	92	G3	3	3	2	2			40	mastectomy	
A 1h	breast	breast cancer, ductal	f	48	G2	3	3	1	2	0	0	19	mastectomy	
A 2a	breast	breast cancer, ductal	f	31	G2	3	2	1	2	1	3	20	mastectomy	
A 2b	breast	breast cancer, ductal	f	67	G1	1	2	1	1	0	0	20	mastectomy	
A 2c	breast	breast cancer, ductal	f	49	G2	3	2	1	2	1	6	18	mastectomy	
A 2d	breast	breast cancer, ductal	f	80	G2	3	2	1	1	0	0	1	20	mastectomy
A 2e	breast	breast cancer, ductal	f	69	G2	3	2	1	3	0	0	3	55	mastectomy
A 2f	breast	breast cancer, ductal	f	61	G2	3	2	1	1	0	0	10	20	mastectomy
A 2g	breast	breast cancer, ductal	f	39	G3	3	3	2	1	1	5	19	mastectomy	
A 2h	breast	breast cancer, ductal	f	33	G3	3	3	3	2			30	lumpectomy	

Table 9

Coordinates	Organ	Histologic tumor type	sex	age	BRE grade	Tubuli	Polymorphy	Mitoses	pT	LN pos	LN all	Tumor diameter	surgery
A 3a	breast	breast cancer, ductal	f		G3	2	3	3	2			40	mastectomy
A 3b	breast	breast cancer, ductal	f	80	G2	2	3	1	4			65	mastectomy
A 3c	breast	breast cancer, ductal	f	62	G2	3	2	1	1	1	2	15	lumpectomy
A 3d	breast	breast cancer, ductal	f	80	G3	3	3	2	1	1	3	5	mastectomy
A 3e	breast	breast cancer, ductal	f	60	G3	3	3	2	2	1	3	9	mastectomy
A 3f	breast	breast cancer, lobular	f	75	G2	3	2	1	3	1	9	11	mastectomy
A 3g	breast	breast cancer, ductal	f	68	G1	2	2	1					lumpectomy
A 3h	breast	breast cancer, ductal	f	65	G2	2	3	1	4			85	lumpectomy
A 4a	breast	breast cancer, cribriform	f		G1	1	2	1	2			29	
A 4b	breast	breast cancer, ductal	f	72	G1	2	2	1	2			30	lumpectomy
A 4c	breast	breast cancer, ductal	f	46	G2	3	3	1	1			15	lumpectomy
A 4d	breast	breast cancer, mucinous	f		G1	2	1	1					
A 4e	breast	breast cancer, ductal	f	87	G3	3	3	2					lumpectomy
A 4f	breast	breast cancer, ductal	f	44	G3	3	3	3	1			20	lumpectomy
A 4g	breast	breast cancer, ductal	f	69	G1	1	2	1		0	0	14	mastectomy
A 4h	breast	breast cancer, ductal	f	88	G2	3	2	2	1			7	lumpectomy

Table 9

Coordinates	Organ	Histologic tumor type	sex	age	BRE grade	Tubuli	Polymorphy	Mitoses	pT	pN	LN pos	LN all	Tumor diameter	surgery
A 5a	breast	breast cancer, ductal	f	76	G2	3	2	1	1				10	lumpectomy
A 5b	breast	breast cancer, ductal	f		G3	3	3	2	2				25	lumpectomy
A 5c	breast	breast cancer, lobular	f	78	G2	3	2	1	2				25	lumpectomy
A 5d	breast	breast cancer, metaplastic (adenosquamous)	f		G3	3	3	2	1				20	lumpectomy
A 5e	breast	breast cancer, lobular	f	66	G2	3	2	1						mastectomy
A 5f	breast	breast cancer, cribriform	f	69	G1	1	2	1	1				9	lumpectomy
A 5g	breast	breast cancer, ductal	f	47	G2	2	3	1	4	1	1	7		mastectomy
A 6a	breast	breast cancer, ductal	f	70	G3	3	3	3	2	0	0	12	27	lumpectomy
A 6b	breast	breast cancer, ductal	f	84	G3	3	2	3						lumpectomy
A 6c	breast	breast cancer, ductal	f	53	G3	3	3	2	1	1	4	13	20	lumpectomy
A 6d	breast	breast cancer, ductal	f	43	G3	3	3	3	4	1	3	14	45	lumpectomy
A 6e	breast	breast cancer, ductal	f	78	G3	3	3	3	3	2			22	lumpectomy
A 6f	breast	breast cancer, ductal	f	54	G1	2	2	1	1				18	lumpectomy
A 6g	breast	breast cancer, ductal	f	79	G2	3	3	1	2				31	lumpectomy
A 7a	breast	breast cancer, ductal	f	67	G1	2	2	1	1	1	3	9	15	lumpectomy

Table 9

Coordinates	Organ	Histologic tumor type	sex	age	BRE grade	Tubuli	Polymorphy	Mitoses	pT	LN pos	LN all	Tumor diameter	surgery
A 7b	breast	breast cancer, ductal	f	77	G1	2	2	1	4			30	lumpectomy
A 7c	breast	breast cancer, ductal	f	66	G2	3	2	1	2			30	lumpectomy
A 7d	breast	breast cancer, ductal	f		G2	3	3	1	2			30	
A 7e	breast	breast cancer, ductal	f	77	G2	3	2	1		1	1	24	mastectomy
A 7f	breast	breast cancer, ductal	f	50	G2	3	2	2	1			15	lumpectomy
A 7g	breast	breast cancer, medullary	f	61	G3	3	3	3	1			19	lumpectomy
A 8a	breast	breast cancer, tubular	f	69	G1	1	2	1	2			23	lumpectomy
A 8b	breast	breast cancer, ductal	f	53	G3	5	2	2	2	1	3	14	mastectomy
A 8c	breast	breast cancer, ductal	f	81	G3	3	3	2	2	0	0	2	mastectomy
A 8d	breast	breast cancer, ductal	f		G2	3	2	1	2			22	lumpectomy
A 8e	breast	breast cancer, lobular	f	64	G2	3	2	1	1			20	lumpectomy
A 8f	breast	breast cancer, lobular	f	68	G2	3	2	1	2	1	17	21	lumpectomy
A 8g	breast	breast cancer, ductal	f	57	G2	3	3	1		1	3	30	mastectomy
B 1a	breast	fibroadenoma	f	22									
B 1b	breast	fibroadenoma	f	29									
B 1c	salivary gland,	normal	m	52									

Table 9

Coordinates	Organ	Histologic tumor type	sex	age	BRE grade	Tubuli	Polymorphy	Mitoses	pT	pN	LN pos	LN all	Tumor diameter	surgery
	parotis													
B 2a	salivary gland, submandibular	normal	f	31										
B 2b	colon	normal	m	72										
B 2c	colon	normal	f	59										
B 3a	seminal vesicle	normal	m	68										
B 3b	seminal vesicle	normal	m	60										
B 3c	tonsil	normal	f	17										
B 4a	tonsil	normal	f	18										
B 4b	kidney	normal	m	78										
B 4c	kidney	normal	m	87										
B 5a	liver	normal	f	71										
B 5b	liver	normal	f	26										
B 6a	lymph node	normal	m	60										
B 6b	lymph node	normal	f	76										
B 7a	prostate	normal	m											
B 7b	prostate	normal	m	68										

Table 9

Coordinates	Organ	Histologic tumor type	sex	age	BRt grade	Tubuli	Polymorphy	Mitoses	pT	pN	LN pos	LN all	Tumor diameter	surgery
B 8a	thyroid	normal	f	47										
B 8b	thyroid	normal	m	26										

TABLE 10

Coordinates	identical biopsy	age	sex	Organ	Histologic diagnosis	tissue represented, lot 1	underlying disease	material
A 1a		47	f	thyroid	normal	ok	adenoma	biopsy
A 1b		26	m	thyroid	normal	ok	adenoma	biopsy
A 1c 1		65	m	thyroid	normal	ok	adenoma	biopsy
A 1d 1		65	m	thyroid	normal	ok	adenoma	biopsy
A 1e		32	f	adrenal gland	normal	ok	trauma	autopsy, 3 hrs.
A 1f		41	m	adrenal gland	normal	ok	trauma	autopsy, 5 hrs.
A 1g		37	m	adrenal gland	normal	ok	trauma	autopsy, 4 hrs.
A 1h		74	m	adrenal gland	normal	ok	kidney cancer	biopsy
A 2a		28	f	placenta, third trimester	normal	ok		biopsy
A 2b		29	f	placenta, third trimester	normal	ok		biopsy
A 2c		32	f	placenta, third trimester	normal	ok		biopsy
A 2d		29	f	placenta, third trimester	normal	ok		biopsy

TABLE 10

Coordinates	identical biopsy	age	sex	Organ	Histologic diagnosis	tissue represented, lot 1	underlying disease	material
A 2c		25	m	tonsil	normal	ok	chronic tonsillitis	biopsy
A 2f		18	f	tonsil	normal	ok	chronic tonsillitis	biopsy
A 2g		17	f	tonsil	normal	ok	chronic tonsillitis	biopsy
A 2h		34	m	tonsil	normal	ok	chronic tonsillitis	biopsy
A 3a		16	m	lymph node	normal	ok	cholecystitis	biopsy
A 3b				lymph node	normal	ok	gastric cancer	biopsy
A 3c		62	f	lymph node	normal	ok	breast cancer	biopsy
A 3d		54	f	lymph node	normal	ok	breast cancer	biopsy
A 3e		21	f	spleen	normal	ok	trauma	biopsy
A 3f		43	m	spleen	normal	ok	old hematoma	biopsy
A 3g		74	f	spleen	normal	ok	hyperplasia	biopsy
A 3h		26	f	spleen	normal	ok	Hodgkin disease	biopsy
A 4a		32	f	heart	normal	ok	trauma	autopsy, 3 hrs.
A 4b		41	m	heart	normal	ok	trauma	autopsy, 5 hrs.
A 4c 2		37	m	heart	normal	ok	trauma	autopsy, 4 hrs.
A 4d 2		37	m	heart	normal	ok	trauma	autopsy, 4 hrs.
A 4c		27	m	skeletal muscle	normal	ok	Seminoma	biopsy

TABLE 10

Coordinates	identical biopsy	age	sex	Organ	Histologic diagnosis	tissue represented, lot 1	underlying disease	material
A 4f		43	m	skeletal muscle	normal	ok	hernia	biopsy
A 4g		67	m	skeletal muscle	normal	ok	eyelid resection	biopsy
A 4h		31	f	skeletal muscle	normal	ok	thyroid cancer	biopsy
A 5a		74	f	liver	normal	ok	mild non-specific portal triaditis	biopsy
A 5b		85	m	liver	normal	ok	colon cancer, metastatic	biopsy
A 5c		71	m	liver	mild chronic inflammation	ok	cholecystitis	biopsy
A 5d		26	f	liver	normal	mild chronic inflammation	Hodgkin disease	biopsy
A 5e 3		32	f	pancreas	normal	ok	trauma	autopsy, 3 hrs.
A 5f 4		41	m	pancreas	normal	ok	trauma	autopsy, 5 hrs.
A 5g 3		32	f	pancreas	normal	ok	trauma	autopsy, 3 hrs.
A 6a 4		41	m	pancreas	normal	ok	trauma	autopsy, 5 hrs.
A 6b		44	f	ovary, stroma	normal	ok	abnormal bleedings	biopsy
A 6c				ovary, stroma	normal	ok	carcinoma in situ cervix	biopsy

TABLE 10

Coordinates	identical biopsy	age	sex	Organ	Histologic diagnosis	tissue represented, lot 1	underlying disease	material
A 6d		47	f	ovary, stroma	normal	ok	hysterectomy	biopsy
A 6e		47	f	ovary, stroma	normal	ok	myoma uterus	biopsy
A 6f		30	f	myometrium	normal	ok	pelvic pain	biopsy
A 6g		45	f	myometrium	normal	ok	menometrarhagia	biopsy
A 7a		49	f	myometrium	normal	ok	endometrium cancer	biopsy
A 7b				myometrium	normal	ok	carcinoma in situ cervix	biopsy
A 7c		31	f	endo sekr	normal	ok	prolaps	biopsy
A 7d		39	f	endo sekr	normal	ok	prolaps	biopsy
A 7e		32	f	endo sekr	normal	ok	carcinoma in situ cervix	biopsy
A 7f				endo sekr	normal	ok	carcinoma in situ cervix	biopsy
A 7g		74	m	kidney cortex	normal	ok	kidney cancer	biopsy
A 8a		78	m	kidney cortex	normal	ok	transitional cell carcinoma	biopsy
A 8b		88	m	kidney cortex	normal	ok	kidney cancer	biopsy
A 8c		87	m	kidney cortex	normal	ok	transitional cell carcinoma	biopsy

TABLE 10

Coordinates	identical biopsy	age	sex	Organ	Histologic diagnosis	tissue represented, lot 1	underlying disease	material
A 8d			m	prostate	normal	ok	BPH	biopsy
A 8e		68	m	prostate	normal	ok	prostate cancer	biopsy
A 8f		86	m	prostate	normal	ok	BPH	biopsy
A 8g		58	m	prostate	normal	ok	BPH	biopsy
B 1a		60	m	seminal vesicle	normal	ok	prostate cancer	biopsy
B 1b		63	m	seminal vesicle	normal	ok	prostate cancer	biopsy
B 1c		68	m	seminal vesicle	normal	ok	prostate cancer	biopsy
B 2a		65	m	seminal vesicle	normal	no epithelium	prostate cancer	biopsy
B 2b		77	m	testis	decreased spermiogenesis	ok	prostate cancer	biopsy
B 2c		87	m	testis	decreased spermiogenesis	ok	prostate cancer	biopsy
B 3a		86	m	testis	normal	ok	prostate cancer	biopsy
B 3b		73	m	testis	normal	ok	prostate cancer	biopsy
B 3c		74	f	lung	normal	ok	lung cancer	biopsy
B 4a		62	m	lung	normal	ok	lung cancer	biopsy

TABLE 10

Coordinates	identical biopsy	age	sex	Organ	Histologic diagnosis	tissue represented, lot 1	underlying disease	material
B 4b		68	f	lung	normal	ok	lung cancer	biopsy
B 4c		69	f	lung	normal	ok	lung cancer	biopsy
B 5a		41	m	cerebellum	normal	ok	trauma	autopsy, 5 hrs.
B 5b		33	f	cerebellum	normal	ok	trauma	autopsy, <10 hrs.
B 6a	5	37	m	cerebellum	normal	ok	trauma	autopsy, 4 hrs.
B 6b	5	37	m	cerebellum	normal	ok	trauma	autopsy, 4 hrs.
B 7a		32	f	cerebrum	normal	ok	trauma	autopsy, 3 hrs.
B 7b		41	m	cerebrum	normal	ok	trauma	autopsy, 5 hrs.
B 8a		33	f	cerebrum	normal	ok	trauma	autopsy, <10 hrs.
B 8b		37	m	cerebrum	normal	ok	trauma	autopsy, 4 hrs.

Table 11

Localisation	Identical Biopsy	Age	Sex	Organ	Underlying Disease	Histologic DX	Tissue Represented, Lot1	Material
A1a	1	47	F	Thyroid	Adenoma	Normal	Ok	Biopsy
A1b	1	47	F	Thyroid	Thyroid cancer	Normal	Ok	Biopsy
A1c	1	47	F	Thyroid	Adenoma	Normal	Ok	Biopsy
A1d	1	47	F	Thyroid	Adenoma	Normal	Ok	Biopsy
A1e	2	26	M	Thyroid	Adenoma	Normal	Ok	Biopsy
A1f	2	26	M	Thyroid	Adenoma	Normal	Ok	Biopsy
A1g	2	26	M	Thyroid	Adenoma	Normal	Ok	Biopsy
A1h	3	65	M	Thyroid	Adenoma	Normal	Ok	Biopsy
A1i	3	65	M	Thyroid	Adenoma	Normal	Ok	Biopsy
A1j	3	65	M	Thyroid	Adenoma	Normal	Ok	Biopsy
A1k	4	32	F	Adrenal gland	Depression, trauma	Normal	Ok	Biopsy
A1l	4	32	F	Adrenal gland	Depression, trauma	Normal	Ok	Autopsy, 3h
A1m	4	32	F	Adrenal gland	Depression, trauma	Normal	Ok	Autopsy, 3h
A1n	5	41	M	Adrenal gland	Trauma	Normal	Ok	Autopsy, 3h
A1o	5	41	M	Adrenal gland	Trauma	Normal	Ok	Autopsy, 3h
A1p	5	41	M	Adrenal gland	Trauma	Normal	Ok	Autopsy, 5h
A2a	6	37	M	Adrenal gland	Trauma	Normal	Few epithelial cells	Autopsy, 4h
A2b	6	37	M	Adrenal gland	Trauma	Normal	Ok	Autopsy, 5h
A2c	7	74	M	Adrenal gland	Trauma	Normal	Few epithelial cells	Autopsy, 4h
A2d	7	74	M	Adrenal gland	Clear cell RCC	Normal	Few epithelial cells	Biopsy
A2e	12	28	F	Placenta, third trimester	Rapid labor	Normal	Ok	Biopsy
A2f	12	28	F	Placenta, third trimester	Rapid labor	Normal	Ok	Biopsy
A2g	12	28	F	Placenta, third trimester	Rapid labor	Normal	Ok	Biopsy
A2h	13	29	F	Placenta, third trimester	Rapid labor	Normal	Ok	Biopsy
A2i	13	29	F	Placenta, third trimester	Prolonged labor	Normal	Ok	Biopsy
A2j	13	29	F	Placenta, third trimester	Prolonged labor	Normal	Ok	Biopsy
A2k	14	32	F	Placenta, third trimester	Prolonged labor	Normal	Ok	Biopsy
A2l	14	32	F	Placenta, third trimester	Prolonged labor	Normal	Ok	Biopsy
A2m	15	29	F	Placenta, third trimester	Full term pregnancy	Normal	Ok	Biopsy
A2n	15	29	F	Placenta, third trimester	Full term pregnancy	Normal	Ok	Biopsy
A2o	16	25	M	Tonsil	Chronic tonsillitis	Normal	Ok	Biopsy
A2p	17	18	F	Tonsil	Chronic tonsillitis	Normal	Ok	Biopsy
A3a	18	17	F	Tonsil	Chronic tonsillitis	Normal	Ok	Biopsy
A3b	18	17	F	Tonsil	Chronic tonsillitis	Normal	Ok	Biopsy
A3c	19	22	M	Tonsil	Chronic tonsillitis	Normal	Ok	Biopsy
A3d	19	22	M	Tonsil	Chronic tonsillitis	Normal	Ok	Biopsy

Localisation	Identical Biopsy	Age	Sex	Organ	Underlying Disease	Histologic DX	Tissue Represented, Lot1	Material
A3c	20	42	F	Tonsil	Chronic tonsillitis	Normal	Ok	Biopsy
A3f	20	42	F	Tonsil	Chronic tonsillitis	Normal	Ok	Biopsy
A3g	21	34	M	Tonsil	Chronic tonsillitis	Normal	Ok	Biopsy
A3h	21	34	M	Tonsil	Chronic tonsillitis	Normal	Ok	Biopsy
A3i	22	16	M	Lymph node	Normal	Normal	Ok	Biopsy
A3j	22	16	M	Lymph node	Normal	Normal	Ok	Biopsy
A3k	23	76	M	Lymph node	Gastric cancer	Normal	Ok	Biopsy
A3l	23	76	M	Lymph node	Gastric cancer	Normal	Ok	Biopsy
A3m	24	62	F	Lymph node	Breast cancer	Normal	Ok	Biopsy
A3n	24	62	F	Lymph node	Breast cancer	Normal	Ok	Biopsy
A3o	24	62	F	Lymph node	Breast cancer	Normal	Ok	Biopsy
A3p	25	54	F	Lymph node	Breast cancer	Normal	Ok	Biopsy
A4a	25	54	F	Lymph node	Breast cancer	Normal	Ok	Biopsy
A4b	25	54	F	Lymph node	Breast cancer	Normal	Ok	Biopsy
A4c	26	32	F	Spleen	Depression trauma	Normal	Ok	Autopsy, 3h
A4d	26	32	F	Spleen	Depression trauma	Normal	Ok	Autopsy, 3h
A4e	27	21	F	Spleen	Trauma	Normal	Ok	Biopsy
A4f	27	21	F	Spleen	Trauma	Normal	Ok	Biopsy
A4g	28	43	M	Spleen	Old hematoma	Normal	Ok	Biopsy
A4h	28	43	M	Spleen	Old hematoma	Normal	Ok	Biopsy
A4i	29	74	F	Spleen	Old hematoma	Normal	Ok	Biopsy
A4j	29	74	F	Spleen	Old hematoma	Normal	Ok	Biopsy
A4k	30	26	F	Spleen	Hodgkin disease	Normal	Ok	Biopsy
A4l	30	26	F	Spleen	Hodgkin disease	Normal	Ok	Biopsy
A4m	31	68	F	Skin	Breast cancer	Normal	Ok	Biopsy
A4n	31	68	F	Skin	Breast cancer	Normal	Ok	Biopsy
A4o	32	44	F	Skin	Breast cancer	Normal	Ok	Biopsy
A4p	32	44	F	Skin	Breast cancer	Normal	Ok	Biopsy
A5a	33	53	F	Skin	Breast cancer	Normal	Ok	Biopsy
A5b	33	53	F	Skin	Breast cancer	Normal	Ok	Biopsy
A5c	33	53	F	Skin	Breast cancer	Normal	Ok	Biopsy
A5d	34	57	F	Skin	Breast cancer	Normal	Ok	Biopsy
A5e	34	57	F	Skin	Breast cancer	Normal	Ok	Biopsy
A5f	34	57	F	Skin	Breast cancer	Normal	Ok	Biopsy
A5g	35	32	F	Heart	Depression, trauma	Normal	Ok	Autopsy, 3h
A5h	35	32	F	Heart	Depression, trauma	Normal	Ok	Autopsy, 3h
A5i	35	32	F	Heart	Depression, trauma	Normal	Ok	Autopsy, 3h
A5j	35	32	F	Heart	Depression, trauma	Normal	Ok	Autopsy, 3h
A5k	36	41	M	Heart	Trauma	Normal	Ok	Autopsy, 5h
A5l	36	41	M	Heart	Trauma	Normal	Ok	Autopsy, 5h

Localisation	Identical Biopsy	Age	Sex	Organ	Underlying Disease	Histologic DX	Tissue Represented, Lot1	Material
A5l	36	41	M	Heart	Trauma	Normal	Ok	Autopsy, 5h
A5m	37	37	M	Heart	Trauma	Normal	Ok	Autopsy, 4h
A5n	37	37	M	Heart	Trauma	Normal	Ok	Autopsy, 4h
A5o	37	37	M	Heart	Trauma	Normal	Ok	Autopsy, 4h
A5r	37	37	M	Heart	Trauma	Normal	Ok	Autopsy, 4h
A6a	38	25	M	Skeletal muscle	Tonsillitis chronica	Normal	Ok	Biopsy
A6b	39	27	M	Skeletal muscle	Seminoma	Normal	Ok	Biopsy
A6c	40	22	M	Skeletal muscle	Chronic tonsillitis	Normal	Ok	Biopsy
A6d	41	43	M	Skeletal muscle	Hernia	Normal	Ok	Biopsy
A6e	42	67	M	Skeletal muscle	Eyid resection	Normal	Ok	Biopsy
A6f	42	67	M	Skeletal muscle	Eyid resection	Normal	Ok	Biopsy
A6g	44	31	F	Skeletal muscle	Thyroid cancer	Normal	Bleeding, no muscle	Biopsy
A6h	45			Skeletal muscle	Breast cancer	Normal	Ok	Biopsy
A6i	46			Skeletal muscle	Breast cancer	Normal	Ok	Biopsy
A6j	46			Skeletal muscle	Breast cancer	Normal	Ok	Biopsy
A6k	47	75	F	Smooth muscle, intestine	Gastric ulcer	Normal	Ok	Biopsy
A6l	48	68	M	Smooth muscle, intestine	Gastric cancer	Normal	Ok	Biopsy
A6m	49	91	M	Smooth muscle, intestine	Gastric cancer	Normal	Ok	Biopsy
A6n	49	91	M	Smooth muscle, intestine	Gastric cancer	Normal	Ok	Biopsy
A6o	50	76	M	Smooth muscle, intestine	Gastric cancer	Normal	Ok	Biopsy
A6p	50	76	M	Smooth muscle, intestine	Gastric cancer	Normal	Ok	Biopsy
A7a	51	76	M	Smooth muscle, intestine	Gastric cancer	Normal	Ok	Biopsy
A7b	51	47	F	Smooth muscle, intestine	Reflux esophagitis	Normal	Ok	Biopsy
A7c	52	47	F	Smooth muscle, intestine	Reflux esophagitis	Normal	Ok	Biopsy
A7d	52	47	F	Smooth muscle, intestine	Reflux esophagitis	Normal	Ok	Biopsy
A7e	53	75	F	Stomach, antrum	Gastric ulcer	Normal	Lipomatous tissue	Biopsy
A7f	53	75	F	Stomach, antrum	Gastric ulcer	Normal	Intestinal metaplasia	Biopsy
A7g	53	75	F	Stomach, antrum	Gastric ulcer	Normal	Ok	Biopsy
A7h	53	75	F	Stomach, antrum	Gastric ulcer	Normal	Chronic inflammation	Biopsy

Localisation	Identical Biopsy	Age	Sex	Organ	Underlying Disease	Histologic DX	Tissue Represented, Lot1	Material
A7i	53	75	F	Stomach, antrum	Gastric ulcer	Normal	Chronic inflammation	Biopsy
A7j	54	68	M	Stomach, antrum	Gastric cancer	Normal	Chronic inflammation	Biopsy
A7k	54	68	M	Stomach, antrum	Gastric cancer	Normal	Chronic inflammation	Biopsy
A7l	54	68	M	Stomach, antrum	Gastric cancer	Normal	Ok	Biopsy
A7m	54	68	M	Stomach, antrum	Gastric cancer	Normal	Ok	Biopsy
A7n	54	68	M	Stomach, antrum	Gastric cancer	Normal	Ok	Biopsy
A7o	56	68	M	Stomach, corpus	Gastric cancer	Normal	Ok	Biopsy
A7p	56	68	M	Stomach, corpus	Gastric cancer	Normal	Ok	Biopsy
A8a	57	76	M	Stomach, corpus	Gastric cancer	Normal	Ok	Biopsy
A8b	57	76	M	Stomach, corpus	Gastric cancer	Normal	Ok	Biopsy
A8c	58	47	F	Stomach, corpus	Reflux esophagitis	Normal	Ok	Biopsy
A8d	58	47	F	Stomach, corpus	Reflux esophagitis	Normal	Ok	Biopsy
A8e	59	76	F	Stomach, corpus	Gastric cancer, chronic active gastritis	Normal	Ok	Biopsy
A8f	59	76	F	Stomach, corpus	Gastric cancer, chronic active gastritis	Normal	Ok	Biopsy
A8g	60	90	F	Stomach, corpus	Duodenal ulcer	Normal	No epithelial cells	Biopsy
A8h	60	90	F	Stomach, corpus	Duodenal ulcer	Normal	Ok	Biopsy
A8i	55	75	F	Duodenum	Gastric cancer	Normal	Ok	Biopsy
A8j	55	75	F	Duodenum	Gastric cancer	Normal	Ok	Biopsy
A8k	61	81	F	Duodenum	Colon cancer	Normal	Ok	Biopsy
A8l	61	81	F	Duodenum	Colon cancer	Normal	Ok	Biopsy
A8m	62	76	F	Duodenum	Gastric cancer, chronic active gastritis	Normal	Ok	Biopsy
A8n	62	76	F	Duodenum	Gastric cancer, chronic active gastritis	Normal	Ok	Biopsy
A8o	62	76	F	Duodenum	Gastric cancer, chronic active gastritis	Normal	Ok	Biopsy
A8p	63	90	F	Duodenum	Duodenal ulcer	Normal	No epithelial cells	Biopsy
A9a	63	90	F	Duodenum	Duodenal ulcer	Normal	Ok	Biopsy
A9b	63	90	F	Duodenum	Duodenal ulcer	Normal	Ok	Biopsy
A9c	64	66	F	Duodenum ileum	Colon cancer	Normal	Ok	Biopsy
A9d	65	79	M	Ileum	Colon cancer	Normal	Ok	Biopsy
A9e	66	72	M	Ileum	Colon cancer	Normal	Ok	Biopsy
A9f	67	57	M	Ileum	Colon cancer	Normal	Ok	Biopsy
A9g	68	72	M	Ileum	Colon cancer	Normal	Ok	Biopsy
A9h	68	72	M	Ileum	Colon cancer	Normal	Ok	Biopsy
A9i	69	85	M	Ileum	Colon cancer	Normal	Ok	Biopsy
A9j	69	85	M	Ileum	Colon cancer	Normal	Ok	Biopsy

Localisation	Identical Biopsy	Age	Sex	Organ	Underlying Disease	Histologic DX	Tissue Represented, Lot1	Material
A9k	70	82	F	Ileum	Colon cancer	Normal	Ok	Biopsy
A9l	70	82	F	Ileum	Colon cancer	Normal	Ok	Biopsy
A9m	71	79	M	Colon	Colon cancer	Normal	Ok	Biopsy
A9n	71	79	M	Colon	Colon cancer	Normal	Ok	Biopsy
A9o	72	85	F	Colon	Colon cancer	Normal	Ok	Biopsy
A9p	72	85	F	Colon	Colon cancer	Normal	No epithelial cells	Biopsy
B1a	73	72	M	Colon	Colon cancer	Normal	Ok	Biopsy
B1b	73	72	M	Colon	Colon adenoma	Normal	Ok	Biopsy
B1c	74	57	M	Colon	Colon adenoma	Normal	Ok	Biopsy
B1d	74	57	M	Colon	Colon cancer	Normal	Ok	Biopsy
B1e	75	85	M	Colon	Colon cancer	Normal	Sample missing on first section	Biopsy
B1f	75	85	M	Colon	Colon cancer	Normal	Ok	Biopsy
B1g	76	72	M	Appendix	Colon cancer	Normal	Ok	Biopsy
B1h	77	57	M	Appendix	Colon adenoma	Normal	Ok	Biopsy
B1i	77	57	M	Appendix	Colon cancer	Normal	Ok	Biopsy
B1j	78	25	F	Appendix	Colon cancer	Normal	Only smooth muscle	Biopsy
B1k	79	85	M	Appendix	Idiopathic megacolon	Normal	Connective tissue	Biopsy
B1l	79	85	M	Appendix	Colon cancer	Normal	Ok	Biopsy
B1m	80	32	F	Appendix	Colon cancer	Normal	Ok	Biopsy
B1n	80	32	F	Appendix	Uterus endometriosis	Normal	Ok	Biopsy
B1o	81	88	M	Appendix	Uterus endometriosis	Normal	Debris	Biopsy
B1p	81	88	M	Appendix	Colon cancer	Normal	Ok	Biopsy
B2a	82	78	M	Gall bladder	Colon cancer	Normal	Ok	Biopsy
B2b	82	78	M	Gall bladder	Normal	Normal	Ok	Biopsy
B2c	83	16	M	Gall bladder	Normal	Normal	Ok	Biopsy
B2d	83	16	M	Gall bladder	Normal	Normal	Ok	Biopsy
B2e	84	56	F	Gall bladder	Normal	Normal	Ok	Biopsy
B2f	84	56	F	Gall bladder	Normal	Normal	Ok	Biopsy
B2g	85	54	F	Gall bladder	Normal	Normal	Ok	Biopsy
B2h	85	54	F	Gall bladder	Normal	Normal	Ok	Biopsy
B2i	86			Gall bladder	Normal	Normal	Ok	Biopsy
B2j	86			Gall bladder	Normal	Normal	Ok	Biopsy
B2k	87	74	F	Liver	Mild non-specific portal triaditis	Normal	Ok	Biopsy
B2l	87	74	F	Liver	Mild non-specific portal triaditis	Normal	Ok	Biopsy
B2m	88	85	M	Liver	Colon cancer, metastatic	Normal	Ok	Biopsy
B2n	88	85	M	Liver	Colon cancer, metastatic	Normal	Ok	Biopsy
B2o	89	71	M	Liver	Cholecystitis	Normal	Ok	Biopsy
B2p	89	71	M	Liver	Cholecystitis	Normal	Inflammation	Biopsy
B3a	89	71	M	Liver	Cholecystitis	Normal	Ok	Biopsy

Localisation	Identical	Age	Sex	Organ	Underlying Disease	Histologic	Tissue Represented, Lot1	Material
	Biopsy					DX		
B3b	90	26	F	Liver	Hodgkin disease	Normal	Ok	Biopsy
B3c	90	26	F	Liver	Hodgkin disease	Normal	Ok	Biopsy
B3d	90	26	F	Liver	Hodgkin disease	Normal	Ok	Biopsy
B3e	93			Pancreas		Normal	Ok	Autopsy, <12h
B3f	93			Pancreas		Normal	Ok	Autopsy, <12h
B3g	93			Pancreas		Normal	Ok	Autopsy, <12h
B3h	93			Pancreas		Normal	Ok	Autopsy, <12h
B3i	91	32	F	Pancreas	Depression, trauma	Normal	Ok	Autopsy, 3h
B3j	91	32	F	Pancreas	Depression, trauma	Normal	Ok	Autopsy, 3h
B3k	91	32	F	Pancreas	Depression, trauma	Normal	Ok	Autopsy, 3h
B3l	92	41	M	Pancreas	Trauma	Normal	Ok	Autopsy, 5h
B3m	92	41	M	Pancreas	Trauma	Normal	Ok	Autopsy, 5h
B3n	92	41	M	Pancreas	Trauma	Normal	Ok	Autopsy, 5h
B3o	94	31	M	Submandibular gland	Sialadenitis other area (behind stone)	Normal	Ok	Biopsy
B3p	94	31	M	Submandibular gland	Sialadenitis other area (behind stone)	Normal	Ok	Biopsy
B4a	94	31	M	Submandibular gland	Sialadenitis other area (behind stone)	Normal	Ok	Biopsy
B4b	95	62	F	Submandibular gland	Mucoepidermoid carcinoma	Normal	Ok	Biopsy
B4c	95	62	F	Submandibular gland	Mucoepidermoid carcinoma	Normal	Ok	Biopsy
B4d	95	62	F	Submandibular gland	Mucoepidermoid carcinoma	Normal	Ok	Biopsy
B4e	96	31	F	Submandibular gland	Thyroid cancer	Normal	Ok	Biopsy
B4f	96	31	F	Submandibular gland	Thyroid cancer	Normal	Ok	Biopsy
B4g	96	31	F	Submandibular gland	Thyroid cancer	Normal	Ok	Biopsy
B4h	96	31	F	Submandibular gland	Thyroid cancer	Normal	Ok	Biopsy
B4i	100	44	F	Ovary, stroma	Abnormal bleedings	Normal	Ok	Biopsy
B4j	98		F	Ovary, stroma	CIS cervix	Normal	Fallopian tube	Biopsy
B4k	99	45	F	Ovary, stroma	Menometrorrhagia	Normal	Ok	Biopsy
B4l	100	44	F	Ovary, stroma	Abnormal bleedings	Normal	Ok	Biopsy
B4m	101	45	F	Ovary, stroma	Myoma uterus	Normal	Ok	Biopsy
B4n	98		F	Ovary, stroma	CIS cervix	Normal	Ok	Biopsy
B4o	102	47	F	Ovary, stroma	Hysterectomy	Normal	Sample missing on first section	Biopsy
B4p	102	47	F	Ovary, stroma	Hysterectomy	Normal	Ok	Biopsy
B5a	103	47	F	Ovary, stroma	Myoma uterus	Normal	Ok	Biopsy
B5b	103	47	F	Ovary, stroma	Myoma uterus	Normal	Ok	Biopsy
B5c	100	44	F	Ovary, corpus luteum	Abnormal bleedings	Normal	Ok	Biopsy
B5d	105	32	F	Ovary, corpus luteum	Endometriosis uterus	Normal	Ok	Biopsy
B5e	106	45	F	Ovary, corpus luteum	Menometrorrhagia	Normal	Ok	Biopsy

Localisation	Identical Biopsy	Age	Sex	Organ	Underlying Disease	Histologic DX	Tissue Represented, Lot1	Material
B5f	106	45	F	Ovary, corpus luteum	Menometrorrhagia	Normal	Ok	Biopsy
B5g	107	44	F	Ovary, corpus luteum	Abnormal bleedings	Normal	Ok	Biopsy
B5h	107	44	F	Ovary, corpus luteum	Abnormal bleedings	Normal	Ok	Biopsy
B5i	108	45	F	Ovary, corpus luteum	Myoma uterus	Normal	Ok	Biopsy
B5j	108	45	F	Ovary, corpus luteum	Myoma uterus	Normal	Ok	Biopsy
B5k	109	47	F	Ovary, corpus luteum	Hysterectomy	Normal	Ok	Biopsy
B5l	109	47	F	Ovary, corpus luteum	Hysterectomy	Normal	Ok	Biopsy
B5m	110	25	F	Fallopian tube	Hysterectomy	Normal	Ok	Biopsy
B5n	110	25	F	Fallopian tube		Normal	Ok	Biopsy
B5o	111	30	F	Fallopian tube		Normal	Ok	Biopsy
B5r	111	30	F	Fallopian tube		Normal	Ok	Biopsy
B6a	112	30	F	Fallopian tube	CIS cervix	Normal	Ok	Biopsy
B6b	113	30	F	Fallopian tube		Normal	Ok	Biopsy
B6c	113	45	F	Fallopian tube	Myoma uterus	Normal	Ok	Biopsy
B6d	113	45	F	Fallopian tube	Myoma uterus	Normal	Ok	Biopsy
B6e	114	47	F	Fallopian tube	Myoma uterus	Normal	Ok	Biopsy
B6f	114	47	F	Fallopian tube	Myoma uterus	Normal	Ok	Biopsy
B6g	115	42	F	Myometrium	Dysfunctional bleeding, myoma, adenomyosis	Normal	Some endometrium included	Biopsy
B6h	116	28	F	Myometrium	Ruptured ovarian cyst (endometriosis)	Normal	Ok	Biopsy
B6i	119	30	F	Myometrium	Pelvic pain	Normal	Ok	Biopsy
B6j	118	42	F	Myometrium	Ovarian cyst (endometriosis)	Normal	Endometrium	Biopsy
B6k	119	30	F	Myometrium	Pelvic pain	Normal	Ok	Biopsy
B6l	120	45	F	Myometrium	Menometrorrhagia	Normal	Ok	Biopsy
B6m	121	49	F	Myometrium	Endometrium cancer	Normal	Ok	Biopsy
B6n	121	49	F	Myometrium	Endometrium cancer	Normal	Ok	Biopsy
B6o	122	49	F	Myometrium	CIS cervix	Normal	Ok	Biopsy
B6p	122	49	F	Myometrium	CIS cervix	Normal	Ok	Biopsy
B7a	123	31	F	Endo sekr	Prolaps	Normal	Ok	Biopsy
B7b	123	31	F	Endo sekr	Prolaps	Normal	Ok	Biopsy
B7c	124	39	F	Endo sekr	Prolaps	Normal	Ok	Biopsy
B7d	123	31	F	Endo sekr	Prolaps	Normal	Ok	Biopsy
B7e	125	32	F	Endo sekr	CIS cervix	Normal	Ok	Biopsy
B7f	125	32	F	Endo sekr	CIS cervix	Normal	Ok	Biopsy
B7g	126	32	F	Endo sekr	CIS cervix	Normal	Ok	Biopsy
B7h	126	32	F	Endo sekr	CIS cervix	Normal	Ok	Biopsy
B7i	127	47	F	Endo sekr	Hysterectomy	Normal	Ok	Biopsy
B7j	127	47	F	Endo sekr	Hysterectomy	Normal	Ok	Biopsy

Localisation	Identical Biopsy	Age	Sex	Organ	Underlying Disease	Histologic DX	Tissue Represented, Lot1	Material
B7k	128	28	F	Endo prol	Ruptured ovarian cyst (endometriosis)	Normal	Ok	Biopsy
B7l	128	28	F	Endo prol	Ruptured ovarian cyst (endometriosis)	Normal	Ok	Biopsy
B7m	129	40	F	Endo prol	Menorrhagia	Normal	Ok	Biopsy
B7n	129	40	F	Endo prol	Menorrhagia	Normal	Few epithelial cells	Biopsy
B7o	130	41	F	Endo prol	Ovarian cyst (endometriosis)	Normal	Ok	Biopsy
B7p	130	41	F	Endo prol	Ovarian cyst (endometriosis)	Normal	Ok	Biopsy
B8a	130	41	F	Endo prol	Ovarian cyst (endometriosis)	Normal	Ok	Biopsy
B8b	131	42	F	Endo prol	Ovarian cyst (endometriosis)	Normal	Ok	Biopsy
B8c	131	42	F	Endo prol	Ovarian cyst (endometriosis)	Normal	Few epithelial cells	Biopsy
B8d	131	42	F	Endo prol	Ovarian cyst (endometriosis)	Normal	Few epithelial cells	Biopsy
B8e	136	45	F	Endocervix	Menometrorrhagia	Normal	Ok	Biopsy
B8f	133		F	Endocervix	CIS cervix	Normal	Ok	Biopsy
B8g	134		F	Endocervix	CIS cervix	Normal	Ok	Biopsy
B8h	135		F	Endocervix	CIS cervix	Normal	Ok	Biopsy
B8i	136	45	F	Endocervix	Menometrorrhagia	Normal	Ok	Biopsy
B8j	136	45	F	Endocervix	Menometrorrhagia	Normal	Ok	Biopsy
B8k	137	49	F	Endocervix	Endometrium cancer	Normal	Ok	Biopsy
B8l	137	49	F	Endocervix	Endometrium cancer	Normal	Ok	Biopsy
B8m	138	47	F	Endocervix	Hysterectomy	Normal	Ok	Biopsy
B8n	138	47	F	Endocervix	Hysterectomy	Normal	Ok	Biopsy
B8o	139	41	F	Endocervix	Ovarian cyst (endometriosis)	Normal	Ok	Biopsy
B8p	140	32	F	Ektocervix	Endometriosis	Normal	Ok	Biopsy
B9a	141		F	Ektocervix	CIS cervix	Normal	Ok	Biopsy
B9b	142	49	F	Ektocervix	CIS cervix	Normal	Ok	Biopsy
B9c	143	49	F	Ektocervix	Endometrium cancer	Normal	Ok	Biopsy
B9d	143	49	F	Ektocervix	Endometrium cancer	Normal	Ok	Biopsy
B9e	144	47	F	Ektocervix	Hysterectomy	Normal	Stroma only	Biopsy
B9f	144	47	F	Ektocervix	Hysterectomy	Normal	Ok	Biopsy
B9g	145	47	F	Ektocervix	Hysterectomy	Normal	Ok	Biopsy
B9h	145	47	F	Ektocervix	Myoma uterus	Normal	Ok	Biopsy
B9i	146	74	M	Kidney cortex	Clear cell RCC	Normal	Ok	Biopsy
B9j	146	74	M	Kidney cortex	Cancer pylon	Normal	Ok	Biopsy
B9k	147	78	M	Kidney cortex	Cancer pylon	Normal	Ok	Biopsy
B9l	147	78	M	Kidney cortex	Clear cell RCC	Normal	Ok	Biopsy
B9m	148	88	M	Kidney cortex	Clear cell RCC	Normal	Ok	Biopsy
B9n	148	88	M	Kidney cortex	Clear cell RCC	Normal	Ok	Biopsy
B9o	148	88	M	Kidney cortex	Clear cell RCC	Normal	Ok	Biopsy

Localisation	Identical Biopsy	Age	Sex	Organ	Underlying Disease	Histologic DX	Tissue Represented, Lot1	Material
B9p	148	88	M	Kidney cortex	Cancer pylon	Normal	Ok	Biopsy
C1a	149	87	M	Kidney cortex	Cancer pylon	Normal	Ok	Biopsy
C1b	149	87	M	Kidney cortex	Cancer pylon	Normal	Ok	Biopsy
C1c	150	74	M	Kidney papilla	Clear cell RCC	Normal	Ok	Biopsy
C1d	150	74	M	Kidney papilla	Clear cell RCC	Normal	Ok	Biopsy
C1e	151	78	M	Kidney papilla	Cancer pylon	Normal	Ok	Biopsy
C1f	151	78	M	Kidney papilla	Cancer pylon	Normal	Ok	Biopsy
C1g	152	88	M	Kidney papilla	Clear cell RCC	Normal	Ok	Biopsy
C1h	152	88	M	Kidney papilla	Clear cell RCC	Normal	Ok	Biopsy
C1i	152	88	M	Kidney papilla	Clear cell RCC	Normal	Ok	Biopsy
C1j	153	87	M	Kidney papilla	Cancer pylon	Normal	Ok	Biopsy
C2a	153	87	M	Kidney papilla	Cancer pylon	Normal	Ok	Biopsy
C2b	153	87	M	Kidney papilla	Cancer pylon	Normal	Ok	Biopsy
C2c	154	M	M	Prostate	Benign prostatic hyperplasia	Normal	Ok	Biopsy
C2d	154	M	M	Prostate	Benign prostatic hyperplasia	Normal	Ok	Biopsy
C2e	155	66	M	Prostate	Benign prostatic hyperplasia	Normal	Ok	Biopsy
C2f	155	66	M	Prostate	Benign prostatic hyperplasia	Normal	Ok	Biopsy
C2g	156	70	M	Prostate	Benign prostatic hyperplasia	Normal	Ok	Biopsy
C2h	156	70	M	Prostate	Benign prostatic hyperplasia	Normal	Ok	Biopsy
C2i	156	70	M	Prostate	Benign prostatic hyperplasia	Normal	Ok	Biopsy
C2j	157	74	M	Prostate	Benign prostatic hyperplasia	Normal	Ok	Biopsy
C3a	157	74	M	Prostate	Benign prostatic hyperplasia	Normal	Ok	Biopsy
C3b	157	74	M	Prostate	Benign prostatic hyperplasia	Normal	Ok	Biopsy
C3c	158	60	M	Seminal vesicle	Prostate cancer	Normal	Ok	Biopsy
C3d	158	60	M	Seminal vesicle	Prostate cancer	Normal	Ok	Biopsy
PAGE MISSING								
C6b	167	73	M	Testis	Prostate cancer	Normal	Ok	Biopsy
C6c	168	87	M	Kidney pelvis	Cancer pylon	Normal	No epithelial cells	Biopsy
C6d	169	87	M	Kidney pelvis	Cancer pylon	Normal	No epithelial cells	Biopsy
C6e	168	87	M	Kidney pelvis	Cancer pylon	Normal	Ok	Biopsy
C6f	169	87	M	Kidney pelvis	Cancer pylon	Normal	No epithelial cells	Biopsy
C6g	168	87	M	Kidney pelvis	Cancer pylon	Normal	Ok	Biopsy
C6h	170	85	F	Kidney pelvis	Cancer pylon	Normal	No epithelial cells	Biopsy
C6i	170	85	F	Kidney pelvis	Cancer pylon	Normal	No epithelial cells	Biopsy
C6j	170	85	F	Kidney pelvis	Cancer pylon	Normal	No epithelial cells	Biopsy
C7a	170	85	F	Kidney pelvis	Cancer pylon	Normal	Ok	Biopsy
C7b	170	85	F	Kidney pelvis	Cancer pylon	Normal	Inflammation	Biopsy
C7c	171	63	F	bronchus	Lung cancer	Normal	No epithelial cells	Biopsy

Localisation	Identical Biopsy	Age	Sex	Organ	Underlying Disease	Histologic DX	Tissue Represented, Lot1	Material
C7d	171	63	F	Bronchus	Lung cancer	Normal	Ok	Biopsy
C7e	172	74	M	Bronchus	Lung cancer	Normal	Ok	Biopsy
C7f	172	74	M	Bronchus	Lung cancer	Normal	Ok	Biopsy
C7g	172	74	M	Bronchus	Lung cancer	Normal	Ok	Biopsy
C7h	173	51	F	Bronchus	Lung cancer	Normal	Ok	Biopsy
C7i	173	51	F	Bronchus	Lung cancer	Normal	Ok	Biopsy
C7j	174			Bronchus	Lung cancer	Normal	Ok	Biopsy
C8a	174			Bronchus	Lung cancer	Normal	Ok	Biopsy
C8b	174			Bronchus	Lung cancer	Normal	Ok	Biopsy
C8c	175	74	F	Lung	Lung cancer	Normal	No epithelial cells	Biopsy
C8d	176	62	M	Lung	Lung cancer	Normal	Ok	Biopsy
C8e	177	68	F	Lung	Lung cancer	Normal	Ok	Biopsy
C8f	178	69	F	Lung	Lung cancer	Normal	Ok	Biopsy
C8g	179	51	F	Lung	Lung cancer	Normal	Ok	Biopsy
C8h	179	51	F	Lung	Lung cancer	Normal	Ok	Biopsy
C8i	180	50	M	Lung	Lung cancer	Normal	Ok	Biopsy
C8j	180	50	M	Lung	Lung cancer	Normal	Ok	Biopsy
C9a	181	56	M	Lung	Lung cancer	Normal	Ok	Biopsy
C9b	178	69	F	Lung	Lung cancer	Normal	Ok	Biopsy
C9c	182	41	M	Cerebellum	Trauma	Normal	Ok	Autopsy, 5h
C9d	182	41	M	Cerebellum	Trauma	Normal	Ok	Autopsy, 5h
C9e	182	41	M	Cerebellum	Trauma	Normal	Ok	Autopsy, 5h
C9f	183	33	F	Cerebellum	Trauma	Normal	Ok	Autopsy, <10h
C9g	183	33	F	Cerebellum	Trauma	Normal	Ok	Autopsy, <10h
C9h	183	33	F	Cerebellum	Trauma	Normal	Ok	Autopsy, <10h
C9i	184	37	M	Cerebellum	Trauma	Normal	Ok	Autopsy, 4h
C9j	184	37	M	Cerebellum	Trauma	Normal	Ok	Autopsy, 4h
D1a	184	37	M	Cerebellum	Trauma	Normal	Ok	Autopsy, 4h
D1b	184	37	M	Cerebellum	Trauma	Normal	Ok	Autopsy, 4h
D1c	185	32	F	Cerebrum, grey substance	Depression, trauma	Normal	Ok	Autopsy, 3h
D1d	185	32	F	Cerebrum, grey substance	Depression, trauma	Normal	Ok	Autopsy, 3h
D1e	186	41	M	Cerebrum, grey substance	Trauma	Normal	Ok	Autopsy, 5h
D1f	186	41	M	Cerebrum, grey substance	Trauma	Normal	Ok	Autopsy, 5h
D1g	187	33	F	Cerebrum, grey substance	Trauma	Normal	Ok	Autopsy, <10h

408260 2429660

Localisation	Identical Biopsy	Age	Sex	Organ	Underlying Disease	Histologic DX	Tissue Represented, Lot1	Material
Dlh	187	33	F	Cerebrum, grey substance	Trauma	Normal	Ok	Autopsy, <10h

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

Sample #	age	received	associated with	new	prognosis request
1	66				60
2	55				60
3	75				60
4	77				60
5	81				60
6	33			1	60
7	75			1	60
8	77				60
9	76				60
10	51				60
11	45				60
12	65				60
13	69				60
14	61				60
15	68				60
16	78				60
17	79				60
18	55				60
19	53				60
20	82				60
21	62				60
22	63				60
23	66				60
24	67				60
25	72				60
26	79				60
27	75				60
28	68				60
29	77				60
30	76				60
31	51	07/31/1996			60
32	45	07/31/1996			60
33	65	07/31/1996			60
34	69	07/31/1996			60
35	61	07/31/1996			60
36	68	07/31/1996			60
37	78	07/31/1996			60
38	79	07/31/1996			60
39	55	07/31/1996			60
40	53	07/31/1996			60
41	82	07/31/1996			60
42	62	07/31/1996			60
43	63	07/31/1996			60
44	66	07/31/1996			60
45	67	07/31/1996			60
46	72	07/31/1996			60
47	79	07/31/1996			60
48	75	07/31/1996			60
49	68	07/31/1996			60
50	59	07/31/1996			60
51	56	07/31/1996			60
52	49	07/31/1996			60
53	63	07/31/1996			60

bcl-2a Breast Cancer TMA data Oncology Data

[illegible]

COPIES OF THE REPORT

use b89.7117 for PR50

slides + blocks not found
slides + blocks not found
SEARCH FOR PREVIOUS BIOPSY!
DD papillary
cancer only seen on frozen section

residual tumor
small tumor

residual tumor
dob 21.4.23
sent previously

142

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

pT	pN	nodes all	nodes pos	diameter/mm	surgery
1	0	23	0	15	mastectomy
1	0	17	0	40	lumpectomy
1	0	8	0	8	mastectomy
1	0		0	85	m
1	0		0	29	l
1	0		0	6	l
1	0		0	9	l
1	0	20	0	45	mastectomy
1	0	14	0	30	mastectomy
1	0	0	0	40	mastectomy
1	0	19	0	35	mastectomy
1	0	20	0	25	mastectomy
1	0	20	0	10	mastectomy
1	0	18	0	23	mastectomy
1	0	3	0	55	mastectomy
1	0	10	0	20	mastectomy
1	0	19	0	15	mastectomy
1	0	0	0	30	lumpectomy
1	0	0	0	40	mastectomy
1	0	21	0	15	lumpectomy
1	0	17	0	60	mastectomy
1	0	11	0	21	lumpectomy
1	0	0	0	15	lumpectomy
1	0	0	0	30	mastectomy
1	0	17	0	70	mastectomy
1	0	8	0	15	mastectomy
1	0	0	0	30	lumpectomy
1	0	16	0		mastectomy
1	0	13	0	10	mastectomy
1	0	7	0	10	mastectomy
1	0		0	10	l
1	0		0	21	l
1	0		0	18	
1	0		0	10	
1	0		0	38	
1	0		0	18	
1	0		0		
1	0		0	20	
1	0	16	0		m
1	0		0		
1	0		0	8	l
1	0	14	0		
1	0		0	12	l
1	0		0	27	
1	0	7	0		m
1	0		0	15	l
1	0		0	10	
1	0		0	15	
1	0		0		
1	0		0		
1	0		0	15	l
1	0		0	>20	l
1	0		0	10	

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

resection border	array	Histotyp GS	sex	category
free	BR50	ductal	f	ca
free	BR50	ductal	f	ca+meta
free	BR50	ductal	f	ca+dcis
f	BR50	ductal	f	ca+meta
f	BR50	ductal	f	ca+dcis
n	n	ductal		ca+meta
n	n	ductal	f	ca+dcis
free	BR50	ductal	f	ca+meta
free	BR50	ductal	f	ca
free	BR50	ductal	f	ca
free	BR50	ductal	f	ca+meta
free	BR50	ductal	f	ca+dcis
free	BR50	ductal	f	ca
free	BR50	ductal	f	ca+meta
free	BR50	ductal	f	ca
free	BR50	ductal	f	ca
free	BR50	ductal	f	ca+dcis+meta+no
?	BR50	ductal	f	ca
free	BR50	ductal	f	ca
free	BR50	ductal	f	ca
free	ev	ductal	f	ca+meta
free	ev	ductal	f	dcis
?	n	ductal	f	ca
free	y	ductal	f	ca
free	y	ductal	f	ca+dcis+meta
free	y	ductal	f	ca
free	y	ductal	f	ca
f	y	ductal	f	ca
free		ductal	f	ca
		ductal		ca
f		ductal		ca
pos		ductal		ca
		ductal		ca
		ductal		ca
pos		ductal		ca
		ductal		ca
		ductal		ca
		ductal		ca
		ductal		ca
		ductal		ca
		ductal		ca
		ductal		ca
pos		ductal		ca
		ductal		ca
		ductal		ca
		ductal		ca
free		ductal		ca
		ductal		ca
		ductal		ca
?		ductal		ca
free		ductal		ca
pos		ductal		ca

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

sec ndary type	Tub GS	Poly GS	mito gs	DCIS type
	3	2	1	
	3	3	2	
	3	2	1	
	2	3	1	solid, crib low
	1	2	1	
	2	3	3	
	3	2	1	
	3	2	1	
	3	3	2	
	3	3	1	
	3	2	1	
	1	2	1	
	3	2	1	
	3	2	1	
	3	2	1	
	3	3	2	
	3	3	3	
	2	2	2	
	3	2	1	
	2	3	2	
	3	2	2	
	3	2	3	
	3	3	2	sol/crib low grade
	2	2	1	
	3	3	1	
	3	2	3	
	2	2	1	
	3			
	3			
	2			
	3			
	3			
	2			

0096373 002001

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

tumor slides	dcis slides	lcis slides
1; 2; 3		
1; 2; 3		
1; 2	3; 4	
1; 2; 3; 4		
1		
1		
1 to 5		
1; 2; 3; 4		
1; 2; 3		
1		
1; 2	2	
1; 2		
1; 2; 3; 4		
1 to 7		
1; 2		
1; 5; 6; 8; 9; 11	2-9; 12	
1; 2; 3; 4		
1 to 7		
1; 2; 3		
1; 2	1; 2; 3	
1		
1; 2; 3		
1; 2; 3; 4	3; 4	
1; 2		
1; 2; 3; 4; 5		
2		
1		

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

mastopathia slides	normal slides 2; 3	meta slides
		b89.6424
	2	
	3	
	8	b89.8818
	10	b91.3181
	1; 2; 3; lactating breast	
		3; 4; 5; 6
		5; 6
	6	

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

distant meta	normal skin	normal mamilla	normal nodes	normal muscle
--------------	-------------	----------------	--------------	---------------

7; 8

1

1

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

others

1; 2; 3: lactating breast

2; 3; 4; 5 scar formation, fat necrosis

100260-270000

Localisation	Identical Biopsy	Age	Sex	Organ	Underlying Disease	Histologic DX	Tissue Represented, Lot1	Material
A5l	36	41	M	Heart	Trauma	Normal	Ok	Autopsy, 5h
A5m	37	37	M	Heart	Trauma	Normal	Ok	Autopsy, 4h
A5n	37	37	M	Heart	Trauma	Normal	Ok	Autopsy, 4h
A5o	37	37	M	Heart	Trauma	Normal	Ok	Autopsy, 4h
A5r	37	37	M	Heart	Trauma	Normal	Ok	Autopsy, 4h
A6a	38	25	M	Skeletal muscle	Tonsillitis chronica	Normal	Ok	Biopsy
A6b	39	27	M	Skeletal muscle	Seminoma	Normal	Ok	Biopsy
A6c	40	22	M	Skeletal muscle	Chronic tonsillitis	Normal	Ok	Biopsy
A6d	41	43	M	Skeletal muscle	Hernia	Normal	Ok	Biopsy
A6e	42	67	M	Skeletal muscle	Eyid resection	Normal	Ok	Biopsy
A6f	42	67	M	Skeletal muscle	Eyid resection	Normal	Ok	Biopsy
A6g	44	31	F	Skeletal muscle	Thyroid cancer	Normal	Bleeding, no muscle	Biopsy
A6h	45			Skeletal muscle	Breast cancer	Normal	Ok	Biopsy
A6i	46			Skeletal muscle	Breast cancer	Normal	Ok	Biopsy
A6j	46			Skeletal muscle	Breast cancer	Normal	Ok	Biopsy
A6k	47	75	F	Smooth muscle, intestine	Gastric ulcer	Normal	Ok	Biopsy
A6l	48	68	M	Smooth muscle, intestine	Gastric cancer	Normal	Ok	Biopsy
A6m	49	91	M	Smooth muscle, intestine	Gastric cancer	Normal	Ok	Biopsy
A6n	49	91	M	Smooth muscle, intestine	Gastric cancer	Normal	Ok	Biopsy
A6o	50	76	M	Smooth muscle, intestine	Gastric cancer	Normal	Ok	Biopsy
A6p	50	76	M	Smooth muscle, intestine	Gastric cancer	Normal	Ok	Biopsy
A7a	51	76	M	Smooth muscle, intestine	Gastric cancer	Normal	Ok	Biopsy
A7b	51	47	F	Smooth muscle, intestine	Reflux esophagitis	Normal	Ok	Biopsy
A7c	52	47	F	Smooth muscle, intestine	Reflux esophagitis	Normal	Ok	Biopsy
A7d	52	47	F	Smooth muscle, intestine	Reflux esophagitis	Normal	Ok	Biopsy
A7e	53	75	F	Stomach, antrum	Gastric ulcer	Normal	Lipomatous tissue	Biopsy
A7f	53	75	F	Stomach, antrum	Gastric ulcer	Normal	Intestinal metaplasia	Biopsy
A7g	53	75	F	Stomach, antrum	Gastric ulcer	Normal	Ok	Biopsy
A7h	53	75	F	Stomach, antrum	Gastric ulcer	Normal	Chronic inflammation	Biopsy

Localisation	Identical Biopsy	Age	Sex	Organ	Underlying Disease	Histologic DX	Tissue Represented, Lot1	Material
A7i	53	75	F	Stomach, antrum	Gastric ulcer	Normal	Chronic inflammation	Biopsy
A7j	54	68	M	Stomach, antrum	Gastric cancer	Normal	Chronic inflammation	Biopsy
A7k	54	68	M	Stomach, antrum	Gastric cancer	Normal	Chronic inflammation	Biopsy
A7l	54	68	M	Stomach, antrum	Gastric cancer	Normal	Ok	Biopsy
A7m	54	68	M	Stomach, antrum	Gastric cancer	Normal	Ok	Biopsy
A7n	54	68	M	Stomach, antrum	Gastric cancer	Normal	Ok	Biopsy
A7o	56	68	M	Stomach, corpus	Gastric cancer	Normal	Ok	Biopsy
A7p	56	68	M	Stomach, corpus	Gastric cancer	Normal	Ok	Biopsy
A8a	57	76	M	Stomach, corpus	Gastric cancer	Normal	Ok	Biopsy
A8b	57	76	M	Stomach, corpus	Gastric cancer	Normal	Ok	Biopsy
A8c	58	47	F	Stomach, corpus	Reflux esophagitis	Normal	Ok	Biopsy
A8d	58	47	F	Stomach, corpus	Reflux esophagitis	Normal	Ok	Biopsy
A8e	59	76	F	Stomach, corpus	Gastric cancer, chronic active gastritis	Normal	Ok	Biopsy
A8f	59	76	F	Stomach, corpus	Gastric cancer, chronic active gastritis	Normal	Ok	Biopsy
A8g	60	90	F	Stomach, corpus	Duodenal ulcer	Normal	No epithelial cells	Biopsy
A8h	60	90	F	Stomach, corpus	Duodenal ulcer	Normal	Ok	Biopsy
A8i	55	75	F	Duodenum	Gastric cancer	Normal	Ok	Biopsy
A8j	55	75	F	Duodenum	Gastric cancer	Normal	Ok	Biopsy
A8k	61	81	F	Duodenum	Colon cancer	Normal	Ok	Biopsy
A8l	61	81	F	Duodenum	Colon cancer	Normal	Ok	Biopsy
A8m	62	76	F	Duodenum	Gastric cancer, chronic active gastritis	Normal	Ok	Biopsy
A8n	62	76	F	Duodenum	Gastric cancer, chronic active gastritis	Normal	Ok	Biopsy
A8o	62	76	F	Duodenum	Gastric cancer, chronic active gastritis	Normal	Ok	Biopsy
A8p	63	90	F	Duodenum	Duodenal ulcer	Normal	No epithelial cells	Biopsy
A9a	63	90	F	Duodenum	Duodenal ulcer	Normal	Ok	Biopsy
A9b	63	90	F	Duodenum	Duodenal ulcer	Normal	Ok	Biopsy
A9c	64	66	F	Ileum	Colon cancer	Normal	Ok	Biopsy
A9d	65	79	M	Ileum	Colon cancer	Normal	Ok	Biopsy
A9e	66	72	M	Ileum	Colon cancer	Normal	Ok	Biopsy
A9f	67	57	M	Ileum	Colon cancer	Normal	Ok	Biopsy
A9g	68	72	M	Ileum	Colon cancer	Normal	Ok	Biopsy
A9h	68	72	M	Ileum	Colon cancer	Normal	Ok	Biopsy
A9i	69	85	M	Ileum	Colon cancer	Normal	Ok	Biopsy
A9j	69	85	M	Ileum	Colon cancer	Normal	Ok	Biopsy

Localisation	Identical Biopsy	Age	Sex	Organ	Underlying Disease	Histologic DX	Tissue Represented, Lot1	Material
A9k	70	82	F	Ileum	Colon cancer	Normal	Ok	Biopsy
A9l	70	82	F	Ileum	Colon cancer	Normal	Ok	Biopsy
A9m	71	79	M	Colon	Colon cancer	Normal	Ok	Biopsy
A9n	71	79	M	Colon	Colon cancer	Normal	Ok	Biopsy
A9o	72	85	F	Colon	Colon cancer	Normal	Ok	Biopsy
A9p	72	85	F	Colon	Colon cancer	Normal	No epithelial cells	Biopsy
B1a	73	72	M	Colon	Colon adenoma	Normal	Ok	Biopsy
B1b	73	72	M	Colon	Colon adenoma	Normal	Ok	Biopsy
B1c	74	57	M	Colon	Colon cancer	Normal	Ok	Biopsy
B1d	74	57	M	Colon	Colon cancer	Normal	Sample missing on first section	Biopsy
B1e	75	85	M	Colon	Colon cancer	Normal	Ok	Biopsy
B1f	75	85	M	Colon	Colon cancer	Normal	Ok	Biopsy
B1g	76	72	M	Appendix	Colon adenoma	Normal	Ok	Biopsy
B1h	77	57	M	Appendix	Colon cancer	Normal	Ok	Biopsy
B1i	77	57	M	Appendix	Colon cancer	Normal	Only smooth muscle	Biopsy
B1j	78	25	F	Appendix	Idiopathic megacolon	Normal	Connective tissue	Biopsy
B1k	79	85	M	Appendix	Colon cancer	Normal	Ok	Biopsy
B1l	79	85	M	Appendix	Colon cancer	Normal	Ok	Biopsy
B1m	80	32	F	Appendix	Uterus endometriosis	Normal	Ok	Biopsy
B1n	80	32	F	Appendix	Uterus endometriosis	Normal	Ok	Biopsy
B1o	81	88	M	Appendix	Colon cancer	Normal	Ok	Biopsy
B1p	81	88	M	Appendix	Colon cancer	Normal	Ok	Biopsy
B2a	82	78	M	Gall bladder	Normal	Normal	Ok	Biopsy
B2b	82	78	M	Gall bladder	Normal	Normal	Ok	Biopsy
B2c	83	16	M	Gall bladder	Normal	Normal	Ok	Biopsy
B2d	83	16	M	Gall bladder	Normal	Normal	Ok	Biopsy
B2e	84	56	F	Gall bladder	Normal	Normal	Ok	Biopsy
B2f	84	56	F	Gall bladder	Normal	Normal	Ok	Biopsy
B2g	85	54	F	Gall bladder	Normal	Normal	Ok	Biopsy
B2h	85	54	F	Gall bladder	Normal	Normal	Ok	Biopsy
B2i	86			Gall bladder	Normal	Normal	Ok	Biopsy
B2j	86			Gall bladder	Normal	Normal	Ok	Biopsy
B2k	87	74	F	Liver	Mild non-specific portal triaditis	Normal	Ok	Biopsy
B2l	87	74	F	Liver	Mild non-specific portal triaditis	Normal	Ok	Biopsy
B2m	88	85	M	Liver	Colon cancer, metastatic	Normal	Ok	Biopsy
B2n	88	85	M	Liver	Colon cancer, metastatic	Normal	Ok	Biopsy
B2o	89	71	M	Liver	Cholecystitis	Normal	Ok	Biopsy
B2p	89	71	M	Liver	Cholecystitis	Normal	Inflammation	Biopsy
B3a	89	71	M	Liver	Cholecystitis	Normal	Ok	Biopsy

Localisation	Identical Biopsy	Age	Sex	Organ	Underlying Disease	Histologic DX	Tissue Represented, Lot1	Material
B3b	90	26	F	Liver	Hodgkin disease	Normal	Ok	Biopsy
B3c	90	26	F	Liver	Hodgkin disease	Normal	Ok	Biopsy
B3d	90	26	F	Liver	Hodgkin disease	Normal	Ok	Biopsy
B3e	93			Pancreas		Normal	Ok	Autopsy, <12h
B3f	93			Pancreas		Normal	Ok	Autopsy, <12h
B3g	93			Pancreas		Normal	Ok	Autopsy, <12h
B3h	93			Pancreas		Normal	Ok	Autopsy, <12h
B3i	91	32	F	Pancreas	Depression, trauma	Normal	Ok	Autopsy, <12h
B3j	91	32	F	Pancreas	Depression, trauma	Normal	Ok	Autopsy, 3h
B3k	91	32	F	Pancreas	Depression, trauma	Normal	Ok	Autopsy, 3h
B3l	92	41	M	Pancreas	Trauma	Normal	Ok	Autopsy, 3h
B3m	92	41	M	Pancreas	Trauma	Normal	Ok	Autopsy, 5h
B3n	92	41	M	Pancreas	Trauma	Normal	Ok	Autopsy, 5h
B3o	94	31	M	Submandibular gland	Sialadenitis other area (behind stone)	Normal	Ok	Biopsy
B3p	94	31	M	Submandibular gland	Sialadenitis other area (behind stone)	Normal	Ok	Biopsy
B4a	94	31	M	Submandibular gland	Sialadenitis other area (behind stone)	Normal	Ok	Biopsy
B4b	95	62	F	Submandibular gland	Mucoepidermoid carcinoma	Normal	Ok	Biopsy
B4c	95	62	F	Submandibular gland	Mucoepidermoid carcinoma	Normal	Ok	Biopsy
B4d	95	62	F	Submandibular gland	Mucoepidermoid carcinoma	Normal	Ok	Biopsy
B4e	96	31	F	Submandibular gland	Thyroid cancer	Normal	Ok	Biopsy
B4f	96	31	F	Submandibular gland	Thyroid cancer	Normal	Ok	Biopsy
B4g	96	31	F	Submandibular gland	Thyroid cancer	Normal	Ok	Biopsy
B4h	96	31	F	Submandibular gland	Thyroid cancer	Normal	Ok	Biopsy
B4i	100	44	F	Ovary, stroma	Abnormal bleedings	Normal	Ok	Biopsy
B4j	98		F	Ovary, stroma	CIS cervix	Normal	Fallopian tube	Biopsy
B4k	99	45	F	Ovary, stroma	Menometrorrhagia	Normal	Ok	Biopsy
B4l	100	44	F	Ovary, stroma	Abnormal bleedings	Normal	Ok	Biopsy
B4m	101	45	F	Ovary, stroma	Myoma uterus	Normal	Ok	Biopsy
B4n	98		F	Ovary, stroma	CIS cervix	Normal	Ok	Biopsy
B4o	102	47	F	Ovary, stroma	Hysterectomy	Normal	Sample missing on first section	Biopsy
B4p	102	47	F	Ovary, stroma	Hysterectomy	Normal	Ok	Biopsy
B5a	103	47	F	Ovary, stroma	Myoma uterus	Normal	Ok	Biopsy
B5b	103	47	F	Ovary, stroma	Myoma uterus	Normal	Ok	Biopsy
B5c	100	44	F	Ovary, corpus luteum	Abnormal bleedings	Normal	Ok	Biopsy
B5d	105	32	F	Ovary, corpus luteum	Endometriosis uterus	Normal	Ok	Biopsy
B5e	106	45	F	Ovary, corpus luteum	Menometrorrhagia	Normal	Ok	Biopsy

Localisation	Identical	Age	Sex	Organ	Underlying Disease	Histologic DX	Tissue Represented, Lot1	Material
B5f	Biopsy	45	F	Ovary, corpus luteum	Menometrorrhagia	Normal	Ok	Biopsy
B5g		106	F	Ovary, corpus luteum	Abnormal bleedings	Normal	Ok	Biopsy
B5h		107	F	Ovary, corpus luteum	Abnormal bleedings	Normal	Ok	Biopsy
B5i		108	F	Ovary, corpus luteum	Myoma uterus	Normal	Ok	Biopsy
B5j		108	F	Ovary, corpus luteum	Myoma uterus	Normal	Ok	Biopsy
B5k		109	F	Ovary, corpus luteum	Hysterectomy	Normal	Ok	Biopsy
B5l		109	F	Ovary, corpus luteum	Hysterectomy	Normal	Ok	Biopsy
B3m		110	F	Fallopian tube		Normal	Ok	Biopsy
B3n		110	F	Fallopian tube		Normal	Ok	Biopsy
B5o		111	F	Fallopian tube		Normal	Ok	Biopsy
B5r		111	F	Fallopian tube		Normal	Ok	Biopsy
B6a		112	F	Fallopian tube	CIS cervix	Normal	Ok	Biopsy
B6b		111	F	Fallopian tube		Normal	Ok	Biopsy
B6c		113	F	Fallopian tube	Myoma uterus	Normal	Ok	Biopsy
B6d		113	F	Fallopian tube	Myoma uterus	Normal	Ok	Biopsy
B6e		114	F	Fallopian tube	Myoma uterus	Normal	Ok	Biopsy
B6f		114	F	Fallopian tube	Myoma uterus	Normal	Ok	Biopsy
B6g		115	F	Myometrium	Dysfunctional bleeding, myoma, adenomyosis	Normal	Some endometrium included	Biopsy
B6h		116	F	Myometrium	Ruptured ovarian cyst (endometriosis)	Normal	Ok	Biopsy
B6i		119	F	Myometrium	Pelvic pain	Normal	Ok	Biopsy
B6j		118	F	Myometrium	Ovarian cyst (endometriosis)	Normal	Endometrium	Biopsy
B6k		119	F	Myometrium	Pelvic pain	Normal	Ok	Biopsy
B6l		120	F	Myometrium	Menometrorrhagia	Normal	Ok	Biopsy
B6m		121	F	Myometrium	Endometrium cancer	Normal	Ok	Biopsy
B6n		121	F	Myometrium	Endometrium cancer	Normal	Ok	Biopsy
B6o		122	F	Myometrium	CIS cervix	Normal	Ok	Biopsy
B6p		122	F	Myometrium	CIS cervix	Normal	Ok	Biopsy
B7a		123	F	Endo sekr	Prolaps	Normal	Ok	Biopsy
B7b		123	F	Endo sekr	Prolaps	Normal	Ok	Biopsy
B7c		124	F	Endo sekr	Prolaps	Normal	Ok	Biopsy
B7d		123	F	Endo sekr	Prolaps	Normal	Ok	Biopsy
B7e		125	F	Endo sekr	CIS cervix	Normal	Ok	Biopsy
B7f		125	F	Endo sekr	CIS cervix	Normal	Ok	Biopsy
B7g		126	F	Endo sekr	CIS cervix	Normal	Ok	Biopsy
B7h		126	F	Endo sekr	CIS cervix	Normal	Ok	Biopsy
B7i		127	F	Endo sekr	Hysterectomy	Normal	Ok	Biopsy
B7j		127	F	Endo sekr	Hysterectomy	Normal	Ok	Biopsy

Localisation	Identical Biopsy	Age	Sex	Organ	Underlying Disease	Histologic DX	Tissue Represented, Lot1	Material
B7k	128	28	F	Endo prol	Ruptured ovarian cyst (endometriosis)	Normal	Ok	Biopsy
B7l	128	28	F	Endo prol	Ruptured ovarian cyst (endometriosis)	Normal	Ok	Biopsy
B7m	129	40	F	Endo prol	Menorrhagia	Normal	Ok	Biopsy
B7n	129	40	F	Endo prol	Menorrhagia	Normal	Few epithelial cells	Biopsy
B7o	130	41	F	Endo prol	Ovarian cyst (endometriosis)	Normal	Ok	Biopsy
B7p	130	41	F	Endo prol	Ovarian cyst (endometriosis)	Normal	Ok	Biopsy
B8a	130	41	F	Endo prol	Ovarian cyst (endometriosis)	Normal	Ok	Biopsy
B8b	131	42	F	Endo prol	Ovarian cyst (endometriosis)	Normal	Few epithelial cells	Biopsy
B8c	131	42	F	Endo prol	Ovarian cyst (endometriosis)	Normal	Few epithelial cells	Biopsy
B8d	131	42	F	Endo prol	Ovarian cyst (endometriosis)	Normal	Few epithelial cells	Biopsy
B8e	136	45	F	Endocervix	Menometrorrhagia	Normal	Ok	Biopsy
B8f	133		F	Endocervix	CIS cervix	Normal	Ok	Biopsy
B8g	134		F	Endocervix	CIS cervix	Normal	Ok	Biopsy
B8h	135		F	Endocervix	CIS cervix	Normal	Ok	Biopsy
B8i	136	45	F	Endocervix	Menometrorrhagia	Normal	Ok	Biopsy
B8j	136	45	F	Endocervix	Menometrorrhagia	Normal	Ok	Biopsy
B8k	137	49	F	Endocervix	Endometrium cancer	Normal	Ok	Biopsy
B8l	137	49	F	Endocervix	Endometrium cancer	Normal	Ok	Biopsy
B8m	138	47	F	Endocervix	Hysterectomy	Normal	Ok	Biopsy
B8n	138	47	F	Endocervix	Hysterectomy	Normal	Ok	Biopsy
B8o	139	41	F	Ekocervix	Ovarian cyst (endometriosis)	Normal	Ok	Biopsy
B8p	140	32	F	Ekocervix	Endometriosis	Normal	Ok	Biopsy
B9a	141		F	Ekocervix	Endometriosis	Normal	Ok	Biopsy
B9b	142	49	F	Ekocervix	CIS cervix	Normal	Ok	Biopsy
B9c	143	49	F	Ekocervix	CIS cervix	Normal	Ok	Biopsy
B9d	143	49	F	Ekocervix	Endometrium cancer	Normal	Ok	Biopsy
B9e	144	47	F	Ekocervix	Endometrium cancer	Normal	Stroma only	Biopsy
B9f	144	47	F	Ekocervix	Hysterectomy	Normal	Ok	Biopsy
B9g	144	47	F	Ekocervix	Hysterectomy	Normal	Ok	Biopsy
B9h	145	47	F	Ekocervix	Myoma uterus	Normal	Ok	Biopsy
B9i	145	47	F	Ekocervix	Myoma uterus	Normal	Ok	Biopsy
B9j	146	74	M	Kidney cortex	Clear cell RCC	Normal	Ok	Biopsy
B9k	146	74	M	Kidney cortex	Clear cell RCC	Normal	Ok	Biopsy
B9l	147	78	M	Kidney cortex	Cancer pylon	Normal	Ok	Biopsy
B9m	147	78	M	Kidney cortex	Cancer pylon	Normal	Ok	Biopsy
B9n	148	88	M	Kidney cortex	Clear cell RCC	Normal	Ok	Biopsy
B9o	148	88	M	Kidney cortex	Clear cell RCC	Normal	Ok	Biopsy
B9p	148	88	M	Kidney cortex	Clear cell RCC	Normal	Ok	Biopsy

Localisation	Identical	Age	Sex	Organ	Underlying Disease	Histologic DX	Tissue Represented, Lot1	Material
B9p	Biopsy							
C1a	148	88	M	Kidney cortex	Cancer pylon	Normal	Ok	Biopsy
C1b	149	87	M	Kidney cortex	Cancer pylon	Normal	Ok	Biopsy
C1c	150	74	M	Kidney papilla	Cancer pylon	Normal	Ok	Biopsy
C1d	150	74	M	Kidney papilla	Cancer pylon	Normal	Ok	Biopsy
C1e	151	78	M	Kidney papilla	Cancer pylon	Normal	Ok	Biopsy
C1f	151	78	M	Kidney papilla	Cancer pylon	Normal	Ok	Biopsy
C1g	152	88	M	Kidney papilla	Cancer pylon	Normal	Ok	Biopsy
C1h	152	88	M	Kidney papilla	Cancer pylon	Normal	Ok	Biopsy
C1i	152	88	M	Kidney papilla	Cancer pylon	Normal	Ok	Biopsy
C1j	153	87	M	Kidney papilla	Cancer pylon	Normal	Ok	Biopsy
C2a	153	87	M	Kidney papilla	Cancer pylon	Normal	Ok	Biopsy
C2b	153	87	M	Kidney papilla	Cancer pylon	Normal	Ok	Biopsy
C2c	154	M		Prostate	Benign prostatic hyperplasia	Normal	Ok	Biopsy
C2d	154	M		Prostate	Benign prostatic hyperplasia	Normal	Ok	Biopsy
C2e	155	66	M	Prostate	Benign prostatic hyperplasia	Normal	Ok	Biopsy
C2f	155	66	M	Prostate	Benign prostatic hyperplasia	Normal	Ok	Biopsy
C2g	156	70	M	Prostate	Benign prostatic hyperplasia	Normal	Ok	Biopsy
C2h	156	70	M	Prostate	Benign prostatic hyperplasia	Normal	Ok	Biopsy
C2i	156	70	M	Prostate	Benign prostatic hyperplasia	Normal	Ok	Biopsy
C2j	157	74	M	Prostate	Benign prostatic hyperplasia	Normal	Ok	Biopsy
C3a	157	74	M	Prostate	Benign prostatic hyperplasia	Normal	Ok	Biopsy
C3b	157	74	M	Prostate	Benign prostatic hyperplasia	Normal	Ok	Biopsy
C3c	158	60	M	Seminal vesicle	Prostate cancer	Normal	Ok	Biopsy
C3d	158	60	M	Seminal vesicle	Prostate cancer	Normal	Ok	Biopsy
PAGE MISSING								
C6b	167	73	M	Testis	Prostate cancer	Normal	Ok	Biopsy
C6c	168	87	M	Kidney pelvis	Cancer pylon	Normal	No epithelial cells	Biopsy
C6d	169	87	M	Kidney pelvis	Cancer pylon	Normal	No epithelial cells	Biopsy
C6e	168	87	M	Kidney pelvis	Cancer pylon	Normal	No epithelial cells	Biopsy
C6f	169	87	M	Kidney pelvis	Cancer pylon	Normal	No epithelial cells	Biopsy
C6g	168	87	M	Kidney pelvis	Cancer pylon	Normal	No epithelial cells	Biopsy
C6h	170	85	F	Kidney pelvis	Cancer pylon	Normal	No epithelial cells	Biopsy
C6i	170	85	F	Kidney pelvis	Cancer pylon	Normal	No epithelial cells	Biopsy
C6j	170	85	F	Kidney pelvis	Cancer pylon	Normal	No epithelial cells	Biopsy
C7a	170	85	F	Kidney pelvis	Cancer pylon	Normal	No epithelial cells	Biopsy
C7b	170	85	F	Kidney pelvis	Cancer pylon	Normal	Inflammation	Biopsy
C7c	171	63	F	bronchus	Lung cancer	Normal	No epithelial cells	Biopsy

Localisation	Identical	Age	Sex	Organ	Underlying Disease	Histologic DX	Tissue Represented, Lot1	Material
C7d	171	63	F	Bronchus	Lung cancer	Normal	Ok	Biopsy
C7e	172	74	M	Bronchus	Lung cancer	Normal	Ok	Biopsy
C7f	172	74	M	Bronchus	Lung cancer	Normal	Ok	Biopsy
C7g	172	74	M	Bronchus	Lung cancer	Normal	Ok	Biopsy
C7h	173	51	F	Bronchus	Lung cancer	Normal	Ok	Biopsy
C7i	173	51	F	Bronchus	Lung cancer	Normal	Ok	Biopsy
C7j	174			Bronchus	Lung cancer	Normal	Ok	Biopsy
C8a	174			Bronchus	Lung cancer	Normal	Ok	Biopsy
C8b	174			Bronchus	Lung cancer	Normal	No epithelial cells	Biopsy
C8c	175	74	F	Lung	Lung cancer	Normal	Ok	Biopsy
C8d	176	62	M	Lung	Lung cancer	Normal	Ok	Biopsy
C8e	177	68	F	Lung	Lung cancer	Normal	Ok	Biopsy
C8f	178	69	F	Lung	Lung cancer	Normal	Ok	Biopsy
C8g	179	51	F	Lung	Lung cancer	Normal	Ok	Biopsy
C8h	179	51	F	Lung	Lung cancer	Normal	Ok	Biopsy
C8i	180	50	M	Lung	Lung cancer	Normal	Ok	Biopsy
C8j	180	50	M	Lung	Lung cancer	Normal	Ok	Biopsy
C9a	181	56	M	Lung	Lung cancer	Normal	Ok	Biopsy
C9b	178	69	F	Lung	Lung cancer	Normal	Ok	Biopsy
C9c	182	41	M	Cerebellum	Trauma	Normal	Ok	Autopsy, 5h
C9d	182	41	M	Cerebellum	Trauma	Normal	Ok	Autopsy, 5h
C9e	182	41	M	Cerebellum	Trauma	Normal	Ok	Autopsy, 5h
C9f	183	33	F	Cerebellum	Trauma	Normal	Ok	Autopsy, <10h
C9g	183	33	F	Cerebellum	Trauma	Normal	Ok	Autopsy, <10h
C9h	183	33	F	Cerebellum	Trauma	Normal	Ok	Autopsy, <10h
C9i	184	37	M	Cerebellum	Trauma	Normal	Ok	Autopsy, 4h
C9j	184	37	M	Cerebellum	Trauma	Normal	Ok	Autopsy, 4h
D1a	184	37	M	Cerebellum	Trauma	Normal	Ok	Autopsy, 4h
D1b	184	37	M	Cerebellum	Trauma	Normal	Ok	Autopsy, 4h
D1c	185	32	F	Cerebrum, grey substance	Depression, trauma	Normal	Ok	Autopsy, 3h
D1d	185	32	F	Cerebrum, grey substance	Depression, trauma	Normal	Ok	Autopsy, 3h
D1e	186	41	M	Cerebrum, grey substance	Trauma	Normal	Ok	Autopsy, 5h
D1f	186	41	M	Cerebrum, grey substance	Trauma	Normal	Ok	Autopsy, 5h
D1g	187	33	F*	Cerebrum, grey substance	Trauma	Normal	Ok	Autopsy, <10h

TC9260: 6269660

Localisation	Identical Biopsy	Age	Sex	Organ	Underlying Disease	Histologic DX	Tissue Represented, Lot1	Material
Dlh	187	33	F	Cerebrum, grey substance	Trauma	Normal	Ok	Autopsy, <10h

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

Sample #	age	received	associated with	new	prognosis request
1	66				60
2	55				60
3	75				60
4	77				60
5	81				60
6	33			1	60
7	75			1	60
8	77				60
9	76				60
10	51				60
11	45				60
12	65				60
13	69				60
14	61				60
15	68				60
16	78				60
17	79				60
18	55				60
19	53				60
20	82				60
21	62				60
22	63				60
23	66				60
24	67				60
25	72				60
26	79				60
27	75				60
28	68				60
29	77				60
30	76				60
31	51	07/31/1996			60
32	45	07/31/1996			60
33	65	07/31/1996			60
34	69	07/31/1996			60
35	61	07/31/1996			60
36	68	07/31/1996			60
37	78	07/31/1996			60
38	79	07/31/1996			60
39	55	07/31/1996			60
40	53	07/31/1996			60
41	82	07/31/1996			60
42	62	07/31/1996			60
43	63	07/31/1996			60
44	66	07/31/1996			60
45	67	07/31/1996			60
46	72	07/31/1996			60
47	79	07/31/1996			60
48	75	07/31/1996			60
49	68	07/31/1996			60
50	59	07/31/1996			60
51	56	07/31/1996			60
52	49	07/31/1996			60
53	63	07/31/1996			60

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

remarks

use b89.7117 for PR50

primary tumor also in b91.3181

slides + blocks not found
slides + blocks not found
SEARCH FOR PREVIOUS BIOPSY!
DD papillary
cancer only seen on frozen section

paget

residual tumor
small tumor

residual tumor

residual tumor
dob 21.4.23
sent previously

not macroscop measurable
sent previously

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

pT	pN	nodes all	nodes pos	diameter/mm	surgery
1	0	23	0	15	mastectomy
1	0	17	0	40	lumpectomy
1	0	8	0	8	mastectomy
1	0		0	85	m
1	0		0	29	l
1	0		0	6	l
1	0		0	9	l
1	0	20	0	45	mastectomy
1	0	14	0	30	mastectomy
1	0	0	0	40	mastectomy
1	0	19	0	35	mastectomy
1	0	20	0	25	mastectomy
1	0	20	0	10	mastectomy
1	0	18	0	23	mastectomy
1	0	3	0	55	mastectomy
1	0	10	0	20	mastectomy
1	0	19	0	15	mastectomy
1	0	0	0	30	lumpectomy
1	0	0	0	40	mastectomy
1	0	21	0	15	lumpectomy
1	0	17	0	60	mastectomy
1	0	11	0	21	lumpectomy
1	0	0	0	15	lumpectomy
1	0	0	0	30	mastectomy
1	0	17	0	70	mastectomy
1	0	8	0	15	mastectomy
1	0	0	0	30	lumpectomy
1	0	16	0		mastectomy
1	0	13	0	10	mastectomy
1	0	7	0	10	mastectomy
1	0		0	10	l
1	0		0	21	l
1	0		0	18	
1	0		0	10	
1	0		0	38	
1	0		0	18	
1	0		0		
1	0		0	20	
1	0	16	0		m
1	0		0		
1	0		0	8	l
1	0	14	0		
1	0		0	12	l
1	0		0	27	
1	0	7	0		m
1	0		0	15	l
1	0		0	10	
1	0		0	15	
1	0		0		
1	0		0		
1	0		0	15	l
1	0		0	>20	l
1	0		0	10	

0096377_002001

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

resection border	array	Histotyp GS	sex	category
free	BR50	ductal	f	ca
free	BR50	ductal	f	ca+meta
free	BR50	ductal	f	ca+dcis
f	BR50	ductal	f	ca+meta
f	BR50	ductal	f	ca+dcis
n	n	ductal		ca+meta
n	n	ductal	f	ca+dcis
free	BR50	ductal	f	ca+meta
free	BR50	ductal	f	ca
free	BR50	ductal	f	ca
free	BR50	ductal	f	ca+meta
free	BR50	ductal	f	ca+dcis
free	BR50	ductal	f	ca
free	BR50	ductal	f	ca+meta
free	BR50	ductal	f	ca
free	BR50	ductal	f	ca
free	BR50	ductal	f	ca+dcis+meta+no
?	BR50	ductal	f	ca
free	BR50	ductal	f	ca
free	BR50	ductal	f	ca
free	ev	ductal	f	ca+meta
free	ev	ductal	f	dcis
?	n	ductal	f	ca
free	y	ductal	f	ca
free	y	ductal	f	ca+dcis+meta
free	y	ductal	f	ca
free	y	ductal	f	ca
f	y	ductal	f	ca
free		ductal	f	ca
free		ductal	f	ca
		ductal		ca
f		ductal		ca
pos		ductal		ca
		ductal		ca
		ductal		ca
pos		ductal		ca
		ductal		ca
		ductal		ca
		ductal		ca
		ductal		ca
		ductal		ca
		ductal		ca
		ductal		ca
pos		ductal		ca
		ductal		ca
		ductal		ca
free		ductal		ca
		ductal		ca
		ductal		ca
?		ductal		ca
free		ductal		ca
pos		ductal		ca

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

tumor slides	dcis slides	lcis slides
1; 2; 3		
1; 2; 3		
1; 2	3; 4	
1; 2; 3; 4		
1		
1		
1 to 5		
1; 2; 3; 4		
1; 2; 3		
1		
1; 2	2	
1; 2		
1; 2; 3; 4		
1 to 7		
1; 2		
1; 5; 6; 8; 9; 11	2-9; 12	
1; 2; 3; 4		
1 to 7		
1; 2; 3		
1; 2	1; 2; 3	
1		
1; 2; 3		
1; 2; 3; 4	3; 4	
1; 2		
1; 2; 3; 4; 5		
2		
1		

[illegible][illegible]

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

others

1; 2; 3: lactating breast

2; 3; 4; 5 scar formation, fat necrosis

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

cut slides	slide 1 cancer
	0.9
2	1.2
	0.7
1	0.8
1	1.3
	1
1	1.5
	1
all	1
	0.7
all	1
	0.6
	2
	1.3
	1
	1
	1.3
	1
1	1
all	0.4
	0
1	0.2
3	0.2
2	0.4
	0.5
1	1.6
	0.8

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

slide 1 DCIS	slide 1 normal	slide 2 cancer
0	0	0.8
0	0	1.2
0	0	0.4
0	0,8: normal muscle	
0	0	
0	0	1
0	0	0.5
0	0	1
0	0	0
0	0	0.5
0	0	0.2
0	0	2
0	0	1.5
0	0	0.2
0	0	0
0	0	1.3
0	0.5	1
0	0	0.7
0	0	0.4
0.4	0	0
0	0	
0	0	0.3
0	0	1.2
0	0	0.1
0	0	1.5
		0.8
0	0	

Appendix A
Table 12
bci-2a Breast Cancer TMA data Oncology Data

slide 2 DCIS	slide 2 normal	slide 3 cancer	slide 3 DCIS
0	0.3	0.7	0
0	0	0.7	0
0	0	0	0.6
0	0	1	0
0	0	0.4	0
0	0	0.5	0
0	0.4		
0.3	0	0	0
0	0		
0	0	1.5	0
0	0	1	0
0	0		
1.3	0	0	0.7
0	0.5	1.3	0
0	0	0.8	0
0	0	0.4	0
0	0	0.6	0
0.3	0	0	0.2
0	0	0.4	0
0	0	0.7	1
0	0		
0	0	1.2	0
0	0		

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

slide 3 normal	slide 4 cancer	slide 4 DCIS	slide 4 normal
0.5			
0			
0	0	0.8	0
0	.7	0	0
0	0.6	0	0
0			
0.3			
0	1.3	0	0
0	1.2	0	0
0	0	0.6	0
0.2	1	0	0
0	1	0	0
0			
0	0.5	0	0
0			
0			
0	0.5	0.6	0
0	1	0	0
4 skin			

100250-2299690

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

slide 5 cancer	slide 5 DCIS	slide 5 normal	slide 6 cancer	slide 6 DCIS
----------------	--------------	----------------	----------------	--------------

0.3	0	0		
0.7	0	0	0.8	0
0.2	0.5	0	0.4	0.4
0.6	0	0	0.6	0
0.3	0	0	0.1	0
0.9	0	0	0.6	0
0.8	0	0	0	0

00000000000000000000

00000000000000000000

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

2nd DCIS type	2nd Tub GS	2nd Poly GS	2nd mito gs
---------------	------------	-------------	-------------

bcl-2a Breast Cancer TMA data Oncology Data

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

Sample #	age	received	associated with	new	prognosis request
54	79	07/31/1996			60
55	55	07/31/1996			60
56	53	07/31/1996			60
57	82	07/31/1996			60
58	62				60
59	63				60
60	66				60
61	67				60
62	72				60
63	79				60
64	75				60
65	68				60
66	59				60
67	56				60
68	49				60
69	63				60
70	66				60
71	79		h91.167	add	60
72	55		h91.273	no add	60
73	53				60
74	82				60
75	62				60
76	63		h91.939	add	60
77	66				60
78	67		h92.1084	add	60
79	72		h92.1084		60
80	79		h92.1146		60
81	75				60
82	68				60
83	59				60
84	79				60
85	75				60
86	68				60
87	59				60
88	56				60
89	49				60
90	63				60
91	66				60
92	79		h87.1408?		60
93	55		h87.1408?		60
94	53				60
95	82				60
96	62				60
97	63				60
98	66				60
99	67				60
100	72		h92.636		60
101	79				60
102	75				60
103	68				60
104	59				60
105	56				60
106	49				60

[illegible][illegible]

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

remarks
dob 29.1.19

second tumor: mucoid 10mm diameter, BRE grade 1 (slides 4 and 5)

has also colon cancer!!

small carcinoma

multicentric
extranodal extension in lymph node marked in black

difficult type, DD lobular cancer solid variant check
small dcis on 1
dcis very small

small focus of cribriform dcis too small to be used

scirrous
DD lob difficult, clarify, dcis too small to punch

SEARCH FOR PREVIOUS BIOPSY! AND NODAL META OF H92.479

lobular?
meta

DD: histiocytic, lipid rich, apocrine

residual cancer. Same pat as h87.1408? meta only small

large
large

1 was frozen, 2 small
small intraductal components intermingled with cancer
SEARCH FOR PREVIOUS BIOPSY!

large dcis, smaller cancer, problem: there is also sclerosing adenosis, ca difficult to prove at many places
little mat

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

pT	pN	nodes all	nodes pos	diameter/mm	surgery
1	0		0	fragmented	
1	0		0	20	I
1	0		0	22	I
1	0		0	30	I
1	0	1	0	20	mastectomy
1	0	0	0	x	lumpectomy
1	0	0	0	30	lumpectomy
1	0	0	0	15	I
1	0	0	0	x	lumpectomy
1	0	0	0	20	lumpectomy
1	0	14	0	x	mastectomy
1	0		0	6 rt, 7 l	lump. both sides
1	0		0	10	lumpectomy
1	0	0	0	25	lumpectomy
1	0	7	0	x	mastectomy
1	0	12	0	27	lumpectomy
1	0		0	x	lumpectomy
1	0	13	0	20	lumpectomy
1	0	14	0	45	lumpectomy
1	0		0	22	lumpectomy
1	0		0	18	lumpectomy
1	0		0	31	lumpectomy
1	0	9	0	15	lumpectomy
1	0		0	30	lumpectomy
1	0		0	30	lumpectomy
1	0		0	30	m
1	0	24	0	x	mastectomy
1	0	0	0	15	lumpectomy
1	0	14	0	23 residual	mastectomy
1	0	2	0	30	mastectomy
1	0		0	22	lumpectomy
1	0	30	0	x	mastectomy
1	0		0	16	I
1	0	0	0	10	lumpectomy
1	0	0	0	14	I
1	0	many	0	28	m
1	0		0	18	I
1	0		0	31	I
1	0		0	23	I
1	0	10	0	>30	m
1	0	17	0	35	m
1	0		0	22	I
1	0		0	9	I
1	0		0	9	I
1	0	13	0	40	m
1	0		0	35	I
1	0	12	0	16	I
1	0	0	0	25	lumpectomy
1	0		0	15	I
1	0	16	0	39	lumpectomy
1	0		0	11	lumpectomy
1	0		0	x	lumpectomy
1	0		0	10	lumpectomy

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

resection border	array	Histotyp GS	sex	category
?		ductal		ca
pos		ductal		ca
pos		ductal		ca
pos		ductal		ca
free	BR50	ductal	f	2xca
	BR50	ductal	f	ca
free	BR50	ductal	f	ca
not free	BR50	ductal	f	ca
free	BR50	ductal	f	ca
not free	BR50	ductal	f	ca
free	BR50	ductal	f	ca
free both	BR50	ductal	f	ca
	BR50	ductal	f	ca
free	BR50	ductal	f	ca
free	BR50	ductal	f	ca
free	BR50	ductal	f	ca
not free	BR50	ductal	f	ca
free	BR50	ductal	f	ca
free	BR50	ductal	f	ca
not free	BR50	ductal	f	ca
not free	BR50	ductal	f	ca
free	BR50	ductal	f	ca
not free	BR50	ductal	f	ca
not free	BR50	ductal	f	ca
f	BR50	ductal	f	ca
f	BR50	ductal	f	ca
	BR50	ductal	f	ca
free	BR50	ductal	f	ca
free	BR50	ductal	f	ca
not free	BR50	ductal	f	ca
	BR50	ductal	f	ca
n	n	ductal	f	ca
free	n	ductal	f	ca
f	y	ductal	f	ca
f	y	ductal	f	ca
n	y	ductal	f	ca
not free	y	ductal	f	ca
not free	y	ductal	f	ca
f	y	ductal	f	ca
f	y	ductal	f	ca
n	y	ductal	f	ca
n	y	ductal	f	ca
f	y	ductal	f	ca
n	y	ductal	f	ca
f	y	ductal	f	ca
not free	y	ductal	f	ca
	y	ductal	f	ca
free		ductal	f	ca
		ductal	f	ca
not free		ductal	f	ca
free		ductal	f	ca

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

secondary type	Tub GS	Poly GS	mito gs	DCIS type
second tumor: mucinous	3	2	1	
	2	2	1	
	2	2	1	
	3	3	1	
	3	3	2	
	3	3	3	
	1	2	1	
	3	2	2	
	3	2	1	
	3	3	2	
	2	3	1	
	3	3	3	
	3	2	3	
	3	3	2	
	3	3	3	comedo high
	3	3	3	
cribriform	2	2	1	
	3	3	1	
lobular	2	2	1	
	2	2	1	
lobular	3	2	1	
	3	3	1	
	3	2	1	
	3	2	2	
	5	2	2	
	3	3	2	
	3	2	1	
	3	3	1	
	2	3	3	
	2	2	1	
	1	2	1	
	3	3	1	
	2	2	2	
	2	3	1	
	3	3	2	
	3	3	2	
	2	3	2	
	3	2	1	
	3	2	1	
	3	3	1	
	3	2	1	
	3	3	3	
	3	2	2	crib, pap low
dcis	2	3	2	comedo high
mucinous 40%	3	2	1	
	3	3	2	
	2	2	2	
	3	2	1	solid low
	3	2	1	

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

tumor slides	dcis slides	lcis slides
--------------	-------------	-------------

1; 2; 3 / 4; 5		
----------------	--	--

1; 2		
------	--	--

1		
---	--	--

1		
---	--	--

1		
---	--	--

1; 2		
------	--	--

1		
---	--	--

3		
---	--	--

1; 3 fs		
---------	--	--

1; 2; 3; 4		
------------	--	--

1; 2		
------	--	--

1		
---	--	--

1; 2; 3; 4		
------------	--	--

1; 2; 3; 4; 5	1	
---------------	---	--

1; 2; 3; 4	3	
------------	---	--

1; 2; 3; 4		
------------	--	--

1; 2; 3		
---------	--	--

1; 2; 3; 4; 5		
---------------	--	--

1; 2		
------	--	--

1; ?		
------	--	--

1; 2; 3; 4		
------------	--	--

1; 2; 3		
---------	--	--

1; 2		
------	--	--

1; 2		
------	--	--

1	1	
---	---	--

1; 2; 3		
---------	--	--

1; 2		
------	--	--

2; 3; 4; 5		
------------	--	--

1; 2		
------	--	--

1 fs		
------	--	--

1		
---	--	--

1; 2		
------	--	--

1		
---	--	--

1; 2; 3		
---------	--	--

1; 2		
------	--	--

1; 2		
------	--	--

1; 2		
------	--	--

1; 2; 3		
---------	--	--

1; 2; 4		
---------	--	--

1		
---	--	--

1; 2; 3		
---------	--	--

1; 2; 3		
---------	--	--

1 fs		
------	--	--

1; 2	2; 1	
------	------	--

1		
---	--	--

1; 2		
------	--	--

1; 2; 3; 4		
------------	--	--

1; 2; 3 fs		
------------	--	--

1		
---	--	--

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

mastopathia slides

normal slides

meta slides

1

4

h91.315

3

h87.1623

3: scleros adenosis, prol mastopath w. atypia

4; 5; 6; 7

0966373 092604

THE UNIVERSITY OF CHICAGO

3

2

3

3

1

2

2

1

☐ 1. ☐ 2. ☐ 3. ☐ 4. ☐ 5. ☐ 6. ☐ 7. ☐ 8. ☐ 9. ☐ 10. ☐ 11. ☐ 12. ☐ 13. ☐ 14. ☐ 15. ☐ 16. ☐ 17. ☐ 18. ☐ 19. ☐ 20. ☐ 21. ☐ 22. ☐ 23. ☐ 24. ☐ 25. ☐ 26. ☐ 27. ☐ 28. ☐ 29. ☐ 30. ☐ 31. ☐ 32. ☐ 33. ☐ 34. ☐ 35. ☐ 36. ☐ 37. ☐ 38. ☐ 39. ☐ 40. ☐ 41. ☐ 42. ☐ 43. ☐ 44. ☐ 45. ☐ 46. ☐ 47. ☐ 48. ☐ 49. ☐ 50. ☐ 51. ☐ 52. ☐ 53. ☐ 54. ☐ 55. ☐ 56. ☐ 57. ☐ 58. ☐ 59. ☐ 60. ☐ 61. ☐ 62. ☐ 63. ☐ 64. ☐ 65. ☐ 66. ☐ 67. ☐ 68. ☐ 69. ☐ 70. ☐ 71. ☐ 72. ☐ 73. ☐ 74. ☐ 75. ☐ 76. ☐ 77. ☐ 78. ☐ 79. ☐ 80. ☐ 81. ☐ 82. ☐ 83. ☐ 84. ☐ 85. ☐ 86. ☐ 87. ☐ 88. ☐ 89. ☐ 90. ☐ 91. ☐ 92. ☐ 93. ☐ 94. ☐ 95. ☐ 96. ☐ 97. ☐ 98. ☐ 99. ☐ 100. ☐ 101. ☐ 102. ☐ 103. ☐ 104. ☐ 105. ☐ 106. ☐ 107. ☐ 108. ☐ 109. ☐ 110. ☐ 111. ☐ 112. ☐ 113. ☐ 114. ☐ 115. ☐ 116. ☐ 117. ☐ 118. ☐ 119. ☐ 120. ☐ 121. ☐ 122. ☐ 123. ☐ 124. ☐ 125. ☐ 126. ☐ 127. ☐ 128. ☐ 129. ☐ 130. ☐ 131. ☐ 132. ☐ 133. ☐ 134. ☐ 135. ☐ 136. ☐ 137. ☐ 138. ☐ 139. ☐ 140. ☐ 141. ☐ 142. ☐ 143. ☐ 144. ☐ 145. ☐ 146. ☐ 147. ☐ 148. ☐ 149. ☐ 150. ☐ 151. ☐ 152. ☐ 153. ☐ 154. ☐ 155. ☐ 156. ☐ 157. ☐ 158. ☐ 159. ☐ 160. ☐ 161. ☐ 162. ☐ 163. ☐ 164. ☐ 165. ☐ 166. ☐ 167. ☐ 168. ☐ 169. ☐ 170. ☐ 171. ☐ 172. ☐ 173. ☐ 174. ☐ 175. ☐ 176. ☐ 177. ☐ 178. ☐ 179. ☐ 180. ☐ 181. ☐ 182. ☐ 183. ☐ 184. ☐ 185. ☐ 186. ☐ 187. ☐ 188. ☐ 189. ☐ 190. ☐ 191. ☐ 192. ☐ 193. ☐ 194. ☐ 195. ☐ 196. ☐ 197. ☐ 198. ☐ 199. ☐ 200. ☐ 201. ☐ 202. ☐ 203. ☐ 204. ☐ 205. ☐ 206. ☐ 207. ☐ 208. ☐ 209. ☐ 210. ☐ 211. ☐ 212. ☐ 213. ☐ 214. ☐ 215. ☐ 216. ☐ 217. ☐ 218. ☐ 219. ☐ 220. ☐ 221. ☐ 222. ☐ 223. ☐ 224. ☐ 225. ☐ 226. ☐ 227. ☐ 228. ☐ 229. ☐ 230. ☐ 231. ☐ 232. ☐ 233. ☐ 234. ☐ 235. ☐ 236. ☐ 237. ☐ 238. ☐ 239. ☐ 240. ☐ 241. ☐ 242. ☐ 243. ☐ 244. ☐ 245. ☐ 246. ☐ 247. ☐ 248. ☐ 249. ☐ 250. ☐ 251. ☐ 252. ☐ 253. ☐ 254. ☐ 255. ☐ 256. ☐ 257. ☐ 258. ☐ 259. ☐ 260. ☐ 261. ☐ 262. ☐ 263. ☐ 264. ☐ 265. ☐ 266. ☐ 267. ☐ 268. ☐ 269. ☐ 270. ☐ 271. ☐ 272. ☐ 273. ☐ 274. ☐ 275. ☐ 276. ☐ 277. ☐ 278. ☐ 279. ☐ 280. ☐ 281. ☐ 282. ☐ 283. ☐ 284. ☐ 285. ☐ 286. ☐ 287. ☐ 288. ☐ 289. ☐ 290. ☐ 291. ☐ 292. ☐ 293. ☐ 294. ☐ 295. ☐ 296. ☐ 297. ☐ 298. ☐ 299. ☐ 300. ☐ 301. ☐ 302. ☐ 303. ☐ 304. ☐ 305. ☐ 306. ☐ 307. ☐ 308. ☐ 309. ☐ 310. ☐ 311. ☐ 312. ☐ 313. ☐ 314. ☐ 315. ☐ 316. ☐ 317. ☐ 318. ☐ 319. ☐ 320. ☐ 321. ☐ 322. ☐ 323. ☐ 324. ☐ 325. ☐ 326. ☐ 327. ☐ 328. ☐ 329. ☐ 330. ☐ 331. ☐ 332. ☐ 333. ☐ 334. ☐ 335. ☐ 336. ☐ 337. ☐ 338. ☐ 339. ☐ 340. ☐ 341. ☐ 342. ☐ 343. ☐ 344. ☐ 345. ☐ 346. ☐ 347. ☐ 348. ☐ 349. ☐ 350. ☐ 351. ☐ 352. ☐ 353. ☐ 354. ☐ 355. ☐ 356. ☐ 357. ☐ 358. ☐ 359. ☐ 360. ☐ 361. ☐ 362. ☐ 363. ☐ 364. ☐ 365. ☐ 366. ☐ 367. ☐ 368. ☐ 369. ☐ 370. ☐ 371. ☐ 372. ☐ 373. ☐ 374. ☐ 375. ☐ 376. ☐ 377. ☐ 378. ☐ 379. ☐ 380. ☐ 381. ☐ 382.

4 scar formation, fat necrosis

168

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

cut slides	slide 1 cancer
1	1.2
1; 2; 5	0.8
1	0.7
1	0.7
1	1.2
1	0.6
1; 3	0.5
1	0.5
1; 2; 3; 4	1.5
1; 4	1
1	0.6
1	2
1	0.9
1; 3	1.5
1	2
1	0.5
1	0.9
1	1.2
1	1.2
1	1.5
1	0.5
1	0.9
	0.8
1	1.3
1	1.5
1	2
2	0.9
	0.5
1	0.8
	3
	3
	1.5
	3
	1
	3
	1
	0.9
	0.9
	2.5
	3
1; 2; 3	0.6
1	0.8
	1
1; 3; 4	0.4
1	0.4
1; 2	do IHC scleros ad?
1	0.4

109260 5299660

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

slide 1 DCIS	slide 1 normal	slide 2 cancer
0	0	1.5
0	0	
0	0	
0	0	
0	0	
0	0	
0	0	
0.3	0.2	
,3 not pure	0	
0	0	0.3
0	0	
0	0	
0	0	
0	0	
0	0	
0	0	0.5
0.2	0	
0	0	
0	0	
0.1	0	0.4
		1.5
		2
		1
		1
		1
		0.5
		0.9
	3 no skin	2
		2.5
0.5	0	0.2
1	0	
0	0	0.15

$\frac{1}{\sqrt{2}} \frac{\partial \psi}{\partial x}$	$\frac{1}{\sqrt{2}} \frac{\partial \psi}{\partial y}$	$\frac{1}{\sqrt{2}} \frac{\partial \psi}{\partial z}$	$\frac{1}{\sqrt{2}} \frac{\partial \psi}{\partial t}$	$\frac{1}{\sqrt{2}} \frac{\partial \psi}{\partial x}$	$\frac{1}{\sqrt{2}} \frac{\partial \psi}{\partial y}$	$\frac{1}{\sqrt{2}} \frac{\partial \psi}{\partial z}$	$\frac{1}{\sqrt{2}} \frac{\partial \psi}{\partial t}$
---	---	---	---	---	---	---	---

$\frac{1}{\sqrt{2}} \frac{\partial \psi}{\partial x}$	$\frac{1}{\sqrt{2}} \frac{\partial \psi}{\partial y}$	$\frac{1}{\sqrt{2}} \frac{\partial \psi}{\partial z}$	$\frac{1}{\sqrt{2}} \frac{\partial \psi}{\partial t}$	$\frac{1}{\sqrt{2}} \frac{\partial \psi}{\partial x}$	$\frac{1}{\sqrt{2}} \frac{\partial \psi}{\partial y}$	$\frac{1}{\sqrt{2}} \frac{\partial \psi}{\partial z}$	$\frac{1}{\sqrt{2}} \frac{\partial \psi}{\partial t}$
---	---	---	---	---	---	---	---

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

slide 5 cancer	slide 5 DCIS	slide 5 normal	slide 6 cancer	slide 6 DCIS
----------------	--------------	----------------	----------------	--------------

1.2

0

0

2

1.5

1.5

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

Sample #	age	received	associated with	new	prognosis request
107	63				60
108	79		h91.307	add	60
109	55		h91.167		60
110	41		h91.307	add	60
111	49		h91.307		60
112	53		h91.273		60
113	61		h91.273		60
114	66				60
115	68				60
116	59	07/31/1996			60
117	56				60
118	49	07/31/1996			60
119	63				60
120	79				60
121	75				60
122	68				60
123	59				60
124	79				60
125	75				60
126	68	07/31/1996			60
127	59				60
128	56				60
129	49				60
130	63		h92.960	not add	60
131	79				60
132	75				60
133	68				60
134	59				60
135	79				60
136	75			1	60
137	68				60
138	59				60
139	68		h92.1146	add	60
140	59				60
141	56			1	60
142	49			1	60
143	63			1	60
144	63			1	60
145	66				60
146	67				60
147	72				60
148	79				60
149	75			1	60
150	68			1	60
151	77			1	60
152	76			1	60
153	63	07/31/1996			60
154	62			1	60
155	63			1	60
156	66			1	60
157	67			1	60
158	72			1	60
159	79			1	60

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

remarks

2: frozen but foto cribriform
 2 blocks w.o. sections
 Cancer here too small

SEARCH FOR PREVIOUS BIOPSY!

SEARCH FOR PREVIOUS BIOPSY!, dcis small but feasible

SEARCH FOR PREVIOUS BIOPSY!, dcis too small for punching, lymphangiosis carcinomatosa
 only one section, was used for frozen

SEARCH FOR PREVIOUS BIOPSY! Only very small cancer in this biopsy, already punched to death
 dob 2.1.08

dob 19.8.35
 ductal?

primary tumor missing

difficult first path says mixed
 difficult

useful

a bit atrophic breast tissue

epithelium rich suited for array

residual tumor
 shipped incomplete,

Table 12

bcl-2a Breast Cancer TMA data Oncology Data[illegible]

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

secondary type	Tub GS	Poly GS	mito gs	DCIS type
cribriform	1	2	1	cribriform low
	3	2	1	
	3	2	1	
mucinous	3	2	1	comedo high
	2	2	2	
	3	3		
	3	3	3	
	1	2	1	
	2	2	1	
	3	2	1	
lobular	3	3	3	
	2	1	1	
	3	3	1	
	3	3	2	
	3	2	1	
	3	2	1	
	3	2	1	
ductal	3	2	1	
	3	2	1	
	3	2	1	
ductal	3	2	1	
	3	2	1	
	3	2	1	
	3	2	1	
	3	3	1	comedo high
	3	3	2	
	3	3	2	
d	1	2	1	

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

tumor slides	dcis slides	lcis slides
1; 2 fs ?	1	
1; 2; 3; 5 1		
1; 2; 3 2; 3 1 fs 1	1	
1; 2 1		
1; 2; 3 1; 2; 3		
1; 2; b91.7829 (1-4) 1; 2; and b91.6507 V-XI		
1; 2; 3 1		
1; 2; 3; 4 1; 2 1; 2 1; 2; 3 1 1		1; 2 1 small
1; 2; 3		
1 1; 2 1	1; 2	
1; 2 1; 2; 3		
1; 2; 3 1 2 1		

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

mastopathia slides	normal slides	meta slides
		h91.427
		6
		4; 6
		3; 4; 5; 6
		b91.7829
		b91.6507
		2; 3
		3
		h92.1092
	2	
	1; 2; 3	
	1	
		2; 3; 4; 5; 6
	1	
	1; 2	
	1; 2	
1 to 5	1 to 5	

distant meta normal skin normal mamilla normal nodes normal muscle

2 3

FOR THE RECORD

3

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

others

1; 2; 3; 4; 5 scar formation, fat necrosis

4; 5 scar formation, fat necrosis

1: fibroadenoma

1: lactating breast

1; 2: ductectasia (0,5 each)

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

cut slides	slide 1 cancer
1	0.4
2; 3	0
6	
1; 2; 3; 4	0.3
1	0.3
1; 2	wait until first bx arrives,. Not too useful
2	0.3
1	0.2
all	1
1	1.5
1	1.3
	2
	0.6
1	1.2
	0.4
	0.5
1	0.7
1; 2; 3	2.5
1	1.5
1	2
	2
	1
	1.5
	0.9
	1
	0.5
	3
	2
1	2.5
1; 2; 3; 4; 5; 6	1.5
	3: fibroadenoma
1	0.7

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

slide 1 DCIS	slide 1 normal	slide 2 cancer
0.3	0	0.4
0	0	0.3
0	0	wait until first bx arrives,. Not too useful
0	0	0.5
0	0	2
0	0	0.5
0	0	1
0	0	0.4
0	0	2
0	0	0.7
0	0	0.8
0	0	
		1.5
0.8		0
		0.8
0	0	
	0.8	2
	0.8	0.6
	1.5	
	0.4	
	0.8	
	1.2	
	0.8	

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

slide 2 DCIS	slide 2 normal	slide 3 cancer	slide 3 DCIS
0	0	0.3	0
0	0	0.2	0
0	0	1	0
0	0	1.3	
0	0		
0	0	0.3	0
0	0	3	0
		0.7	
		.8	
		1.5	
0.8	0.3		
	0.5	1	
	1		
	0.5		
	1		
	0.8		

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

slide 3 normal	slide 4 cancer	slide 4 DCIS	slide 4 normal
0			
0	1.5	0	0
0	0.7	0	0
0			
0			
	0.5		
0.7			
0.5			0.3
0.7			0.6

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

slide 5 cancer	slide 5 DCIS	slide 5 normal	slide 6 cancer	slide 6 DCIS
----------------	--------------	----------------	----------------	--------------

0.3			2 0.5	0
-----	--	--	----------	---

0.5	0	0	0.2	0
-----	---	---	-----	---

0.6

0.6

0596573:002634

SECRET

SECRET

[illegible]

2nd mito gs

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

HER-2/Neu	ER
Neg	Neg
Neg	Neg
Neg	Neg
Pos	Pos
Pos	Pos
Pos	Pos
Pos	Pos
Pos	Pos
Pos	Pos
Pos	Pos
Pos	Pos
Pos	Pos
Neg	Neg
Neg	Neg
Neg	Neg
Pos	Pos
Pos	Pos
Neg	Neg
Neg	Neg
Neg	Neg
Pos	Pos
Pos	Pos
Pos	Pos
Pos	Pos
Pos	Pos
Pos	Neg
Pos	Neg
Neg	Pos
Neg	Pos
Pos	Pos
Pos	Pos
Pos	Pos
Pos	Neg
Pos	Neg
Neg	Neg
Neg	Neg
Neg	Neg
Neg	Neg
Neg	Neg
Pos	Neg
Pos	Pos
Pos	Neg
Pos	Neg
Neg	Pos
Neg	Pos
Neg	Pos
Pos	Pos
Pos	Pos
Pos	Neg
Pos	Neg
Neg	Neg
Neg	Neg
Neg	Pos
Neg	Pos

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

Sample #	age	received	associated with	new	prognosis request
160	75			1	60
161	68			1	60
162	75			1	60
163	68			1	60
164	59			1	60
165	56			1	60
166	49			1	60
167	63			1	60
168	79			1	60
169	75			1	60
170	68		h87.306		60
171	59				60
172	79				60
173	75				60
174	68	07/31/1996			60
175	59			1	60
176	75			1	60
177	68			1	60
178	59				60
179	79			1	60
180	68			1	60
181	66			1	60
182	67				60
183	72			1	60
184	79				60
185	75	07/31/1996			60
186	68				60
187	59				60
188	56				60
189	49				60
190	63				60
191	66				60
192	79				60
193	55	07/31/1996			60
194	53				60
195	82			1	60
196	62				60
197	63	07/31/1996			60
198	66	07/31/1996			60
199	68	07/31/1996			60
200	75	07/31/1996			60
201	68	07/31/1996			60
202	59	07/31/1996			60
203	56				60
204	68				60
205	59				60
206	56				60
207	49				60
208	63		h91.273		60
209	66		h92.636		60
210	79	07/31/1996			60
211	63	07/31/1996			60
212	66			1	60

3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600 601 602 603 604 605 606 607 608 609 610 611 612 613 614 615 616 617 618 619 620 621 622 623 624 625 626 627 628 629 630 631 632 633 634 635 636 637 638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 653 654 655 656 657 658 659 660 661 662 663 664 665 666 667 668 669 670 671 672 673 674 675 676 677 678 679 680 681 682 683 684 685 686 687 688 689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 733 734 735 736 737 738 739 740 741 742 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 759 760 761 762 763 764 765 766 767 768 769 770 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 788 789 790 791 792 793 794 795 796 797 798 799 800 801 802 803 804 805 806 807 808 809 810 811 812 813 814 815 816 817 818 819 820 821 822 823 824 825 826 827 828 829 830 831 832 833 834 835 836 837 838 839 840 841 842 843 844 845 846 847 848 849 850 851 852 853 854 855 856 857 858 859 860 861 862 863 864 865 866 867 868 869 870 871 872 873 874 875 876 877 878 879 880 881 882 883 884 885 886 887 888 889 890 891 892 893 894 895 896 897 898 899 900 901 902 903 904 905 906 907 908 909 910 911 912 913 914 915 916 917 918 919 920 921 922 923 924 925 926 927 928 929 930 931 932 933 934 935 936 937 938 939 940 941 942 943 944 945 946 947 948 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 967 968 969 970 971 972 973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000 1001 1002 1003 1004 1005 1006 1007 1008 1009 1010 1011 1012 1013 1014 1015 1016 1017 1018 1019 1020 1021 1022 1023 1024 1025 1026 1027 1028 1029 1030 1031 1032 1033 1034 1035 1036 1037 1038 1039 1040 10

[illegible]

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

remarks

normal glands quite diluted, not every punch will hit

mild mastopathia

very large normal tissue areas, search for primary tumor
 jejunal meta
 lung meta of h89.411
 difficult, clarify

slight fibrosis and mild sclerosing adenosis
 normal glands quite diluted, not every punch will hit

extensive sclerosing adenosis, intraductal involvement difficult to see in sclerosing adenosis
 differential diagnosis: papillary tumor

2: frozen but larger than 1
 high grade, same as h88.146

dcis
 dcis
 DCIS
 dcis
 dcis
 dcis
 dcis
 dcis
 dcis

SEARCH FOR PREVIOUS BIOPSY! dcis too small to be used

SEARCH FOR PREVIOUS BIOPSY!,
 microinvasion?
 Small foci of microinvasion
 dcis quite small

dob 16.8.25

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

pT	pN	nodes all	nodes pos	diameter/mm	surgery
1	0		0		
1	0		0		
1	0		0		
1	0		0		
1	0		0		
1	0		0		
1	0		0		
1	0		0		
1	0		0		
1	0		0		
1	0		0		I
1	0		0		
1	0		0	20	lumpectomy
1	0		0	?	I
1	0	15	0		m
1	0		0		
1	0	14	0		
1	0		0		
1	0		0		
1	0		0		
1	0		0		
1	0		0	35	I
1	0		0		
1	0		0		
1	0	x	0	65	mastectomy
1	0	5	0	15	mastectomy
1	0	0	0	8	lumpectomy
1	0	14	0	15	mastectomy
1	0	14	0	6	mastectomy
1	0		0	9	I
1	0		0	9	lumpectomy
1	0		0		
1	0	15	0	x	lumpectomy
1	0		0		I
1	0	20	0	x	mastectomy
1	0		0		
1	0		0		
1	0		0		
1	0		0		
1	0		0		
1	0		0		
1	0	0	0	x	lumpectomy
1	0	15	0	19	lumpectomy
1	0		0	x	x
1	0	12	0	24	lumpectomy
1	0		0	5	lumpectomy
1	0		0		lumpectomy
1	0	12	0		mastectomy
1	0		0		
1	0		0	1	
1	0		0		
1	0		0		

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

resection border	array	Histotyp GS	sex	category
		ductal	f	ca
		ductal		ca
		ductal		ca
		ductal	f	ca
		ductal		ca
		ductal		ca
		ductal		ca
		ductal	f	ca
		ductal	f	ca
		ductal		ca
f	y	ductal	f	ca
		ductal	f	ca
		ductal	f	ca
	BR50	ductal	f	ca
pos		ductal		ca
f	no	ductal		ca
		ductal		ca
		ductal		ca
	ev	ductal	f	ca
	y	ductal	f	ca
		ductal		ca
		ductal		ca
n	y	ductal	f	ca
		ductal		ca
		ductal	f	ca
		ductal		ca
free	BR50	ductal	f	ca
free	BR50	ductal	f	ca
free	ev	ductal	f	ca
free	n	ductal	f	ca
free	n	ductal	f	ca
n	y	ductal	f	ca
	BR50	ductal	f	ca
		ductal		ca
free	ev	ductal	f	ca
f	ev	ductal		ca
free		ductal	f	ca
		ductal		ca
		ductal		ca
		ductal		ca
		ductal		ca
		ductal		ca
		ductal		ca
		ductal		ca
		ductal	f	ca
free		ductal	f	ca
		ductal	f	ca
free		ductal	f	ca
not free		ductal	f	ca
free		ductal	f	ca
free		ductal	f	ca
		ductal		ca
		ductal		ca
	n	ductal		ca

0
0
0
0
0
0
0
=
0
0
0
0
0
0

0
0
0
0
0
0
0
=
0
0
0
0
0
0

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

tumor slides	dcis slides	lcis slides
--------------	-------------	-------------

1; 2; 3; 4		
------------	--	--

1 to 5		
--------	--	--

1; 2		
------	--	--

1 to 6		
--------	--	--

1; 2; 3		
---------	--	--

1		
---	--	--

	1 to 4	
--	--------	--

1	1; 2; 3	
---	---------	--

1		
---	--	--

1; 2 fs		
---------	--	--

	1; 2; 3	
--	---------	--

	1; 2; 3; 4	
--	------------	--

	1	
--	---	--

	1	
--	---	--

	1	
--	---	--

	1; 2	
--	------	--

	1; 2	
--	------	--

	1; 3	
--	------	--

2		
---	--	--

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

mastopathia slides	normal slides 1; 2; 3	meta slides
	1 to 6	
1; 2; 3		
1 to 7	1 to 7	
	1 to 11	
	1	
	1; 2; 3	
	b91.5863	b91.5863

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

distant meta normal skin normal mamilla normal nodes normal muscle

1; 2; 3; 4; 5
1

2

1

2

2

096673-092604

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

others

6: no jejunum

1; 2; 3; 4: 5: massive sclerosing adenosis

2: fat necrosis

1 scar formation, fat necrosis

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

cut slides	slide 1 cancer
1; 6	2
1	2
1	0.9
	0
	1.5
1; 2	1.5
	1.2
	0.8
	0.3
	0
1	0.3
1	0.5
	0
1; 2; 3; 4	
1	
1	
1	
1; 2	0
1; 2; 3	0.1

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

slide 1 DCIS	slide 1 normal 0.8	slide 2 cancer
	2	
	2.5	
0	0	
0	0	
0	1	0
	1	
	3	
		2
0.4	0	0.6
0	0	1.3
0	0	0.8
0	0	0
1	0	0
0.6	0	0
0	0	
0.7	0	0
0.7		
0.1		
0.3		
0.3		
0.4	0	0
0.5	0	0
0.3		

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

slide 2 DCIS	slide 2 normal 0.8	slide 3 cancer	slide 3 DCIS
	2.5		
	1.5		
0	1.3	0	0
	2.5		
		1.5	
0			
0	0	1	0
0	0	0.3	0
0	0	0	0
1	0	0	0.7
0.9	0	0	0.4
0.4	0	0	0.5
0.5			0.4
0.2	0		0
0.7	0	1.3	0.5

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

slide 3 normal	slide 4 cancer	slide 4 DCIS	slide 4 normal
0.8			
1.5			1
0.7			0.4
1	0	0	0.8
3	2		
0	1.2	0	0
0	0	0	0
0	0	?	0
0			
0			
		0.7	
0			

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

slide 5 cancer slide 5 DCIS slide 5 normal slide 6 cancer slide 6 DCIS

1.3

0	0	0.8	0	0
1				
1	0	0	0.4	0
0	0	0		

$$\frac{1}{\Gamma} \frac{d\Gamma}{d\ln Q^2} = \frac{1}{\Gamma} \frac{d\Gamma}{d\ln Q^2} \bigg|_{\text{LO}} + \frac{1}{\Gamma} \frac{d\Gamma}{d\ln Q^2} \bigg|_{\text{NLO}} + \frac{1}{\Gamma} \frac{d\Gamma}{d\ln Q^2} \bigg|_{\text{NNLO}} + \dots$$
$$\frac{1}{\Gamma} \frac{d\Gamma}{d\ln Q^2} = \frac{1}{\Gamma} \frac{d\Gamma}{d\ln Q^2} \bigg|_{\text{LO}} + \frac{1}{\Gamma} \frac{d\Gamma}{d\ln Q^2} \bigg|_{\text{NLO}} + \frac{1}{\Gamma} \frac{d\Gamma}{d\ln Q^2} \bigg|_{\text{NNLO}} + \dots$$

[illegible]

Figure 1

2nd mito gs

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

Sample #	age	received	associated with	new	prognosis request
213	68			1	60
214	75			1	60
215	68	07/31/1996			60
216	56			1	60
217	68			1	60
218	59			1	60
219	56			1	60
220	49			1	60
221	63			1	60
222	66			1	60
223	79			1	60
224	55			1	60
225	53			1	60
226	61	07/31/1996			60
227	68	07/31/1996			60
228	59	07/31/1996			60
229	56	07/31/1996			60
230	68			1	60
231	59			1	60
232	56			1	60
233	68			1	60
234	75			1	60
235	68			1	60
236	59			1	60
237	56			1	60
238	68			1	60
239	59			1	60
240	56			1	60
241	49			1	60
242	63				60
243	66				60
244	79				60
245	55				60
246	53				60
247	61				60
248	68				60
249	59				60
250	56		h87.264		60
251	68				60
252	56				60
253	49				60
254	56				60
255	49				60
256	63				60
257	66		h91.939		60
258	79				60
259	55				60
260	53				60
261	61				60
262	68				60
263	59				60
264	56				60
265	68				60

[illegible]

only fragments of cancer

residual cancer contained in bx

residual tumor

very small dcis
cancer previously resected
SEARCH FOR PREVIOUS BIOPSY!, meta

SEARCH FOR PREVIOUS BIOPSY!

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

pT	pN	nodes all	nodes pos	diameter/mm	surgery
1	0		0		
1	0		0		I
1	0		0		
1	0		0		
1	0		0		
1	0		0		
1	0		0		
1	0		0		
1	0		0		
1	0		0		
1	0		0		
1	0		0		
1	0		0		
1	0		0		
1	0	11	0		mast
1	0	13	0		m
1	0	7	0		
1	0		0		
1	0		0		
1	0		0		
1	0		0		
1	0		0		
1	0		0		
1	0		0		
1	0		0		
1	0		0		
1	0		0		
1	0		0		
1	0		0		
1	0		0		
1	0		0		
1	0		0		
1	0		0		
1	0	22	0		mastectomy
1	0		0		I
1	0		0		
1	0		0		
1	0		0		
1	0		0		
1	0		0		
1	0		0		
1	0		0		
1	0		0		
1	0		0		
1	0		0		
1	0	15	0	x	mastectomy
1	0	9	0		lumpectomy
1	0		0		
1	0		0		
1	0		0		
1	0	5	0	x	mastectomy
1	0	?	0	x	lumpectomy
1	0	24	0	x	lumpectomy
1	0		0		
1	0		0		

[illegible][illegible]

FOR THE
FEDERAL
BUREAU OF
INVESTIGATION
U. S. DEPARTMENT OF JUSTICE

1. **Introduction**
 2. **Background**
 3. **Methodology**
 4. **Results**
 5. **Discussion**
 6. **Conclusion**
 7. **References**
 8. **Appendix**
 9. **Index**
 10. **Table of Contents**
 11. **Figure 1**
 12. **Figure 2**
 13. **Figure 3**
 14. **Figure 4**
 15. **Figure 5**
 16. **Figure 6**
 17. **Figure 7**
 18. **Figure 8**
 19. **Figure 9**
 20. **Figure 10**
 21. **Figure 11**
 22. **Figure 12**
 23. **Figure 13**
 24. **Figure 14**
 25. **Figure 15**
 26. **Figure 16**
 27. **Figure 17**
 28. **Figure 18**
 29. **Figure 19**
 30. **Figure 20**
 31. **Figure 21**
 32. **Figure 22**
 33. **Figure 23**
 34. **Figure 24**
 35. **Figure 25**
 36. **Figure 26**
 37. **Figure 27**
 38. **Figure 28**
 39. **Figure 29**
 40. **Figure 30**
 41. **Figure 31**
 42. **Figure 32**
 43. **Figure 33**
 44. **Figure 34**
 45. **Figure 35**
 46. **Figure 36**
 47. **Figure 37**
 48. **Figure 38**
 49. **Figure 39**
 50. **Figure 40**
 51. **Figure 41**
 52. **Figure 42**
 53. **Figure 43**
 54. **Figure 44**
 55. **Figure 45**
 56. **Figure 46**
 57. **Figure 47**
 58. **Figure 48**
 59. **Figure 49**
 60. **Figure 50**
 61. **Figure 51**
 62. **Figure 52**
 63. **Figure 53**
 64. **Figure 54**
 65. **Figure 55**
 66. **Figure 56**
 67. **Figure 57**
 68. **Figure 58**
 69. **Figure 59**
 70. **Figure 60**
 71. **Figure 61**
 72. **Figure 62**
 73. **Figure 63**
 74. **Figure 64**
 75. **Figure 65**
 76. **Figure 66**
 77. **Figure 67**
 78. **Figure 68**
 79. **Figure 69**
 80. **Figure 70**
 81. **Figure 71**
 82. **Figure 72**
 83. **Figure 73**
 84. **Figure 74**
 85. **Figure 75**
 86. **Figure 76**
 87. **Figure 77**
 88. **Figure 78**
 89. **Figure 79**
 90. **Figure 80**
 91. **Figure 81**
 92. **Figure 82**
 93. **Figure 83**
 94. **Figure 84**
 95. **Figure 85**
 96. **Figure 86**
 97. **Figure 87**
 98. **Figure 88**
 99. **Figure 89**
 100. **Figure 90**
 101. **Figure 91**
 102. **Figure 92**
 103. **Figure 93**
 104. **Figure 94**
 105. **Figure 95**
 106. **Figure 96**
 107. **Figure 97**
 108. **Figure 98**
 109. **Figure 99**
 110. **Figure 100**
 111. **Figure 101**
 112. **Figure 102**
 113. **Figure 103**
 114. **Figure 104**
 115. **Figure 105**
 116. **Figure 106**
 117. **Figure 107**
 118. **Figure 108**
 119. **Figure 109**
 120. **Figure 110**
 121. **Figure 111**
 122. **Figure 112**
 123. **Figure 113**
 124. **Figure 114**
 125. **Figure 115**
 126. **Figure 116**
 127. **Figure 117**
 128. **Figure 118**
 129. **Figure 119**
 130. **Figure 120**
 131. **Figure 121**
 132. **Figure 122**
 133. **Figure 123**
 134. **Figure 124**
 135. **Figure 125**
 136. **Figure 126**
 137. **Figure 127**
 138. **Figure 128**
 139. **Figure 129**
 140. **Figure 130**
 141. **Figure 131**
 142. **Figure 132**
 143. **Figure 133**
 144. **Figure 134**
 145. **Figure 135**
 146. **Figure 136**
 147. **Figure 137**
 148. **Figure 138**
 149. **Figure 139**
 150. **Figure 140**
 151. **Figure 141**
 152. **Figure 142**
 153. **Figure 143**
 154. **Figure 144**
 155. **Figure 145**
 156. **Figure 146**
 157. **Figure 147**
 158. **Figure 148**
 159. **Figure 149**
 160. **Figure 150**
 161. **Figure 151**
 162. **Figure 152**
 163. **Figure 153**
 164. **Figure 154**
 165. **Figure 155**
 166. **Figure 156**
 167. **Figure 157**
 168. **Figure 158**
 169. **Figure 159**
 170. **Figure 160**
 171. **Figure 161**
 172. **Figure 162**
 173. **Figure 163**
 174. **Figure 164**
 175. **Figure 165**
 176. **Figure 166**
 177. **Figure 167**
 178. **Figure 168**
 179. **Figure 169**
 180. **Figure 170**
 181. **Figure 171**
 182. **Figure 172**
 183. **Figure 173**
 184. **Figure 174**
 185. **Figure 175**
 186. **Figure 176**
 187. **Figure 177**
 188. **Figure 178**
 189. **Figure 179**
 190. **Figure 180**
 191. **Figure 181**
 192. **Figure 182**
 193. **Figure 183**
 194. **Figure 184**
 195. **Figure 185**
 196. **Figure 186**
 197. **Figure 187**
 198. **Figure 188**
 199. **Figure 189**
 200. **Figure 190**
 201. **Figure 191**
 202. **Figure 192**
 203. **Figure 193**
 204. **Figure 194**
 205. **Figure 195**
 206. **Figure 196**
 207. **Figure 197**
 208. **Figure 198**
 209. **Figure 199**
 210. **Figure 200**
 211. **Figure 201**
 212. **Figure 202**
 213. **Figure 203**
 214. **Figure 204**
 215. **Figure 205**
 216. **Figure 206**
 217. **Figure 207**
 218

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

tumor slides	dcis slides	lcis slides
--------------	-------------	-------------

00966372-002801

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

mastopathia slides

normal slides

meta slides

14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

distant meta	normal skin	normal mamilla	normal nodes	normal muscle
--------------	-------------	----------------	--------------	---------------

	3			
--	---	--	--	--

		3		
--	--	---	--	--

			4	
--	--	--	---	--

				1; 2; 3
--	--	--	--	---------

				1; 2; 3
--	--	--	--	---------

				2
--	--	--	--	---

Abstract

1; 3 scar formation, 2; 3 fat necrosis

1; 2: scar formation

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

cut slides

slide 1 cancer

1

0

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

slide 1 DCIS

slide 1 normal

slide 2 cancer

0

1.5

slide 4 normal

229

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

slide 5 cancer	slide 5 DCIS	slide 5 normal	slide 6 cancer	slide 6 DCIS
----------------	--------------	----------------	----------------	--------------

20060721-000001

[illegible][illegible]

2nd DCIS type	2nd Tub GS	2nd Poly GS	2nd mito gs
1	1	1	1
2	2	2	2
3	3	3	3
4	4	4	4
5	5	5	5
6	6	6	6
7	7	7	7
8	8	8	8
9	9	9	9
10	10	10	10
11	11	11	11
12	12	12	12
13	13	13	13
14	14	14	14
15	15	15	15
16	16	16	16
17	17	17	17
18	18	18	18
19	19	19	19
20	20	20	20
21	21	21	21
22	22	22	22
23	23	23	23
24	24	24	24
25	25	25	25
26	26	26	26
27	27	27	27
28	28	28	28
29	29	29	29
30	30	30	30
31	31	31	31
32	32	32	32
33	33	33	33
34	34	34	34
35	35	35	35
36	36	36	36
37	37	37	37
38	38	38	38
39	39	39	39
40	40	40	40
41	41	41	41
42	42	42	42
43	43	43	43
44	44	44	44
45	45	45	45
46	46	46	46
47	47	47	47
48	48	48	48
49	49	49	49
50	50	50	50
51	51	51	51
52	52	52	52
53	53	53	53
54	54	54	54
55	55	55	55
56	56	56	56
57	57	57	57
58	58	58	58
59	59	59	59
60	60	60	60
61	61	61	61
62	62	62	62
63	63	63	63
64	64	64	64
65	65	65	65
66	66	66	66
67	67	67	67
68	68	68	68
69	69	69	69
70	70	70	70
71	71	71	71
72	72	72	72
73	73	73	73
74	74	74	74
75	75	75	75
76	76	76	76
77	77	77	77
78	78	78	78
79	79	79	79
80	80	80	80
81	81	81	81
82	82	82	82
83	83	83	83
84	84	84	84
85	85	85	85
86	86	86	86
87	87	87	87
88	88	88	88
89	89	89	89
90	90	90	90
91	91	91	91
92	92	92	92
93	93	93	93
94	94	94	94
95	95	95	95
96	96	96	96
97	97	97	97
98	98	98	98
99	99	99	99
100	100	100	100

233

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

Sample #	age	received	associated with	new	prognosis request
266	78				60
267	79				60
268	55				60
269	53				60
270	82				60
271	62				60
272	63				60
273	66			1	60
274	67			1	60
275	72			1	60
276	79		h92.960		60
277	75	07/31/1996			60
278	68				60
279	59				60
280	56				60
281	49				60
282	63		h87.1535		60
283	79				60
284	55		b89.6893		60
285	53		b89.8602		60
286	82		b91.2889		60
287	62		b91.5691		60
288	66		b91.6053		60
289	67		b91.5890		60
290	63		h87.1180		60
291	66				60
292	67				60
293	72				60
294	79				60
295	75				60
296	68				60
297	77				60
298	76				60
299	63				60
300	62				60
301	63				60
302	66				60
303	67				60
304	72				60
305	79				60
306	75				60
307	68				60
308	75				60
309	68				60
310	59				60
311	56				60
312	49				60
313	63				60
314	79				60
315	75				60
316	68				60
317	59				60
318	79				60

1. The first part of the document is a list of references. The references are listed in a standard format, with the author's name, the title of the work, and the publisher. The references are as follows:

most likely non invasive DCIS

Many meta of lobular cancer
recurrence, get primary tumor: b86.3889, dob 23.10.23

residual cancer.

237

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

pT	pN	nodes all	nodes pos	diameter/mm	surgery
1	0	15	0	x	lumpectomy
1	0		0		
1	0		0		
1	0		0		
1	0	0	0	25	lumpectomy
1	0		0	7	lumpectomy
1	0		0		
1	0		0		
1	0		0		
1	0		0		
1	0	21	0	x	mastectomy
1	0		0	3?	I
1	0	0	0	10	mastectomy
1	0		0	23	lumpectomy
1	0		0		
1	0		0		lumpectomy
1	0		0	h87.1535	m
1	0	15	0	6	mastectomy
1	0		0		
1	0		0		
1	0		0		
1	0		0		
1	0		0		
1	0		0		
1	0	many	0		m
1	0		0		
1	0	9	0		m
1	0		0		m
1	0		0		
1	0		0		
1	0		0		
1	0		0		
1	0		0		mastectomy
1	0		0		mastectomy
1	0		0		mastectomy
1	0		0		mastectomy
1	0		0		mastectomy
1	0		0		mastectomy
1	0	19	0		mastectomy
1	0	8	0		mastectomy
1	0	20	0		mastectomy
1	0	18	0		mastectomy
1	0	7	0		mastectomy
1	0	10	0		mastectomy
1	0	8	0		mastectomy
1	0	0	0		mastectomy
1	0	0	0		mastectomy
1	0	21	0		mastectomy
1	0	17	0		mastectomy
1	0	4	0		mastectomy
1	0	0	0		mastectomy
1	0	0	0		mastectomy
1	0		0		mastectomy
1	0		0		mastectomy
1	0		0		mastectomy

Figure 1. The effect of the number of iterations (n) on the accuracy of the proposed algorithm. The error is defined as the difference between the exact solution and the numerical solution. The error decreases as the number of iterations increases.

239

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

secondary type	Tub GS	Poly GS	mito gs	DCIS type
	1	2	1	solid, crib low
	1	2	1	
	3	2	1	
	5			
	3			
	3			
	3			
	2			
	2	1		
	1	1		
	3	1		
	2	2		
	2	1		
	3	2		
	3	2		
	2	2		
	3	1		
	3	1		
	3	1		
	3	1		
	3	3		
	3	2		
	2	2		
	3	1		
	3	2		
	2	2		
	3	1		
	3	1		
	1	1		

0906077-002001

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

tumor slides	dcis slides	lcis slides
--------------	-------------	-------------

1 to 13

1; 2
1

1; 2
1; 2; 3
1

3; 4; 5

1

1; 2

4

3

5 to 11
1; 2; 3; 4

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

distant meta	normal skin	normal mamilla	normal nodes 1	normal muscle 2; 3
--------------	-------------	----------------	-------------------	-----------------------

1

0966672-096601

[illegible]

2: scar formation

1: papillomatosis (DM 0,7)

4: difficult dcis, lobular cancerisation, and invasive component

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

cut slides	slide 1 cancer
	0.6
	0.6
	0.6
all	0.5
1	0.8
	0.3
	1.2
	1.8
	2
	0.5
	2
	0.7
	3
1	3
1	2.5

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

slide 1 DCIS	slide 1 normal	slide 2 cancer
0	0	0.3
	1.5	0.3
	0.8	
0	0	0.4
0	0	
		1
0	0	0.5
0	0	2
0	0	0.7
0	0	0
0	0	1.5
0	0	0.5
		2
		1

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

slide 2 DCIS	slide 2 normal	slide 3 cancer	slide 3 DCIS
--------------	----------------	----------------	--------------

0

0

0

0

0

2.5

2

0

0

0

0

0

0

0.8

0

0

0.4

0

0

0

0

1

0

0

0

0.2

0

2

2.8

0996672 000001

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

slide 3 normal	slide 4 cancer	slide 4 DCIS	slide 4 normal
0	0	1	0
3			
0.6	0	0	0.6
0.3			
0	0.4	0	0
0	0.5	0	0
	1.5		

00000000000000000000000000000000

0	1	0		
0	0	0.6	0	0
1	0	0	1	0
0.3	0	0		

[illegible][illegible]

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

BR50 pos	BNr1 status	Chemotherapy	Radiation	Hormonal
54	ok	NA	NA	NA
		NA	NA	NA
		NA	NA	NA
		NA	NA	NA
		NA	NA	NA
		NA	NA	NA
		NA	NA	NA
		NA	NA	NA
		NA	NA	NA
		NA	NA	NA
	ok	NA	NA	NA
		NA	NA	NA
		NA	NA	NA
		NA	NA	NA
		NA	NA	NA
		NA	NA	NA
		NA	NA	NA
		NA	NA	NA
		NA	NA	NA
		NA	NA	NA
	ok	NA	NA	NA
		NA	NA	NA
		NA	NA	NA
		NA	NA	NA
		NA	NA	NA

100290-2299660

2nd mito gs

[illegible]

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

Sample #	age	received	associated with	new	prognosis request
319	75				60
320	68				60
321	59				60
322	75				60
323	68				60
324	68				60
325	59				60
326	79				60
327	75				60
328	79				60
329	75				60
330	68				60
331	59				60
332	75				60
333	68				60
334	59				60
335	79				60
336	75				60
337	68				60
338	66				60
339	67				60
340	72				60
341	76				60
342	63				60
343	62				60
344	63				60
345	66				60
346	67				60
347	72				60
348	79				60
349	75				60
350	79				60
351	75				60
352	68				60
353	75				60
354	69				60
355	77				60
356	76				60
357	63				60
358	66				60
359	67				60
360	79				60

100250 " 24494949

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

remarks

residual cancer contained in bx

SEARCH FOR PREVIOUS BIOPSY!
SEARCH FOR PREVIOUS BIOPSY!

residual tumor

after h90.632
too small

very small dcis
cancer previously resected
SEARCH FOR PREVIOUS BIOPSY!, meta

very small dcis
! small residual tumor
SEARCH FOR PREVIOUS BIOPSY!

SEARCH FOR PREVIOUS BIOPSY!

most likely non invasive DCIS

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

secondary type	Tub GS	Poly GS	mito gs	DCIS type
		2		
		3		
		3		
		2		
		3		
		3		
		3		
		3		
		3		
		3		
		2		
		3		
		3		

09966373-092604

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

tumor slides

dcis slides lcis slides

Appendix A

Table 12

bcl-2a Breast Cancer TMA data Oncology Data

[illegible]

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

mastopathia slides

normal slides

meta slides

[illegible]

1. *What is the purpose of the study?*
 2. *What are the research objectives?*
 3. *What is the research design?*
 4. *What are the variables?*
 5. *What is the sample size?*
 6. *What are the data sources?*
 7. *What are the data collection methods?*
 8. *What are the data analysis methods?*
 9. *What are the results?*
 10. *What are the conclusions?*
 11. *What are the limitations?*
 12. *What are the implications?*
 13. *What are the future research directions?*
 14. *What are the references?*
 15. *What are the appendices?*
 16. *What are the glossary?*
 17. *What are the abbreviations?*
 18. *What are the symbols?*
 19. *What are the units?*
 20. *What are the definitions?*
 21. *What are the notes?*
 22. *What are the footnotes?*
 23. *What are the endnotes?*
 24. *What are the acknowledgments?*
 25. *What are the acknowledgments?*
 26. *What are the acknowledgments?*
 27. *What are the acknowledgments?*
 28. *What are the acknowledgments?*
 29. *What are the acknowledgments?*
 30. *What are the acknowledgments?*
 31. *What are the acknowledgments?*
 32. *What are the acknowledgments?*
 33. *What are the acknowledgments?*
 34. *What are the acknowledgments?*
 35. *What are the acknowledgments?*
 36. *What are the acknowledgments?*
 37. *What are the acknowledgments?*
 38. *What are the acknowledgments?*
 39. *What are the acknowledgments?*
 40. *What are the acknowledgments?*
 41. *What are the acknowledgments?*
 42. *What are the acknowledgments?*
 43. *What are the acknowledgments?*
 44. *What are the acknowledgments?*
 45. *What are the acknowledgments?*
 46. *What are the acknowledgments?*
 47. *What are the acknowledgments?*
 48. *What are the acknowledgments?*
 49. *What are the acknowledgments?*
 50. *What are the acknowledgments?*
 51. *What are the acknowledgments?*
 52. *What are the acknowledgments?*
 53. *What are the acknowledgments?*
 54. *What are the acknowledgments?*
 55. *What are the acknowledgments?*
 56. *What are the acknowledgments?*
 57. *What are the acknowledgments?*
 58. *What are the acknowledgments?*
 59. *What are the acknowledgments?*
 60. *What are the acknowledgments?*
 61. *What are the acknowledgments?*
 62. *What are the acknowledgments?*
 63. *What are the acknowledgments?*
 64. *What are the acknowledgments?*
 65. *What are the acknowledgments?*
 66. *What are the acknowledgments?*
 67. *What are the acknowledgments?*
 68. *What are the acknowledgments?*
 69. *What are the acknowledgments?*
 70. *What are the acknowledgments?*
 71. *What are the acknowledgments?*
 72. *What are the acknowledgments?*
 73. *What are the acknowledgments?*
 74. *What are the acknowledgments?*
 75. *What are the acknowledgments?*
 76. *What are the acknowledgments?*
 77. *What are the acknowledgments?*
 78. *What are the acknowledgments?*
 79. *What are the acknowledgments?*
 80. *What are the acknowledgments?*
 81. *What are the acknowledgments?*
 82. *What are the acknowledgments?*
 83. *What are the acknowledgments?*
 84. *What are the acknowledgments?*
 85. *What are the acknowledgments?*
 86. *What are the acknowledgments?*
 87. *What are the acknowledgments?*
 88. *What are the acknowledgments?*
 89. *What are the acknowledgments?*
 90. *What are the acknowledgments?*
 91. *What are the acknowledgments?*
 92. *What are the acknowledgments?*
 93. *What are the acknowledgments?*
 94. *What are the acknowledgments?*
 95. *What are the acknowledgments?*
 96. *What are the acknowledgments?*
 97. *What are the acknowledgments?*
 98. *What are the acknowledgments?*
 99. *What are the acknowledgments?*
 100. *What are the acknowledgments?*

1. The first step is to identify the problem or question that needs to be addressed. This involves understanding the context and the specific requirements of the task.

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

others

0966273-092604

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

cut slides

slide 1 cancer

[illegible]

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

slide 1 DCIS

slid 1 normal

slide 2 cancer

09966373-092601

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

slide 2 DCIS

slide 2 normal

slide 3 cancer

slide 3 DCIS

00
40
40
07
07
W
W
W
W
00
40
W
00
00
00

09030306000

slide 4 cancer

slide 4 DCIS

slide 4 normal

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

slide 5 cancer	slide 5 DCIS	slide 5 normal	slide 6 cancer	slide 6 DCIS
----------------	--------------	----------------	----------------	--------------

0966373-092001

[illegible]

BNr second resection

Survival

[illegible]**BNr1 status**

Chemotherapy

Radiation

Hormonal

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

2nd DCIS type	2nd Tub GS	2nd Poly GS	2nd mito gs
---------------	------------	-------------	-------------

0996677.092604

Appendix A
Table 12
bcl-2a Breast Cancer TMA data Oncology Data

HER-2/Neu	ER
Pos	Pos
Pos	Pos
Pos	Neg
Neg	Neg
Neg	Neg
Pos	Neg
Pos	Pos
Pos	Pos
Pos	Pos
Pos	Neg
Pos	Neg
Pos	Pos
Neg	Pos
Neg	Pos
Neg	Pos
Neg	Pos
Pos	Pos
Neg	Pos
Neg	Pos
Neg	Neg
Neg	Pos
Neg	Neg
Pos	Neg
Pos	Pos
Pos	Pos
Neg	Pos
Neg	Neg
Pos	Neg
Pos	Neg
Pos	Neg
Neg	Pos
Neg	Pos
Neg	Pos
Neg	Pos
Pos	Pos
Pos	Pos
Pos	Neg
Pos	Neg

bcl-2a Case Controlled Study - Clinomics 3 Experiment Study - Oncology Array
Table 13
Scoring Sheet

Sample #	Experiment I	Experiment II	Experiment	HER-2/Neu	ER	Age
1	3/4	4/3	3/3	Neg	Neg	66
2	4/4	2/3	4/3	Neg	Neg	55
3	3/3	3/3	3/4	Neg	Neg	75
4	3/4	3/4	4/4	Neg	Neg	77
5	4/3	4/3	3/3	Neg	Pos	81
6	4/3	4/4	3/4	Neg	Pos	33
7	3/3	4/3	4/4	Pos	Pos	75
8	4/3	4/3	4/3	Pos	Pos	77
9	3/4	3/3	4/3	Pos	Neg	76
10	4/4	4/3	3/3	Pos	Neg	51
11	3/3	2/3	4/3	Neg	Neg	45
12	3/4	3/4	2/3	Neg	Pos	65
13	4/3	2/3	3/3	Neg	Pos	69
14	4/3	2/4	4/3	Pos	Pos	61
15	3/3	2/3	2/3	Pos	Neg	68
16	4/3	4/4	3/3	Pos	Neg	78
17	2/3	3/3	3/4	Pos	Neg	79
18	3/3	3/4	2/3	Pos	Pos	55
19	3/4	4/3	3/3	Pos	Pos	53
20	2/3	3/3	3/4	Neg	Pos	82
21	3/3	4/3	4/4	Neg	Pos	62
22	3/4	2/3	3/3	Pos	Pos	63
23	4/3	3/3	3/4	Pos	Pos	66
24	4/4	4/3	4/3	Pos	Neg	67
25	4/3	1/1	4/3	Pos	Neg	72
26	4/3	1/2	3/3	Pos	Pos	79
27	3/3	2/1	4/3	Pos	Pos	75
28	4/3	2/1	3/4	Pos	Pos	68
29	2/3	2/3	4/4	Pos	Pos	77
30	3/3	3/3	3/3	Pos	Pos	76
31	3/4	3/4	3/4	Pos	Pos	51
32	2/3	2/3	4/3	Neg	Pos	45
33	3/3	3/3	3/3	Neg	Pos	69
34	3/4	3/4	3/4	Neg	Neg	61

Table 13

bcl-2a Case Controlled Study - Clinomics 3 Experiment Study - Oncology Array

Scoring Sheet

Sample #	Experiment I	Experiment II	Experiment	HER-2/Neu	ER	Age
35	4/4	4/4	4/4	Neg	Neg	68
36	3/3	3/3	3/3	Neg	Neg	78
37	3/4	3/4	3/4	Neg	Neg	79
38	4/3	4/3	4/3	Pos	Pos	55
39	4/3	4/3	4/3	Pos	Pos	53
40	3/3	3/3	3/3	Pos	Pos	82
41	4/3	4/3	4/3	Pos	Pos	62
42	3/4	3/4	3/4	Neg	Neg	63
43	4/4	4/4	4/4	Neg	Neg	66
44	3/3	3/3	3/3	Neg	Neg	67
45	3/4	3/4	3/4	Neg	Neg	72
46	4/3	4/3	4/3	Neg	Neg	79
47	2/3	2/3	2/3	Pos	Pos	75
48	3/3	3/3	3/3	Pos	Pos	68
49	3/4	3/4	3/4	Pos	Pos	59
50	4/3	4/3	4/3	Neg	Neg	56
51	4/4	4/4	4/4	Neg	Neg	49
52	4/3	4/3	4/4	Neg	Neg	63
53	2/4	4/3	4/4	Neg	Neg	79
54	2/3	2/2	3/3	Neg	Neg	55
55	1/1	1/2	3/4	Neg	Neg	53
56	1/1	1/2	4/4	Neg	Neg	82
57	1/2	2/2	4/3	Neg	Neg	62
58	2/3	2/3	4/3	Neg	Neg	63
59	3/3	2/4	3/3	Neg	Neg	66
60	3/4	2/3	4/3	Neg	Neg	67
61	2/3	4/4	2/3	Neg	Neg	72
62	3/3	3/3	3/3	Neg	Neg	79
63	2/3	3/4	3/4	Neg	Neg	75
64	2/4	4/3	2/3	Neg	Neg	66
65	3/4	2/3	3/3	Neg	Neg	59
66	4/3	2/3	3/4	Neg	Neg	56
67	4/3	3/4	4/4	Neg	Neg	49
68	3/3	4/3	4/3	Neg	Neg	63
69	4/3	4/3	3/4	Neg	Neg	79

Table 13

bcl-2a Case Controlled Study - Clinomics 3 Experiment Study - Oncology Array

Scoring Sheet

Sample #	Experiment I	Experiment II	Experiment	HER-2/Neu	ER	Age
70	2/3	3/3	4/4	Neg	Neg	55
71	3/3	4/3	3/3	Neg	Neg	53
72	3/4	3/4	3/4	Neg	Neg	82
73	2/3	4/4	4/3	Neg	Neg	62
74	3/3	3/3	3/4	Neg	Neg	63
75	3/4	3/4	3/4	Neg	Neg	66
76	4/3	4/4	4/3	Neg	Neg	67
77	4/3	4/3	4/3	Neg	Neg	72
78	3/4	4/3	3/4	Neg	Neg	79
79	4/4	3/3	4/4	Pos	Pos	75
80	3/3	3/4	3/3	Neg	Neg	68
81	3/4	2/3	3/4	Neg	Neg	59
82	4/3	3/3	4/3	Neg	Neg	79
83	2/3	3/4	2/3	Neg	Neg	75
84	3/3	4/3	3/3	Neg	Neg	68
85	3/3	4/3	3/4	Pos	Pos	59
86	3/4	3/4	4/3	Pos	Pos	56
87	4/3	4/4	4/4	Neg	Neg	49
88	2/3	3/3	4/3	Neg	Neg	63
89	3/3	2/3	NA	Neg	Neg	66
90	3/4	2/2	3/3	Pos	Pos	79
91	4/3	2/3	4/3	Pos	Pos	55
92	4/4	3/3	2/3	Pos	Pos	53
93	4/3	3/4	3/4	Pos	Pos	82
94	2/3	4/3	4/3	Pos	Pos	62
95	2/2	4/4	4/3	Pos	Pos	63
96	3/3	4/3	3/3	Neg	Neg	66
97	4/3	4/3	NA	Neg	Neg	67
98	3/4	4/3	3/4	Pos	Pos	72
99	4/4	3/3	4/4	Pos	Pos	79
100	3/3	4/3	2/3	Pos	Pos	75
101	3/4	3/4	2/2	Pos	Pos	68
102	4/4	4/4	3/4	Pos	Pos	59
103	NA	3/3	4/4	Pos	Pos	56
104	4/3	3/4	3/3	Pos	Pos	49

Table 13
bcl-2a Case Controlled Study - Clinomics 3 Experiment Study - Oncology Array

Scoring Sheet

Sample #	Experiment I	Experiment II	Experiment	HER-2/Neu	ER	Age
105	3/3	4/4	3/4	Neg	Neg	79
106	4/3	4/3	4/3	Neg	Neg	55
107	2/3	4/3	2/3	Pos	Pos	41
108	3/3	3/3	3/3	Pos	Pos	49
109	3/4	4/3	3/4	Pos	Pos	53
110	2/3	2/3	4/3	Pos	Pos	61
111	3/3	3/3	4/4	Pos	Pos	66
112	3/4	3/4	4/3	Pos	Pos	68
113	4/4	2/3	4/3	Pos	Pos	59
114	3/3	3/3	3/3	Pos	Pos	56
115	3/4	3/4	4/3	Pos	Pos	49
116	4/3	4/4	2/3	Pos	Pos	63
117	4/3	4/3	3/4	Neg	Neg	79
118	3/3	3/4	4/3	Neg	Neg	75
119	4/3	4/4	4/3	Neg	Neg	68
120	3/4	3/3	3/3	Pos	Pos	59
121	4/4	3/4	4/3	Pos	Pos	79
122	3/3	4/3	2/3	Neg	Neg	75
123	3/4	3/4	3/3	Neg	Neg	68
124	4/3	4/4	3/4	Neg	Neg	59
125	3/4	3/3	4/3	Pos	Pos	56
126	4/4	3/4	4/4	Pos	Pos	49
127	3/3	4/3	4/3	Pos	Pos	63
128	3/4	2/3	4/3	Pos	Pos	79
129	4/3	3/3	3/4	Pos	Neg	75
130	2/3	3/4	4/4	Pos	Neg	68
131	3/3	4/3	3/3	Neg	Pos	59
132	3/4	4/4	3/4	Neg	Pos	79
133	4/3	4/3	4/3	Pos	Pos	75
134	4/4	4/3	2/3	Pos	Pos	68
135	4/3	3/3	3/3	Pos	Pos	59
136	4/3	4/3	3/4	Pos	Neg	68
137	3/3	3/3	4/3	Pos	Neg	59
138	4/3	3/4	4/4	Neg	Neg	56
139	2/3	4/3	4/3	Neg	Neg	49

Table 13

bcl-2a Case Controlled Study - Clinomics 3 Experiment Study - Oncology Array
Scoring Sheet

Sample #	Experiment I	Experiment II	Experiment	HER-2/Neu	ER	Age
140	3/4	3/4	4/3	Neg	Neg	63
141	4/4	4/4	3/3	Neg	Neg	63
142	3/3	3/3	4/3	Pos	Neg	66
143	3/4	3/4	2/3	Pos	Pos	67
144	4/4	4/3	3/4	Pos	Neg	72
145	4/3	2/3	4/3	Pos	Neg	79
146	4/3	3/3	4/3	Neg	Pos	75
147	3/3	3/4	3/3	Neg	Pos	68
148	4/3	4/3	4/3	Neg	Pos	77
149	2/3	4/4	2/3	Pos	Pos	76
150	3/3	4/3	3/3	Pos	Pos	63
151	3/4	4/3	3/4	Pos	Neg	62
152	2/3	3/4	2/3	Pos	Neg	63
153	3/3	4/4	3/3	Neg	Neg	66
154	3/4	3/3	3/4	Neg	Pos	67
155	4/4	3/4	4/4	Neg	Pos	72
156	3/3	4/3	3/3	Pos	Pos	79
157	3/4	2/3	3/4	Pos	Pos	75
158	4/3	3/3	3/3	Pos	Pos	68
159	4/3	3/4	3/4	Pos	Pos	75
160	3/3	4/3	4/3	Pos	Pos	68
161	4/3	4/4	3/4	Pos	Pos	59
162	3/4	4/3	4/4	Pos	Pos	56
163	4/4	4/3	3/3	Pos	Pos	49
164	3/3	3/3	2/3	Pos	Pos	63
165	3/4	4/3	4/4	Pos	Pos	79
166	4/3	2/3	3/3	Pos	Neg	75
167	3/4	3/3	3/3	Pos	Neg	68
168	4/4	3/3	4/3	Pos	Neg	59
169	3/3	1/1	2/3	Pos	Neg	79
170	3/4	1/2	3/3	Neg	Pos	75
171	4/3	2/1	3/4	Neg	Neg	68
172	3/4	2/1	3/3	Neg	Neg	59
173	4/4	2/2	3/3	Pos	Pos	75
174	3/3	4/4	3/4	Pos	Pos	68

Table 13

bcl2a Case Controlled Study - Clinomics 3 Experiment Study - Oncology Array

Scoring Sheet

Sample #	Experiment I	Experiment II	Experiment	HER-2/Neu	ER	Age
175	3/4	3/3	4/3	Pos	Neg	59
176	4/3	3/4	4/3	Pos	Pos	79
177	2/3	4/3	3/4	Pos	Pos	68
178	3/3	2/3	4/4	Neg	Pos	66
179	3/3	3/3	3/3	Pos	Pos	67
180	3/3	3/4	3/4	Pos	Pos	72
181	2/2	4/3	4/3	Pos	Pos	79
182	1/2	4/4	2/3	Pos	Pos	75
183	2/2	4/3	2/4	Pos	Neg	68
184	2/3	2/3	2/3	Pos	Pos	59
185	2/4	2/4	4/4	Neg	Pos	56
186	2/3	2/3	3/3	Neg	Pos	49
187	1/1	1/1	3/4	Neg	Pos	63
188	1/1	1/1	4/3	Neg	Pos	66
189	1/2	1/2	3/3	Pos	Pos	79
190	2/1	2/1	4/3	Pos	Neg	55
191	2/1	2/1	2/3	Neg	Neg	53
192	2/2	2/2	3/3	Neg	Neg	82
193	2/2	2/2	3/3	Neg	Neg	62
194	1/2	1/2	1/1	Neg	Pos	63
195	2/2	2/3	1/2	Neg	Pos	66
196	2/3	2/4	2/1	Neg	Neg	68
197	2/4	2/3	2/1	Neg	Neg	75
198	2/3	4/4	2/2	Neg	Neg	68
199	4/4	3/3	4/4	Pos	Pos	59
200	3/3	3/4	3/3	Pos	Pos	56
201	3/4	4/3	3/4	Pos	Pos	68
202	4/3	2/3	4/3	Neg	Neg	59
203	2/3	2/2	2/3	Neg	Neg	56
204	2/2	2/1	3/3	Pos	Pos	49
205	2/1	2/3	3/4	Pos	Pos	63
206	2/3	3/3	4/4	Pos	Pos	66
207	3/3	3/3	4/4	Pos	Pos	79
208	3/3	3/3	4/3	Pos	Pos	63
209	3/3	2/2	2/3	Pos	Pos	66

Table 13

bel-2a Case Controlled Study - Clinomics 3 Experiment Study - Oncology Array

Scoring Sheet

Sample #	Experiment I	Experiment II	Experiment	HER-2/Neu	ER	Age
210	2/2	1/2	2/4	Pos	Pos	68
211	1/2	2/1	2/3	Pos	Pos	75
212	2/2	2/1	1/1	Pos	Pos	68
213	2/3	2/2	2/2	Pos	Pos	56
214	2/3	2/2	2/1	Pos	Pos	68
215	2/4	1/2	2/3	Pos	Pos	59
216	2/3	2/2	3/3	Pos	Pos	56
217	1/1	2/3	3/3	Pos	Pos	49
218	1/1	2/4	3/3	Pos	Pos	63
219	1/2	2/3	2/2	Pos	Pos	66
220	2/1	4/4	1/2	Pos	Pos	79
221	2/1	3/3	1/2	Pos	Pos	55
222	2/2	3/4	2/2	Pos	Pos	53
223	3/4	4/3	2/3	Pos	Pos	61
224	4/3	3/3	2/4	Pos	Pos	68
225	2/3	4/3	2/3	Pos	Pos	59
226	2/2	2/3	4/4	Pos	Pos	56
227	2/1	3/3	3/3	Pos	Pos	68
228	2/3	3/3	3/4	Pos	Pos	59
229	3/3	1/1	4/3	Pos	Neg	56
230	3/3	1/2	2/3	Pos	Pos	68
231	3/3	2/1	2/2	Pos	Pos	75
232	1/2	2/1	2/1	Pos	Neg	68
233	2/2	2/2	2/3	Pos	Pos	59
234	2/2	4/4	4/3	Pos	Pos	56
235	2/3	3/3	3/3	Pos	Pos	68
236	2/3	3/4	4/3	Pos	Pos	59
237	2/4	4/3	2/3	Pos	Pos	56
238	2/3	2/3	3/3	Pos	Pos	49
239	1/1	3/3	3/3	Pos	Pos	63
240	1/1	3/4	1/1	Pos	Pos	66
241	1/2	4/3	1/2	Pos	Pos	79
242	2/1	4/4	2/1	Pos	Pos	55
243	2/1	4/3	2/1	Neg	Pos	53
244	2/2	2/3	2/2	Neg	Pos	61

Table 13

bcl-2a Case Controlled Study - Clinomics 3 Experiment Study - Oncology Array

Scoring Sheet

Sample #	Experiment I	Experiment II	Experiment	HER-2/Neu	ER	Age
245	4/3	2/4	4/4	Neg	Pos	68
246	2/3	2/3	3/3	2/3	Pos	59
247	2/2	1/1	3/4	Pos	Pos	56
248	2/1	2/2	4/3	Pos	Pos	68
249	2/3	2/1	2/3	Pos	Pos	56
250	3/3	2/3	3/3	Pos	Pos	49
251	3/3	3/3	3/4	Pos	Pos	56
252	3/3	3/3	4/3	Pos	Pos	49
253	2/2	3/3	4/4	Pos	Pos	63
254	1/2	2/2	4/3	Pos	Pos	66
255	2/2	1/2	2/3	Pos	Pos	79
256	2/3	1/2	2/4	Pos	Pos	55
257	2/3	2/2	2/3	Pos	Pos	53
258	2/4	2/3	1/1	Pos	Pos	61
259	2/3	2/4	2/2	Pos	Pos	68
260	4/4	2/3	2/1	Pos	Pos	59
261	4/3	4/4	2/3	Pos	Pos	56
262	4/3	3/3	3/3	Pos	Pos	68
263	3/3	3/4	3/3	Pos	Pos	78
264	4/3	4/3	3/3	Pos	Pos	79
265	4/3	2/3	2/2	Pos	Pos	55
266	2/2	2/2	1/2	Pos	Pos	53
267	2/1	2/1	1/2	Pos	Pos	82
268	2/3	2/3	2/3	Neg	Neg	62
269	3/3	3/3	2/4	Neg	Neg	63
270	3/3	3/3	2/3	Neg	Neg	66
271	3/3	3/3	1/1	Neg	Neg	67
272	2/2	2/2	1/1	Pos	Neg	72
273	1/2	3/3	1/2	Pos	Neg	79
274	1/2	4/3	2/1	Neg	Neg	75
275	2/2	3/3	2/1	Neg	Neg	68
276	2/3	3/4	2/2	Neg	Neg	59
277	2/4	4/3	2/2	Neg	Neg	56
278	2/3	2/2	1/2	Neg	Pos	49
279	3/3	2/3	2/3	Neg	Pos	63

Table 13

bcl-2a Case Controlled Study - Clinomics 3 Experiment Study - Oncology Array

Scoring Sheet

Sample #	Experiment I	Experiment II	Experiment	HER-2/Neu	ER	Age
280	4/3	2/3	2/4	Neg	Pos	79
281	3/3	2/4	2/3	Neg	Neg	55
282	3/4	2/3	4/4	Pos	Neg	53
283	4/3	3/3	3/3	Pos	Pos	82
284	3/4	4/3	3/4	Pos	Pos	62
285	4/4	3/3	4/3	Neg	Pos	66
286	3/3	2/3	2/3	Pos	Pos	67
287	3/4	3/3	2/2	Pos	Pos	63
288	4/3	3/3	2/1	Pos	Pos	66
289	2/3	3/3	2/3	Pos	Pos	67
290	3/3	2/2	3/3	Pos	Pos	72
291	3/4	1/2	3/3	Pos	Pos	79
292	4/3	2/2	3/3	Pos	Pos	75
293	4/4	2/3	2/2	Pos	Neg	68
294	4/3	2/3	1/2	Pos	Neg	77
295	4/3	2/4	2/1	Pos	Neg	76
296	3/4	2/3	3/3	Pos	Neg	63
297	4/4	1/1	2/2	Neg	Pos	62
298	3/3	2/2	1/2	Neg	Pos	63
299	3/4	1/2	2/2	Neg	Pos	66
300	4/3	2/1	4/4	Neg	Neg	67
301	2/3	3/3	3/3	Pos	Neg	72
302	3/3	2/2	3/4	Pos	Pos	79
303	3/4	1/2	4/3	Neg	Pos	75
304	4/3	2/2	2/3	Neg	Pos	68
305	4/4	4/4	3/3	Neg	Pos	75
306	4/3	3/3	3/4	Neg	Pos	68
307	4/3	1/1	4/3	Neg	Pos	59
308	3/3	1/2	4/4	Neg	Pos	56
309	4/3	2/1	4/3	Neg	Pos	49
310	2/3	2/1	2/3	Neg	Pos	63
311	3/3	2/2	2/4	Pos	Pos	79
312	3/3	4/4	2/3	Pos	Pos	75
313	1/1	3/3	1/1	Pos	Neg	68
314	1/2	3/4	2/2	Neg	Neg	59

Table 13
bcl-2a Case Controlled Study - Clinomics 3 Experiment Study - Oncology Array
Scoring Sheet

Sample #	Experiment I	Experiment II	Experiment	HER-2/Neu	ER	Age
315	2/1	4/3	2/1	Neg	Neg	79
316	2/1	2/3	2/3	Pos	Neg	75
317	2/2	3/3	3/3	Pos	Pos	68
318	4/4	3/4	3/3	Pos	Pos	59
319	3/3	4/3	3/3	Pos	Pos	75
320	3/4	3/4	2/2	Pos	Neg	68
321	4/3	4/3	1/2	Pos	Pos	68
322	2/3	2/3	1/2	Neg	Pos	59
323	3/3	2/4	2/2	Neg	Pos	79
324	3/4	2/3	2/3	Neg	Pos	75
325	4/3	1/1	2/4	Neg	Pos	79
326	4/4	1/1	2/3	Neg	Pos	75
327	4/3	1/2	4/4	Neg	Pos	68
328	2/3	2/1	2/4	Neg	Pos	59
329	2/4	2/1	2/3	Pos	Pos	75
330	2/3	2/2	1/1	Neg	Pos	68
331	3/1	2/2	1/1	Neg	Pos	59
332	1/1	1/2	1/2	Neg	Neg	79
333	1/2	2/3	2/1	Neg	Pos	75
334	2/1	2/4	4/3	Neg	Neg	68
335	2/1	2/3	3/3	Pos	Neg	66
336	2/2	4/4	2/2	Pos	Pos	67
337	2/2	3/3	1/2	Pos	Pos	72
338	1/2	3/4	2/3	Neg	Pos	76
339	2/3	4/3	2/4	Neg	Neg	63
340	2/4	2/3	2/3	Pos	Neg	62
341	2/3	2/2	1/2	Pos	Neg	63
342	4/4	2/1	2/1	Pos	Neg	66
343	3/3	2/3	2/1	Neg	Pos	67
344	3/4	2/3	2/2	Neg	Pos	72
345	4/3	1/1	4/4	Neg	Neg	79
346	2/3	1/1	3/3	Neg	Pos	75
347	2/2	1/2	3/4	Pos	Pos	79
348	2/1	2/1	4/3	Pos	Neg	75
349	2/3	2/1	2/3	Neg	Neg	68

Table 13

tbl-2a Case Controlled Study - Clinomics 3 Experiment Study - Oncology Array

Sample #	Scoring Sheet					ER	Age
	Experiment I	Experiment II	Experiment	HER-2/Neu	Pos		
350	1/1	2/2	3/3	Pos	Pos	75	
351	2/2	2/2	3/4	Pos	Neg	77	
352	2/1	1/2	4/3	Neg	Neg	77	
353	2/3	2/3	4/4	Neg	Neg	76	
354	3/3	2/4	4/3	Neg	Neg	63	
355	3/3	2/3	3/3	Neg	Neg	66	
356	3/3	2/4	2/2	Neg	Neg	67	
357	2/2	2/3	1/2	Neg	Pos	79	
358	1/2	4/4	2/2	Neg	Pos	75	
359	1/2	3/3	2/3	Pos	Pos	68	
360	2/2	3/4	2/3	Pos	Neg	75	

KEY from Clinical Study P27 Staining
1-180 samples - Non Metastatic Good Prognosis
181-360 samples - Metastatic Poor Prognosis

Appendix A
Table 14
Clinomics Breast Cancer Array Data for Known Molecular Markers

localization	Coordinates	Category	Histologic type	Subtype
A 1a	0/0	normal breast	ductal	comedo, high grade
A 1b	800/0	normal breast	ductal	solid, low grade
A 1c	1600/0	normal breast	ductal	comedo, high grade
A 1d	2400/0	normal breast	ductal	solid, low grade
A 1e	3200/0	normal breast	ductal	comedo, high grade
A 1f	4000/0	normal breast	ductal	micropapillary, low grade
A 1g	4800/0	normal breast	ductal	comedo, high grade
A 1h	5600/0	normal breast	ductal	solid, low grade
A 1i	6400/0	normal breast	ductal	comedo, high grade
A 1j	7200/0	normal breast	ductal	micropapillary, low grade
A 1k	8000/0	normal breast	ductal	comedo, high grade
A 1l	8800/0	normal breast	ductal	comedo, high grade
A 1m	9600/0	normal breast	ductal	comedo, high grade
A 1n	10400/0	normal breast	ductal	cribriform, low grade
A 1o	11200/0	normal breast	ductal	comedo, high grade
A 1p	12000/0	normal breast	ductal	comedo, high grade
A 2a	0/800	normal breast	ductal	solid, low grade
A 2b	800/800	normal breast	ductal	comedo, high grade
A 2c	1600/800	normal breast	ductal	solid, low grade
A 2d	2400/800	normal breast	ductal	comedo, high grade
A 2e	3200/800	breast cancer, tubular	ductal	solid, low grade
A 2f	4000/800	breast cancer, lobular	ductal	comedo, high grade
A 2g	4800/800	breast cancer, ductal	ductal	solid, low grade
A 2h	5600/800	breast cancer, lobular	ductal	comedo, high grade
A 2i	6400/800	breast cancer, lobular	ductal	micropapillary, low grade
A 2j	7200/800	breast cancer, lobular	ductal	comedo, high grade
A 2k	8000/800	breast cancer, ductal	ductal	comedo, high grade
A 2l	8800/800	breast cancer, ductal	ductal	micropapillary, low grade
A 2m	9600/800	breast cancer, ductal	ductal	comedo, high grade
A 2n	10400/800	breast cancer, ductal	ductal	comedo, high grade
A 2o	11200/800	breast cancer, ductal	ductal	comedo, high grade
A 2p	12000/800	breast cancer, ductal	ductal	cribriform, low grade
A 3a	0/1600	breast cancer, ductal	ductal	comedo, high grade
A 3b	800/1600	breast cancer, ductal	ductal	comedo, high grade
A 3c	1600/1600	breast cancer, ductal	ductal	comedo, high grade
A 3d	2400/1600	breast cancer, ductal	ductal	comedo, high grade
A 3e	3200/1600	breast cancer, mucinous	DCIS	solid, low grade
A 3f	4000/1600	breast cancer, ductal	DCIS	comedo, high grade
A 3g	4800/1600	breast cancer, lobular	DCIS	solid, low grade
A 3h	5600/1600	breast cancer, medullary	DCIS	comedo, high grade
A 3i	6400/1600	breast cancer, ductal	ductal	solid, low grade
A 3j	7200/1600	breast cancer, mucinous	ductal	comedo, high grade
A 3k	8000/1600	breast cancer, ductal	ductal	solid, low grade
A 3l	8800/1600	breast cancer, ductal	ductal	comedo, high grade
A 3m	9600/1600	breast cancer, ductal	ductal	micropapillary, low grade
A 3n	10400/1600	breast cancer, ductal	ductal	comedo, high grade
A 3o	11200/1600	breast cancer, ductal	ductal	comedo, high grade
A 3p	12000/1600	breast cancer, ductal	ductal	micropapillary, low grade
A 4a	0/2400	breast cancer, medullary	ductal	comedo, high grade
A 4b	800/2400	breast cancer, ductal	ductal	comedo, high grade
A 4c	1600/2400	breast cancer, ductal	ductal	comedo, high grade
A 4d	2400/2400	breast cancer, ductal	ductal	cribriform, low grade
A 4e	3200/2400	breast cancer, ductal	ductal	comedo, high grade
A 4f	4000/2400	breast cancer, ductal	ductal	comedo, high grade
A 4g	4800/2400	breast cancer, ductal	ductal	solid, low grade
A 4h	5600/2400	breast cancer, ductal	ductal	comedo, high grade
A 4i	6400/2400	breast cancer, ductal	ductal	solid, low grade
A 4j	7200/2400	breast cancer, ductal	ductal	comedo, high grade
A 4k	8000/2400	breast cancer, ductal	ductal	solid, low grade
A 4l	8800/2400	breast cancer, ductal	ductal	comedo, high grade
A 4m	9600/2400	breast cancer, ductal	ductal	solid, low grade

Appendix A
Table 14
Clinomics Breast Cancer Array Data for Known Molecular Markers

BRE grade	Tubuli	Polymorphy	Mitoses	Tumor diameter	pT	pN	LN all
1	2	2	1	4	1	0	28
1	2	2	1	19	1	0	17
1	3	3	3	33	2	1	15
1	3	3	2	14	1	0	23
1	3	3	2	12	1	0	25
1	3	2	1		2	1	25
1	3	3	3	18	1	0	7
1	3	3	2	13	1	0	17
1	3	2	1	65	4	1	2
1	1	2	1	19	1	0	10
1	3	2	1	13	1	0	10
1	3	3	2	23	2	1	17
1	1	2	1	19	1	0	19
1	2	2	1	9	1	0	21
1	2	2	1	20	1	0	26
1	5	2	2	7	1	2	10
1	3	3	3	15	1	0	20
1	3	2	1	9	1	0	15
1	3	3	3	20	1	0	14
1	3	2	1	12	1		0
1	1	2	1	15	1	0	10
1	3	2	1	9	1	0	24
1	2	3	2	20	1	0	12
1	3	2	1	25	2	0	29
1	3	2	1	15	1	0	23
1	3	2	1	10	1	0	10
1	3	2	1	40	2	1	25
1	3	2	1	30	2	0	32
1	3	3	1	15	1	0	11
1	3	3	3	10	1	0	14
1	3	3	3	25	2	1	22
1	2	3	1	22	2	0	14
1	3	3	2	15	1	0	18
1	3	2	2	10	1	0	17
1	2	3	1	30	2	0	26
1	2	2	1	22	2	1	22
1	2	1	1	15	1	0	14
1	2	2	1	11	1	0	19
1	3	2	1	30	4	1	14
1	3	3	3	22	2	1	7
1	3	3	2	15	1	0	21
1	2	1	1	19	1	0	17
1	3	3	1	33	2	1	15
1	3	3	3	14	1	0	23
1	5	2	2	12	1	0	25
1	3	2	1		2	1	25
1	1	2	1	18	1	0	7
1	3	2	1	13	1	0	17
1	3	3	3	65	4	1	2
1	3	3	2	19	1	0	10
1	2	2	1	13	1	0	10
1	2	2	1	23	2	1	17
1	2	3	1	19	1	0	19
1	2	3	1	9	1	0	21
1	3	3	2	20	1	0	26
1	1	2	1	7	1	2	10
1	3	3	1	15	1	0	20
1	3	3	1	9	1	0	15
1	3	2	3	20	1	0	14
1	3	2	3	12	1		0
1	3	3	3	15	1	0	10

09966373-092801

Appendix A
Table 14
Clinomics Breast Cancer Array Data for Known Molecular Markers

LN pos	age	Survival/Mo	identification nr.	Her-2/neu	Cathepsin D	NM23
0	48	57	1001	Neg	Neg	Pos
0	45	58	1002	Neg	Neg	Neg
1	50	84	1003	Neg	Neg	Neg
0	46	60	1004	Neg	Pos	Neg
0	41	41	1005	Neg	Pos	Pos
3	51	45	1006	Neg	Pos	Pos
0	47	48	1007	Pos	Neg	Pos
0	42	64	1008	Pos	Neg	Neg
2	51	39	1009	Pos	Neg	Neg
0	47	48	1010	Pos	Neg	Neg
0	42	46	1011	Neg	Neg	Pos
3	53	71	1012	Neg	Pos	Pos
0	53	46	1013	Neg	Pos	Pos
0	48	77	1014	Pos	Pos	Pos
0	45	47	1015	Pos	Neg	Pos
7	53	47	1016	Pos	Neg	Pos
0	53	64	1017	Pos	Neg	Neg
0	50	57	1018	Pos	Neg	Neg
0	48	48	1019	Pos	Neg	Pos
0	50	57	1020	Neg	Neg	Pos
0	70	55	1021	Neg	Neg	Pos
0	57	60	1022	Pos	Neg	Pos
0	63	48	1023	Pos	Neg	Pos
0	74	63	1024	Pos	Neg	Pos
0	71	54	1025	Pos	Neg	Pos
0	45	46	1026	Pos	Neg	Neg
3	29	48	1027	Pos	Neg	Neg
0	63	70	1028	Pos	Neg	Neg
0	53	61	1029	Pos	Neg	Neg
0	45	79	1030	Pos	Neg	Neg
16	62	51	1031	Pos	Neg	Neg
0	39	28	1032	Neg	Neg	Pos
0	61	17	1033	Neg	Neg	Pos
0	57	15	1034	Neg	Neg	Pos
0	58	23	1035	Neg	Neg	Pos
10	84	25	1036	Neg	Neg	Neg
0	60	25	1037	Neg	Neg	Neg
0	41	7	1038	Neg	Neg	Neg
8	45	17	1039	Pos	Neg	Neg
1	48	2	1040	Pos	Neg	Neg
0	64	10	1041	Pos	Neg	Pos
0	39	10	1042	Pos	Neg	Pos
1	48	17	1043	Neg	Neg	Pos
0	46	19	1044	Neg	Neg	Neg
0	71	21	1045	Neg	Pos	Neg
3	46	26	1046	Neg	Neg	Neg
0	77	10	1047	Neg	Neg	Neg
0	47	20	1048	Pos	Neg	Neg
2	47	15	1049	Pos	Neg	Neg
0	64	14	1050	Pos	Neg	Neg
0	57	0	1051	Neg	Pos	Pos
3	48	10	1052	Neg	Pos	Pos
0	57	24	1053	Neg	Neg	Pos
0	55	12	1054	Neg	Neg	Neg
0	60	29	1055	Neg	Neg	Neg
7	48	23	1056	Neg	Pos	Neg
0	63	10	1057	Neg	Pos	Neg
0	54	25	1058	Neg	Pos	Neg
0	46	32	1059	Neg	Pos	Neg
0	48	11	1060	Neg	Pos	Neg
0	70	14	1061	Neg	Pos	Neg

Appendix A
Table 14
Clinomics Breast Cancer Array Data for Known Molecular Markers

localization	Coordinates	Category	Histologic type	Subtype
A 4n	10400/2400	breast cancer, ductal	ductal	comedo, high grade
A 4o	11200/2400	breast cancer, ductal	ductal	micropapillary, low grade
A 4p	12000/2400	breast cancer, ductal	ductal	comedo, high grade
A 5a	0/3200	breast cancer, ductal	ductal	comedo, high grade
A 5b	800/3200	breast cancer, ductal	ductal	comedo, high grade
A 5c	1600/3200	breast cancer, ductal	ductal	cribriform, low grade
A 5d	2400/3200	breast cancer, ductal	ductal	comedo, high grade
A 5e	3200/3200	breast cancer, ductal	ductal	comedo, high grade
A 5f	4000/3200	breast cancer, ductal	ductal	comedo, high grade
A 5g	4800/3200	breast cancer, ductal	ductal	comedo, high grade
A 5h	5600/3200	breast cancer, ductal	ductal	solid, low grade
A 5i	6400/3200	breast cancer, ductal	ductal	comedo, high grade
A 5j	7200/3200	breast cancer, ductal	ductal	micropapillary, low grade
A 5k	8000/3200	breast cancer, ductal	ductal	comedo, high grade
A 5l	8800/3200	breast cancer, ductal	ductal	micropapillary, low grade
A 5m	9600/3200	breast cancer, ductal	ductal	comedo, high grade
A 5n	10400/3200	breast cancer, ductal	ductal	comedo, high grade
A 5o	11200/3200	breast cancer, ductal	ductal	comedo, high grade
A 5r	12000/3200	breast cancer, ductal	ductal	cribriform, low grade
A 6a	0/4000	breast cancer, ductal	ductal	comedo, high grade
A 6b	800/4000	breast cancer, ductal	ductal	comedo, high grade
A 6c	1600/4000	breast cancer, ductal	ductal	solid, low grade
A 6d	2400/4000	breast cancer, ductal	ductal	comedo, high grade
A 6e	3200/4000	breast cancer, ductal	ductal	solid, low grade
A 6f	4000/4000	breast cancer, ductal	ductal	comedo, high grade
A 6g	4800/4000	breast cancer, ductal	ductal	solid, low grade
A 6h	5600/4000	breast cancer, ductal	ductal	comedo, high grade
A 6i	6400/4000	breast cancer, ductal	ductal	solid, low grade
A 6j	7200/4000	breast cancer, ductal	ductal	comedo, high grade
A 6k	8000/4000	breast cancer, ductal	ductal	micropapillary, low grade
A 6l	8800/4000	breast cancer, ductal	ductal	comedo, high grade
A 6m	9600/4000	breast cancer, ductal	ductal	comedo, high grade
A 6n	10400/4000	breast cancer, ductal	ductal	micropapillary, low grade
A 6o	11200/4000	breast cancer, ductal	ductal	comedo, high grade
A 6p	12000/4000	breast cancer, ductal	ductal	comedo, high grade
A 7a	0/4800	breast cancer, ductal	ductal	comedo, high grade
A 7b	800/4800	breast cancer, ductal	ductal	cribriform, low grade
A 7c	1600/4800	breast cancer, ductal	ductal	comedo, high grade
A 7d	2400/4800	breast cancer, ductal	ductal	comedo, high grade
A 7e	3200/4800	breast cancer, ductal	ductal	solid, low grade
A 7f	4000/4800	breast cancer, ductal	ductal	comedo, high grade
A 7g	4800/4800	breast cancer, ductal	ductal	solid, low grade
A 7h	5600/4800	breast cancer, ductal	ductal	comedo, high grade
A 7i	6400/4800	breast cancer, ductal	ductal	solid, low grade
A 7j	7200/4800	breast cancer, ductal	ductal	comedo, high grade
A 7k	8000/4800	breast cancer, ductal	ductal	solid, low grade
A 7l	8800/4800	breast cancer, ductal	ductal	comedo, high grade
A 7m	9600/4800	breast cancer, ductal	ductal	micropapillary, low grade
A 7n	10400/4800	breast cancer, ductal	ductal	comedo, high grade
A 7o	11200/4800	breast cancer, ductal	ductal	comedo, high grade
A 7p	12000/4800	breast cancer, ductal	ductal	comedo, high grade
A 8a	0/5600	breast cancer, ductal	ductal	cribriform, low grade
A 8b	800/5600	breast cancer, ductal	ductal	comedo, high grade
A 8c	1600/5600	breast cancer, ductal	ductal	comedo, high grade
A 8d	2400/5600	breast cancer, ductal	ductal	comedo, high grade
A 8e	3200/5600	breast cancer, ductal	ductal	comedo, high grade
A 8f	4000/5600	breast cancer, ductal	ductal	solid, low grade
A 8g	4800/5600	breast cancer, ductal	ductal	comedo, high grade
A 8h	5600/5600	breast cancer, ductal	ductal	micropapillary, low grade
A 8i	6400/5600	breast cancer, ductal	ductal	comedo, high grade
A 8j	7200/5600	breast cancer, ductal	ductal	comedo, high grade
A 8k	8000/5600	breast cancer, ductal	ductal	micropapillary, low grade

[illegible]

[illegible]291

Appendix A
Table 14
Clinomics Breast Cancer Array Data for Known Molecular Markers

localization	Coordinates	Category	Histologic type	Subtype
A 8l	8800/5600	breast cancer, ductal	ductal	comedo, high grade
A 8m	9600/5600	breast cancer, ductal	ductal	comedo, high grade
A 8n	10400/5600	breast cancer, ductal	ductal	comedo, high grade
A 8o	11200/5600	breast cancer, ductal	ductal	cribriform, low grade
A 8p	12000/5600	breast cancer, ductal	ductal	comedo, high grade
A 9a	0/6400	breast cancer, ductal	ductal	comedo, high grade
A 9b	800/6400	breast cancer, ductal	ductal	solid, low grade
A 9c	1600/6400	breast cancer, ductal	ductal	comedo, high grade
A 9d	2400/6400	breast cancer, ductal	ductal	solid, low grade
A 9e	3200/6400	breast cancer, ductal	ductal	comedo, high grade
A 9f	4000/6400	breast cancer, ductal	ductal	solid, low grade
A 9g	4800/6400	breast cancer, ductal	ductal	comedo, high grade
A 9h	5600/6400	breast cancer, ductal	ductal	solid, low grade
A 9i	6400/6400	breast cancer, ductal	ductal	comedo, high grade
A 9j	7200/6400	breast cancer, ductal	ductal	micropapillary, low grade
A 9k	8000/6400	breast cancer, ductal	ductal	comedo, high grade
A 9l	8800/6400	breast cancer, ductal	ductal	comedo, high grade
A 9m	9600/6400	breast cancer, ductal	ductal	comedo, high grade
A 9n	10400/6400	breast cancer, ductal	ductal	cribriform, low grade
A 9o	11200/6400	breast cancer, ductal	ductal	comedo, high grade
A 9p	12000/6400	breast cancer, ductal	ductal	comedo, high grade
B 1a	0/0	normal breast	normal breast	
B 1b	800/0	normal breast	normal breast	
B 1c	1600/0	normal breast	normal breast	
B 1d	2400/0	normal breast	normal breast	
B 1e	3200/0	normal breast	normal breast	
B 1f	4000/0	normal breast	normal breast	
B 1g	4800/0	normal breast	normal breast	
B 1h	5600/0	normal breast	normal breast	
B 1i	6400/0	normal breast	normal breast	
B 1j	7200/0	normal breast	normal breast	
B 1k	8000/0	normal breast	normal breast	
B 1l	8800/0	normal breast	normal breast	
B 1m	9600/0	normal breast	normal breast	
B 1n	10400/0	normal breast	normal breast	
B 1o	11200/0	normal breast	normal breast	
B 1p	12000/0	normal breast	normal breast	
B 2a	0/800	normal breast	normal breast	
B 2b	800/800	normal breast	normal breast	
B 2c	1600/800	normal breast	normal breast	
B 2d	2400/800	normal breast	normal breast	
B 2e	3200/800	breast cancer, ductal	DCIS	cribriform, low grade
B 2f	4000/800	breast cancer, ductal	DCIS	comedo, high grade
B 2g	4800/800	breast cancer, ductal	DCIS	cribriform, low grade
B 2h	5600/800	breast cancer, ductal	DCIS	cribriform, low grade
B 2i	6400/800	breast cancer, ductal	DCIS	solid, low grade
B 2j	7200/800	breast cancer, ductal	DCIS	comedo, high grade
B 2k	8000/800	breast cancer, ductal	DCIS	solid, low grade
B 2l	8800/800	breast cancer, ductal	DCIS	comedo, high grade
B 2m	9600/800	breast cancer, ductal	DCIS	solid, low grade
B 2n	10400/800	breast cancer, ductal	DCIS	comedo, high grade
B 2o	11200/800	breast cancer, ductal	DCIS	solid, low grade
B 2p	12000/800	breast cancer, ductal	DCIS	comedo, high grade
B 3a	0/1600	breast cancer, ductal	DCIS	comedo, high grade
B 3b	800/1600	breast cancer, ductal	DCIS	solid, low grade
B 3c	1600/1600	breast cancer, ductal	DCIS	comedo, high grade
B 3d	2400/1600	breast cancer, ductal	DCIS	solid, low grade
B 3e	3200/1600	breast cancer, ductal	DCIS	comedo, high grade
B 3f	4000/1600	breast cancer, ductal	DCIS	micropapillary, low grade
B 3g	4800/1600	breast cancer, ductal	DCIS	comedo, high grade
B 3h	5600/1600	breast cancer, ductal	DCIS	solid, low grade

Appendix A
Table 14

Clinomics Breast Cancer Array Data for Known Molecular Markers

BRE grade	Tubuli	Polymorphy	Mitoses	Tumor diameter	pT	pN	LN all
2	1	2	1	25	2	1	15
2	3	2	1	12	1	0	25
2	3	3	3	22	2	0	16
2	3	3	2	60	3	2	18
2	2	2	1	28	2	1	27
2	2	2	1	25	2	1	19
2	2	3	1	15	1	1	23
2	2	3	1	22	2	0	17
2	3	3	1	30	2	1	23
2	3	3	1	19	1	1	31
2	3	2	3	25	2	1	27
2	3	2	3	76	3	1	28
2	3	3	3	12	1	0	16
2	3	3	2	15	1	0	15
2	3	3	2	30	2	1	25
2	3	2	1	16	1	0	40
2	3	3	3	15	1	0	16
2	3	3	2	27	2	0	33
2	2	2	1	35	2	1	28
2	2	2	1	17	1	0	33
2	5	2	2	13	1	1	12

1	1	2	1	10	1	0	10
1	3	2	1	40	2	1	25
1	2	3	2	30	2	0	32
1	3	2	1	15	1	0	11
1	3	2	1	10	1	0	14
1	3	2	1	25	2	1	22
1	3	3	3	22	2	0	14
1	5	2	2	15	1	0	18
1	3	2	1	10	1	0	17
1	1	2	1	30	2	0	26
1	3	2	1	22	2	1	22
1	3	3	3	15	1	0	14
1	3	3	2	11	1	0	19
1	2	2	1	30	4	1	14
1	2	2	1	22	2	1	7
1	2	3	1	15	1	0	21
1	2	3	1	12	1	0	16
1	3	3	1	40	2	2	12
1	3	3	1	12	1	0	0
1	3	2	3	15	1	0	15

Appendix A
Table 14
Clinomics Breast Cancer Array Data for Known Molecular Markers

LN pos	age	Survival/Mo	identification nr.	Her-2/neu	Cathepsin D	NM23
1	55	66	1124	Neg	Pos	Neg
0	42	46	1125	Neg	Neg	Neg
0	49	57	1126	Neg	Neg	Neg
7	52	40	1127	Neg	Pos	Neg
6	55	48	1128	Neg	Pos	Neg
5	42	52	1129	Neg	Pos	Neg
3	49	55	1130	Neg	Pos	Neg
0	53	39	1131	Neg	Pos	Neg
2	55	48	1132	Neg	Pos	Neg
1	43	51	1133	Neg	Pos	Neg
2	49	54	1134	Neg	Neg	Neg
4	53	40	1135	Neg	Neg	Neg
0	56	48	1136	Neg	Neg	Neg
0	45	51	1137	Neg	Neg	Neg
1	49	55	1138	Neg	Pos	Neg
0	54	40	1139	Neg	Pos	Neg
0	56	48	1140	Neg	Pos	Neg
0	46	52	1141	Neg	Pos	Neg
6	49	55	1142	Pos	Neg	Pos
0	54	41	1143	Neg	Neg	Neg
2	46	49	1144	Neg	Neg	Neg
	55		1001	Neg	Neg	Neg
	41		1002	Neg	Neg	Neg
	49		1003	Neg	Neg	Neg
	52		1004	Neg	Neg	Neg
	55		1005	Neg	Neg	Neg
	42		1006	Neg	Pos	Neg
	49		1007	Neg	Neg	Neg
	52		1008	Neg	Neg	Neg
	55		1009	Neg	Neg	Neg
	42		1010	Neg	Neg	Neg
	49		1011	Neg	Pos	Neg
	53		1012	Neg	Pos	Neg
	55		1013	Neg	Neg	Pos
	43		1014	Neg	Neg	Neg
	49		1015	Neg	Neg	Neg
	53		1016	Neg	Neg	Pos
	56		1017	Neg	Neg	Neg
	45		1018	Pos	Neg	Neg
	49		1019	Neg	Neg	Neg
	54		1020	Neg	Neg	Neg
0	70	56	1021	Pos	Neg	Pos
3	57	46	1022	Neg	Pos	Neg
0	63	53	1023	Neg	Pos	Neg
0	74	63	1024	Pos	Pos	Neg
0	71	66	1025	Pos	Pos	Neg
16	45	46	1026	Pos	Pos	Neg
0	29	57	1027	Pos	Neg	Neg
0	63	40	1028	Pos	Neg	Neg
0	53	48	1029	Neg	Neg	Neg
0	45	52	1030	Neg	Neg	Neg
10	62	55	1031	Neg	Pos	Neg
0	39	39	1032	Pos	Pos	Neg
0	61	48	1033	Pos	Pos	Neg
8	57	46	1034	Pos	Pos	Neg
1	58	53	1035	Pos	Neg	Pos
0	84	63	1036	Pos	Neg	Neg
0	60	66	1037	Pos	Neg	Neg
9	41	46	1038	Neg	Pos	Neg
	45	57	1039	Pos	Neg	Neg
0	48	40	1040	Pos	Pos	Neg

0956373-092804

Appendix A
Table 14
Clinomics Breast Cancer Array Data for Known Molecular Markers

localization	Coordinates	Category	Histologic type	Subtype
B 3i	6400/1600	breast cancer, ductal	ductal	comedo, high grade
B 3j	7200/1600	breast cancer, ductal	ductal	micropapillary, low grade
B 3k	8000/1600	breast cancer, ductal	ductal	comedo, high grade
B 3l	8800/1600	breast cancer, ductal	ductal	comedo, high grade
B 3m	9600/1600	breast cancer, ductal	ductal	comedo, high grade
B 3n	10400/1600	breast cancer, ductal	ductal	cribriform, low grade
B 3o	11200/1600	breast cancer, ductal	ductal	comedo, high grade
B 3p	12000/1600	breast cancer, ductal	ductal	comedo, high grade
B 4a	0/2400	breast cancer, ductal	ductal	solid, low grade
B 4b	800/2400	breast cancer, ductal	ductal	comedo, high grade
B 4c	1600/2400	breast cancer, ductal	ductal	solid, low grade
B 4d	2400/2400	breast cancer, ductal	ductal	comedo, high grade
B 4e	3200/2400	breast cancer, ductal	ductal	solid, low grade
B 4f	4000/2400	breast cancer, ductal	ductal	comedo, high grade
B 4g	4800/2400	breast cancer, ductal	ductal	solid, low grade
B 4h	5600/2400	breast cancer, ductal	ductal	comedo, high grade
B 4i	6400/2400	breast cancer, ductal	ductal	micropapillary, low grade
B 4j	7200/2400	breast cancer, ductal	ductal	comedo, high grade
B 4k	8000/2400	breast cancer, ductal	ductal	comedo, high grade
B 4l	8800/2400	breast cancer, ductal	ductal	micropapillary, low grade
B 4m	9600/2400	breast cancer, ductal	ductal	comedo, high grade
B 4n	10400/2400	breast cancer, ductal	ductal	comedo, high grade
B 4o	11200/2400	breast cancer, ductal	ductal	comedo, high grade
B 4p	12000/2400	breast cancer, ductal	ductal	cribriform, low grade
B 5a	0/3200	breast cancer, ductal	ductal	comedo, high grade
B 5b	800/3200	breast cancer, ductal	ductal	comedo, high grade
B 5c	1600/3200	breast cancer, ductal	ductal	comedo, high grade
B 5d	2400/3200	breast cancer, ductal	ductal	comedo, high grade
B 5e	3200/3200	breast cancer, ductal	ductal	solid, low grade
B 5f	4000/3200	breast cancer, ductal	ductal	comedo, high grade
B 5g	4800/3200	breast cancer, ductal	ductal	solid, low grade
B 5h	5600/3200	breast cancer, ductal	ductal	comedo, high grade
B 5i	6400/3200	breast cancer, ductal	ductal	solid, low grade
B 5j	7200/3200	breast cancer, ductal	ductal	comedo, high grade
B 5k	8000/3200	breast cancer, ductal	ductal	solid, low grade
B 5l	8800/3200	breast cancer, ductal	ductal	comedo, high grade
B 5m	9600/3200	breast cancer, ductal	ductal	micropapillary, low grade
B 5n	10400/3200	breast cancer, ductal	ductal	comedo, high grade
B 5o	11200/3200	breast cancer, ductal	ductal	comedo, high grade
B 5r	12000/3200	breast cancer, ductal	ductal	micropapillary, low grade
B 6a	0/4000	breast cancer, ductal	ductal	comedo, high grade
B 6b	800/4000	breast cancer, ductal	ductal	comedo, high grade
B 6c	1600/4000	breast cancer, ductal	ductal	comedo, high grade
B 6d	2400/4000	breast cancer, ductal	ductal	cribriform, low grade
B 6e	3200/4000	breast cancer, ductal	ductal	comedo, high grade
B 6f	4000/4000	breast cancer, ductal	ductal	comedo, high grade
B 6g	4800/4000	breast cancer, ductal	ductal	solid, low grade
B 6h	5600/4000	breast cancer, ductal	ductal	comedo, high grade
B 6i	6400/4000	breast cancer, ductal	ductal	solid, low grade
B 6j	7200/4000	breast cancer, ductal	ductal	comedo, high grade
B 6k	8000/4000	breast cancer, ductal	ductal	solid, low grade
B 6l	8800/4000	breast cancer, ductal	ductal	comedo, high grade
B 6m	9600/4000	breast cancer, ductal	ductal	solid, low grade
B 6n	10400/4000	breast cancer, ductal	ductal	comedo, high grade
B 6o	11200/4000	breast cancer, ductal	ductal	micropapillary, low grade
B 6p	12000/4000	breast cancer, ductal	ductal	comedo, high grade
B 7a	0/4800	breast cancer, ductal	ductal	comedo, high grade
B 7b	800/4800	breast cancer, ductal	ductal	comedo, high grade
B 7c	1600/4800	breast cancer, ductal	ductal	cribriform, low grade
B 7d	2400/4800	breast cancer, ductal	ductal	comedo, high grade
B 7e	3200/4800	breast cancer, ductal	ductal	comedo, high grade
B 7f	4000/4800	breast cancer, ductal	ductal	comedo, high grade

Appendix A
Table 14
Clinomics Breast Cancer Array Data for Known Molecular Markers

BRE grade	Tubuli	Polymorphy	Mitoses	Tumor diameter	pT	pN	LN all
1	3	2	3	7	1	0	16
1	2	2	1	20	1	0	8
1	2	2	1	45	2	1	19
1	3	3	3	15	1	0	24
1	3	3	2	12	1	0	21
1	3	3	2	35	2	0	9
1	3	2	1	18	1	0	7
1	3	3	3	13	1	0	17
1	3	3	2	65	4	1	2
1	3	2	1	19	1	0	10
1	1	2	1	13	1	0	10
1	3	2	1	23	2	1	17
1	3	3	2	19	1	0	19
1	1	2	1	9	1	0	21
1	2	2	1	20	1	0	26
1	2	2	1	7	1	2	10
1	5	2	2	15	1	0	20
1	3	3	3	9	1	0	15
1	3	2	1	20	1	0	14
1	3	3	3	12	1	0	0
1	3	2	1	15	1	0	10
1	1	2	1	9	1	0	24
1	3	2	1	20	1	0	12
1	2	3	2	25	2	0	29
1	3	2	1	15	1	0	23
1	2	2	1	10	1	0	10
1	2	2	1	40	2	1	25
1	3	3	3	30	2	0	32
1	3	3	2	15	1	0	11
1	3	3	2	10	1	0	14
1	3	2	1	25	2	1	22
1	3	3	3	22	2	0	14
1	3	3	2	15	1	0	18
1	3	2	1	10	1	0	17
1	1	2	1	30	2	0	26
1	3	2	1	22	2	1	22
1	3	3	2	15	1	0	14
1	1	2	1	11	1	0	19
1	2	2	1	30	4	1	14
1	2	2	1	22	2	1	7
1	5	2	2	15	1	0	21
1	3	3	3	12	1	0	16
1	3	2	1	40	2	2	12
1	3	3	3	12	1	0	0
1	3	2	1	15	1	0	15
1	1	2	1	7	1	0	16
1	3	2	1	20	1	0	8
1	2	3	2	45	2	1	19
1	3	2	1	15	1	0	24
1	3	3	3	12	1	0	21
1	3	3	2	35	2	0	9
1	3	2	1	21	2	1	9
1	1	2	1	15	1	0	7
1	3	2	1	12	1	0	2
1	3	3	2	22	2	0	7
1	1	2	1	25	2	1	21
1	2	2	1	15	1	0	21
1	2	2	1	12	1	0	14
1	5	2	2	30	2	0	14
1	3	3	3	15	1	0	10
2	3	2	1	40	2	2	16
2	3	3	3	35	2	1	28

09066373-092801

Appendix A
Table 14
Clinomics Breast Cancer Array Data for Known Molecular Markers

LN pos	age	Survival/Mo	identification nr.	Her-2/neu	Cathepsin D	NM23
0	64	48	1041	Pos	Pos	Neg
0	39	52	1042	Pos	Pos	Pos
3	48	55	1043	Pos	Pos	Pos
0	46	39	1044	Pos	Pos	Neg
0	71	48	1045	Neg	Pos	Neg
0	46	51	1046	Neg	Neg	Neg
0	77	54	1047	Neg	Neg	Pos
0	47	40	1048	Neg	Neg	Pos
2	47	48	1049	Pos	Neg	Pos
0	64	51	1050	Pos	Pos	Neg
0	57	55	1051	Neg	Pos	Neg
3	48	40	1052	Neg	Neg	Pos
0	57	48	1053	Neg	Neg	Pos
0	55	52	1054	Neg	Neg	Pos
0	60	55	1055	Neg	Neg	Pos
7	48	39	1056	Neg	Neg	Neg
0	63	48	1057	Neg	Neg	Neg
0	54	46	1058	Neg	Neg	Pos
0	46	53	1059	Pos	Pos	Pos
	48	63	1060	Pos	Pos	Pos
0	70	66	1061	Pos	Pos	Pos
0	61	46	1062	Neg	Pos	Neg
0	79	57	1063	Neg	Neg	Pos
0	51	40	1064	Pos	Pos	Neg
0	73	48	1065	Pos	Pos	Neg
0	47	52	1066	Pos	Pos	Neg
3	41	55	1067	Pos	Neg	Neg
0	51	39	1068	Pos	Pos	Neg
0	78	48	1069	Pos	Pos	Neg
0	69	51	1070	Pos	Pos	Pos
16	42	48	1071	Pos	Pos	Pos
0	52	51	1072	Pos	Pos	Neg
0	62	55	1073	Pos	Pos	Neg
0	75	40	1074	Pos	Neg	Neg
0	43	48	1075	Pos	Neg	Pos
10	52	52	1076	Pos	Neg	Pos
0	56	55	1077	Pos	Neg	Pos
0	62	41	1078	Pos	Pos	Neg
8	44	49	1079	Pos	Pos	Neg
1	52	52	1080	Pos	Neg	Pos
0	57	55	1081	Pos	Neg	Pos
0	40	41	1082	Pos	Neg	Pos
9	44	49	1083	Pos	Neg	Pos
	52	52	1084	Pos	Neg	Neg
0	52	55	1085	Pos	Neg	Neg
0	58	42	1086	Pos	Neg	Pos
0	55	49	1087	Pos	Pos	Pos
3	48	52	1088	Pos	Pos	Pos
0	61	55	1089	Pos	Pos	Pos
0	60	42	1090	Pos	Neg	Neg
0	45	49	1091	Pos	Neg	Neg
1	53	53	1092	Pos	Pos	Neg
0	68	55	1093	Pos	Pos	Pos
0	41	48	1094	Pos	Neg	Pos
0	46	51	1095	Pos	Neg	Neg
3	53	55	1096	Pos	Neg	Neg
0	63	40	1097	Pos	Neg	Neg
0	66	48	1098	Pos	Neg	Neg
0	46	52	1099	Pos	Neg	Neg
0	57	55	1100	Pos	Neg	Neg
9	40	41	1101	Pos	Neg	Neg
5	48	49	1102	Pos	Pos	Pos

Appendix A
Table 14
Clinomics Breast Cancer Array Data for Known Molecular Markers

BRE grade	Tubuli	Polymorphy	Mitoses	Tumor diameter	pT	pN	LN all
2	3	2	1	19	1	0	5
2	1	2	1	22	4	1	12
2	2	2	1	45	2	1	16
2	5	2	2	10	1	0	23
2	3	3	3	18	1	0	10
2	3	2	1	60	3	2	10
2	3	3	3	12	1	1	16
2	3	2	1	13	1	0	12
2	1	2	1	24	2	1	22
2	3	2	1	25	2	0	10
2	2	3	2	40	2	2	36
2	3	2	1	25	2	0	16
2	3	3	3	11	1	0	11
2	3	3	2	20	1	1	9
2	3	2	1	11	1	0	19
2	1	2	1	13	1	0	14
2	3	2	1	30	4	0	20
2	3	3	2	24	2	1	14
2	1	2	1	27	2	1	14
2	2	2	1	18	1	0	16
2	2	2	1	24	2	1	10
2	5	2	2	25	2	1	15
2	3	3	3	12	1	0	25
2	3	2	1	22	2	0	16
2	3	3	3	60	3	2	18
2	3	2	1	28	2	1	27
2	1	2	1	25	2	1	19
2	3	3	3	15	1	1	23
2	3	3	2	22	2	0	17
2	3	3	2	30	2	1	23
2	3	2	1	19	1	1	31
2	3	3	3	25	2	1	27
2	3	3	2	76	3	1	28
2	3	2	1	12	1	0	16
2	1	2	1	15	1	0	15
2	3	2	1	30	2	1	25
2	3	3	2	16	1	0	40
2	1	2	1	15	1	0	16
2	2	2	1	27	2	0	33
2	2	2	1	35	2	1	28
2	5	2	2	17	1	0	33
2	3	3	3	13	1	1	12
	3	2	1				
2	3	3	3	15	4	1	8
2	3	2	1	18	1	1	27
2	1	2	1	24	2		0
2	3	2	1	40	2	1	22
2	2	3	2	24	2	0	26
2	3	2	1	22	2	1	19
2	3	2	1	18	1	1	10
2	3	2	1	15	1	1	16
2	3	2	1	20	1	1	31
2	3	2	1	40	2	2	16
2	3	3	1	78	4	1	12
2	3	3	3	29	2	1	13
2	3	3	3	30	2	0	15
2	2	3	1		3	1	16
2	3	3	2	8	1	0	22
2	3	2	2	30	2	1	11
3	2	3	1	28	2	0	21
3	2	2	1	19	1	2	18
3	2	1	1	22	2	1	12

Appendix A
Table 14
Clinomics Breast Cancer Array Data for Known Molecular Markers

localization	Coordinates	Category	Histologic type	Subtype
C 2j	7200/800	breast cancer, ductal	ductal	comedo, high grade
C 3a	0/1600	breast cancer, ductal	ductal	solid, low grade
C 3b	800/1600	breast cancer, ductal	ductal	comedo, high grade
C 3c	1600/1600	breast cancer, ductal	ductal	solid, low grade
C 3d	2400/1600	breast cancer, ductal	ductal	solid, low grade
C 3e	3200/1600	breast cancer, ductal	ductal	comedo, high grade
C 3f	4000/1600	breast cancer, ductal	ductal	solid, low grade
C 3g	4800/1600	breast cancer, ductal	ductal	comedo, high grade
C 3h	5600/1600	breast cancer, ductal	ductal	solid, low grade
C 3i	6400/1600	breast cancer, ductal	ductal	comedo, high grade
C 3j	7200/1600	breast cancer, ductal	ductal	solid, low grade
C 4a	0/2400	breast cancer, ductal	ductal	comedo, high grade
C 4b	800/2400	breast cancer, ductal	ductal	comedo, high grade
C 4c	1600/2400	breast cancer, ductal	ductal	solid, low grade
C 4d	2400/2400	breast cancer, ductal	ductal	comedo, high grade
C 4e	3200/2400	breast cancer, ductal	ductal	solid, low grade
C 4f	4000/2400	breast cancer, ductal	ductal	comedo, high grade
C 4g	4800/2400	breast cancer, ductal	ductal	micropapillary, low grade
C 4h	5600/2400	breast cancer, ductal	ductal	comedo, high grade
C 4i	6400/2400	breast cancer, ductal	ductal	solid, low grade
C 4j	7200/2400	breast cancer, ductal	ductal	comedo, high grade
C 5a	0/3200	breast cancer, ductal	ductal	micropapillary, low grade
C 5b	800/3200	breast cancer, ductal	ductal	comedo, high grade
C 5c	1600/3200	breast cancer, ductal	ductal	comedo, high grade
C 5d	2400/3200	breast cancer, ductal	ductal	comedo, high grade
C 5e	3200/3200	breast cancer, ductal	ductal	cribriform, low grade
C 5f	4000/3200	breast cancer, ductal	ductal	comedo, high grade
C 5g	4800/3200	breast cancer, ductal	ductal	comedo, high grade
C 5h	5600/3200	breast cancer, ductal	ductal	solid, low grade
C 5i	6400/3200	breast cancer, ductal	ductal	comedo, high grade
C 5j	7200/3200	breast cancer, ductal	ductal	solid, low grade
C 6a	0/4000	breast cancer, ductal	ductal	comedo, high grade
C 6b	800/4000	breast cancer, ductal	ductal	solid, low grade
C 6c	1600/4000	breast cancer, ductal	ductal	comedo, high grade
C 6d	2400/4000	breast cancer, ductal	ductal	solid, low grade
C 6e	3200/4000	breast cancer, ductal	ductal	comedo, high grade
C 6f	4000/4000	breast cancer, ductal	ductal	micropapillary, low grade
C 6g	4800/4000	breast cancer, ductal	ductal	comedo, high grade
C 6h	5600/4000	breast cancer, ductal	ductal	comedo, high grade
C 6i	6400/4000	breast cancer, ductal	ductal	micropapillary, low grade
C 6j	7200/4000	breast cancer, ductal	ductal	comedo, high grade
C 7a	0/4800	breast cancer, ductal	ductal	comedo, high grade
C 7b	800/4800	breast cancer, ductal	ductal	comedo, high grade
C 7c	1600/4800	breast cancer, ductal	ductal	cribriform, low grade
C 7d	2400/4800	breast cancer, ductal	ductal	comedo, high grade
C 7e	3200/4800	breast cancer, ductal	ductal	comedo, high grade
C 7f	4000/4800	breast cancer, ductal	ductal	comedo, high grade
C 7g	4800/4800	breast cancer, ductal	ductal	comedo, high grade
C 7h	5600/4800	breast cancer, ductal	ductal	solid, low grade
C 7i	6400/4800	breast cancer, ductal	ductal	comedo, high grade
C 7j	7200/4800	breast cancer, ductal	ductal	solid, low grade
C 8a	0/5600	breast cancer, ductal	ductal	comedo, high grade
C 8b	800/5600	breast cancer, ductal	ductal	solid, low grade
C 8c	1600/5600	breast cancer, ductal	ductal	comedo, high grade
C 8d	2400/5600	breast cancer, ductal	ductal	solid, low grade
C 8e	3200/5600	breast cancer, ductal	ductal	comedo, high grade
C 8f	4000/5600	breast cancer, ductal	ductal	micropapillary, low grade
C 8g	4800/5600	breast cancer, ductal	ductal	comedo, high grade
C 8h	5600/5600	breast cancer, ductal	ductal	comedo, high grade
C 8i	6400/5600	breast cancer, ductal	ductal	micropapillary, low grade
C 8j	7200/5600	breast cancer, ductal	ductal	comedo, high grade
C 9a	0/6400	breast cancer, ductal	ductal	solid, low grade

Appendix A
Table 14
Clinomics Breast Cancer Array Data for Known Molecular Markers

BRE grade	Tubuli	Polymorphy	Mitoses	Tumor diameter	pT	pN	LN all
3	2	2	1	15	1	1	26
3	3	2	1	17	1	0	7
3	3	3	3	30	2		0
3	3	3	2	35	2	1	21
3	2	1	1	42	2	1	26
3	3	3	1	20	1	1	20
3	3	3	3	17	1	0	12
3	5	2	2	38	2	0	16
3	3	2	1	17	1	1	31
3	1	2	1	30	2		0
3	3	2	1	23	2	0	28
3	3	3	3	17	1	1	21
3	3	3	2	25	2	1	19
3	2	2	1	13	1	0	27
3	2	2	1	24	2	2	13
3	2	3	1	23	2	1	20
3	2	3	1	21	2	0	20
3	3	3	2	38	2	1	19
3	1	2	1	80	4	2	12
3	3	3	1	21	2	0	20
3	3	3	1	40	4	1	14
3	3	2	3	36	4		0
3	3	2	3	40	2	1	24
3	3	3	3	22	2	0	20
3	3	3	2	22	2	0	13
3	3	3	2	16	1	0	16
3	3	2	1		2	0	18
3	3	3	3	20	1	1	15
3	3	3	2	22	2	1	11
3	2	2	1		2	2	15
3	2	2	1	21	2	1	11
3	5	2	2	60	3	1	19
3	3	3	3	60	4		0
3	3	2	1	23	2	1	12
3	3	3	3	40	2	1	29
3	3	2	1	13	1	0	30
3	1	2	1		4		0
3	3	3	3	22	2	0	9
3	3	3	2	35	2	1	8
3	3	3	2		2	0	12
3	3	2	1	7	1	0	11
3	3	3	3		1	1	25
3	3	3	2	14	1	0	12
3	3	2	1	11	1	1	9
3	1	2	1	35	2	1	17
3	3	2	1	24	2	0	24
3	3	3	2	52	3	0	28
3	1	2	1	18	1	1	22
3	2	2	1	14	1	0	27
3	2	2	1	34	2	0	17
3	5	2	2	33	2	1	18
3	3	3	3	28	2	1	34
3	3	2	1	23	2	0	14
3	3	3	3	35	2	0	6
3	3	2	1	35	2	1	24
3	1	2	1	37	2	1	20
3	3	2	1	20	1	1	21
2	2	3	2	15	4	1	8
2	3	2	1	18	1	1	27
2	3	2	1	24	2		0
2	3	2	1	40	2	1	22
2	3	2	1	24	2	0	26

Appendix A
Table 14
Clinomics Breast Cancer Array Data for Known Molecular Markers

LN pos	age	Survival/Mo	identification nr.	Her-2/neu	Cathepsin D	NM23
5	50	10	1164	Pos	Pos	Neg
0	46	10	1165	Pos	Neg	Neg
	48	17	1166	Pos	Neg	Pos
8	37	19	1167	Pos	Neg	Pos
6	44	21	1168	Pos	Neg	Pos
3	52	26	1169	Pos	Pos	Neg
0	49	10	1170	Pos	Pos	Neg
0	38	20	1171	Pos	Neg	Pos
7	45	15	1172	Pos	Neg	Pos
	52	14	1173	Pos	Pos	Pos
0	50	0	1174	Pos	Pos	Pos
1	38	10	1175	Pos	Pos	Pos
4	45	24	1176	Pos	Pos	Pos
0	53	12	1177	Pos	Neg	Neg
11	46	29	1178	Pos	Neg	Neg
1	54	23	1179	Pos	Neg	Pos
0	40	10	1180	Pos	Pos	Pos
2	50	7	1181	Pos	Pos	Pos
4	46	17	1182	Pos	Pos	Pos
0	40	2	1183	Pos	Pos	Neg
7	50	10	1184	Pos	Pos	Neg
	46	10	1185	Neg	Pos	Neg
1	41	17	1185	Neg	Neg	Pos
0	51	19	1187	Neg	Pos	Neg
0	47	21	1188	Neg	Pos	Pos
0	42	26	1189	Neg	Pos	Pos
0	51	10	1190	Neg	Pos	Pos
1	47	20	1191	Neg	Pos	Pos
4	42	15	1192	Pos	Pos	Pos
8	51	14	1193	Pos	Pos	Pos
1	47	0	1194	Pos	Pos	Pos
15	42	10	1195	Neg	Pos	Pos
	51	24	1196	Neg	Neg	Pos
1	47	12	1197	Neg	Neg	Neg
14	33	29	1198	Neg	Pos	Pos
0	43	10	1199	Neg	Pos	Pos
	51	17	1200	Neg	Pos	Pos
0	48	19	1201	Neg	Pos	Neg
4	35	1	1202	Neg	Pos	Pos
0	43	26	1203	Neg	Pos	Neg
0	52	0	1204	Pos	Pos	Neg
1	46	20	1205	Pos	Pos	Neg
0	54	15	1206	Pos	Pos	Neg
1	39	14	1207	Neg	Pos	Pos
2	50	0	1208	Pos	Pos	Pos
0	48	10	1209	Pos	Pos	Pos
0	37	24	1210	Pos	Pos	Pos
3	43	0	1211	Pos	Pos	Pos
0	52	29	1212	Neg	Neg	Neg
0	48	23	1213	Neg	Neg	Neg
10	37	10	1214	Neg	Neg	Pos
1	44	9	1215	Pos	Pos	Pos
0	52	17	1216	Pos	Pos	Pos
0	48	2	1217	Pos	Pos	Pos
11	37	10	1218	Pos	Pos	Neg
2	44	60	1219	Neg	Pos	Neg
14	52	48	1220	Neg	Pos	Neg
5	50	7		Neg	Neg	Pos
2	54	17		Pos	Pos	Neg
	40	2		Pos	Pos	Pos
5	48	10		Pos	Pos	Pos
0	52	10		Pos	Pos	Pos

307

Appendix A
Table 14
Clinomics Breast Cancer Array Data for Known Molecular Markers

localization	Coordinates	Category	Histologic type	Subtype
C 9b	800/6400	breast cancer, ductal	ductal	comedo, high grade
C 9c	1600/6400	breast cancer, ductal	ductal	solid, low grade
C 9d	2400/6400	breast cancer, ductal	ductal	comedo, high grade
C 9e	3200/6400	breast cancer, ductal	ductal	solid, low grade
C 9f	4000/6400	breast cancer, ductal	ductal	comedo, high grade
C 9g	4800/6400	breast cancer, ductal	ductal	solid, low grade
C 9h	5600/6400	breast cancer, ductal	ductal	comedo, high grade
C 9i	6400/6400	breast cancer, ductal	ductal	comedo, high grade
C 9j	7200/6400	breast cancer, ductal	ductal	solid, low grade
		breast cancer, ductal	ductal	comedo, high grade
D 1a	0/0	breast cancer, ductal	ductal	solid, low grade
D 1b	800/0	breast cancer, ductal	ductal	comedo, high grade
D 1c	1600/0	breast cancer, ductal	ductal	micropapillary, low grade
D 1d	2400/0	breast cancer, ductal	ductal	comedo, high grade
D 1e	3200/0	breast cancer, ductal	ductal	solid, low grade
D 1f	4000/0	breast cancer, ductal	ductal	comedo, high grade
D 1g	4800/0	breast cancer, ductal	ductal	micropapillary, low grade
D 1h	5600/0	breast cancer, ductal	ductal	comedo, high grade
D 1i	6400/0	breast cancer, ductal	ductal	comedo, high grade
D 1j	7200/0	breast cancer, ductal	ductal	comedo, high grade
D 2a	0/800	breast cancer, ductal	ductal	cribriform, low grade
D 2b	800/800	breast cancer, ductal	ductal	comedo, high grade
D 2c	1600/800	breast cancer, ductal	ductal	comedo, high grade
D 2d	2400/800	breast cancer, ductal	ductal	solid, low grade
D 2e	3200/800	breast cancer, ductal	ductal	comedo, high grade
D 2f	4000/800	breast cancer, ductal	ductal	solid, low grade
D 2g	4800/800	breast cancer, ductal	ductal	comedo, high grade
D 2h	5600/800	breast cancer, ductal	ductal	solid, low grade
D 2i	6400/800	breast cancer, ductal	ductal	comedo, high grade
D 2j	7200/800	breast cancer, ductal	ductal	solid, low grade
D 3a	0/1600	breast cancer, ductal	ductal	comedo, high grade
D 3b	800/1600	breast cancer, ductal	ductal	micropapillary, low grade
D 3c	1600/1600	breast cancer, ductal	ductal	comedo, high grade
D 3d	2400/1600	breast cancer, ductal	ductal	comedo, high grade
D 3e	3200/1600	breast cancer, ductal	ductal	micropapillary, low grade
D 3f	4000/1600	breast cancer, ductal	ductal	comedo, high grade
D 3g	4800/1600	breast cancer, ductal	ductal	comedo, high grade
D 3h	5600/1600	breast cancer, ductal	ductal	comedo, high grade
D 3i	6400/1600	breast cancer, ductal	ductal	cribriform, low grade
D 3j	7200/1600	breast cancer, ductal	ductal	comedo, high grade
D 4a	0/2400	breast cancer, ductal	ductal	comedo, high grade
D 4b	800/2400	breast cancer, ductal	ductal	comedo, high grade
D 4c	1600/2400	breast cancer, ductal	ductal	comedo, high grade
D 4d	2400/2400	breast cancer, ductal	ductal	solid, low grade
D 4e	3200/2400	breast cancer, ductal	ductal	comedo, high grade
D 4f	4000/2400	breast cancer, ductal	ductal	solid, low grade
D 4g	4800/2400	breast cancer, ductal	ductal	comedo, high grade
D 4h	5600/2400	breast cancer, ductal	ductal	solid, low grade
D 4i	6400/2400	breast cancer, ductal	ductal	comedo, high grade
D 4j	7200/2400	breast cancer, ductal	ductal	solid, low grade
D 5a	0/3200	breast cancer, ductal	ductal	comedo, high grade
D 5b	800/3200	breast cancer, ductal	ductal	micropapillary, low grade
D 5c	1600/3200	breast cancer, ductal	ductal	comedo, high grade
D 5d	2400/3200	breast cancer, ductal	ductal	comedo, high grade
D 5e	3200/3200	breast cancer, ductal	ductal	micropapillary, low grade
D 5f	4000/3200	breast cancer, ductal	ductal	comedo, high grade
D 5g	4800/3200	breast cancer, ductal	ductal	comedo, high grade
D 5h	5600/3200	breast cancer, ductal	ductal	comedo, high grade
D 5i	6400/3200	breast cancer, ductal	ductal	comedo, high grade
D 5j	7200/3200	breast cancer, ductal	ductal	solid, low grade
D 6a	0/4000	breast cancer, ductal	ductal	comedo, high grade
D 6b	800/4000	breast cancer, ductal	ductal	comedo, high grade

00966673-092601

Appendix A
Table 14
Clinomics Breast Cancer Array Data for Known Molecular Markers

BRE grade	Tubuli	Polymorphy	Mitoses	Tumor diameter	pT	pN	LN all
2	3	2	1	22	2	1	19
2	3	3	1	18	1	1	10
2	3	3	3	15	4	1	8
2	3	3	3	18	1	1	27
2	2	3	1	24	2		0
2	3	3	2	40	2	1	22
2	3	2	2	24	2	0	26
2	2	3	1	22	2	1	19
2	2	2	1	18	1	1	10
2	2	1	1	15	1	1	16
2	2	2	1	20	1	1	31
2	3	2	1	40	2	2	16
2	3	3	3	78	4	1	12
2	3	3	2	29	2	1	13
2	2	1	1	24	2	0	26
2	3	3	1	22	2	1	19
2	3	3	3	18	1	1	10
2	5	2	2	15	1	1	16
2	3	2	1	20	1	1	31
2	1	2	1	40	2	2	16
2	3	2	1	78	4	1	12
2	3	3	3	29	2	1	13
2	3	3	2	30	2	0	15
2	2	2	1		3	1	16
2	2	2	1	8	1	0	22
2	2	3	1	30	2	1	11
3	2	3	1	28	2	0	21
3	3	3	2	19	1	2	18
3	1	2	1	22	2	1	12
3	3	3	1	15	1	1	26
3	3	3	1	17	1	0	7
3	3	2	3	30	2		0
3	3	2	3	35	2	1	21
3	3	3	3	42	2	1	26
3	3	3	2	20	1	1	20
3	3	3	2	17	1	0	12
3	3	2	1	38	2	0	16
3	3	3	3	17	1	1	31
3	3	3	2	30	2		0
3	2	2	1	23	2	0	28
3	2	2	1	17	1	1	21
3	5	2	2	25	2	1	19
3	3	3	3	13	1	0	27
3	3	2	1	24	2	2	13
3	3	3	3	23	2	1	20
3	3	2	1	21	2	0	20
3	1	2	1	38	2	1	19
3	3	3	3	80	4	2	12
3	3	3	2	21	2	0	20
3	3	3	2	40	4	1	14
3	3	2	1	36	4		0
3	3	3	3	40	2	1	24
3	3	3	2	22	2	0	20
3	3	2	1	22	2	0	13
3	1	2	1	16	1	0	16
3	3	2	1		2	0	18
3	3	3	2	20	1	1	15
3	1	2	1	22	2	1	11
3	2	2	1		2	2	15
3	2	2	1	21	2	1	11
3	5	2	2	60	3	1	19
3	3	3	3	60	4		0

311

Appendix A
Table 14
Clinomics Breast Cancer Array Data for Known Molecular Markers

localization	Coordinates	Category	Histologic type	Subtype
D 6c	1800/4000	breast cancer, ductal	ductal	solid, low grade
D 6d	2400/4000	breast cancer, ductal	ductal	comedo, high grade
D 6e	3200/4000	breast cancer, ductal	ductal	solid, low grade
D 6f	4000/4000	breast cancer, ductal	ductal	comedo, high grade
D 6g	4800/4000	breast cancer, ductal	ductal	micropapillary, low grade
D 6h	5600/4000	breast cancer, ductal	ductal	comedo, high grade
D 6i	6400/4000	breast cancer, ductal	ductal	solid, low grade
D 6j	7200/4000	breast cancer, ductal	ductal	comedo, high grade
D 7a	0/4800	breast cancer, ductal	ductal	micropapillary, low grade
D 7b	800/4800	breast cancer, ductal	ductal	comedo, high grade
D 7c	1600/4800	breast cancer, ductal	ductal	comedo, high grade
D 7d	2400/4800	breast cancer, ductal	ductal	comedo, high grade
D 7e	3200/4800	breast cancer, ductal	ductal	cribriform, low grade
D 7f	4000/4800	breast cancer, ductal	ductal	comedo, high grade
D 7g	4800/4800	breast cancer, ductal	ductal	comedo, high grade
D 7h	5600/4800	breast cancer, ductal	ductal	solid, low grade
D 7i	6400/4800	breast cancer, ductal	ductal	comedo, high grade
D 7j	7200/4800	breast cancer, ductal	ductal	solid, low grade
D 8a	0/5600	breast cancer, ductal	ductal	comedo, high grade
D 8b	800/5600	breast cancer, ductal	ductal	solid, low grade
D 8c	1600/5600	breast cancer, ductal	ductal	comedo, high grade
D 8d	2400/5600	breast cancer, ductal	ductal	solid, low grade
D 8e	3200/5600	breast cancer, ductal	ductal	comedo, high grade
D 8f	4000/5600	breast cancer, ductal	ductal	micropapillary, low grade
D 8g	4800/5600	breast cancer, ductal		comedo, high grade
D 8h	5600/5600	breast cancer, ductal		comedo, high grade
D 8i	6400/5600	breast cancer, ductal		micropapillary, low grade
D 8j	7200/5600	breast cancer, ductal		comedo, high grade
D 9a	0/6400	breast cancer, ductal		comedo, high grade
D 9b	800/6400	breast cancer, ductal		comedo, high grade
D 9c	1600/6400	breast cancer, ductal		cribriform, low grade
D 9d	2400/6400	breast cancer, ductal		comedo, high grade
D 9e	3200/6400	breast cancer, ductal		comedo, high grade
D 9f	4000/6400	breast cancer, ductal		comedo, high grade
D 9g	4800/6400	breast cancer, ductal		comedo, high grade
D 9h	5600/6400	breast cancer, ductal		solid, low grade
D 9i	6400/6400	breast cancer, ductal		comedo, high grade
D 9j	7200/6400	breast cancer, ductal		solid, low grade
Normal				
E 1a	0/0		normal brain	
E 1b	800/0		normal brain	
E 1c	1600/0		normal heart	
E 1d	2400/0		normal heart	
E 2a	0/800		normal lymph node	
E 2b	800/800		normal lymph node	
E 3a	0/1600		normal muscle	
E 3b	800/1600		normal muscle	
E 4a	0/2400		normal adrenal gland	
E 4b	800/2400		normal adrenal gland	
E 5a	0/3200		normal liver	
E 5b	800/3200		normal liver	
E 6a	0/4000		normal testis	
E 6b	800/4000		normal testis	
E 7a	0/4800		normal kidney	
E 7b	800/4800		normal kidney	
E 8a	0/5600		normal spleen	
E 8b	800/5600		normal spleen	
E 9a	0/6400		normal thyroid	
E 9b	800/6400		normal thyroid	
F				
F 1a	0/0		normal brain	
F 1b	800/0		normal brain	

Appendix A
Table 14
Clinomics Breast Cancer Array Data for Known Molecular Markers

BRE grade	Tubuli	Polymorphy	Mitoses	Tumor diameter	pT	pN	LN all
3	3	2	1	23	2	1	12
3	3	3	3	40	2	1	29
3	3	2	1	13	1	0	30
3	1	2	1		4		0
3	3	2	1	22	2	0	9
3	2	3	2	35	2	1	8
3	3	2	1		2	0	12
3	3	2	1	7	1	0	11
3	3	2	1		1	1	25
3	3	2	1	14	1	0	12
3	3	2	1	11	1	1	9
3	3	3	1	35	2	1	17
3	3	3	3	24	2	0	24
3	3	3	3	52	3	0	28
3	2	3	1	18	1	1	22
3	3	3	2	14	1	0	27
3	3	2	2	34	2	0	17
3	2	3	1	33	2	1	18
3	2	2	1	28	2	1	34
3	2	1	1	23	2	0	14
3	2	2	1	35	2	0	6
3	3	2	1	35	2	1	24
3	3	3	3	37	2	1	20
3	3	3	2	20	1	1	21
4	2	1	1	33	2	1	18
4	3	3	1	28	2	1	34
4	3	3	3	23	2	0	14
4	5	2	2	35	2	0	6
4	3	2	1	35	2	1	24
4	1	2	1	37	2	1	20
4	3	2	1	20	1	1	21
4	3	3	3	23	2	0	14
4	3	3	2	35	2	0	6
4	2	2	1	35	2	1	24
4	2	2	1	37	2	1	20
4	2	3	1	20	1	1	21
4	2	3	1	33	2	1	18
4	3	3	2	28	2	1	34

Appendix A
Table 14
Clinomics Breast Cancer Array Data for Known Molecular Markers

LN pos	age	Survival/Mo	identification nr.	Her-2/neu	Cathepsin D	NM23
1	47	14	1197	Neg	Pos	Neg
14	33	0	1198	Pos	Pos	Neg
0	43	10	1199	Pos	Pos	Neg
	51	24	1200	Pos	Pos	Neg
0	48	12	1201	Neg	Neg	Pos
4	35	29	1202	Pos	Neg	Neg
0	43	23	1203	Pos	Neg	Neg
0	52	10	1204	Pos	Pos	Neg
1	46	7	1205	Pos	Neg	Neg
0	54	17	1206	Neg	Pos	Neg
1	39	10	1207	Neg	Neg	Neg
2	50	10	1208	Neg	Neg	Pos
0	48	8	1209	Pos	Pos	Pos
0	37	19	1210	Pos	Pos	Pos
3	43	5	1211	Pos	Pos	Pos
0	54	26	1212	Pos	Pos	Neg
0	40	10	1213	Neg	Pos	Neg
10	50	20	1214	Neg	Pos	Neg
1	46	15	1215	Neg	Neg	Pos
0	40	14	1216	Pos	Pos	Neg
0	50	0	1217	Pos	Pos	Pos
11	46	10	1218	Pos	Pos	Pos
2	41	24	1219	Pos	Pos	Pos
14	51	12	1220	Pos	Pos	Pos
10	47	29		Pos	Pos	Pos
1	54	23		Pos	Neg	Pos
0	40	10		Pos	Neg	Neg
0	50	10		Pos	Neg	Neg
11	46	10		Pos	Neg	Neg
2	40	8		Pos	Pos	Neg
14	50	19		Pos	Pos	Pos
0	46	5		Pos	Neg	Pos
0	41	26		Pos	Neg	Neg
11	51	10		Pos	Neg	Neg
2	47	20		Pos	Neg	Neg
14	42	15		Neg	Neg	Neg
10	51	14		Neg	Neg	Neg
1	47	0		Neg	Neg	Neg
	51		1221	Neg	Neg	Neg
	47		1222	Neg	Neg	Neg
	42		1223	Neg	Neg	Neg
	51		1224	Neg	Neg	Neg
	40		1225	Neg	Neg	Neg
	51		1226	Neg	Neg	Neg
	45		1227	Neg	Neg	Neg
	51		1228	Neg	Neg	Neg
	47		1229	Neg	Neg	Neg
	42		1230	Neg	Neg	Neg
	42		1231	Neg	Neg	Pos
	46		1232	Neg	Neg	Neg
	50		1233	Neg	Neg	Neg
	51		1234	Neg	Neg	Neg
	50		1235	Neg	Pos	Neg
	46		1236	Neg	Neg	Neg
	41		1237	Neg	Neg	Neg
	51		1238	Neg	Neg	Neg
	47		1239	Neg	Neg	Neg
	42		1240	Neg	Neg	Neg
				Neg	Neg	Neg
	49		1221	Neg	Neg	Neg
	51		1222	Neg	Neg	Neg

[illegible]

Appendix A
Table 14
Clinomics Breast Cancer Array Data for Known Molecular Markers

localization	Coordinates	Category	Histologic type	Subtype
F 1c	1600/0		normal heart	
F 1d	2400/0		normal heart	
F 2a	0/800		normal lymph node	
F 2b	800/800		normal lymph node	
F 3a	0/1600		normal muscle	
F 3b	800/1600		normal muscle	
F 4a	0/2400		normal adrenal gland	
F 4b	800/2400		normal adrenal gland	
F 5a	0/3200		normal liver	
F 5b	800/3200		normal liver	
F 6a	0/4000		normal testis	
F 6b	800/4000		normal testis	
F 7a	0/4800		normal kidney	
F 7b	800/4800		normal kidney	
F 8a	0/5600		normal spleen	
F 8b	800/5600		normal spleen	
F 9a	0/6400		normal thyroid	
F 9b	800/6400		normal thyroid	

Appendix A
Table 14
Clinomics Breast Cancer Array Data for Known Molecular Markers

BRE grade	Tubuli	Polymorphy	Mitoses	Tumor diameter	pT	pN	LN all
-----------	--------	------------	---------	----------------	----	----	--------

0956573 : 092804

00000000000000000000

318

Coordinate	Sex	Age	Organ	Tumor Type	Grad	Pt	Pn	LN	LN	DM	Surgery	Resection	Clark	Distant	a-FRBP51
												Margins	Level	Metastasis	Staining
Gnd 1	M	74	Colon	Adenocarcinoma	T3	N1	10	2	5		Colectomy	Negative			2
A-2	F	81	Colon	Adenocarcinoma	T3	N1	14	3	3		Colectomy	Negative			0
A-3	F	65	Colon	Adenocarcinoma	T3	N0	16	0	5		Colectomy	Negative			0
A-4	M	69	Colon	Adenocarcinoma	T2	N0	10	0	1		Colectomy	Negative			0
A-5	M	67	Colon	Adenocarcinoma	T3	N0	5	0	2		Colectomy	Negative			2
A-6	F	83	Colon	Adenocarcinoma	T1	NX			2		Colectomy	Negative			1
A-7	F	70	Colon	Adenocarcinoma	T3	N2	7	7	4		Colectomy	Negative			3
A-8	F	79	Colon	Colorectal Carcinoma	T3	N0	10	0	2		Colectomy	Negative			1
A-9	F	60	Colon	Adenocarcinoma	T3	NX			3		Colectomy	Negative			2
A-10	F	52	Colon	Adenocarcinoma	T3	NX			2		Colectomy	Negative			2
B-1	F	59	Colon	Adenocarcinoma	T2	NX			2		Colectomy	Negative			N
B-2	F	71	Colon	Adenocarcinoma	T3	NX			2		Colectomy	Negative			N
B-3	M	82	Colon	Adenocarcinoma	T3	NX			1		Colectomy	Negative			0
B-4	F	81	Colon	Adenocarcinoma	T3	NX			1		Colectomy	Negative			1
B-5	M	35	Colon	Adenocarcinoma	T3	NX			3		Colectomy	Negative			1
B-6	M	50	Colon	Adenocarcinoma	T3	NX			1		Colectomy	Negative			N
B-7	F	74	Colon	Adenocarcinoma	T3	N2	10	8	6		Colectomy	Positive			1
B-8	F	69	Colon	Adenocarcinoma	T3	N1	3	1	3		Colectomy	Positive			2
B-9	M	71	Colon	Adenocarcinoma	T3	NX			2		Colectomy	Positive			3
B-10	F	52	Colon	Adenocarcinoma	T3	NX					Colectomy	Positive			3
C-1	M	82	Prostate	Transitional cell carcinoma	T2	NX					Needle biopsy				N
C-2	M	72	Prostate	Adenocarcinoma	T1	NX					TUR				N
C-3	M	66	Prostate	Adenocarcinoma	T1	NX					Needle biopsy				0
C-4	M	66	Prostate	Adenocarcinoma	T1	NX					TUR				1
C-5	M	75	Prostate	Adenocarcinoma	T1	NX					TUR				1
C-6	M	75	Prostate	Adenocarcinoma	T1	NX					TUR				1
C-7	M	55	Prostate	Adenocarcinoma	T1	NX					TUR				2
C-8	M	72	Prostate	Adenocarcinoma	T1	NX					TUR				N
C-9	M	56	Prostate	Adenocarcinoma	T1	NX					TUR				2
C-10	M	69	Prostate	Adenocarcinoma	T1	NX					TUR				2
D-1	M	69	Prostate	Adenocarcinoma	T1	NX					TUR				4
D-2	M	74	Prostate	Adenocarcinoma	T1	NX					TUR				0
D-3	M	N/A	Prostate	Adenocarcinoma	T1	NX					TUR				N
D-4	M	83	Prostate	Transitional cell carcinoma	T1S	NX					TUR				N
D-5	M	69	Prostate	Adenocarcinoma	T1	NX					TUR				1
D-6	M	90	Prostate	Adenocarcinoma	T1	NX					TUR				2
D-7	M	82	Prostate	Transitional cell carcinoma	T2	NX					Needle biopsy				2
D-8	M	72	Prostate	Adenocarcinoma	T1	NX					TUR				2
D-9	M	66	Prostate	Adenocarcinoma	T1	NX					TUR				2

Coordinates	Sex	Age	Organ	Tumor Type	Grad	Pt	Pn	LN	LN	DM	Surgery	Resection	Clark	Distant	a-FKBP51
D-10	M	55	Possible	Adenocarcinoma											
E-1	M	82	Bladder	Transitional cell carcinoma	4	T2	NX				TUR	Margins	Level	Metastasis	Shaving
E-2	M	N/A	Bladder	Transitional cell carcinoma	3,4	T2	NX				Needle biopsy				2
E-3	N/A	71	Bladder	Transitional cell carcinoma	1	T1	NX				TUR				1
E-4	M	72	Bladder	Transitional cell carcinoma	2	T1	NX				Needle biopsy				0
E-5	N/A	80	Bladder	Transitional cell carcinoma	2	T1	NX				Needle biopsy				2
E-6	F	74	Bladder	Transitional cell carcinoma	2	T1	NX				Needle biopsy				N
E-7	F	77	Bladder	Transitional cell carcinoma	2	T1	NX				Needle biopsy				N
E-8	M	46	Bladder	Transitional cell carcinoma	2	T1	NX				Needle biopsy				N
E-9	F	68	Bladder	Transitional cell carcinoma	3,4	T2	NX				Needle biopsy				3
E-10	M	61	Bladder	Transitional cell carcinoma	3	T2	NX				Needle biopsy				3
G4-2	M	83	Bladder	Transitional cell carcinoma	2	T1	NX				TUR				1
F-1	M	82	Bladder	Transitional cell carcinoma	2	T1	NX				Needle biopsy				1
F-2	M	86	Bladder	Adenocarcinoma	1	T1	NX				Needle biopsy				1
F-3	N/A	N/A	Bladder	Transitional cell carcinoma	3,4	T1	NX				Needle biopsy				N
F-4	N/A	87	Bladder	Transitional cell carcinoma	2	T1	NX				Needle biopsy				3
F-5	M	81	Bladder	Transitional cell carcinoma	3,4	T2	NX				Needle biopsy				3
F-6	M	78	Bladder	Transitional cell carcinoma	2	T1	NX				Needle biopsy				N
F-7	M	89	Bladder	Transitional cell carcinoma	3	T2	NX				Needle biopsy				2
F-8	M	84	Bladder	Transitional cell carcinoma	2,3	T2	NX				Needle biopsy				3
F-9	F	77	Bladder	Transitional cell carcinoma	2	T1	NX				Needle biopsy				4
F-10	F	73	Lung	Squamous cell carcinoma	17	NX					Biopsy				4
G-1	N/A	62	Lung	Bronchio alveolar carcinoma	11	NX					Wedge resection				1
G-2	F	32	Lung	Adenocarcinoma	7	0	3				Left lobectomy				2
G-3	N/A	55	Lung	Lymphoma	11	NX					Biopsy				2
G-4	F	77	Lung	Squamous cell carcinoma	11	10	3				Left lobectomy				2
G-5	M	85	Lung	Lymphatic carcinoma	11	7	2				Right lobectomy				2
G-6	N/A	71	Lung	Keratinous carcinoma	11	NO	2				Left lobectomy				1
G-7	N/A	76	Lung	Squamous cell carcinoma	13	NX					Right lobectomy				1
G-8	M	57	Lung	Adenocarcinoma	13	NX					Right lobectomy				2
G-9	M	67	Lung	Squamous cell carcinoma	13	NX					Right lobectomy				2
G-10	M	68	Lung	Adenocarcinoma	13	NX					Right lobectomy				2
H-1	M	68	Lung	Epidermoid carcinoma	12	NO					Right lobectomy				1
H-2	M	69	Lung	Adenocarcinoma	12	N1	4				Right lobectomy				1
H-3	M	46	Lung	Adenocarcinoma	11	NX					Biopsy				1
H-4	M	71	Lung	Poorly differentiated carcinoma	11	NX					Biopsy				1
H-5	M	32	Lung	Adenocarcinoma	12	NX					Wedge resection				1
H-6	M	32	Lung	Lymphatic carcinoma	12	NX					Left lobectomy				1
H-7	M	32	Lung	Adenocarcinoma	12	NX					Left lobectomy				1
H-8	N/A	61	Lung	Lymphatic carcinoma	12	NX					Left lobectomy				1

321

a-FKBP51 Data

322

2-FKBP51 Data

323

Cancer Screening Array

324

Coordinates	Sex	Age	Organ	Tumor Type	Grade	PI	Ph	LN	LN	LN	DM	Surgery	Resection Margins	Clark Level	Distant Metastasis	RCAT Staining
E-1	M	82	Bladder	Transitional cell carcinoma	3-4	12	NX					Needle biopsy.				3
E-2	M	N/A	Bladder	Transitional cell carcinoma	1	11	NX					TUR				N
E-3	N/A	71	Bladder	Transitional cell carcinoma	2	11	NX					Needle biopsy				N
E-4	M	72	Bladder	Transitional cell carcinoma	1	11	NX					Needle biopsy				N
E-5	N/A	80	Bladder	Transitional cell carcinoma	2	11	NX					Needle biopsy				N
E-6	F	74	Bladder	Transitional cell carcinoma	2	11	NX					Needle biopsy				N
E-7	F	77	Bladder	Transitional cell carcinoma	2	11	NX					Needle biopsy				N
E-8	M	46	Bladder	Transitional cell carcinoma	3-4	12	NX					Needle biopsy				3
E-9	F	68	Bladder	Transitional cell carcinoma	3	12	NX					Needle biopsy				3
E-10	M	61	Bladder	Transitional cell carcinoma	2	11	NX					Needle biopsy				3
G1-2	M	83	Bladder	Transitional cell carcinoma	2	11	NX					TUR				3
F-1	M	62	Bladder	Transitional cell carcinoma	2	11	NX					Needle biopsy				2
F-2	M	85	Bladder	Adenocarcinoma	1	11	NX					Needle biopsy				N
F-3	M	N/A	Bladder	Transitional cell carcinoma	3-4	11	NX					Needle biopsy				N
F-4	N/A	87	Bladder	Transitional cell carcinoma	2	11	NX					Needle biopsy				N
F-5	M	81	Bladder	Transitional cell carcinoma	3-4	12	NX					Needle biopsy				N
F-6	M	76	Bladder	Transitional cell carcinoma	2	11	NX					Needle biopsy				N
F-7	F	89	Bladder	Transitional cell carcinoma	2	11	NX					Needle biopsy				N
F-8	M	84	Bladder	Transitional cell carcinoma	2-3	12	NX					Needle biopsy				N
F-9	F	77	Bladder	Transitional cell carcinoma	2	11	NX					Needle biopsy				N
F-10	F	77	Bladder	Transitional cell carcinoma	2	11	NX					Needle biopsy				N
G-1	N/A	73	Lung	Squamous cell carcinoma	12	NX						Biopsy				N
G-2	F	62	Lung	Bronchio alveolar carcinoma	12	NX						Right lobectomy				N
G-3	N/A	32	Lung	Adenocarcinoma	11	NX						Wedge resection				3
G-4	N/A	35	Lung	Adenocarcinoma	11	NX						Left lobectomy				3
G-5	F	17	Lung	Lymphoma	12	NX						Biopsy				3
G-6	M	85	Lung	Squamous cell carcinoma	12	NX						Left lobectomy				N
G-7	N/A	61	Lung	Lymphangitic carcinoma	14	NX						Right lobectomy				N
G-8	N/A	71	Lung	Keratinizing carcinoma	11	NX						Left lobectomy				N
G-9	F	76	Lung	Squamous cell carcinoma	11	NX						Left lobectomy				N
G-10	M	57	Lung	Adenocarcinoma	13	NX						Right lobectomy				4
H-1	M	67	Lung	Squamous cell carcinoma	13	NX						Right lobectomy				3
H-2	F	68	Lung	Adenocarcinoma	13	NX						Right lobectomy				N
H-3	M	68	Lung	Epidermoid carcinoma	13	NX						Right lobectomy				N
H-4	F	69	Lung	Adenocarcinoma	12	NX						Right lobectomy				N
H-5	M	46	Lung	Adeno-squamous cell carcinoma	12	NX						Right lobectomy				N
H-6	M	71	Lung	Mesothelioma	11	NX						Biopsy				3
H-7	M	32	Lung	Poorly differentiated carcinoma	11	NX						Wedge resection				N
H-8	N/A	32	Lung	Adenocarcinoma	11	NX						Left lobectomy				1
H-9	N/A	61	Lung	Keratinizing carcinoma	12	NX						Left lobectomy				4
H-10	N/A	71	Lung	Keratinizing carcinoma	14	NX						Right lobectomy				2

CS 200 83100 Clinomics Oncology Array
Cancer Screening Array
CA125 Staining of Ovarian, Endometrial, and Cervical Adenocarcinomas

Coordinates	Sex	Age	Organ	Tumor Type	Grade	Pt.	Ph.	LN	LN	DM	Surgery	Resection	Clark	Distant	RCAT
								all	pos			Margins	level	metastase	Staining
L-1	N/A	64	Kidney	Renal cell carcinoma	T1	NX				6	Left nephrectomy	Negative	4	M1	1
L-2	M	60	Kidney	Adenocarcinoma	T3	N0		4		7	Left nephrectomy	Positive	4	M1	3
L-3	M	76	Kidney	Adenocarcinoma	T1	N0		6		7	Left nephrectomy	Negative	4	M1	3
L-4	M	76	Kidney	Adenocarcinoma	TX	NX				7	Needle biopsy	Negative	3	M1	3
L-5	M	50	Kidney	Adenocarcinoma	T1	N0		2		6	Left nephrectomy	Negative	2	M0	2
L-6	M	55	Kidney	Adenocarcinoma	T1	N0		2		6	Left nephrectomy	Negative	2	M0	2
L-7	M	55	Kidney	Adenocarcinoma	T1	N0		2		7	Left nephrectomy	Negative	3	M0	3
L-8	M	76	Kidney	Renal cell carcinoma	T1	NX		6		7	Right nephrectomy	Negative	4	M1	3
L-9	F	65	Kidney	Renal cell carcinoma	T1	NX				7	Right nephrectomy	Negative	4	M1	3
L-10	F	65	Kidney	Renal cell carcinoma	T1	NX				7	Right nephrectomy	Negative	4	M1	3
L-1	F	66	Skin	Malignant melanoma	TX	NX				3	Excisional biopsy	Negative	4	M1	1
L-2	F	66	Skin	Malignant melanoma	T4	NX				2	Excisional biopsy	Positive	4	M1	3
L-3	F	N/A	Skin	Malignant melanoma	T4	NX				2	Excisional biopsy	Negative	4	M1	3
L-4	F	N/A	Skin	Malignant melanoma	T4	NX				2	Excisional biopsy	Negative	4	M1	3
L-5	M	66	Skin	Malignant melanoma	T2	NX				2	Excisional biopsy	Negative	3	M1	3
L-6	M	70	Skin	Malignant melanoma	T2	NX				2	Excisional biopsy	Negative	3	M1	3
L-7	M	N/A	Skin	Malignant melanoma	T1	NX				2	Excisional biopsy	Negative	2	M0	2
L-8	M	36	Skin	Malignant melanoma	T2	NX				2	Excisional biopsy	Negative	3	M0	2
L-9	F	50	Skin	Malignant melanoma	T3	NX				2	Excisional biopsy	Negative	4	M1	3
L-10	N/A	N/A	Skin	Malignant melanoma	T1	NX				2	Excisional biopsy	Positive	2	M1	2
Grid 3															
K-1	M	85	Skin	Basal cell carcinoma	T1	NX				1	Excisional biopsy	Negative		MX	N
K-2	M	64	Skin	Basal cell carcinoma	T1	NX				1	Excisional biopsy	Positive		MX	N
K-3	M	87	Skin	Basal cell carcinoma	T1	NX				1	Excisional biopsy	Negative		MX	N
K-4	N/A	82	Skin	Basal cell carcinoma	T2	NX				2	Excisional biopsy	Negative		MX	N
K-5	M	52	Skin	Basal cell carcinoma	T1	NX				1	Excisional biopsy	Positive		M1	N
K-6	F	69	Skin	Basal cell carcinoma	T1	NX				1	Excisional biopsy	Negative		MX	N
K-7	M	39	Skin	Basal cell carcinoma	T2	NX				2	Excisional biopsy	Negative		MX	N
K-8	M	N/A	Skin	Basal cell carcinoma	T2	NX				2	Excisional biopsy	Negative		MX	N
K-9	F	56	Skin	Squamous cell carcinoma	T2	NX				1	Excisional biopsy	Negative		M0	N
K-10	F	81	Skin	Basal cell carcinoma	T1	NX				1	Excisional biopsy	Negative		MX	N
L-1	M	57	Skin	Basal cell carcinoma	T2	NX				2	Excisional biopsy	Positive		MX	2
L-2	M	57	Skin	Basal cell carcinoma	T2	NX				2	Excisional biopsy	Negative		MX	2
L-3	M	78	Skin	Basal cell carcinoma	T1	NX				1	Excisional biopsy	Negative		MX	N
L-4	N/A	N/A	Skin	Squamous cell carcinoma	T1	NX				1	Excisional biopsy	Negative		MX	2
L-5	N/A	N/A	Skin	Basal cell carcinoma	T1	NX				1	Excisional biopsy	Negative		MX	N
L-6	N/A	42	Skin	Basal cell carcinoma	T1	NX				1	Excisional biopsy	Negative		MX	N
L-7	F	69	Skin	Basal cell carcinoma	T2	NX				2	Excisional biopsy	Negative		MX	N
L-8	M	82	Skin	Basal cell carcinoma	T2	NX				2	Excisional biopsy	Negative		MX	N
L-9	N/A	75	Skin	Basal cell carcinoma	T1	NX				1	Excisional biopsy	Negative		MX	N
L-10	N/A	75	Skin	Squamous cell carcinoma	T1	NX				1	Excisional biopsy	Negative		MX	2

Coordinates	Sex	Age	Organ	Tumor Type	Grade	Pt	Ph	LN	LN	pos	DM	Surgery	Reaction	Clark	RCAS
													Margins	Level	Distant
															Staining
M-1	M	82	Skin	Basal cell carcinoma	T2	NX						Mastectomy	Positive		MX
M-2	F	46	Skin	Basal cell carcinoma	T1	NX						Excisional biopsy	Positive		MX
M-3	M	60	Skin	Basal cell carcinoma	T1	NX						Excisional biopsy	Positive		MX
M-4	M	63	Skin	Basal cell carcinoma	T1	NX						Excisional biopsy	Positive		MX
M-5	F	52	Tongue	Squamous cell carcinoma	T1	NX						Excisional biopsy	Positive		M1
M-6	F	78	Skin	Basal cell carcinoma	T1	NX						Excisional biopsy	Positive		MX
M-7	M	73	Skin	Basal cell carcinoma	T1	NX						Excisional biopsy	Positive		MX
M-8	M	51	Skin	Basal cell carcinoma	T2	NX						Excisional biopsy	Negative		MX
M-9	F	53	Skin	Basal cell carcinoma	T2	NX						Excisional biopsy	Negative		MX
M-10	M	76	Skin	Squamous cell carcinoma	T2	NX						Excisional biopsy	Negative		MX
N-1	F	46	Breast	Ductal carcinoma	T1	N1	6	1				Mastectomy	Negative		N
N-2	F	65	Breast	Ductal carcinoma	T2	NX						Lumpectomy	Positive		N
N-3	F	59	Breast	Ductal carcinoma	T2	NX						Lumpectomy	Positive		N
N-4	F	79	Breast	Ductal carcinoma	T2	NX						Lumpectomy	Positive		N
N-5	F	56	Breast	Lobular carcinoma	T1	NX						Lumpectomy	Positive		N
N-6	F	58	Breast	Ductal carcinoma	T2	NX						Lumpectomy	Positive		N
N-7	F	61	Breast	Ductal carcinoma	T2	NX						Lumpectomy	Positive		N
N-8	F	83	Breast	Ductal carcinoma	T2	NX						Lumpectomy	Positive		N
N-9	F	73	Breast	Ductal carcinoma	T1	NX						Lumpectomy	Positive		N
N-10	F	68	Breast	Ductal carcinoma	T1	NX						Lumpectomy	Negative		N
O-1	F	57	Breast	Adenoid cystic carcinoma	T2	NX						Lumpectomy	Positive		1
O-2	F	67	Breast	Ductal carcinoma	T2	NX						Lumpectomy	Positive		N
O-3	F	71	Breast	Ductal carcinoma	T2	NX						Mastectomy	Positive		N
O-4	F	71	Breast	Ductal carcinoma	T2	NX						Mastectomy	Positive		N
O-5	F	68	Breast	Lobular carcinoma	T2	NX						Lumpectomy	Positive		N
O-6	F	43	Breast	Ductal carcinoma	T2	NX						Lumpectomy	Positive		N
O-7	F	88	Breast	Ductal carcinoma	T1	N1	17	5				Mastectomy	Negative		1
O-8	F	46	Breast	Ductal carcinoma	T1	N1	6	1				Mastectomy	Negative		N
O-9	F	59	Breast	Ductal carcinoma	T2	NX						Lumpectomy	Positive		N
O-10	F	67	Breast	Ductal carcinoma	T2	NX						Lumpectomy	Positive		N
Gird 4															
P-1	F	62	Cervix	Squamous cell carcinoma	T1	NX						Biopsy	Negative		N
P-2	F	33	Cervix	Carcinoma-in-situ	T1S	NX						Biopsy	Negative		N
P-3	F	29	Cervix	Carcinoma-in-situ	T1S	NX						Biopsy	Negative		N
P-4	F	61	Cervix	Squamous cell carcinoma	T1	NX						Biopsy	Positive		N
P-5	F	40	Cervix	Carcinoma-in-situ	T1S	NX						Biopsy	Negative		N
P-6	F	34	Cervix	Carcinoma-in-situ	2	T1S	NX					Biopsy	Negative		N
P-7	F	27	Cervix	Carcinoma-in-situ	T1S	NX						Biopsy	Negative		N
P-8	F	51	Cervix	Squamous cell carcinoma	T1S	NX						Biopsy	Negative		N
P-9	F	28	Cervix	Carcinoma-in-situ	T1S	NX						Biopsy	Negative		N

Table 16
CS 200 83100 Clinicomics Oncology Array
Cancer Screening Array
CA125 Staining of Ovarian, Endometrial, and Cervical Adenocarcinomas

Coordinates	Sex	Age	Organ	Tumor Type	Grade	Pr	LN	LN	DM	Surgery	Reaction	Clk	Diast	RCAS
O-1	F	91	Tonsil	Squamous cell carcinoma	Grade	Pr	LN	LN	DM	Surgery	Reaction	Clk	Diast	RCAS
O-2	F	92	Lymph node	Lymphoma	T1	NX			1	Biopsy	Positive			3
O-3	F	94	Stomach	Adenocarcinoma	T4	N0	7	0	2	Stomach resection				3
O-4	F	95	Stomach	Adenocarcinoma	T4	NX	5	5	2	Biopsy	Negative			4
O-5	M	79	Stomach	Adenocarcinoma	T4	N1	5	5	2	Distal resection	Negative			2
O-6	M	82	Penis	Malignant melanoma	T2	N1	3	1	5	Lobectomy	Negative			4
O-7	M	75	Lung	Adenocarcinoma	T2	N1	3	1	5	Part. gastrectomy	Negative			4
O-8	F	82	Stomach	Gastrointestinal tumor	T2	N1	17	1	3	Part. gastrectomy	Negative			4
O-9	F	69	Liver	Adenocarcinoma	T2	N1	17	1	3	Wedge resection	Negative			4
O-10	F	71	Breast	Ductal carcinoma	T2	NX			3	Biopsy	Positive			3
R-1	F	33	Thyroid	Follicular adenoma	T2	NX			4	Biopsy				2
R-2	F	33	Thyroid	Follicular adenoma	T2	NX			4	Biopsy				2
R-3	M	64	Bladder	Transitional cell carcinoma	T2	NX			4	Biopsy				2
R-4	M	66	Bladder	Transitional cell carcinoma	T2	NX			4	Biopsy				2
R-5	M	83	Bladder	Transitional cell carcinoma	T2	NX			4	Biopsy				2
R-6	M	71	Bladder	Transitional cell carcinoma	T2	NX			4	Biopsy				2
R-7	M	82	Bladder	Transitional cell carcinoma	T2	NX			4	Biopsy				2
R-8	F	77	Bladder	Transitional cell carcinoma	T2	NX			4	Biopsy				2
R-9	M	75	Bladder	Transitional cell carcinoma	T2	NX			4	Biopsy				2
R-10	M	60	Bladder	Transitional cell carcinoma	T2	NX			4	Biopsy				2
S-1	F	63	Bladder	Transitional cell carcinoma	T4	NX			1	Biopsy				3
S-2	M	73	Bladder	Transitional cell carcinoma	T4	NX			1	Biopsy				3
S-3	N/A	78	Bladder	Transitional cell carcinoma	T4	NX			1	Biopsy				3
S-4	M	77	Bladder	Transitional cell carcinoma	T4	NX			1	Biopsy				3
S-5	M	76	Bladder	Transitional cell carcinoma	T4	NX			1	Biopsy				3
S-6	F	72	Tibia	Lymphoma	T2	NX			2	Biopsy				4
S-7	M	54	Lymph node	Lymphoma	T2	NX			2	Biopsy				4
S-8	F	55	Subcutaneous mass	Lymphoma	T2	NX			2	Biopsy				4
S-9	M	57	Lymph node	Lymphoma	T2	NX			2	Biopsy				4
S-10	F	82	Lymph node	Lymphoma	T2	NX			2	Biopsy				4
T-1	M	42	Lymph node	Lymphoma	T2	NX			2	Biopsy				4
T-2	M	88	Colon	Lymphoma	T2	NX			2	Biopsy				4
T-3	F	73	Lymph node	Lymphoma	T2	NX			2	Biopsy				4
T-4	M	66	Lymph node	Lymphoma	T2	NX			2	Biopsy				4
T-5	F	80	Lymph node	Lymphoma	T2	NX			2	Biopsy				4
T-6	N/A	N/A	Lymph node	Lymphoma	T2	NX			2	Biopsy				4
T-7	M	57	Lymph node	Lymphoma	T2	NX			2	Biopsy				4
T-8	M	42	Lymph node	Lymphoma	T2	NX			2	Biopsy				4
T-9	N/A	N/A	Colon	Lymphoma	T2	NX			2	Biopsy				4
T-10	F	73	Lymph node	Lymphoma	T2	NX			2	Biopsy				4

Appendix A
Table 17
NO 200 #90100 Clinomics Oncology and Normal Array Job #1190
Normal Tissue Array
CA125 Staining of Ovarian, Endometrial, and Cervical Adenocarcinomas

Coordinates	Sex	Ag	Organ	Diagnosis	Surgery	RCAS1 Staining
Grid 1						
A-1	M	60	Prostate	Prostatic hyperplasia	TUR	N
A-2	M	75	Prostate	Prostatic hypertrophy	TUR	N
A-3	M	66	Prostate	Prostatic hyperplasia	TUR	N
A-4	M	89	Prostate	Prostatic hyperplasia	TUR	N
A-5	M	67	Prostate	Prostatic hyperplasia	TUR	2+
A-6	M	71	Prostate	Prostatic hyperplasia	TUR	N
A-7	M	74	Prostate	Prostatic hyperplasia	TUR	N
A-8	M	72	Prostate	Prostatic hyperplasia	TUR	N
A-9	M	74	Prostate	Prostatic hyperplasia	TUR	3+
A-10	M	71	Prostate	Prostatic hyperplasia	TUR	N
B-1	M	68	Prostate	Prostatic hyperplasia	TUR	N
B-2	M	71	Prostate	Prostatic hyperplasia	TUR	3+
B-3	M	84	Prostate	Prostatic hyperplasia	TUR	N
B-4	M	69	Prostate	Prostatic hyperplasia	TUR	N
B-5	M	69	Prostate	Prostatic hyperplasia	TUR	3+
B-6	M	62	Prostate	Prostatic hyperplasia	TUR	2+
B-7	M	57	Prostate	Prostatic hyperplasia	TUR	N
B-8	M	68	Prostate	Prostatic hyperplasia	TUR	N
B-9	M	68	Prostate	Prostatic hyperplasia	TUR	N
B-10	M	65	Prostate	Prostatic hyperplasia	TUR	N
C-1	M	86	Prostate	Prostatic hyperplasia	TUR	N
C-2	M	68	Prostate	Prostatic hyperplasia	TUR	3+
C-3	M	72	Prostate	Prostatic hyperplasia	TUR	N
C-4	M	70	Prostate	Prostatic hyperplasia	TUR	1+
C-5	M	71	Prostate	Prostatic hyperplasia	TUR	2+
C-6	M	60	Prostate	Prostatic hyperplasia	TUR	N
C-7	M	64	Prostate	Prostatic hyperplasia	TUR	N
C-8	M	77	Prostate	Prostatic hyperplasia	TUR	N
C-9	M	73	Prostate	Prostatic hyperplasia	TUR	N
C-10	M	77	Prostate	Prostatic hyperplasia	TUR	3+
D-1	M	78	Prostate	Prostatic hyperplasia	TUR	2+
D-2	M	65	Prostate	Prostatic hyperplasia	TUR	N
D-3	M	78	Prostate	Prostatic hyperplasia	TUR	N
D-4	M	73	Prostate	Prostatic hyperplasia	TUR	N
D-5	M	77	Prostate	Prostatic hyperplasia	TUR	3+
D-6	M	75	Prostate	Prostatic hyperplasia	TUR	2+
D-7	M	80	Prostate	Prostatic hyperplasia	TUR	2+
D-8	M	73	Prostate	Prostatic hyperplasia	TUR	2+
D-9	M	75	Prostate	Prostatic hyperplasia	TUR	3+
D-10	M	80	Prostate	Prostatic hyperplasia	TUR	4+
E-1	M	78	Prostate	Prostatic hyperplasia	TUR	N
E-2	M	63	Prostate	Prostatic hyperplasia	TUR	N
E-3	M	69	Prostate	Prostatic hyperplasia	TUR	N
E-4	M	82	Prostate	Prostatic hyperplasia	TUR	2+
E-5	M	78	Prostate	Prostatic hyperplasia	TUR	N
E-6	M	75	Prostate	Prostatic hyperplasia	TUR	1+
E-7	M	60	Prostate	Prostatic hyperplasia	TUR	N
E-8	M	66	Prostate	Prostatic hyperplasia	TUR	N
E-9	M	64	Prostate	Prostatic hyperplasia	TUR	N
E-10	M	73	Prostate	Prostatic hyperplasia	TUR	N
Grid 2						
F-1	F	N/A	Breast		Mastectomy	N

Appendix A

Table 17

NO 200 #90100 Clinomics Oncology and Normal Array Job #1190

Normal Tissue Array

CA125 Staining of Ovarian, Endometrial, and Cervical Adenocarcinomas

F-2	F	52	Breast	Fibrocystic disease	Biopsy	N
F-3	F	69	Breast	Fibrocystic disease	Biopsy	3+
F-4	F	43	Breast	Epidermal inclusion cyst	Biopsy	N
F-5	F	50	Breast	Fibrocystic disease	Biopsy	3+
F-6	F	39	Breast	Fibrocystic disease	Biopsy	N
F-7	F	49	Breast	Fibrocystic disease	Biopsy	N
F-8	F	38	Breast	Fibrocystic disease	Biopsy	3+
F-9	F	53	Breast	Fibrocystic disease	Biopsy	N
F-10	F	74	Breast	Fibrocystic disease	Biopsy	N
G-1	F		Breast	Fibrocystic disease	Biopsy	N
G-2	F		Breast	Fibrocystic disease	Biopsy	N
G-3	F		Breast	Fibrocystic disease	Biopsy	3+
G-4	F		Breast	Fibrocystic disease	Biopsy	N
G-5	F		Breast	Chronic mastitis	Biopsy	N
G-6	F		Breast	Fibrocystic disease	Biopsy	N
G-7	F		Breast	Fibrocystic disease	Biopsy	N
G-8	F		Breast	Perilobular fibrosis	Biopsy	N
G-9	F		Breast	Fibroadenoma	Biopsy	N
G-10	F		Breast	Fibrocystic disease	Biopsy	N
H-1	F		Breast	Fibrocystic disease	Biopsy	3+
H-2	F		Breast	Fibrocystic disease	Biopsy	N
H-3	F		Breast	Fibrocystic disease	Biopsy	N
H-4	F		Breast	Fibrosis	Biopsy	N
H-5	F		Breast	Fibroadenoma	Biopsy	N
H-6	F		Breast	Fibrocystic disease	Biopsy	N
H-7	F		Breast	Fibrocystic disease	Biopsy	N
H-8	F		Breast	Fibrocystic disease	Biopsy	N
H-9	F		Breast	Fibrocystic disease	Biopsy	3+
H-10	F		Breast	Fibrocystic disease	Biopsy	3+
I-1	F	N/A	Breast	Fibrocystic disease	Biopsy	N
I-2	F	35	Breast	Fibrocystic disease	Biopsy	N
I-3	F	29	Breast	Fibrocystic disease	Biopsy	N
I-4	F	77	Breast	Fibrocystic disease	Biopsy	N
I-5	F	69	Breast	Fibrocystic disease	Biopsy	N
I-6	F	68	Breast	Fibrocystic disease	Biopsy	N
I-7	F	51	Breast	Fibrocystic disease	Biopsy	4+
I-8	F	52	Breast		Biopsy	3+
I-9	F	54	Breast	Chronic inflammation	Biopsy	3+
I-10	F	80	Breast	Fibrocystic disease	Biopsy	N
J-1	F	39	Breast	Fibrocystic disease	Biopsy	3+
J-2	F	41	Breast	No pathological diagnosis	Biopsy	N
J-3	F	48	Breast	Fibrocystic disease	Biopsy	N
J-4	F	61	Breast	Fibrocystic disease	Biopsy	N
J-5	F	65	Breast	Fibrocystic disease	Biopsy	N
J-6	F	52	Breast	Fibrocystic disease	Biopsy	N
J-7	F	72	Breast	Fibrocystic disease	Biopsy	N
J-8	F	56	Breast	Fibrocystic disease	Mastectomy	N
J-9	F	54	Breast	Fibrocystic disease	Biopsy	N
J-10	F	N/A	Breast	Fibrocystic disease	Biopsy	N
Grid 3						
K-1	F	48	Skin	Hemangioma	Biopsy	3+
K-2	M	10	Skin	Pyogenic granuloma	Biopsy	3+
K-3	M	51	Skin	Parakeratosis; dermatitis	Biopsy	N
K-4		45	Skin	Seborrheic keratosis	Biopsy	N
K-5	MF	55	Skin	Hemangioma	Biopsy	N

Appendix A

Table 17

NO 200 #90100 Clinomics Oncology and Normal Array Job #1190

Normal Tissue Array

CA125 Staining of Ovarian, Endometrial, and Cervical Adenocarcinomas

K-6	F	73	Skin	Hemangioma	Biopsy	N
K-7	M	33	Skin	Chronic dermatitis	Biopsy	3+
K-8	F	19	Skin	Intradermal nevus	Biopsy	N
K-9	F	28	Skin	Dermatofibroma	Biopsy	N
L-1	M	13	Skin	Pyogenic granuloma	Biopsy	3+
L-2	F	42	Skin	Angiokeratoma	Biopsy	N
L-3	M	33	Skin	Intradermal nevus	Biopsy	3+
L-4	M	56	Skin	Hemangioma	Biopsy	0
L-5	F	43	Skin	Hemangioma	Biopsy	N
L-6	F	23	Skin	Dermatofibroma	Biopsy	2+
L-7	M	24	Skin	Pyogenic granuloma	Biopsy	3+
L-8	F	68	Skin	Intradermal nevus	Biopsy	3+
L-9	F	30	Skin	Intradermal nevus	Biopsy	3+
L-10	M	32	Skin	Dermatofibroma	Biopsy	N
M-1	M	36	Skin	Dermatofibroma	Biopsy	3+
M-2	F	71	Skin	Intradermal nevus	Biopsy	3+
M-3	F	35	Skin	Epidermal inclusion cyst	Biopsy	N
M-4	M	47	Skin	Dermatofibroma	Biopsy	N
M-5	M	N/A	Skin	Dermatofibroma	Biopsy	N
M-6	F	N/A	Skin	Dermatofibroma	Biopsy	3+
M-7	F	53	Skin	Intradermal nevus	Biopsy	3+
M-8	F	43	Skin	Epidermal inclusion cyst	Biopsy	N
M-9	M	28	Skin	Dermatofibroma	Biopsy	N
M-10	M	48	Skin	Intradermal nevus	Biopsy	3+
N-1	M	28	Testes	Testicular atrophy	Testectomy	N
N-2	M	38	Testes	Testicular atrophy	Testectomy	4+
N-3	M	53	Epididymis; testes	Necrosis of testicular parenchyma	Testectomy	3+
N-4	M	74	Epididymis; testes	Spermatocele	Testectomy	3+
N-5	M	78	Testes	Decreased spermatogenesis	Testectomy	3+
N-6	M	78	Testes	Decreased spermatogenesis	Testectomy	2+
N-7	M	78	Testes	Decreased spermatogenesis	Testectomy	N
N-8	M	82	Testes	Decreased spermatogenesis	Testectomy	3+
N-9	M	82	Testes	Decreased spermatogenesis	Testectomy	4+
N-10	M	53	Epididymis; testes	Ectatic epididymis tubules	Testectomy	N
O-1	M	77	Liver	Capsular angioma	Biopsy	N
O-2	F	67	Liver	Fatty metamorphosis	Biopsy	N
O-3	F	32	Liver	Chronic inflammation; fibrosis	Biopsy	3+
O-4	F	26	Liver	Chronic triaditis	Biopsy	4+
O-5	N/A	55	Gallbladder	Cholecystitis	Cholecystectomy	N
O-6	M	40	Liver	Chronic triaditis	Biopsy	N
O-7	F	32	Liver	No diagnostic alterations	Biopsy	3+
O-8	M	73	Liver	Chronic inflammation; fibrosis	Biopsy	N
O-9	M	73	Liver	Chronic inflammation; fibrosis	Biopsy	N
O-10	M	73	Liver	Chronic inflammation; fibrosis	Biopsy	N
P-1	M	N/A	Colon	Tubular adenoma	Biopsy	3+
P-2	F	91	Colon	Tubular adenoma	Biopsy	N
P-3	F	41	Colon	Tubular adenoma	Biopsy	4+
P-4	M	71	Colon	Tubular adenoma	Biopsy	N
P-5	F	58	Colon	Tubular adenoma	Biopsy	3+
P-6	M	69	Colon	Tubular adenoma	Biopsy	1+
P-7	M	81	Colon	Tubular adenoma	Biopsy	N
P-8	F	44	Colon	Tubular adenoma	Biopsy	3+
P-9	M	66	Colon	Tubular adenoma	Biopsy	2+
P-10	F	60	Colon	Tubular adenoma	Biopsy	N

Appendix A

Table 17

NO 200 #90100 Clinomics Oncology and Normal Array Job #1190
Normal Tissue Array
CA125 Staining of Ovarian, Endometrial, and Cervical Adenocarcinomas

Q-1	M	84	Colon	Tubular adenoma	Biopsy	3+
Q-2	M	42	Substantia nigra	Unremarkable	Autopsy	2+
Q-3	M	42	Medulla oblongata	Unremarkable	Autopsy	2+
Q-4	M	42	Cerebellum	Unremarkable	Autopsy	3+
Q-5	M	40	Parathyroid	Nodular hyperplasia	Parathyroidectomy	3+
Q-6	M	100	Lung	Bronchopneumonia	Autopsy	N
Q-7	F	52	Spleen	Unremarkable	Autopsy	4+
Q-8	F	100	Spleen	Unremarkable	Autopsy	4+
Q-9	F	44	Thyroid	Unremarkable	Autopsy	1+
Q-10	M	15	Tonsil	Lymphoid hyperplasia	Tonsilectomy	3+
R-1	F	79	Cervix	No diagnostic abnormality	Hysterectomy	N
R-2	F	79	Cervix	No diagnostic abnormality	Hysterectomy	N
R-3	F	43	Cervix	Dysplasia	Cone biopsy	N
R-4	F	43	Cervix	Dysplasia	Cone biopsy	N
R-5	F	35	Ovary	Paraovarian cysts	Hysterectomy	N
R-6	F	52	Ovary	No diagnostic abnormality	Autopsy	N
R-7	F	31	Uterus	No diagnostic abnormality	Autopsy	2+
R-8	F	80	Cervix	No diagnostic abnormality	Hysterectomy	N
R-9	F	35	Uterus	Adenomyosis	Hysterectomy	N
R-10	F	35	Cervix	No diagnostic abnormality	Hysterectomy	N
S-1	F	71	Kidney	Arterial nephrosclerosis	Autopsy	N
S-2	F	71	Kidney	Arterial nephrosclerosis	Autopsy	N
S-3	F	31	Coronary artery	Unremarkable		1+
S-4	F	31	Coronary artery	Unremarkable		1+
S-5	F	71	Left ventricle	Chronic ischemic cardiomyopathy	Autopsy	4+
S-6	F	31	Heart	Unremarkable	Autopsy	4+
S-7	F	31	Heart	Unremarkable	Autopsy	4+
S-8	F	71	Right ventricle	Chronic ischemic cardiomyopathy	Autopsy	3+
S-9	F	71	Right atrium	Chronic ischemic cardiomyopathy	Autopsy	3+
S-10	F	52	Trachea	Unremarkable	Autopsy	N
T-1	F	70	Appendix	Appendicitis	Appendectomy	N
T-2	F	35	Small bowel	Serositis	Resection	N
T-3	F	35	Retroperitoneum	Lipoma	Biopsy	N
T-4	M	82	Skin; penis	No diagnostic abnormalities	Biopsy	N
T-5	M	63	Prostate	BPH	TUR	3+
T-6	M	5	Tonsil	Tonsillitis	Tonsilectomy	4+
T-7	M	15	Tonsil	Tonsillitis	Tonsilectomy	4+
T-8	F	70	Appendix	Appendicitis	Appendectomy	4+
T-9	M	51	Prostate	No diagnostic abnormalities	Prostatectomy	3+
T-10	F	79	Cervix	No diagnostic abnormalities	Hysterectomy	N

TMA PR 200 Lot 1 #2

333

NO 50 LOT 1 #2 Clinomics Laboratories Frozen Array Data
a-Testosterone Staining of Prostate and Normal Tissue Arrays
TMA PR 200 Lot 1 #2

COORDINATES	SEX	AGE	ORGAN	TUMOR TYPE	GLEASON 1	GLEASON 2	GLEASON SUM	PT	PN	SURGERY	a-Test Staining Epithelium	Stroma
A-10d	M	78	Prostate	Adenocarcinoma	3	4	7	T1	Nx	TUR	1+	1+
A-1e	M	78	Prostate	Adenocarcinoma	3	4	7	T1	Nx	TUR	2+	1+
A-2e	M	78	Prostate	Adenocarcinoma	3	4	7	T1	Nx	TUR	M	M
A-3e	M	78	Prostate	Adenocarcinoma	3	4	7	T1	Nx	TUR	2+	1+
A-4e	M	78	Prostate	Adenocarcinoma	3	4	7	T1	Nx	TUR	1+	1+
A-5e	M	78	Prostate	Adenocarcinoma	3	4	7	T1	Nx	TUR	2+	1+
A-6e	M	78	Prostate	Adenocarcinoma	3	4	7	T1	Nx	TUR	2+	1+
A-7e	M	78	Prostate	Adenocarcinoma	3	4	7	T1	Nx	TUR	2+	1+
A-8e	M	78	Prostate	Adenocarcinoma	3	4	7	T1	Nx	TUR	2+	1+
A-9e	M	78	Prostate	Adenocarcinoma	3	4	7	T1	Nx	TUR	2+	1+
A-10e	M	78	Prostate	Adenocarcinoma	3	4	7	T1	Nx	TUR	2+	1+
B-1a	M	83	Prostate	Adenocarcinoma	2	3	5	T1b	Nx	TUR	2+	1+
B-2a	M	83	Prostate	Adenocarcinoma	2	3	5	T1b	Nx	TUR	M	M
B-3a	M	83	Prostate	Adenocarcinoma	2	3	5	T1b	Nx	TUR	2+	1+
B-4a	M	83	Prostate	Adenocarcinoma	2	3	5	T1b	Nx	TUR	2+	2+
B-5a	M	83	Prostate	Adenocarcinoma	2	3	5	T1b	Nx	TUR	2+	1+
B-6a	M	83	Prostate	Adenocarcinoma	2	3	5	T1b	Nx	TUR	2+	2+
B-7a	M	83	Prostate	Adenocarcinoma	2	3	5	T1b	Nx	TUR	1+	1+
B-8a	M	76	Prostate	Adenocarcinoma	3	5	8	T1b	Nx	TUR	M	M
B-9a	M	76	Prostate	Adenocarcinoma	3	5	8	T1b	Nx	TUR	3+	3+
B-10a	M	76	Prostate	Adenocarcinoma	3	5	8	T1b	Nx	TUR	3+	4+
B-1b	M	76	Prostate	Adenocarcinoma	3	5	8	T1b	Nx	TUR	2+	3+
B-2b	M	76	Prostate	Adenocarcinoma	3	5	8	T1b	Nx	TUR	N	3+
B-3b	M	76	Prostate	Adenocarcinoma	3	5	8	T1b	Nx	TUR	2+	2+
B-4b	M	76	Prostate	Adenocarcinoma	3	5	8	T1b	Nx	TUR	2+	2+
B-5b	M	76	Prostate	Adenocarcinoma	3	5	8	T1b	Nx	TUR	2+	2+
B-6b	M	76	Prostate	Adenocarcinoma	3	5	8	T1b	Nx	TUR	2+	3+
B-7b	M	76	Prostate	Adenocarcinoma	3	5	8	T1b	Nx	TUR	2+	2+
B-8b	M	76	Prostate	Adenocarcinoma	3	5	8	T1b	Nx	TUR	M	M
B-9b	M	76	Prostate	Adenocarcinoma	3	5	8	T1b	Nx	TUR	2+	3+
B-10b	M	76	Prostate	Adenocarcinoma	3	5	8	T1b	Nx	TUR	3+	3+
B-1c	M	69	Prostate	Adenocarcinoma	5	5	10	T1	Nx	TUR	N	3+
B-2c	M	69	Prostate	Adenocarcinoma	5	5	10	T1	Nx	TUR	2+	2+
B-3c	M	69	Prostate	Adenocarcinoma	5	5	10	T1	Nx	TUR	N	3+
B-4c	M	69	Prostate	Adenocarcinoma	5	5	10	T1	Nx	TUR	3+	2+
B-5c	M	69	Prostate	Adenocarcinoma	5	5	10	T1	Nx	TUR	N	3+
B-6c	M	69	Prostate	Adenocarcinoma	5	5	10	T1	Nx	TUR	2+	2+
B-7c	M	69	Prostate	Adenocarcinoma	5	5	10	T1	Nx	TUR	3+	2+

COORDINATES		SEX	AGE	ORGAN	TUMOR TYPE	GLEASON 1	GLEASON 2	GLEASON SUM	PT	PN	SURGERY	Stroma
											Epithelium	
B-3c	M	69		Prostate	Adenocarcinoma	5	5	10	T1	Nx	TUR	2+
B-3c	M	69		Prostate	Adenocarcinoma	5	5	10	T1	Nx	TUR	2+
B-10c	M	69		Prostate	Adenocarcinoma	5	5	10	T1	Nx	TUR	2+
B-1d	M	66		Prostate	Adenocarcinoma	5	3	8	T1	Nx	TUR	2+
B-1d	M	66		Prostate	Adenocarcinoma	5	3	8	T1	Nx	TUR	2+
B-3d	M	86		Prostate	Adenocarcinoma	5	3	8	T1	Nx	TUR	2+
B-4d	M	86		Prostate	Adenocarcinoma	5	3	8	T1	Nx	TUR	2+
B-5d	M	86		Prostate	Adenocarcinoma	5	3	8	T1	Nx	TUR	2+
B-6d	M	86		Prostate	Adenocarcinoma	5	3	8	T1	Nx	TUR	2+
B-7d	M	86		Prostate	Adenocarcinoma	5	3	8	T1	Nx	TUR	2+
B-8d	M	86		Prostate	Adenocarcinoma	5	3	8	T1	Nx	TUR	2+
B-9d	M	86		Prostate	Adenocarcinoma	5	3	8	T1	Nx	TUR	2+
B-10d	M	86		Prostate	Adenocarcinoma	5	3	8	T1	Nx	TUR	2+
B-1e	M	86		Prostate	Adenocarcinoma	5	3	8	T1	Nx	TUR	2+
B-2e	M	86		Prostate	Adenocarcinoma	5	3	8	T1	Nx	TUR	2+
B-3e	M	86		Prostate	Adenocarcinoma	5	3	8	T1	Nx	TUR	2+
B-4e	M	86		Prostate	Adenocarcinoma	5	3	8	T1	Nx	TUR	2+
B-5e	M	86		Prostate	Adenocarcinoma	5	3	8	T1	Nx	TUR	2+
B-6e	M	86		Prostate	Adenocarcinoma	5	3	8	T1	Nx	TUR	2+
B-7e	M	86		Prostate	Adenocarcinoma	5	3	8	T1	Nx	TUR	2+
B-8e	M	86		Prostate	Adenocarcinoma	5	3	8	T1	Nx	TUR	2+
B-9e	M	86		Prostate	Adenocarcinoma	5	3	8	T1	Nx	TUR	2+
B-10e	M	86		Prostate	Adenocarcinoma	5	3	8	T1	Nx	TUR	2+
B-1f	M	66		Prostate	prostatic hyperplasia							2+
B-2f	M	81		Prostate	prostatic hyperplasia							2+
B-3f	M	76		Prostate	prostatic hyperplasia							2+
B-4f	M	76		Prostate	prostatic hyperplasia							2+
B-5f	M	76		Prostate	prostatic hyperplasia							2+
GRID C												
C-1a	M	69		Prostate	Adenocarcinoma	1	2	2	T1b	Nx	TUR	2+
C-2a	M	69		Prostate	Adenocarcinoma	1	2	2	T1b	Nx	TUR	2+
C-3a	M	69		Prostate	Adenocarcinoma	1	2	2	T1b	Nx	TUR	2+
C-4a	M	69		Prostate	Adenocarcinoma	1	2	2	T1b	Nx	TUR	2+
C-5a	M	69		Prostate	Adenocarcinoma	1	2	2	T1b	Nx	TUR	2+
C-6a	M	69		Prostate	Adenocarcinoma	1	2	2	T1b	Nx	TUR	2+
C-7a	M	69		Prostate	Adenocarcinoma	1	2	2	T1b	Nx	TUR	2+
C-8a	M	69		Prostate	Adenocarcinoma	1	2	2	T1b	Nx	TUR	2+
C-9a	M	69		Prostate	Adenocarcinoma	1	2	2	T1b	Nx	TUR	2+

Table 18

11/11/14 PM 2:00 L01 1 #2

a-Test Staining

NO 50 LOT 1 #2 Clinometrics Laboratories Frozen Array Data
a-Testosterone Staining of Prostate and Normal Tissue Arrays
TMA PR 200 Lot 1 #2

COORDINATES	SEX	AGE	ORGAN	TUMOR TYPE	GLEASON 1	GLEASON 2	GLEASON SUM	PT	PN	SURGERY	a-Test Staining	
											Epithelium	Stroma
C-7e	M	64	Prostate	Adenocarcinoma	4	5	9	T1	Nx	TUR	3+	2+
C-8e	M	64	Prostate	Adenocarcinoma	4	5	9	T1	Nx	TUR	2+	2+
C-9e	M	64	Prostate	Adenocarcinoma	4	5	9	T1	Nx	TUR	3+	2+
C-10e	M	64	Prostate	Adenocarcinoma	4	5	9	T1	Nx	TUR	1+	1+
C-11	M	66	Prostate	benign prostatic hyperplasia						TUR	2+	2+
C-21	M	66	Prostate	benign prostatic hyperplasia						TUR	1+	1+
C-31	M	66	Prostate	benign prostatic hyperplasia						TUR	2+	2+
GRID D												
D-1a	M	73	Prostate	Adenocarcinoma	2	3	5	T1	Nx	TUR	3+	2+
D-2a	M	73	Prostate	Adenocarcinoma	2	3	5	T1	Nx	TUR	2+	2+
D-3a	M	73	Prostate	Adenocarcinoma	2	3	5	T1	Nx	TUR	M	M
D-4a	M	61	Prostate	Adenocarcinoma	2	3	5	T1	Nx	TUR	3+	2+
D-5a	M	61	Prostate	Adenocarcinoma	2	3	5	T1	Nx	TUR	2+	1+
D-6a	M	68	Prostate	Adenocarcinoma	5	5	10	T1	Nx	TUR	1+	M
D-7a	M	68	Prostate	Adenocarcinoma	5	5	10	T1	Nx	TUR	M	M
D-8a	M	68	Prostate	Adenocarcinoma	5	5	10	T1	Nx	TUR	3+	1+
D-9a	M	68	Prostate	Adenocarcinoma	5	5	10	T1	Nx	TUR	3+	1+
D-10a	M	68	Prostate	Adenocarcinoma	5	5	10	T1	Nx	TUR	3+	2+
D-1b	M	68	Prostate	Adenocarcinoma	5	5	10	T1	Nx	TUR	1+	1+
D-2b	M	68	Prostate	Adenocarcinoma	5	5	10	T1	Nx	TUR	1+	2+
D-3b	M	68	Prostate	Adenocarcinoma	5	5	10	T1	Nx	TUR	1+	1+
D-4b	M	68	Prostate	Adenocarcinoma	5	5	10	T1	Nx	TUR	M	M
D-5b	M	68	Prostate	Adenocarcinoma	5	5	10	T1	Nx	TUR	1+	1+
D-6b	M	68	Prostate	Adenocarcinoma	5	5	10	T1	Nx	TUR	3+	1+
D-7b	M	68	Prostate	Adenocarcinoma	5	5	10	T1	Nx	TUR	3+	2+
D-8b	M	68	Prostate	Adenocarcinoma	5	5	10	T1	Nx	TUR	4+	1+
D-9b	M	68	Prostate	Adenocarcinoma	5	5	10	T1	Nx	TUR	4+	2+
D-10b	M	68	Prostate	Adenocarcinoma	5	5	10	T1	Nx	TUR	M	M
D-1c	M	77	Prostate	Adenocarcinoma	5	5	10	T1	Nx	TUR	1+	2+
D-2c	M	77	Prostate	Adenocarcinoma	5	5	10	T1	Nx	TUR	N	2+
D-3c	M	77	Prostate	Adenocarcinoma	5	5	10	T1	Nx	TUR	2+	1+
D-4c	M	77	Prostate	Adenocarcinoma	5	5	10	T1	Nx	TUR	M	M
D-5c	M	77	Prostate	Adenocarcinoma	5	5	10	T1	Nx	TUR	3+	1+
D-6c	M	77	Prostate	Adenocarcinoma	5	5	10	T1	Nx	TUR	2+	1+
D-7c	M	77	Prostate	Adenocarcinoma	5	5	10	T1	Nx	TUR	2+	1+
D-8c	M	73	Prostate	Adenocarcinoma	2	4	6	T1	Nx	TUR	3+	2+
D-9c	M	73	Prostate	Adenocarcinoma	2	4	6	T1	Nx	TUR	2+	1+
D-10c	M	73	Prostate	Adenocarcinoma	2	4	6	T1	Nx	TUR	1+	1+

0966373 . 092801

NO 50 LOT 1 #2 Clinometrics Laboratories Frozen Array Data
a-Testosterone Staining of Prostate and Normal Tissue Arrays
TMA PR 200 Lot 1 #2

COORDINATES		SE/AGE	ORGAN	TUMOR TYPE	GLEASON 1	GLEASON 2	GLEASON SUM	PT	PN	SURGERY	a-Test Staining Epithelium	Stroma
D-1d	M	73	Prostate	Adenocarcinoma	2	4	6	T1	Nx	TUR	2+	2+
D-2d	M	73	Prostate	Adenocarcinoma	2	4	6	T1	Nx	TUR	3+	1+
D-3d	M	73	Prostate	Adenocarcinoma	2	4	6	T1	Nx	TUR	1+	M
D-4d	M	73	Prostate	Adenocarcinoma	2	4	6	T1	Nx	TUR	M	M
D-5d	M	72	Prostate	Adenocarcinoma	3	4	7	T1	Nx	TUR	3+	2+
D-6d	M	72	Prostate	Adenocarcinoma	3	4	7	T1	Nx	TUR	4+	2+
D-7d	M	72	Prostate	Adenocarcinoma	3	4	7	T1	Nx	TUR	4+	2+
D-8d	M	54	Prostate	Adenocarcinoma	3	2	5	T1	Nx	TUR	2+	1+
D-9d	M	54	Prostate	Adenocarcinoma	3	2	5	T1	Nx	TUR	2+	1+
D-10d	M	94	Prostate	Adenocarcinoma	3	2	5	T1	Nx	TUR	2+	1+
D-16	M	72	Prostate	Adenocarcinoma	5	4	9	T1	Nx	TUR	3+	2+
D-26	M	72	Prostate	Adenocarcinoma	5	4	9	T1	Nx	TUR	3+	1+
D-36	M	72	Prostate	Adenocarcinoma	5	4	9	T1	Nx	TUR	3+	2+
D-46	M	72	Prostate	Adenocarcinoma	5	4	9	T1	Nx	TUR	3+	2+
D-56	M	72	Prostate	Adenocarcinoma	5	4	9	T1	Nx	TUR	4+	2+
D-66	M	72	Prostate	Adenocarcinoma	5	4	9	T1	Nx	TUR	1+	1+
D-76	M	72	Prostate	Adenocarcinoma	5	4	9	T1	Nx	TUR	2+	2+
D-86	M	72	Prostate	Adenocarcinoma	5	4	9	T1	Nx	TUR	N	1+
D-96	M	72	Prostate	Adenocarcinoma	5	4	9	T1	Nx	TUR	3+	2+
#NAME?	M	72	Prostate	Adenocarcinoma	5	4	9	T1	Nx	TUR	1+	2+
D-1f	M	65	Prostate	prostatic hyperplasia						TUR	1+	2+
D-2f	M	81	Prostate	prostatic hyperplasia						TUR	1+	2+
D-3f	M	66	Prostate	prostatic hyperplasia						TUR	1+	1+
D-4f	M	71	Prostate	benign prostatic hyperplasia						TUR	1+	2+
D-5f	M	71	Prostate	benign prostatic hyperplasia						TUR	3+	3+
Controls												
1	F	32	Brain	normal							2+	2+
2	F	6	Heart	normal							2+	2+
3	F	6	Liver	normal							2+	2+
4	F	32	Spleen	normal							1+	1+
5	F	101	Muscle	normal							2+	2+
6	M	62	Testes	normal							3+	3+
7	F	101	Kidney	normal							N	N
8	F	52	Thyroid	normal							2+	2+
9	M	62	Adrenal	normal							2+	2+
10	F	32	Lung	normal							N	N
11	F	36	Breast	normal							4+	4+
12	F	52	Lymph Node	normal								

09566373-092001

Appendix A
Table 19
Oncology Frozen Array
Job #1190

a-CA125 Staining of Ovarian, Endometrial, and Cervical Adenocarcinomas

Case #	Specimen	RCAS1 Staining	Element Stained	RCAS1 Staining	Element Stained	CA125 Staining	Element Stained
1190-1a	Ovarian CA	0 to 4+	Tumor				
1190-1b	Ovarian CA	0 to 4+	Tumor				
1190-1c	Ovarian CA	0 to 4+	Tumor				
1190-2a	Ovarian CA	0	Metastatic Carcinoid				
1190-2b	Ovarian CA	0 to 1+	Metastatic Carcinoid				
1190-3a	Ovarian CA	0 to 1+	Metastatic Carcinoid				
1190-3b	Ovarian CA	0 to 1+	Metastatic Carcinoid				
1190-4a	Ovarian CA	0 to 1+	Tumor				
1190-4b	Ovarian CA	2 to 3+	Tumor				
1190-4c	Ovarian CA	0	Tumor				
1190-5a	Ovarian CA	4+	Tumor				
1190-5b	Ovarian CA	4+	Tumor				
1190-6a	Ovarian CA	1+	Tumor				
1190-6b	Ovarian CA	1 to 2+	Tumor				
1190-6c	Ovarian CA	2 to 3+	Tumor				
1190-7	Ovarian CA	2 to 3+	Tumor				
1190-8a	Ovarian CA	0 to 1+	Metastatic Ovarian CA				
1190-8b	Ovarian CA	0 to 2+	Metastatic Ovarian CA				
1190-9	Ovarian CA	0 to 3+	Tumor				
1190-10	Ovarian CA	0 to 2+	Tumor				
1190-11	Endometrial CA	3 to 4+	Endometrial CA				
1190-12	Endometrial CA	3 to 4+	Endometrial CA				
1190-13	Endometrial CA	4+	Endometrial CA				
1190-14	Endometrial CA	1 to 3+	Endometrial CA				
1190-15	Endometrial CA	1 to 3+	Endometrial CA				
1190-16	Endometrial CA	3 to 4+	Endometrial CA				
1190-17	Endometrial CA	4+	Endometrial CA				
1190-18	Normal Ovary	2 to 4+	Corpus Luteum	1 to 2+	Smooth Muscle*	0	Normal Elements
1190-19	Normal Ovary	2 to 4+	Corpus Luteum	1 to 2+	Smooth Muscle*	0	Normal Elements
1190-20	Normal Ovary	2 to 4+	Corpus Luteum	1 to 2+	Smooth Muscle*	0	Normal Elements
1190-21	Normal Ovary	2 to 4+	Corpus Luteum	1 to 2+	Smooth Muscle*	0	Normal Elements
1190-22	Normal Ovary	2 to 4+	Corpus Luteum	1 to 2+	Smooth Muscle*	0	Normal Elements
1190-23	Cervical CA	3 to 4+	Cervical Adenocarcinoma				
1190-24	Cervical CA	4+	Cervical Adenocarcinoma				
1190-25	Cervical CA	3 to 4+	Cervical Adenocarcinoma				
1190-26	Cervical CA	3 to 4+	Cervical Adenocarcinoma				

Note: The smooth muscle is seen in the section demonstrating fallopian tube

Appendix A
Table 20
NO 50 LOT 1 #2 Clinics Laboratories Frozen Array Data
a-Testosterone Staining of Prostate and Normal Tissue Arrays

Coordinates	Sex	Age	Organ	Diagnosis	Surgery	a-test Staining	
Grid 1						Muscle	Epithelium
A-1	M	60	Prostate	Prostatic hyperplasia	TUR	2+	2+
A-2	M	75	Prostate	Prostatic hypertrophy	TUR	1+	1+
A-3	M	66	Prostate	Prostatic hyperplasia	TUR	M	M
A-4	M	89	Prostate	Prostatic hyperplasia	TUR	M	M
A-5	M	67	Prostate	Prostatic hyperplasia	TUR	1+	3+
A-6	M	71	Prostate	Prostatic hyperplasia	TUR	1+	N
A-7	M	74	Prostate	Prostatic hyperplasia	TUR	2+	N
A-8	M	72	Prostate	Prostatic hyperplasia	TUR	2+	2+
A-9	M	74	Prostate	Prostatic hyperplasia	TUR	1+	2+
A-10	M	71	Prostate	Prostatic hyperplasia	TUR	1+	N
B-1	M	68	Prostate	Prostatic hyperplasia	TUR	1+	N
B-2	M	71	Prostate	Prostatic hyperplasia	TUR	1+	3+
B-3	M	84	Prostate	Prostatic hyperplasia	TUR	2+	N
B-4	M	69	Prostate	Prostatic hyperplasia	TUR	1+	N
B-5	M	69	Prostate	Prostatic hyperplasia	TUR	1+	3+
B-6	M	62	Prostate	Prostatic hyperplasia	TUR	1+	3+
B-7	M	57	Prostate	Prostatic hyperplasia	TUR	2+	N
B-8	M	68	Prostate	Prostatic hyperplasia	TUR	2+	N
B-9	M	68	Prostate	Prostatic hyperplasia	TUR	2+	N
B-10	M	65	Prostate	Prostatic hyperplasia	TUR	M	M
C-1	M	86	Prostate	Prostatic hyperplasia	TUR	1+	N
C-2	M	68	Prostate	Prostatic hyperplasia	TUR	1+	4+
C-3	M	72	Prostate	Prostatic hyperplasia	TUR	2+	N
C-4	M	70	Prostate	Prostatic hyperplasia	TUR	2+	2+
C-5	M	71	Prostate	Prostatic hyperplasia	TUR	2+	3+
C-6	M	60	Prostate	Prostatic hyperplasia	TUR	2+	2+
C-7	M	64	Prostate	Prostatic hyperplasia	TUR	1+	N
C-8	M	77	Prostate	Prostatic hyperplasia	TUR	2+	N
C-9	M	73	Prostate	Prostatic hyperplasia	TUR	1+	N
C-10	M	77	Prostate	Prostatic hyperplasia	TUR	2+	1+
D-1	M	78	Prostate	Prostatic hyperplasia	TUR	2+	2+
D-2	M	65	Prostate	Prostatic hyperplasia	TUR	1+	N
D-3	M	78	Prostate	Prostatic hyperplasia	TUR	M	M
D-4	M	73	Prostate	Prostatic hyperplasia	TUR	1+	N
D-5	M	77	Prostate	Prostatic hyperplasia	TUR	2+	2+
D-6	M	75	Prostate	Prostatic hyperplasia	TUR	1+	2+
D-7	M	80	Prostate	Prostatic hyperplasia	TUR	1+	1+
D-8	M	73	Prostate	Prostatic hyperplasia	TUR	1+	1+
D-9	M	75	Prostate	Prostatic hyperplasia	TUR	1+	2+
D-10	M	80	Prostate	Prostatic hyperplasia	TUR	1+	3+
E-1	M	78	Prostate	Prostatic hyperplasia	TUR	1+	N
E-2	M	63	Prostate	Prostatic hyperplasia	TUR	2+	N
E-3	M	69	Prostate	Prostatic hyperplasia	TUR	1+	N
E-4	M	82	Prostate	Prostatic hyperplasia	TUR	1+	2+
E-5	M	78	Prostate	Prostatic hyperplasia	TUR	2+	N
E-6	M	75	Prostate	Prostatic hyperplasia	TUR	1+	1+
E-7	M	60	Prostate	Prostatic hyperplasia	TUR	0	1+
E-8	M	66	Prostate	Prostatic hyperplasia	TUR	1+	N
E-9	M	64	Prostate	Prostatic hyperplasia	TUR	0	N
E-10	M	73	Prostate	Prostatic hyperplasia	TUR	1+	N
Grid 2						Epithelium	
F-1	F	N/A	Breast		Mastectomy	M	
F-2	F	52	Breast	Fibrocystic disease	Biopsy	M	
F-3	F	69	Breast	Fibrocystic disease	Biopsy	2+	
F-4	F	43	Breast	Epidermal inclusion cyst	Biopsy	3+	
F-5	F	50	Breast	Fibrocystic disease	Biopsy	3+	
F-6	F	39	Breast	Fibrocystic disease	Biopsy	N	
F-7	F	49	Breast	Fibrocystic disease	Biopsy	N	
F-8	F	38	Breast	Fibrocystic disease	Biopsy	N	
F-9	F	53	Breast	Fibrocystic disease	Biopsy	N	
F-10	F	74	Breast	Fibrocystic disease	Biopsy	N	
G-1	F		Breast	Fibrocystic disease	Biopsy	N	

Appendix A

Table 21

NO 50 LOT 1 #2 Clinics Laboratories Frozen Array Data
a-Testosterone Staining of Prostate and Normal Tissue Arrays

Coordinates	Sex	Age	Organ	Diagnosis	Surgery	a-test Staining	
G-2	F		Breast	Fibrocystic disease	Biopsy	N	
G-3	F		Breast	Fibrocystic disease	Biopsy	3+	
G-4	F		Breast	Fibrocystic disease	Biopsy	N	
G-5	F		Breast	Chronic mastitis	Biopsy	N	
G-6	F		Breast	Fibrocystic disease	Biopsy	N	
G-7	F		Breast	Fibrocystic disease	Biopsy	N	
G-8	F		Breast	Perilobular fibrosis	Biopsy	N	
G-9	F		Breast	Fibroadenoma	Biopsy	2+	
G-10	F		Breast	Fibrocystic disease	Biopsy	M	
H-1	F		Breast	Fibrocystic disease	Biopsy	2+	
H-2	F		Breast	Fibrocystic disease	Biopsy	2+	
H-3	F		Breast	Fibrocystic disease	Biopsy	N	
H-4	F		Breast	Fibrosis	Biopsy	N	
H-5	F		Breast	Fibroadenoma	Biopsy	M	
H-6	F		Breast	Fibrocystic disease	Biopsy	N	
H-7	F		Breast	Fibrocystic disease	Biopsy	M	
H-8	F		Breast	Fibrocystic disease	Biopsy	N	
H-9	F		Breast	Fibrocystic disease	Biopsy	3+	
H-10	F		Breast	Fibrocystic disease	Biopsy	N	
I-1	F	N/A	Breast	Fibrocystic disease	Biopsy	0	
I-2	F	35	Breast	Fibrocystic disease	Biopsy	N	
I-3	F	29	Breast	Fibrocystic disease	Biopsy	N	
I-4	F	77	Breast	Fibrocystic disease	Biopsy	N	
I-5	F	69	Breast	Fibrocystic disease	Biopsy	N	
I-6	F	68	Breast	Fibrocystic disease	Biopsy	N	
I-7	F	51	Breast	Fibrocystic disease	Biopsy	3+	
I-8	F	52	Breast	Fibrocystic disease	Biopsy	3+	
I-9	F	54	Breast	Chronic inflammation	Biopsy	3+	
I-10	F	80	Breast	Fibrocystic disease	Biopsy	3+	
J-1	F	39	Breast	Fibrocystic disease	Biopsy	2+	
J-2	F	41	Breast	No pathological diagnosis	Biopsy	N	
J-3	F	48	Breast	Fibrocystic disease	Biopsy	1+	
J-4	F	61	Breast	Fibrocystic disease	Biopsy	N	
J-5	F	65	Breast	Fibrocystic disease	Biopsy	N	
J-6	F	52	Breast	Fibrocystic disease	Biopsy	N	
J-7	F	72	Breast	Fibrocystic disease	Biopsy	N	
J-8	F	56	Breast	Fibrocystic disease	Mastectomy	N	
J-9	F	54	Breast	Fibrocystic disease	Biopsy	N	
J-10	F	N/A	Breast	Fibrocystic disease	Biopsy	N	
Grid 3						Epithelium	Endothelium
K-1	F	48	Skin	Hemangioma	Biopsy	1+	1+
K-2	M	10	Skin	Pyogenic granuloma	Biopsy	2+	2+
K-3	M	51	Skin	Parakeratosis; dermatitis	Biopsy	N	3+
K-4		45	Skin	Seborrheic keratosis	Biopsy	M	M
K-5	MF	55	Skin	Hemangioma	Biopsy	N	2+
K-6	F	73	Skin	Hemangioma	Biopsy	N	N
K-7	M	33	Skin	Chronic dermatitis	Biopsy	N	3+
K-8	F	19	Skin	Intradermal nevus	Biopsy	M	M
K-9	F	28	Skin	Dermatofibroma	Biopsy	M	M
K-10							
L-1	M	13	Skin	Pyogenic granuloma	Biopsy	N	2+
L-2	F	42	Skin	Angiokeratoma	Biopsy	N	2+
L-3	M	33	Skin	Intradermal nevus	Biopsy	N	2+
L-4	M	56	Skin	Hemangioma	Biopsy	N	0
L-5	F	43	Skin	Hemangioma	Biopsy	N	N
L-6	F	23	Skin	Dermatofibroma	Biopsy	N	2+
L-7	M	24	Skin	Pyogenic granuloma	Biopsy	N	2+
L-8	F	68	Skin	Intradermal nevus	Biopsy	N	2+
L-9	F	30	Skin	Intradermal nevus	Biopsy	N	2+
L-10	M	32	Skin	Dermatofibroma	Biopsy	2+	1+
M-1	M	36	Skin	Dermatofibroma	Biopsy	1+	1+
M-2	F	71	Skin	Intradermal nevus	Biopsy	0	2+
M-3	F	35	Skin	Epidermal inclusion cyst	Biopsy	2+	2+
M-4	M	47	Skin	Dermatofibroma	Biopsy	2+	1+

Appendix A
Table 21
NO 50 LOT 1 #2 Clinics Laboratories Frozen Array Data
a-Testosterone Staining of Prostate and Normal Tissue Arrays

Coordinates	Sex	Age	Organ	Diagnosis	Surgery	a-test Staining	
M-5	M	N/A	Skin	Dermatofibroma	Biopsy	2+	1+
M-6	F	N/A	Skin	Dermatofibroma	Biopsy	N	2+
M-7	F	53	Skin	Intradermal nevus	Biopsy	1+	N
M-8	F	43	Skin	Epidermal inclusion cyst	Biopsy	N	2+
M-9	M	28	Skin	Dermatofibroma	Biopsy	2+	2+
M-10	M	48	Skin	Intradermal nevus	Biopsy	0	2+
N-1	M	28	Testes	Testicular atrophy	Testectomy	N	
N-2	M	38	Testes	Testicular atrophy	Testectomy	2+	
N-3	M	53	Epididymis; testis	Crossis of testicular parenchyma	Testectomy	2+	
N-4	M	74	Epididymis; testis	Spermatocele	Testectomy	3+	
N-5	M	78	Testes	Decreased spermatogenesis	Testectomy	2+	
N-6	M	78	Testes	Decreased spermatogenesis	Testectomy	1+	
N-7	M	78	Testes	Decreased spermatogenesis	Testectomy	N	
N-8	M	82	Testes	Decreased spermatogenesis	Testectomy	2+	
N-9	M	82	Testes	Decreased spermatogenesis	Testectomy	3+	
N-10	M	53	Epididymis; testis	Ectatic epididymis tubules	Testectomy	N	
O-1	M	77	Liver	Capsular angioma	Biopsy	3+	
O-2	F	67	Liver	Fatty metamorphosis	Biopsy	M	
O-3	F	32	Liver	Chronic inflammation; fibrosis	Biopsy	1+	
O-4	F	26	Liver	Chronic triaditis	Biopsy	4+	
O-5	N/A	55	Gallbladder	Cholecystitis	Cholecystectomy	N	
O-6	M	40	Liver	Chronic triaditis	Biopsy	2+	
O-7	F	32	Liver	No diagnostic alterations	Biopsy		
O-8	M	73	Liver	Chronic inflammation; fibrosis	Biopsy	2+	
O-9	M	73	Liver	Chronic inflammation; fibrosis	Biopsy	2+	
O-10	M	73	Liver	Chronic inflammation; fibrosis	Biopsy	2+	
P-1	M	N/A	Colon	Tubular adenoma	Biopsy	2+	
P-2	F	91	Colon	Tubular adenoma	Biopsy	1+	
P-3	F	41	Colon	Tubular adenoma	Biopsy	3+	
P-4	M	71	Colon	Tubular adenoma	Biopsy	N	
P-5	F	58	Colon	Tubular adenoma	Biopsy	2+	
P-6	M	69	Colon	Tubular adenoma	Biopsy	2+	
P-7	M	81	Colon	Tubular adenoma	Biopsy	2+	
P-8	F	44	Colon	Tubular adenoma	Biopsy	2+	
P-9	M	66	Colon	Tubular adenoma	Biopsy	2+	
P-10	F	60	Colon	Tubular adenoma	Biopsy	2+	
Q-1	M	84	Colon	Tubular adenoma	Biopsy	3+	
Q-2	M	42	Substantia nigra	Unremarkable	Autopsy	2+	
Q-3	M	42	Adule oblongat	Unremarkable	Autopsy	1+	
Q-4	M	42	Cerebellum	Unremarkable	Autopsy	1+	
Q-5	M	40	Parathyroid	Nodular hyperplasia	Parathyroidectomy	2+	
Q-6	M	100	Lung	Bronchopneumonia	Autopsy	2+	
Q-7	F	52	Spleen	Unremarkable	Autopsy	1+	
Q-8	F	100	Spleen	Unremarkable	Autopsy	2+	
Q-9	F	44	Thyroid	Unremarkable	Autopsy	1+	
Q-10	M	15	Tonsil	Lymphoid hyperplasia	Tonsilectomy	4+	
R-1	F	79	Cervix	No diagnostic abnormality	Hysterectomy	N	
R-2	F	79	Cervix	No diagnostic abnormality	Hysterectomy	N	
R-3	F	43	Cervix	Dysplasia	Cone biopsy	N	
R-4	F	43	Cervix	Dysplasia	Cone biopsy	N	
R-5	F	35	Ovary	Paraovarian cysts	Hysterectomy	2+	
R-6	F	52	Ovary	No diagnostic abnormality	Autopsy	N	
R-7	F	31	Uterus	No diagnostic abnormality	Autopsy	1+	
R-8	F	80	Cervix	No diagnostic abnormality	Hysterectomy	N	
R-9	F	35	Uterus	Adenomyosis	Hysterectomy	M	
R-10	F	35	Cervix	No diagnostic abnormality	Hysterectomy	0	
S-1	F	71	Kidney	Arterial nephrosclerosis	Autopsy	3+	
S-2	F	71	Kidney	Arterial nephrosclerosis	Autopsy	3+	
S-3	F	31	Coronary artery	Unremarkable		0	
S-4	F	31	Coronary artery	Unremarkable		1+	
S-5	F	71	Left ventricle	Ischemic cardiomyopathy	Autopsy	3+	
S-6	F	31	Heart	Unremarkable	Autopsy	2+	
S-7	F	31	Heart	Unremarkable	Autopsy	2+	

Appendix A
Table 21
NO 50 LOT 1 #2 Clinics Laboratories Frozen Array Data
a-Testosterone Staining of Prostate and Normal Tissue Arrays

Coordinates	Sex	Age	Organ	Diagnosis	Surgery	a-test Staining
S-8	F	71	Right ventricle	Ironc ischemic cardiomyopa	Autopsy	2+
S-9	F	71	Right atrium	Ironc ischemic cardiomyopa	Autopsy	2+
S-10	F	52	Trachea	Unremarkable	Autopsy	M
T-1	F	70	Appendix	Appendicitis	Appendectomy	N
T-2	F	35	Small bowel	Serositis	Resection	N
T-3	F	35	Retropentuneum	Lipoma	Biopsy	0
T-4	M	82	Skin; penis	No diagnostic abnormalities	Biopsy	N
T-5	M	63	Prostate	BPH	TUR	2+
T-6	M	5	Tonsil	Tonsillitis	Tonsilectomy	4+
T-7	M	15	Tonsil	Tonsillitis	Tonsilectomy	4+
T-8	F	70	Appendix	Appendicitis	Appendectomy	N
T-9	M	51	Prostate	No diagnostic abnormalities	Prostatectomy	2+
T-10	F	79	Cervix	No diagnostic abnormalities	Hysterectomy	N
Prostate: The antibody demonstrates cytoplasmic and nuclear staining in smooth muscle and epithelium.						
Breast: Scoring is based on cytoplasmic and nuclear staining of epithelial cells. Vascular endothelium also shows staining.						
Skin: Scoring is based on epithelial and endothelial cell staining. Smooth muscle also shows staining.						
Testis: Scoring is based on tubular staining. Leydig cells also stain 2+ to 3+.						
Liver: Scoring is based on hepatocyte cytoplasmic staining.						
Colon: Scoring is based on epithelial cytoplasmic staining.						

0306073-000001

NO. 34, LOT 142, Chimeras Laboratories Private Property, Cape Town
 e-Testimonials Staffing of Prospective and Normal Tissue Arrays

Coordinates	Identical biopsy	Age	Sex	Organ	Histologic diagnosis	Tissue represented, lot 1	Underlying disease	Material	2-Yr Survival	Cell Type
A 1a	47	26	m	thyroid	normal	ok	adenoma	biopsy	2+	Follicular cells
A 1b		65	m	thyroid	normal	ok	adenoma	biopsy	3+	Follicular cells
A 1c	1	65	m	thyroid	normal	ok	adenoma	biopsy	3+	Follicular cells
A 1d		32	f	adrenal gland	normal	ok	trauma	autopsy, 3 hrs	4+	Follicular cells
A 1e		32	f	adrenal gland	normal	ok	trauma	autopsy, 5 hrs	3+	Cortical cells
A 1f		37	m	adrenal gland	normal	ok	trauma	autopsy, 4 hrs	3+	Cortical cells
A 1g		38	m	adrenal gland	normal	ok	kidney cancer	biopsy	2+	Trophoblasts
A 1h		38	m	adrenal gland	normal	ok	kidney cancer	biopsy	2+	Trophoblasts
A 1i		29	f	placenta, third trimester	normal	ok	biopsy	biopsy	3+	Trophoblasts
A 2a		32	f	placenta, third trimester	normal	ok	biopsy	biopsy	3+	Trophoblasts
A 2b		29	f	placenta, third trimester	normal	ok	biopsy	biopsy	3+	Trophoblasts
A 2c		25	m	tonsil	normal	ok	chronic tonsillitis	biopsy	4+	Lymphoid cells
A 2d		18	f	tonsil	normal	ok	chronic tonsillitis	biopsy	3+	Lymphoid cells
A 2e		17	f	tonsil	normal	ok	chronic tonsillitis	biopsy	4+	Lymphoid cells
A 2f		16	m	lymph node	normal	ok	chronic tonsillitis	biopsy	1+	Lymphoid cells
A 2g		16	m	lymph node	normal	ok	chronic tonsillitis	biopsy	1+	Lymphoid cells
A 2h		62	f	lymph node	normal	ok	gastric cancer	biopsy	2+	Lymphoid cells
A 2i		54	f	lymph node	normal	ok	breast cancer	biopsy	2+	Lymphoid cells
A 3a		21	f	spleen	normal	ok	trauma	biopsy	1+	Lymphoid cells
A 3b		43	m	spleen	normal	ok	old hematoma	biopsy	2+	Parenchyma
A 3c		74	f	spleen	normal	ok	hyperplasia	biopsy	2+	Parenchyma
A 3d		32	f	spleen	normal	ok	Hodgkin disease	biopsy	2+	Parenchyma
A 3e		32	f	spleen	normal	ok	trauma	biopsy	2+	Parenchyma
A 4a		41	m	heart	normal	ok	trauma	autopsy, 5 hrs	2+	Cardiac muscle
A 4b		37	m	heart	normal	ok	trauma	autopsy, 4 hrs	1+	Cardiac muscle
A 4c	2	37	m	heart	normal	ok	Semnomia	autopsy, 4 hrs	2+	Cardiac muscle
A 4d	2	37	m	skeletal muscle	normal	ok	trauma	autopsy, 4 hrs	2+	Skeletal muscle
A 4e		43	m	skeletal muscle	normal	ok	hema	biopsy	0	Skeletal muscle
A 4f		43	m	skeletal muscle	normal	ok	lymph node	biopsy	2+	Skeletal muscle
A 4g		97	m	skeletal muscle	normal	ok	lymph node	biopsy	2+	Skeletal muscle
A 4h		74	f	liver	normal	ok	mild non-specific portal radialis	biopsy	0	Hepatocytes
A 4i		85	m	liver	normal	ok	colon cancer, metastatic	biopsy	1+	Hepatocytes
A 5a		71	m	liver	mild chronic inflammation	ok	cholelithiasis	biopsy	0	Hepatocytes
A 5b		26	f	liver	normal	ok	Hodgkin disease	biopsy	0	Hepatocytes
A 5c		32	f	pancreas	normal	ok	trauma	autopsy, 3 hrs	2+	Acinar cells
A 5d	3	41	f	pancreas	normal	ok	trauma	autopsy, 5 hrs	2+	Acinar cells
A 5e	4	32	f	pancreas	normal	ok	trauma	autopsy, 5 hrs	4+	Acinar cells
A 5f		32	f	pancreas	normal	ok	trauma	autopsy, 5 hrs	4+	Acinar cells
A 5g		1	m	ovary, stroma	normal	ok	abnormal bleedings	biopsy	0	Stroma
A 5h	4	47	f	ovary, stroma	normal	ok	carcinoma in situ cervix	biopsy	0	Stroma
A 6a		44	f	ovary, stroma	normal	ok	hysterectomy	biopsy	0	Stroma
A 6b		47	f	ovary, stroma	normal	ok	myoma uterus	biopsy	0	Stroma
A 6c		47	f	ovary, stroma	normal	ok	pelvic pain	biopsy	3+	Cardiac muscle
A 6d		30	f	myometrium	normal	ok	menometrorrhagia	biopsy	0	Cardiac muscle
A 6e		45	f	myometrium	normal	ok	endometrial cancer	biopsy	0	Cardiac muscle
A 6f		49	f	myometrium	normal	ok	carcinoma in situ cervix	biopsy	2+	Endometrial epithelium
A 6g		45	f	myometrium	normal	ok	carcinoma in situ cervix	biopsy	2+	Endometrial epithelium
A 6h		31	f	endometrium	normal	ok	prolapse	biopsy	4+	Endometrial epithelium
A 6i		39	f	endometrium	normal	ok	prolapse	biopsy	4+	Endometrial epithelium

Coordinate	Identical biopsy	age	sex	Organ	Histologic diagnosis	issue represented, lot 1	underlying disease	Material	# Test	Cell Type
A 7a		32	f	endo skel	normal	ok	carcinoma in situ cervix	biopsy	1*	Endometrial epithelium
A 7f		74	m	kidney cortex	normal	ok	kidney cancer	biopsy	4*	Renal tubules
A 8a		78	m	kidney cortex	normal	ok	transitional cell carcinoma	biopsy	4*	Renal tubules
A 8b		88	m	kidney cortex	normal	ok	kidney cancer	biopsy	4*	Renal tubules
A 8c		87	m	prostate	normal	ok	transitional cell carcinoma	biopsy	4*	Prostatic epithelium
A 8d		58	m	prostate	normal	ok	prostatic cancer	biopsy	4*	Prostatic epithelium
A 8e		68	m	prostate	normal	ok	BPH	biopsy	4*	Prostatic epithelium
A 8f		68	m	prostate	normal	ok	BPH	biopsy	4*	Prostatic epithelium
A 8g		58	m	prostate	normal	ok	prostatic cancer	biopsy	3*	Ductal epithelium
B 1a		60	m	seminal vesicle	normal	ok	prostatic cancer	biopsy	4*	Ductal epithelium
B 1b		63	m	seminal vesicle	normal	ok	prostatic cancer	biopsy	4*	Stroma only
B 1c		68	m	seminal vesicle	normal	ok	prostatic cancer	biopsy	0	Prostatic epithelium
B 2a		65	m	testis	decreased spermiogenesis	ok	prostatic cancer	biopsy	3*	Prostatic epithelium
B 2c		87	m	testis	decreased spermiogenesis	ok	prostatic cancer	biopsy	3*	Prostatic epithelium
B 2a		87	m	testis	normal	ok	prostatic cancer	biopsy	4*	Prostatic epithelium
B 3a		73	m	testis	normal	ok	prostatic cancer	biopsy	4*	Prostatic epithelium
B 3c		74	f	lung	normal	ok	lung cancer	biopsy	4*	Pneumocytes
B 3c		74	f	lung	normal	ok	lung cancer	biopsy	4*	Pneumocytes
B 4a		62	m	lung	normal	ok	lung cancer	biopsy	3*	Pneumocytes
B 4b		68	f	lung	normal	ok	lung cancer	biopsy	3*	Pneumocytes
B 4c		69	f	lung	normal	ok	lung cancer	biopsy	N	Pneumocytes
B 5a		41	m	cerebellum	normal	ok	trauma	autopsy, 5 hrs	2*	Neuropil
B 5b		33	f	cerebellum	normal	ok	trauma	autopsy, <10 hrs	2*	Neuropil
B 6a	5	37	m	cerebellum	normal	ok	trauma	autopsy, 4 hrs	4*	Molecular layer
B 6a		37	m	cerebellum	normal	ok	trauma	autopsy, 4 hrs	4*	Molecular layer
B 7a	5	32	f	cerebrum	normal	ok	trauma	autopsy, 3 hrs	3*	Neuropil
B 7b		41	m	cerebrum	normal	ok	trauma	autopsy, 5 hrs	3*	Neuropil
B 8a		33	f	cerebrum	normal	ok	trauma	autopsy, <10 hrs	3*	Neuropil
B 8b		37	m	cerebrum	normal	ok	trauma	autopsy, 4 hrs	3*	Neuropil

NO 50 EO 1142 Clinical Laboratories Frozen Array Data
 a-Testosterone Staining 1 Prostate and Normal Tissue Arrays
 TMA PR 200 Lot 1 #2

Table 11

COORDINATES	SEX	AGE	ORGAN	TUMOR TYPE	GLEASON 1	GLEASON 2	GLEASON SUM	PT	PN	SURGERY	a-Test Staining	
											Epithelium	Stroma
A-1a	M	77	Prostate	Adenocarcinoma	3	3	6	T1a	Nx	TUR	N	3+
A-2a	M	74	Prostate	Adenocarcinoma	3	2	5	T1b	Nx	TUR	1+	M
A-3a	M	74	Prostate	Adenocarcinoma	3	2	5	T1b	Nx	TUR	1+	M
A-4a	M	62	Prostate	Adenocarcinoma	2	2	4	T1	Nx	TUR	3+	1+
A-5a	M	62	Prostate	Adenocarcinoma	2	2	4	T1	Nx	TUR	2+	1+
A-6a	M	62	Prostate	Adenocarcinoma	2	2	4	T1	Nx	TUR	M	M
A-7a	M	62	Prostate	Adenocarcinoma	2	2	4	T1	Nx	TUR	2+	1+
A-8a	M	62	Prostate	Adenocarcinoma	2	2	4	T1	Nx	TUR	3+	1+
A-9a	M	62	Prostate	Prostate - benign hyperplasia	2	2	4	T1	Nx	TUR	2+	1+
A-10a	M	62	Prostate	Adenocarcinoma	2	2	4	T1	Nx	TUR	M	M
A-1b	M	85	Prostate	Adenocarcinoma	5	4	9	T1b	Nx	TUR	3+	1+
A-2b	M	85	Prostate	Adenocarcinoma	5	4	9	T1b	Nx	TUR	4+	2+
A-3b	M	85	Prostate	Adenocarcinoma	5	4	9	T1b	Nx	TUR	4+	2+
A-4b	M	85	Prostate	Adenocarcinoma	5	4	9	T1b	Nx	TUR	3+	2+
A-5b	M	85	Prostate	Adenocarcinoma	5	4	9	T1b	Nx	TUR	3+	1+
A-6b	M	85	Prostate	Adenocarcinoma	5	4	9	T1b	Nx	TUR	3+	2+
A-7b	M	85	Prostate	Adenocarcinoma	5	4	9	T1b	Nx	TUR	3+	2+
A-8b	M	85	Prostate	Adenocarcinoma	5	4	9	T1b	Nx	TUR	3+	2+
A-9b	M	85	Prostate	Adenocarcinoma	5	4	9	T1b	Nx	TUR	3+	1+
A-10b	M	85	Prostate	Adenocarcinoma	5	4	9	T1b	Nx	TUR	3+	1+
A-1c	M	85	Prostate	Adenocarcinoma	5	4	9	T1b	Nx	TUR	2+	2+
A-2c	M	85	Prostate	Adenocarcinoma	5	4	9	T1b	Nx	TUR	3+	2+
A-3c	M	85	Prostate	Adenocarcinoma	5	4	9	T1b	Nx	TUR	4+	3+
A-4c	M	85	Prostate	Adenocarcinoma	5	4	9	T1b	Nx	TUR	4+	1+
A-5c	M	85	Prostate	Adenocarcinoma	5	4	9	T1b	Nx	TUR	3+	3+
A-6c	M	85	Prostate	Adenocarcinoma	5	4	9	T1b	Nx	TUR	2+	2+
A-7c	M	85	Prostate	Adenocarcinoma	5	4	9	T1b	Nx	TUR	2+	1+
A-8c	M	85	Prostate	Adenocarcinoma	5	4	9	T1b	Nx	TUR	3+	2+
A-9c	M	85	Prostate	Adenocarcinoma	5	4	9	T1b	Nx	TUR	3+	3+
A-10c	M	85	Prostate	Adenocarcinoma	5	4	9	T1b	Nx	TUR	2+	2+
A-1d	M	78	Prostate	Adenocarcinoma	3	4	7	T1	Nx	TUR	1+	1+
A-2d	M	78	Prostate	Adenocarcinoma	3	4	7	T1	Nx	TUR	2+	1+
A-3d	M	78	Prostate	Adenocarcinoma	3	4	7	T1	Nx	TUR	1+	1+
A-4d	M	78	Prostate	Adenocarcinoma	3	4	7	T1	Nx	TUR	M	M
A-5d	M	78	Prostate	Adenocarcinoma	3	4	7	T1	Nx	TUR	3+	3+
A-6d	M	78	Prostate	Adenocarcinoma	3	4	7	T1	Nx	TUR	2+	1+
A-7d	M	78	Prostate	Adenocarcinoma	3	4	7	T1	Nx	TUR	1+	1+

Table 23
 NO 50 LOT 1 #2 Cytomic Laboratories Frozen Array Data
 a-Testosterone Staining of Prostate and Normal Tissue Arrays
 TMA PR 200 Lot 1 #2

COORDINATES	SEX	AGE	ORGAN	TUMOR TYPE	GLEASON 1	GLEASON 2	GLEASON SUM	PT	PN	SURGERY	a-Test Staining	0 to 4+
											Epithelium	Stroma
A-8d	M	78	Prostate	Adenocarcinoma	3	4	7	T1	Nx	TUR	2+	1+
A-8e	M	78	Prostate	Adenocarcinoma	3	4	7	T1	Nx	TUR	N	1+
A-10d	M	78	Prostate	Adenocarcinoma	3	4	7	T1	Nx	TUR	1+	1+
A-1e	M	78	Prostate	Adenocarcinoma	3	4	7	T1	Nx	TUR	2+	1+
A-2e	M	78	Prostate	Adenocarcinoma	3	4	7	T1	Nx	TUR	M	M
A-3e	M	78	Prostate	Adenocarcinoma	3	4	7	T1	Nx	TUR	2+	1+
A-4e	M	78	Prostate	Adenocarcinoma	3	4	7	T1	Nx	TUR	1+	1+
A-5e	M	78	Prostate	Adenocarcinoma	3	4	7	T1	Nx	TUR	2+	1+
A-6e	M	78	Prostate	Adenocarcinoma	3	4	7	T1	Nx	TUR	2+	1+
A-7e	M	78	Prostate	Adenocarcinoma	3	4	7	T1	Nx	TUR	2+	1+
A-8e	M	78	Prostate	Adenocarcinoma	3	4	7	T1	Nx	TUR	2+	1+
A-9e	M	78	Prostate	Adenocarcinoma	3	4	7	T1	Nx	TUR	2+	2+
A-10e	M	78	Prostate	Adenocarcinoma	3	4	7	T1	Nx	TUR	2+	1+
B-1a	M	83	Prostate	Adenocarcinoma	2	3	5	T1b	Nx	TUR	2+	1+
B-2a	M	83	Prostate	Adenocarcinoma	2	3	5	T1b	Nx	TUR	M	M
B-3a	M	83	Prostate	Adenocarcinoma	2	3	5	T1b	Nx	TUR	2+	1+
B-4a	M	83	Prostate	Adenocarcinoma	2	3	5	T1b	Nx	TUR	2+	2+
B-5a	M	83	Prostate	Adenocarcinoma	2	3	5	T1b	Nx	TUR	2+	1+
B-6a	M	83	Prostate	Adenocarcinoma	2	3	5	T1b	Nx	TUR	2+	2+
B-7a	M	83	Prostate	Adenocarcinoma	2	3	5	T1b	Nx	TUR	1+	1+
B-8a	M	76	Prostate	Adenocarcinoma	3	5	8	T1b	Nx	TUR	M	M
B-9a	M	76	Prostate	Adenocarcinoma	3	5	8	T1b	Nx	TUR	3+	3+
B-10a	M	76	Prostate	Adenocarcinoma	3	5	8	T1b	Nx	TUR	3+	4+
B-1b	M	76	Prostate	Adenocarcinoma	3	5	8	T1b	Nx	TUR	2+	3+
B-2b	M	76	Prostate	Adenocarcinoma	3	5	8	T1b	Nx	TUR	N	3+
B-3b	M	76	Prostate	Adenocarcinoma	3	5	8	T1b	Nx	TUR	2+	2+
B-4b	M	76	Prostate	Adenocarcinoma	3	5	8	T1b	Nx	TUR	2+	2+
B-5b	M	76	Prostate	Adenocarcinoma	3	5	8	T1b	Nx	TUR	2+	2+
B-6b	M	76	Prostate	Adenocarcinoma	3	5	8	T1b	Nx	TUR	2+	3+
B-7b	M	76	Prostate	Adenocarcinoma	3	5	8	T1b	Nx	TUR	2+	2+
B-8b	M	76	Prostate	Adenocarcinoma	3	5	8	T1b	Nx	TUR	M	M
B-9b	M	76	Prostate	Adenocarcinoma	3	5	8	T1b	Nx	TUR	2+	3+
B-10b	M	76	Prostate	Adenocarcinoma	3	5	8	T1b	Nx	TUR	3+	3+
B-1c	M	69	Prostate	Adenocarcinoma	5	5	10	T1	Nx	TUR	N	3+
B-2c	M	69	Prostate	Adenocarcinoma	5	5	10	T1	Nx	TUR	2+	2+
B-3c	M	69	Prostate	Adenocarcinoma	5	5	10	T1	Nx	TUR	N	3+

Appendix A

Table 23
NO 50 LOT-1 #2 Clinomic Laboratories Frozen Array Data
a-Testosterone Staining of Prostate and Normal Tissue Arrays
TMA PR 200 Lot 1 #2

COORDINATES	SEX	AGE	ORGAN	TUMOR TYPE	GLEASON 1	GLEASON 2	GLEASON SUM	PT	a-Test Staining		0 to 4+	
									PN	SURGERY		Epithellum
B-4c	M	69	Prostate	Adenocarcinoma	5	5	10	T1	Nx	TUR	3+	2+
B-5c	M	69	Prostate	Adenocarcinoma	5	5	10	T1	Nx	TUR	N	3+
B-6c	M	69	Prostate	Adenocarcinoma	5	5	10	T1	Nx	TUR	2+	2+
B-7c	M	69	Prostate	Adenocarcinoma	5	5	10	T1	Nx	TUR	3+	2+
B-8c	M	69	Prostate	Adenocarcinoma	5	5	10	T1	Nx	TUR	3+	2+
B-9c	M	69	Prostate	Adenocarcinoma	5	5	10	T1	Nx	TUR	3+	2+
B-10c	M	69	Prostate	Adenocarcinoma	5	5	10	T1	Nx	TUR	2+	1+
B-1d	M	86	Prostate	Adenocarcinoma	5	3	8	T1	Nx	TUR	2+	1+
B-2e	M	86	Prostate	Adenocarcinoma	5	3	8	T1	Nx	TUR	2+	1+
B-3d	M	86	Prostate	Adenocarcinoma	5	3	8	T1	Nx	TUR	2+	1+
B-4d	M	86	Prostate	Adenocarcinoma	5	3	8	T1	Nx	TUR	2+	1+
B-5d	M	86	Prostate	Adenocarcinoma	5	3	8	T1	Nx	TUR	2+	1+
B-6d	M	86	Prostate	Adenocarcinoma	5	3	8	T1	Nx	TUR	2+	1+
B-7d	M	86	Prostate	Adenocarcinoma	5	3	8	T1	Nx	TUR	2+	1+
B-8d	M	86	Prostate	Adenocarcinoma	5	3	8	T1	Nx	TUR	2+	1+
B-9d	M	86	Prostate	Adenocarcinoma	5	3	8	T1	Nx	TUR	2+	2+
B-10d	M	86	Prostate	Adenocarcinoma	5	3	8	T1	Nx	TUR	N	N
B-1e	M	86	Prostate	Adenocarcinoma	5	3	8	T1	Nx	TUR	1+	1+
B-2e	M	86	Prostate	Adenocarcinoma	5	3	8	T1	Nx	TUR	M	M
B-3e	M	86	Prostate	Adenocarcinoma	5	3	8	T1	Nx	TUR	1+	1+
B-4e	M	86	Prostate	Adenocarcinoma	5	3	8	T1	Nx	TUR	1+	1+
B-5e	M	86	Prostate	Adenocarcinoma	5	3	8	T1	Nx	TUR	2+	2+
B-6e	M	86	Prostate	Adenocarcinoma	5	3	8	T1	Nx	TUR	3+	1+
B-7e	M	86	Prostate	Adenocarcinoma	5	3	8	T1	Nx	TUR	2+	1+
B-8e	M	86	Prostate	Adenocarcinoma	5	3	8	T1	Nx	TUR	2+	1+
B-9e	M	86	Prostate	Adenocarcinoma	5	3	8	T1	Nx	TUR	2+	1+
B-10e	M	86	Prostate	Adenocarcinoma	5	3	8	T1	Nx	TUR	3+	2+
B-1f	M	66	Prostate	prostatic hyperplasia						TUR	2+	2+
B-2f	M	81	Prostate	prostatic hyperplasia						TUR	2+	2+
B-3f	M	78	Prostate	prostatic hyperplasia						TUR	2+	2+
B-4f	M	78	Prostate	prostatic hyperplasia						TUR	2+	3+
B-5f	M	78	Prostate	prostatic hyperplasia						TUR	N	2+
GRID C												
C-1a	M	69	Prostate	Adenocarcinoma	1	2	2	T1b	Nx	TUR	2+	2+
C-2a	M	69	Prostate	Adenocarcinoma	1	2	2	T1b	Nx	TUR	N	2+
C-3a	M	69	Prostate	Adenocarcinoma	1	2	2	T1b	Nx	TUR	2+	1+

Table 23
 NO 50 LOT-1#2 Clinolite Laboratories Frozen Array Data
 a-Testosterone Staining of Prostate and Normal Tissue Arrays
 TMA PR 200 Lot 1#2

COORDINATES	SEX	AGE	ORGAN	TUMOR TYPE	GLEASON 1		GLEASON 2		GLEASON SUM	PT	PN SURGERY		a-Test Staining	
					GLEASON 1	GLEASON 2	GLEASON 1	GLEASON 2			PT	Nx	Epithelium	Stroma
C-4a	M	69	Prostate	Adenocarcinoma	1	2	2	2	4	T1b	Nx	TUR	N	2+
C-5a	M	69	Prostate	Adenocarcinoma	1	2	2	2	4	T1b	Nx	TUR	1+	2+
C-6a	M	69	Prostate	Adenocarcinoma	1	2	2	2	4	T1b	Nx	TUR	1+	2+
C-7a	M	84	Prostate	Adenocarcinoma	5	5	5	10	10	T1	Nx	TUR	2+	2+
C-8a	M	84	Prostate	Adenocarcinoma	5	5	5	10	10	T1	Nx	TUR	2+	1+
C-9a	M	84	Prostate	Adenocarcinoma	5	5	5	10	10	T1	Nx	TUR	M	M
C-10a	M	84	Prostate	Adenocarcinoma	5	5	5	10	10	T1	Nx	TUR	2+	1+
C-1b	M	84	Prostate	Adenocarcinoma	5	5	5	10	10	T1	Nx	TUR	2+	1+
C-2b	M	84	Prostate	Adenocarcinoma	5	5	5	10	10	T1	Nx	TUR	2+	2+
C-3b	M	84	Prostate	Adenocarcinoma	5	5	5	10	10	T1	Nx	TUR	1+	2+
C-4b	M	84	Prostate	Adenocarcinoma	5	5	5	10	10	T1	Nx	TUR	2+	1+
C-5b	M	84	Prostate	Adenocarcinoma	5	5	5	10	10	T1	Nx	TUR	2+	1+
C-6b	M	84	Prostate	Adenocarcinoma	5	5	5	10	10	T1	Nx	TUR	2+	2+
C-7b	M	84	Prostate	Adenocarcinoma	5	5	5	10	10	T1	Nx	TUR	2+	1+
C-8b	M	84	Prostate	Adenocarcinoma	5	5	5	10	10	T1	Nx	TUR	1+	1+
C-9b	M	84	Prostate	Adenocarcinoma	5	5	5	10	10	T1	Nx	TUR	1+	1+
C-10b	M	84	Prostate	Adenocarcinoma	5	5	5	10	10	T1	Nx	TUR	1+	1+
C-1c	M	84	Prostate	Adenocarcinoma	5	5	5	10	10	T1	Nx	TUR	2+	2+
C-2c	M	84	Prostate	Adenocarcinoma	5	5	5	10	10	T1	Nx	TUR	2+	2+
C-3c	M	84	Prostate	Adenocarcinoma	5	5	5	10	10	T1	Nx	TUR	M	M
C-4c	M	84	Prostate	Adenocarcinoma	5	5	5	10	10	T1	Nx	TUR	2+	1+
C-5c	M	84	Prostate	Adenocarcinoma	5	5	5	10	10	T1	Nx	TUR	1+	1+
C-6c	M	84	Prostate	Adenocarcinoma	5	5	5	10	10	T1	Nx	TUR	1+	1+
C-7c	M	84	Prostate	Adenocarcinoma	5	5	5	10	10	T1	Nx	TUR	2+	1+
C-8c	M	84	Prostate	Adenocarcinoma	5	5	5	10	10	T1	Nx	TUR	N	1+
C-9c	M	84	Prostate	Adenocarcinoma	5	5	5	10	10	T1	Nx	TUR	2+	1+
C-10c	M	84	Prostate	Adenocarcinoma	5	5	5	10	10	T1	Nx	TUR	2+	1+
C-1d	M	84	Prostate	Benign prostatic hyperplasia	5	5	5	10	10	T1	Nx	TUR	2+	2+
C-2d	M	84	Prostate	Benign prostatic hyperplasia	5	5	5	10	10	T1	Nx	TUR	2+	1+
C-3d	M	84	Prostate	Benign prostatic hyperplasia	5	5	5	10	10	T1	Nx	TUR	2+	1+
C-4d	M	84	Prostate	Adenocarcinoma	5	5	5	10	10	T1	Nx	TUR	2+	1+
C-5d	M	84	Prostate	Adenocarcinoma	5	5	5	10	10	T1	Nx	TUR	1+	2+
C-6d	M	84	Prostate	Adenocarcinoma	4	5	9	9	9	T1	Nx	TUR	2+	2+
C-7d	M	84	Prostate	Adenocarcinoma	4	5	9	9	9	T1	Nx	TUR	3+	2+
C-8d	M	84	Prostate	Adenocarcinoma	4	5	9	9	9	T1	Nx	TUR	1+	1+
C-9d	M	84	Prostate	Adenocarcinoma	4	5	9	9	9	T1	Nx	TUR	3+	1+
C-10d	M	84	Prostate	Adenocarcinoma	4	5	9	9	9	T1	Nx	TUR	3+	1+

COORDINATES	SEX	AGE	ORGAN	TUMOR TYPE	GLEASON 1	GLEASON 2	GLEASON SUM	PT	PN SURGERY	a-Test Staining Epithelium	Stroma
C-1e	M	64	Prostate	Adenocarcinoma	4	5	9	T1	Nx	TUR	2+
C-2e	M	64	Prostate	Adenocarcinoma	4	5	9	T1	Nx	TUR	1+
C-3e	M	64	Prostate	Adenocarcinoma	4	5	9	T1	Nx	TUR	2+
C-4e	M	64	Prostate	Adenocarcinoma	4	5	9	T1	Nx	TUR	3+
C-5e	M	64	Prostate	Adenocarcinoma	4	5	9	T1	Nx	TUR	1+
C-6e	M	64	Prostate	Adenocarcinoma	4	5	9	T1	Nx	TUR	M
C-7e	M	64	Prostate	Adenocarcinoma	4	5	9	T1	Nx	TUR	2+
C-8e	M	64	Prostate	Adenocarcinoma	4	5	9	T1	Nx	TUR	2+
C-9e	M	64	Prostate	Adenocarcinoma	4	5	9	T1	Nx	TUR	3+
C-10e	M	64	Prostate	Adenocarcinoma	4	5	9	T1	Nx	TUR	1+
C-11	M	66	Prostate	benign prostatic hypertrophy					TUR	TUR	2+
C-21	M	66	Prostate	benign prostatic hypertrophy					TUR	TUR	1+
C-31	M	66	Prostate	benign prostatic hypertrophy					TUR	TUR	2+
GRID D											
D-1a	M	73	Prostate	Adenocarcinoma	2	3	5	T1	Nx	TUR	3+
D-2a	M	73	Prostate	Adenocarcinoma	2	3	5	T1	Nx	TUR	2+
D-3a	M	73	Prostate	Adenocarcinoma	2	3	5	T1	Nx	TUR	M
D-4a	M	61	Prostate	Adenocarcinoma	2	3	5	T1	Nx	TUR	3+
D-5a	M	61	Prostate	Adenocarcinoma	2	3	5	T1	Nx	TUR	2+
D-6a	M	68	Prostate	Adenocarcinoma	5	5	10	T1	Nx	TUR	1+
D-7a	M	68	Prostate	Adenocarcinoma	5	5	10	T1	Nx	TUR	M
D-8a	M	68	Prostate	Adenocarcinoma	5	5	10	T1	Nx	TUR	3+
D-9a	M	68	Prostate	Adenocarcinoma	5	5	10	T1	Nx	TUR	3+
D-10a	M	68	Prostate	Adenocarcinoma	5	5	10	T1	Nx	TUR	3+
D-11b	M	68	Prostate	Adenocarcinoma	5	5	10	T1	Nx	TUR	1+
D-2b	M	68	Prostate	Adenocarcinoma	5	5	10	T1	Nx	TUR	4+
D-3b	M	68	Prostate	Adenocarcinoma	5	5	10	T1	Nx	TUR	1+
D-4b	M	68	Prostate	Adenocarcinoma	5	5	10	T1	Nx	TUR	M
D-5b	M	68	Prostate	Adenocarcinoma	5	5	10	T1	Nx	TUR	1+
D-6b	M	68	Prostate	Adenocarcinoma	5	5	10	T1	Nx	TUR	3+
D-7b	M	68	Prostate	Adenocarcinoma	5	5	10	T1	Nx	TUR	2+
D-8b	M	68	Prostate	Adenocarcinoma	5	5	10	T1	Nx	TUR	4+
D-9b	M	68	Prostate	Adenocarcinoma	5	5	10	T1	Nx	TUR	M
D-10b	M	68	Prostate	Adenocarcinoma	5	5	10	T1	Nx	TUR	M
D-1c	M	77	Prostate	Adenocarcinoma	5	5	10	T1	Nx	TUR	1+

Appendix A
 Table 23
 NO 50 LOT 1 #2 Clinomic Laboratories Frozen Array Data
 a-Testosterone Staining of Prostate and Normal Tissue Arrays
 TMA PR 200 Lot 1 #2

COORDINATES	SEXAGE	ORGAN	TUMOR TYPE	GLEASON 1	GLEASON 2	GLEASON SUM	PT	PN	SURGERY	a-Test Staining Epithelium	Stroma
D-2c	M 77	Prostate	Adenocarcinoma	5	5	10	T1	Nx	TUR	N	2+
D-3c	M 77	Prostate	Adenocarcinoma	5	5	10	T1	Nx	TUR	2+	1+
D-4c	M 77	Prostate	Adenocarcinoma	5	5	10	T1	Nx	TUR	M	M
D-5c	M 77	Prostate	Adenocarcinoma	5	5	10	T1	Nx	TUR	3+	1+
D-6c	M 77	Prostate	Adenocarcinoma	5	5	10	T1	Nx	TUR	2+	1+
D-7c	M 77	Prostate	Adenocarcinoma	5	5	10	T1	Nx	TUR	2+	1+
D-8c	M 73	Prostate	Adenocarcinoma	2	4	6	T1	Nx	TUR	3+	2+
D-9c	M 73	Prostate	Adenocarcinoma	2	4	6	T1	Nx	TUR	2+	1+
D-10c	M 73	Prostate	Adenocarcinoma	2	4	6	T1	Nx	TUR	1+	1+
D-1d	M 73	Prostate	Adenocarcinoma	2	4	6	T1	Nx	TUR	2+	2+
D-2d	M 73	Prostate	Adenocarcinoma	2	4	6	T1	Nx	TUR	3+	1+
D-3d	M 73	Prostate	Adenocarcinoma	2	4	6	T1	Nx	TUR	1+	1+
D-4d	M 73	Prostate	Adenocarcinoma	2	4	6	T1	Nx	TUR	M	M
D-5d	M 72	Prostate	Adenocarcinoma	3	4	7	T1	Nx	TUR	M	M
D-6d	M 72	Prostate	Adenocarcinoma	3	4	7	T1	Nx	TUR	3+	2+
D-7d	M 72	Prostate	Adenocarcinoma	3	4	7	T1	Nx	TUR	4+	2+
D-8d	M 94	Prostate	Adenocarcinoma	3	2	5	T1	Nx	TUR	4+	2+
D-9d	M 94	Prostate	Adenocarcinoma	3	2	5	T1	Nx	TUR	2+	1+
D-10d	M 94	Prostate	Adenocarcinoma	3	2	5	T1	Nx	TUR	2+	1+
D-1e	M 72	Prostate	Adenocarcinoma	5	4	9	T1	Nx	TUR	3+	2+
D-2e	M 72	Prostate	Adenocarcinoma	5	4	9	T1	Nx	TUR	4+	2+
D-3e	M 72	Prostate	Adenocarcinoma	5	4	9	T1	Nx	TUR	3+	1+
D-4e	M 72	Prostate	Adenocarcinoma	5	4	9	T1	Nx	TUR	3+	2+
D-5e	M 72	Prostate	Adenocarcinoma	5	4	9	T1	Nx	TUR	3+	2+
D-6e	M 72	Prostate	Adenocarcinoma	5	4	9	T1	Nx	TUR	4+	2+
D-7e	M 72	Prostate	Adenocarcinoma	5	4	9	T1	Nx	TUR	1+	1+
D-8e	M 72	Prostate	Adenocarcinoma	5	4	9	T1	Nx	TUR	2+	2+
D-9e	M 72	Prostate	Adenocarcinoma	5	4	9	T1	Nx	TUR	N	1+
D-10e	M 72	Prostate	Adenocarcinoma	5	4	9	T1	Nx	TUR	3+	2+
D-1f	M 65	Prostate	prostatic hyperplasia						TUR	1+	2+
D-2f	M 81	Prostate	prostatic hyperplasia						TUR	1+	2+
D-3f	M 66	Prostate	prostatic hyperplasia						TUR	1+	1+
D-4f	M 71	Prostate	benign prostatic hypertrophy						TUR	1+	2+
D-5f	M 71	Prostate	benign prostatic hypertrophy						TUR	3+	3+

Appendix A

Table 23
NO 50 LOT 1 #2 Cytometric Laboratories Frozen Array Data
a-Testosterone Staining of Prostate and Normal Tissue Arrays
TMA PR 200 Lot 1 #2

COORDINATES	SEX	AGE	ORGAN	TUMOR TYPE	GLEASON 1	GLEASON 2	GLEASON SUM	PT	PN	SURGERY	a-Test Staining Epithelium	0 to 4+
Controls												
1	F	32	Brain	normal								2+
2	F	6	Heart	normal								2+
3	F	6	Liver	normal								2+
4	F	32	Spleen	normal								2+
5	F	101	Muscle	normal								1+
6	M	62	Testes	normal								2+
7	F	101	Kidney	normal								3+
8	F	52	Thyroid	normal								N
9	M	62	Adrenal	normal								2+
10	F	32	Lung	normal								2+
11	F	36	Breast	normal								N
12	F	52	Lymph Node	normal								4+